id	sid	tid	token	lemma	pos
ajst-20773	1	1	academic	academic	ADJ
ajst-20773	1	2	journal	journal	NOUN
ajst-20773	1	3	of	of	ADP
ajst-20773	1	4	science	science	NOUN
ajst-20773	1	5	and	and	CCONJ
ajst-20773	1	6	technology	technology	NOUN
ajst-20773	1	7	issn	issn	NOUN
ajst-20773	1	8	:	:	PUNCT
ajst-20773	1	9	2771	2771	NUM
ajst-20773	1	10	-	-	SYM
ajst-20773	1	11	3032	3032	NUM
ajst-20773	1	12	|	|	NOUN
ajst-20773	1	13	vol	vol	NOUN
ajst-20773	1	14	.	.	PROPN
ajst-20773	2	1	10	10	NUM
ajst-20773	2	2	,	,	PUNCT
ajst-20773	2	3	no	no	INTJ
ajst-20773	2	4	.	.	NOUN
ajst-20773	2	5	3	3	NUM
ajst-20773	2	6	,	,	PUNCT
ajst-20773	2	7	2024	2024	NUM
ajst-20773	2	8	12	12	NUM
ajst-20773	2	9	a	a	DET
ajst-20773	2	10	prognosis	prognosis	NOUN
ajst-20773	2	11	and	and	CCONJ
ajst-20773	2	12	immunological	immunological	ADJ
ajst-20773	2	13	study	study	NOUN
ajst-20773	2	14	of	of	ADP
ajst-20773	2	15	cellular	cellular	ADJ
ajst-20773	2	16	aging	age	VERB
ajst-20773	2	17	related	relate	VERB
ajst-20773	2	18	lncrnas	lncrna	NOUN
ajst-20773	2	19	in	in	ADP
ajst-20773	2	20	lung	lung	NOUN
ajst-20773	2	21	adenocarcinoma	adenocarcinoma	PROPN
ajst-20773	2	22	kaiwei	kaiwei	PROPN
ajst-20773	2	23	yang	yang	PROPN
ajst-20773	2	24	,	,	PUNCT
ajst-20773	2	25	baixue	baixue	PROPN
ajst-20773	2	26	li	li	PROPN
ajst-20773	2	27	,	,	PUNCT
ajst-20773	2	28	yi	yi	PROPN
ajst-20773	2	29	liu	liu	PROPN
ajst-20773	2	30	school	school	PROPN
ajst-20773	2	31	of	of	ADP
ajst-20773	2	32	chemical	chemical	PROPN
ajst-20773	2	33	engineering	engineering	NOUN
ajst-20773	2	34	,	,	PUNCT
ajst-20773	2	35	sichuan	sichuan	PROPN
ajst-20773	2	36	university	university	PROPN
ajst-20773	2	37	of	of	ADP
ajst-20773	2	38	science	science	PROPN
ajst-20773	2	39	&	&	CCONJ
ajst-20773	2	40	engineering	engineering	PROPN
ajst-20773	2	41	,	,	PUNCT
ajst-20773	2	42	zigong	zigong	PROPN
ajst-20773	2	43	,	,	PUNCT
ajst-20773	2	44	china	china	PROPN
ajst-20773	2	45	abstract	abstract	NOUN
ajst-20773	2	46	:	:	PUNCT
ajst-20773	2	47	background	background	NOUN
ajst-20773	2	48	:	:	PUNCT
ajst-20773	2	49	recently	recently	ADV
ajst-20773	2	50	,	,	PUNCT
ajst-20773	2	51	cellular	cellular	ADJ
ajst-20773	2	52	senescence	senescence	NOUN
ajst-20773	2	53	has	have	AUX
ajst-20773	2	54	been	be	AUX
ajst-20773	2	55	recognized	recognize	VERB
ajst-20773	2	56	as	as	ADP
ajst-20773	2	57	a	a	DET
ajst-20773	2	58	novel	novel	ADJ
ajst-20773	2	59	hallmark	hallmark	NOUN
ajst-20773	2	60	of	of	ADP
ajst-20773	2	61	cancer	cancer	NOUN
ajst-20773	2	62	.	.	PUNCT
ajst-20773	3	1	however	however	ADV
ajst-20773	3	2	,	,	PUNCT
ajst-20773	3	3	the	the	DET
ajst-20773	3	4	mechanisms	mechanism	NOUN
ajst-20773	3	5	that	that	PRON
ajst-20773	3	6	control	control	VERB
ajst-20773	3	7	cellular	cellular	ADJ
ajst-20773	3	8	senescence	senescence	NOUN
ajst-20773	3	9	remain	remain	AUX
ajst-20773	3	10	poorly	poorly	ADV
ajst-20773	3	11	understood	understand	VERB
ajst-20773	3	12	.	.	PUNCT
ajst-20773	4	1	this	this	DET
ajst-20773	4	2	study	study	NOUN
ajst-20773	4	3	seeks	seek	VERB
ajst-20773	4	4	to	to	PART
ajst-20773	4	5	discover	discover	VERB
ajst-20773	4	6	long	long	ADJ
ajst-20773	4	7	non	non	ADJ
ajst-20773	4	8	-	-	ADJ
ajst-20773	4	9	coding	coding	ADJ
ajst-20773	4	10	rnas	rna	NOUN
ajst-20773	4	11	(	(	PUNCT
ajst-20773	4	12	lncrnas	lncrnas	PROPN
ajst-20773	4	13	)	)	PUNCT
ajst-20773	4	14	that	that	PRON
ajst-20773	4	15	are	be	AUX
ajst-20773	4	16	linked	link	VERB
ajst-20773	4	17	to	to	ADP
ajst-20773	4	18	senescence	senescence	NOUN
ajst-20773	4	19	and	and	CCONJ
ajst-20773	4	20	can	can	AUX
ajst-20773	4	21	predict	predict	VERB
ajst-20773	4	22	outcomes	outcome	NOUN
ajst-20773	4	23	in	in	ADP
ajst-20773	4	24	lung	lung	NOUN
ajst-20773	4	25	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	4	26	(	(	PUNCT
ajst-20773	4	27	luad	luad	NOUN
ajst-20773	4	28	)	)	PUNCT
ajst-20773	4	29	patients	patient	NOUN
ajst-20773	4	30	.	.	PUNCT
ajst-20773	5	1	methods	method	NOUN
ajst-20773	5	2	:	:	PUNCT
ajst-20773	5	3	using	use	VERB
ajst-20773	5	4	rna	rna	NOUN
ajst-20773	5	5	sequencing	sequencing	NOUN
ajst-20773	5	6	data	datum	NOUN
ajst-20773	5	7	from	from	ADP
ajst-20773	5	8	the	the	DET
ajst-20773	5	9	cancer	cancer	NOUN
ajst-20773	5	10	genome	genome	NOUN
ajst-20773	5	11	atlas	atlas	PROPN
ajst-20773	5	12	lung	lung	PROPN
ajst-20773	5	13	adenocarcinoma	adenocarcinoma	PROPN
ajst-20773	5	14	(	(	PUNCT
ajst-20773	5	15	tcga	tcga	NOUN
ajst-20773	5	16	-	-	PUNCT
ajst-20773	5	17	luad	luad	NOUN
ajst-20773	5	18	)	)	PUNCT
ajst-20773	5	19	and	and	CCONJ
ajst-20773	5	20	senescence	senescence	NOUN
ajst-20773	5	21	genes	gene	NOUN
ajst-20773	5	22	from	from	ADP
ajst-20773	5	23	the	the	DET
ajst-20773	5	24	cellage	cellage	NOUN
ajst-20773	5	25	database	database	NOUN
ajst-20773	5	26	,	,	PUNCT
ajst-20773	5	27	a	a	DET
ajst-20773	5	28	group	group	NOUN
ajst-20773	5	29	of	of	ADP
ajst-20773	5	30	lncrnas	lncrna	NOUN
ajst-20773	5	31	related	relate	VERB
ajst-20773	5	32	to	to	ADP
ajst-20773	5	33	senescence	senescence	NOUN
ajst-20773	5	34	was	be	AUX
ajst-20773	5	35	initially	initially	ADV
ajst-20773	5	36	identified	identify	VERB
ajst-20773	5	37	.	.	PUNCT
ajst-20773	6	1	subsequently	subsequently	ADV
ajst-20773	6	2	,	,	PUNCT
ajst-20773	6	3	through	through	ADP
ajst-20773	6	4	univariate	univariate	ADJ
ajst-20773	6	5	and	and	CCONJ
ajst-20773	6	6	multivariate	multivariate	VERB
ajst-20773	6	7	cox	cox	PROPN
ajst-20773	6	8	regression	regression	PROPN
ajst-20773	6	9	analyses	analysis	NOUN
ajst-20773	6	10	,	,	PUNCT
ajst-20773	6	11	a	a	DET
ajst-20773	6	12	senescence	senescence	NOUN
ajst-20773	6	13	-	-	PUNCT
ajst-20773	6	14	related	relate	VERB
ajst-20773	6	15	lncrna	lncrna	NOUN
ajst-20773	6	16	signature	signature	NOUN
ajst-20773	6	17	(	(	PUNCT
ajst-20773	6	18	senlncsig	senlncsig	PROPN
ajst-20773	6	19	)	)	PUNCT
ajst-20773	6	20	linked	link	VERB
ajst-20773	6	21	to	to	ADP
ajst-20773	6	22	the	the	DET
ajst-20773	6	23	prognosis	prognosis	NOUN
ajst-20773	6	24	of	of	ADP
ajst-20773	6	25	luad	luad	NOUN
ajst-20773	6	26	was	be	AUX
ajst-20773	6	27	developed	develop	VERB
ajst-20773	6	28	.	.	PUNCT
ajst-20773	7	1	luad	luad	ADJ
ajst-20773	7	2	patients	patient	NOUN
ajst-20773	7	3	were	be	AUX
ajst-20773	7	4	categorized	categorize	VERB
ajst-20773	7	5	into	into	ADP
ajst-20773	7	6	high	high	ADJ
ajst-20773	7	7	-	-	PUNCT
ajst-20773	7	8	risk	risk	NOUN
ajst-20773	7	9	and	and	CCONJ
ajst-20773	7	10	low	low	ADJ
ajst-20773	7	11	-	-	PUNCT
ajst-20773	7	12	risk	risk	NOUN
ajst-20773	7	13	groups	group	NOUN
ajst-20773	7	14	based	base	VERB
ajst-20773	7	15	on	on	ADP
ajst-20773	7	16	the	the	DET
ajst-20773	7	17	median	median	ADJ
ajst-20773	7	18	risk	risk	NOUN
ajst-20773	7	19	score	score	NOUN
ajst-20773	7	20	of	of	ADP
ajst-20773	7	21	senlncsig	senlncsig	PROPN
ajst-20773	7	22	.	.	PUNCT
ajst-20773	8	1	kaplan	kaplan	PROPN
ajst-20773	8	2	-	-	PUNCT
ajst-20773	8	3	meier	meier	PROPN
ajst-20773	8	4	analysis	analysis	NOUN
ajst-20773	8	5	was	be	AUX
ajst-20773	8	6	employed	employ	VERB
ajst-20773	8	7	to	to	PART
ajst-20773	8	8	assess	assess	VERB
ajst-20773	8	9	differences	difference	NOUN
ajst-20773	8	10	in	in	ADP
ajst-20773	8	11	overall	overall	ADJ
ajst-20773	8	12	survival	survival	NOUN
ajst-20773	8	13	(	(	PUNCT
ajst-20773	8	14	os	os	NOUN
ajst-20773	8	15	)	)	PUNCT
ajst-20773	8	16	between	between	ADP
ajst-20773	8	17	these	these	DET
ajst-20773	8	18	subgroups	subgroup	NOUN
ajst-20773	8	19	.	.	PUNCT
ajst-20773	9	1	additionally	additionally	ADV
ajst-20773	9	2	,	,	PUNCT
ajst-20773	9	3	disparities	disparity	NOUN
ajst-20773	9	4	in	in	ADP
ajst-20773	9	5	gene	gene	NOUN
ajst-20773	9	6	set	set	VERB
ajst-20773	9	7	enrichment	enrichment	NOUN
ajst-20773	9	8	analysis	analysis	NOUN
ajst-20773	9	9	(	(	PUNCT
ajst-20773	9	10	gsea	gsea	NOUN
ajst-20773	9	11	)	)	PUNCT
ajst-20773	9	12	,	,	PUNCT
ajst-20773	9	13	immune	immune	ADJ
ajst-20773	9	14	infiltration	infiltration	NOUN
ajst-20773	9	15	,	,	PUNCT
ajst-20773	9	16	scores	score	NOUN
ajst-20773	9	17	from	from	ADP
ajst-20773	9	18	the	the	DET
ajst-20773	9	19	tumor	tumor	NOUN
ajst-20773	9	20	immune	immune	ADJ
ajst-20773	9	21	dysfunction	dysfunction	NOUN
ajst-20773	9	22	and	and	CCONJ
ajst-20773	9	23	exclusion	exclusion	NOUN
ajst-20773	9	24	(	(	PUNCT
ajst-20773	9	25	tide	tide	NOUN
ajst-20773	9	26	)	)	PUNCT
ajst-20773	9	27	module	module	NOUN
ajst-20773	9	28	,	,	PUNCT
ajst-20773	9	29	and	and	CCONJ
ajst-20773	9	30	choices	choice	NOUN
ajst-20773	9	31	of	of	ADP
ajst-20773	9	32	chemotherapy	chemotherapy	NOUN
ajst-20773	9	33	and	and	CCONJ
ajst-20773	9	34	targeted	target	VERB
ajst-20773	9	35	therapy	therapy	NOUN
ajst-20773	9	36	were	be	AUX
ajst-20773	9	37	also	also	ADV
ajst-20773	9	38	evaluated	evaluate	VERB
ajst-20773	9	39	between	between	ADP
ajst-20773	9	40	the	the	DET
ajst-20773	9	41	high	high	ADJ
ajst-20773	9	42	-	-	PUNCT
ajst-20773	9	43	risk	risk	NOUN
ajst-20773	9	44	and	and	CCONJ
ajst-20773	9	45	lowrisk	lowrisk	NOUN
ajst-20773	9	46	groups	group	NOUN
ajst-20773	9	47	.	.	PUNCT
ajst-20773	10	1	results	result	NOUN
ajst-20773	10	2	:	:	PUNCT
ajst-20773	10	3	based	base	VERB
ajst-20773	10	4	on	on	ADP
ajst-20773	10	5	univariate	univariate	ADJ
ajst-20773	10	6	and	and	CCONJ
ajst-20773	10	7	multivariate	multivariate	VERB
ajst-20773	10	8	cox	cox	PROPN
ajst-20773	10	9	regression	regression	PROPN
ajst-20773	10	10	analyses	analysis	NOUN
ajst-20773	10	11	,	,	PUNCT
ajst-20773	10	12	we	we	PRON
ajst-20773	10	13	established	establish	VERB
ajst-20773	10	14	a	a	DET
ajst-20773	10	15	prognostic	prognostic	ADJ
ajst-20773	10	16	model	model	NOUN
ajst-20773	10	17	composed	compose	VERB
ajst-20773	10	18	of	of	ADP
ajst-20773	10	19	seven	seven	NUM
ajst-20773	10	20	senescence	senescence	NOUN
ajst-20773	10	21	-	-	PUNCT
ajst-20773	10	22	related	relate	VERB
ajst-20773	10	23	lncrnas	lncrna	NOUN
ajst-20773	10	24	,	,	PUNCT
ajst-20773	10	25	named	name	VERB
ajst-20773	10	26	senlncsig	senlncsig	PROPN
ajst-20773	10	27	,	,	PUNCT
ajst-20773	10	28	which	which	PRON
ajst-20773	10	29	includes	include	VERB
ajst-20773	10	30	al031775.2	al031775.2	NUM
ajst-20773	10	31	,	,	PUNCT
ajst-20773	10	32	ac026355.1	ac026355.1	NUM
ajst-20773	10	33	,	,	PUNCT
ajst-20773	10	34	al365181.2	al365181.2	NOUN
ajst-20773	10	35	,	,	PUNCT
ajst-20773	10	36	ac090559.1	ac090559.1	NUM
ajst-20773	10	37	,	,	PUNCT
ajst-20773	10	38	al606489.1	al606489.1	NUM
ajst-20773	10	39	,	,	PUNCT
ajst-20773	10	40	al513550.1	al513550.1	NUM
ajst-20773	10	41	,	,	PUNCT
ajst-20773	10	42	and	and	CCONJ
ajst-20773	10	43	c20orf197	c20orf197	PROPN
ajst-20773	10	44	.	.	PUNCT
ajst-20773	11	1	this	this	DET
ajst-20773	11	2	model	model	NOUN
ajst-20773	11	3	divides	divide	VERB
ajst-20773	11	4	patients	patient	NOUN
ajst-20773	11	5	into	into	ADP
ajst-20773	11	6	high	high	ADJ
ajst-20773	11	7	-	-	PUNCT
ajst-20773	11	8	risk	risk	NOUN
ajst-20773	11	9	and	and	CCONJ
ajst-20773	11	10	low	low	ADJ
ajst-20773	11	11	-	-	PUNCT
ajst-20773	11	12	risk	risk	NOUN
ajst-20773	11	13	groups	group	NOUN
ajst-20773	11	14	,	,	PUNCT
ajst-20773	11	15	with	with	ADP
ajst-20773	11	16	the	the	DET
ajst-20773	11	17	high	high	ADJ
ajst-20773	11	18	-	-	PUNCT
ajst-20773	11	19	risk	risk	NOUN
ajst-20773	11	20	group	group	NOUN
ajst-20773	11	21	showing	show	VERB
ajst-20773	11	22	significantly	significantly	ADV
ajst-20773	11	23	shorter	short	ADJ
ajst-20773	11	24	overall	overall	ADJ
ajst-20773	11	25	survival	survival	NOUN
ajst-20773	11	26	compared	compare	VERB
ajst-20773	11	27	to	to	ADP
ajst-20773	11	28	the	the	DET
ajst-20773	11	29	low	low	ADJ
ajst-20773	11	30	-	-	PUNCT
ajst-20773	11	31	risk	risk	NOUN
ajst-20773	11	32	group	group	NOUN
ajst-20773	11	33	,	,	PUNCT
ajst-20773	11	34	with	with	ADP
ajst-20773	11	35	a	a	DET
ajst-20773	11	36	hazard	hazard	NOUN
ajst-20773	11	37	ratio	ratio	NOUN
ajst-20773	11	38	(	(	PUNCT
ajst-20773	11	39	hr	hr	NOUN
ajst-20773	11	40	)	)	PUNCT
ajst-20773	11	41	of	of	ADP
ajst-20773	11	42	1.326	1.326	NUM
ajst-20773	11	43	.	.	PUNCT
ajst-20773	12	1	the	the	DET
ajst-20773	12	2	predictive	predictive	ADJ
ajst-20773	12	3	accuracy	accuracy	NOUN
ajst-20773	12	4	of	of	ADP
ajst-20773	12	5	senlncsig	senlncsig	PROPN
ajst-20773	12	6	was	be	AUX
ajst-20773	12	7	validated	validate	VERB
ajst-20773	12	8	through	through	ADP
ajst-20773	12	9	roc	roc	PROPN
ajst-20773	12	10	curves	curve	NOUN
ajst-20773	12	11	and	and	CCONJ
ajst-20773	12	12	principal	principal	ADJ
ajst-20773	12	13	component	component	NOUN
ajst-20773	12	14	analysis	analysis	NOUN
ajst-20773	12	15	(	(	PUNCT
ajst-20773	12	16	pca	pca	NOUN
ajst-20773	12	17	)	)	PUNCT
ajst-20773	12	18	.	.	PUNCT
ajst-20773	13	1	additionally	additionally	ADV
ajst-20773	13	2	,	,	PUNCT
ajst-20773	13	3	we	we	PRON
ajst-20773	13	4	developed	develop	VERB
ajst-20773	13	5	an	an	DET
ajst-20773	13	6	intuitive	intuitive	ADJ
ajst-20773	13	7	survival	survival	NOUN
ajst-20773	13	8	prediction	prediction	NOUN
ajst-20773	13	9	tool	tool	NOUN
ajst-20773	13	10	that	that	PRON
ajst-20773	13	11	combines	combine	VERB
ajst-20773	13	12	senlncsig	senlncsig	NOUN
ajst-20773	13	13	with	with	ADP
ajst-20773	13	14	clinical	clinical	ADJ
ajst-20773	13	15	pathological	pathological	ADJ
ajst-20773	13	16	features	feature	NOUN
ajst-20773	13	17	to	to	PART
ajst-20773	13	18	assess	assess	VERB
ajst-20773	13	19	patients	patient	NOUN
ajst-20773	13	20	'	'	PART
ajst-20773	13	21	overall	overall	ADJ
ajst-20773	13	22	survival	survival	NOUN
ajst-20773	13	23	(	(	PUNCT
ajst-20773	13	24	os	os	NOUN
ajst-20773	13	25	)	)	PUNCT
ajst-20773	13	26	.	.	PUNCT
ajst-20773	14	1	enrichment	enrichment	NOUN
ajst-20773	14	2	analysis	analysis	NOUN
ajst-20773	14	3	(	(	PUNCT
ajst-20773	14	4	gsea	gsea	NOUN
ajst-20773	14	5	)	)	PUNCT
ajst-20773	14	6	revealed	reveal	VERB
ajst-20773	14	7	that	that	SCONJ
ajst-20773	14	8	senlncsig	senlncsig	PROPN
ajst-20773	14	9	is	be	AUX
ajst-20773	14	10	involved	involve	VERB
ajst-20773	14	11	in	in	ADP
ajst-20773	14	12	multiple	multiple	ADJ
ajst-20773	14	13	pathways	pathway	NOUN
ajst-20773	14	14	related	relate	VERB
ajst-20773	14	15	to	to	ADP
ajst-20773	14	16	tumor	tumor	NOUN
ajst-20773	14	17	immune	immune	ADJ
ajst-20773	14	18	modulation	modulation	NOUN
ajst-20773	14	19	.	.	PUNCT
ajst-20773	15	1	risk	risk	NOUN
ajst-20773	15	2	model	model	NOUN
ajst-20773	15	3	analysis	analysis	NOUN
ajst-20773	15	4	indicated	indicate	VERB
ajst-20773	15	5	significant	significant	ADJ
ajst-20773	15	6	differences	difference	NOUN
ajst-20773	15	7	between	between	ADP
ajst-20773	15	8	the	the	DET
ajst-20773	15	9	high	high	ADJ
ajst-20773	15	10	and	and	CCONJ
ajst-20773	15	11	low	low	ADJ
ajst-20773	15	12	-	-	PUNCT
ajst-20773	15	13	risk	risk	NOUN
ajst-20773	15	14	groups	group	NOUN
ajst-20773	15	15	in	in	ADP
ajst-20773	15	16	terms	term	NOUN
ajst-20773	15	17	of	of	ADP
ajst-20773	15	18	immune	immune	ADJ
ajst-20773	15	19	status	status	NOUN
ajst-20773	15	20	and	and	CCONJ
ajst-20773	15	21	responses	response	NOUN
ajst-20773	15	22	to	to	ADP
ajst-20773	15	23	immunotherapy	immunotherapy	NOUN
ajst-20773	15	24	,	,	PUNCT
ajst-20773	15	25	chemotherapy	chemotherapy	NOUN
ajst-20773	15	26	,	,	PUNCT
ajst-20773	15	27	and	and	CCONJ
ajst-20773	15	28	targeted	target	VERB
ajst-20773	15	29	therapy	therapy	NOUN
ajst-20773	15	30	.	.	PUNCT
ajst-20773	16	1	conclusion	conclusion	NOUN
ajst-20773	16	2	:	:	PUNCT
ajst-20773	16	3	in	in	ADP
ajst-20773	16	4	this	this	DET
ajst-20773	16	5	study	study	NOUN
ajst-20773	16	6	,	,	PUNCT
ajst-20773	16	7	a	a	DET
ajst-20773	16	8	lncrna	lncrna	NOUN
ajst-20773	16	9	signature	signature	NOUN
ajst-20773	16	10	named	name	VERB
ajst-20773	16	11	as	as	SCONJ
ajst-20773	16	12	senlncsig	senlncsig	PROPN
ajst-20773	16	13	was	be	AUX
ajst-20773	16	14	developed	develop	VERB
ajst-20773	16	15	that	that	SCONJ
ajst-20773	16	16	not	not	PART
ajst-20773	16	17	only	only	ADV
ajst-20773	16	18	identifies	identify	VERB
ajst-20773	16	19	the	the	DET
ajst-20773	16	20	senescence	senescence	NOUN
ajst-20773	16	21	phenotype	phenotype	NOUN
ajst-20773	16	22	and	and	CCONJ
ajst-20773	16	23	predicts	predict	VERB
ajst-20773	16	24	prognosis	prognosis	NOUN
ajst-20773	16	25	but	but	CCONJ
ajst-20773	16	26	also	also	ADV
ajst-20773	16	27	has	have	VERB
ajst-20773	16	28	the	the	DET
ajst-20773	16	29	capability	capability	NOUN
ajst-20773	16	30	to	to	PART
ajst-20773	16	31	forecast	forecast	VERB
ajst-20773	16	32	the	the	DET
ajst-20773	16	33	response	response	NOUN
ajst-20773	16	34	of	of	ADP
ajst-20773	16	35	luad	luad	NOUN
ajst-20773	16	36	to	to	ADP
ajst-20773	16	37	immunotherapy	immunotherapy	NOUN
ajst-20773	16	38	.	.	PUNCT
ajst-20773	17	1	1	1	X
ajst-20773	17	2	.	.	X
ajst-20773	17	3	introduction	introduction	NOUN
ajst-20773	17	4	according	accord	VERB
ajst-20773	17	5	to	to	ADP
ajst-20773	17	6	the	the	DET
ajst-20773	17	7	globocan	globocan	PROPN
ajst-20773	17	8	2018	2018	NUM
ajst-20773	17	9	statistics	statistic	NOUN
ajst-20773	17	10	,	,	PUNCT
ajst-20773	17	11	lung	lung	NOUN
ajst-20773	17	12	cancer	cancer	NOUN
ajst-20773	17	13	has	have	AUX
ajst-20773	17	14	become	become	VERB
ajst-20773	17	15	the	the	DET
ajst-20773	17	16	most	most	ADV
ajst-20773	17	17	common	common	ADJ
ajst-20773	17	18	malignant	malignant	ADJ
ajst-20773	17	19	tumor	tumor	NOUN
ajst-20773	17	20	globally	globally	ADV
ajst-20773	17	21	,	,	PUNCT
ajst-20773	17	22	with	with	ADP
ajst-20773	17	23	high	high	ADJ
ajst-20773	17	24	incidence	incidence	NOUN
ajst-20773	17	25	and	and	CCONJ
ajst-20773	17	26	mortality	mortality	NOUN
ajst-20773	17	27	rates	rate	NOUN
ajst-20773	17	28	(	(	PUNCT
ajst-20773	17	29	bray	bray	PROPN
ajst-20773	17	30	et	et	PROPN
ajst-20773	17	31	al	al	PROPN
ajst-20773	17	32	.	.	PROPN
ajst-20773	17	33	,	,	PUNCT
ajst-20773	17	34	2018	2018	NUM
ajst-20773	17	35	)	)	PUNCT
ajst-20773	17	36	.	.	PUNCT
ajst-20773	18	1	additionally	additionally	ADV
ajst-20773	18	2	,	,	PUNCT
ajst-20773	18	3	non	non	ADJ
ajst-20773	18	4	-	-	ADJ
ajst-20773	18	5	small	small	ADJ
ajst-20773	18	6	cell	cell	NOUN
ajst-20773	18	7	lung	lung	NOUN
ajst-20773	18	8	cancer	cancer	NOUN
ajst-20773	18	9	(	(	PUNCT
ajst-20773	18	10	nsclc	nsclc	NOUN
ajst-20773	18	11	)	)	PUNCT
ajst-20773	18	12	accounts	account	VERB
ajst-20773	18	13	for	for	ADP
ajst-20773	18	14	over	over	ADP
ajst-20773	18	15	85	85	NUM
ajst-20773	18	16	%	%	NOUN
ajst-20773	18	17	of	of	ADP
ajst-20773	18	18	lung	lung	NOUN
ajst-20773	18	19	cancer	cancer	NOUN
ajst-20773	18	20	cases	case	NOUN
ajst-20773	18	21	.	.	PUNCT
ajst-20773	19	1	the	the	DET
ajst-20773	19	2	most	most	ADV
ajst-20773	19	3	common	common	ADJ
ajst-20773	19	4	histological	histological	ADJ
ajst-20773	19	5	subtypes	subtype	NOUN
ajst-20773	19	6	of	of	ADP
ajst-20773	19	7	nsclc	nsclc	NOUN
ajst-20773	19	8	are	be	AUX
ajst-20773	19	9	lung	lung	NOUN
ajst-20773	19	10	squamous	squamous	ADJ
ajst-20773	19	11	cell	cell	NOUN
ajst-20773	19	12	carcinoma	carcinoma	NOUN
ajst-20773	19	13	(	(	PUNCT
ajst-20773	19	14	lusc	lusc	NOUN
ajst-20773	19	15	)	)	PUNCT
ajst-20773	19	16	and	and	CCONJ
ajst-20773	19	17	lung	lung	PROPN
ajst-20773	19	18	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	19	19	(	(	PUNCT
ajst-20773	19	20	luad	luad	NOUN
ajst-20773	19	21	)	)	PUNCT
ajst-20773	19	22	.	.	PUNCT
ajst-20773	20	1	moreover	moreover	ADV
ajst-20773	20	2	,	,	PUNCT
ajst-20773	20	3	the	the	DET
ajst-20773	20	4	complex	complex	ADJ
ajst-20773	20	5	molecular	molecular	ADJ
ajst-20773	20	6	mechanisms	mechanism	NOUN
ajst-20773	20	7	of	of	ADP
ajst-20773	20	8	lung	lung	NOUN
ajst-20773	20	9	cancer	cancer	NOUN
ajst-20773	20	10	pose	pose	VERB
ajst-20773	20	11	significant	significant	ADJ
ajst-20773	20	12	challenges	challenge	NOUN
ajst-20773	20	13	to	to	ADP
ajst-20773	20	14	treatment	treatment	NOUN
ajst-20773	20	15	,	,	PUNCT
ajst-20773	20	16	as	as	SCONJ
ajst-20773	20	17	targeted	target	VERB
ajst-20773	20	18	therapies	therapy	NOUN
ajst-20773	20	19	may	may	AUX
ajst-20773	20	20	be	be	AUX
ajst-20773	20	21	ineffective	ineffective	ADJ
ajst-20773	20	22	for	for	ADP
ajst-20773	20	23	some	some	DET
ajst-20773	20	24	patients	patient	NOUN
ajst-20773	20	25	(	(	PUNCT
ajst-20773	20	26	hoang	hoang	PROPN
ajst-20773	20	27	et	et	PROPN
ajst-20773	20	28	al	al	PROPN
ajst-20773	20	29	.	.	PROPN
ajst-20773	20	30	,	,	PUNCT
ajst-20773	20	31	2022	2022	NUM
ajst-20773	20	32	;	;	PUNCT
ajst-20773	20	33	west	west	PROPN
ajst-20773	20	34	et	et	PROPN
ajst-20773	20	35	al	al	PROPN
ajst-20773	20	36	.	.	PROPN
ajst-20773	20	37	,	,	PUNCT
ajst-20773	20	38	2012	2012	NUM
ajst-20773	20	39	)	)	PUNCT
ajst-20773	20	40	.	.	PUNCT
ajst-20773	21	1	thus	thus	ADV
ajst-20773	21	2	,	,	PUNCT
ajst-20773	21	3	identifying	identify	VERB
ajst-20773	21	4	new	new	ADJ
ajst-20773	21	5	biomarkers	biomarker	NOUN
ajst-20773	21	6	for	for	ADP
ajst-20773	21	7	lung	lung	NOUN
ajst-20773	21	8	adenocarcinoma	adenocarcinoma	PROPN
ajst-20773	21	9	or	or	CCONJ
ajst-20773	21	10	lung	lung	NOUN
ajst-20773	21	11	squamous	squamous	ADJ
ajst-20773	21	12	cell	cell	NOUN
ajst-20773	21	13	carcinoma	carcinoma	NOUN
ajst-20773	21	14	is	be	AUX
ajst-20773	21	15	crucial	crucial	ADJ
ajst-20773	21	16	for	for	ADP
ajst-20773	21	17	aiding	aid	VERB
ajst-20773	21	18	treatment	treatment	NOUN
ajst-20773	21	19	decisions	decision	NOUN
ajst-20773	21	20	and	and	CCONJ
ajst-20773	21	21	guiding	guide	VERB
ajst-20773	21	22	personalized	personalized	ADJ
ajst-20773	21	23	prognosis	prognosis	NOUN
ajst-20773	21	24	.	.	PUNCT
ajst-20773	22	1	in	in	ADP
ajst-20773	22	2	china	china	PROPN
ajst-20773	22	3	,	,	PUNCT
ajst-20773	22	4	lung	lung	NOUN
ajst-20773	22	5	cancer	cancer	NOUN
ajst-20773	22	6	has	have	VERB
ajst-20773	22	7	the	the	DET
ajst-20773	22	8	highest	high	ADJ
ajst-20773	22	9	incidence	incidence	NOUN
ajst-20773	22	10	among	among	ADP
ajst-20773	22	11	malignant	malignant	ADJ
ajst-20773	22	12	tumors	tumor	NOUN
ajst-20773	22	13	,	,	PUNCT
ajst-20773	22	14	with	with	ADP
ajst-20773	22	15	lung	lung	NOUN
ajst-20773	22	16	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	22	17	accounting	accounting	NOUN
ajst-20773	22	18	for	for	ADP
ajst-20773	22	19	about	about	ADV
ajst-20773	22	20	40	40	NUM
ajst-20773	22	21	%	%	NOUN
ajst-20773	22	22	of	of	ADP
ajst-20773	22	23	lung	lung	NOUN
ajst-20773	22	24	cancer	cancer	NOUN
ajst-20773	22	25	cases	case	NOUN
ajst-20773	22	26	.	.	PUNCT
ajst-20773	23	1	surgical	surgical	ADJ
ajst-20773	23	2	resection	resection	NOUN
ajst-20773	23	3	of	of	ADP
ajst-20773	23	4	early	early	ADJ
ajst-20773	23	5	-	-	PUNCT
ajst-20773	23	6	stage	stage	NOUN
ajst-20773	23	7	non	non	ADJ
ajst-20773	23	8	-	-	ADJ
ajst-20773	23	9	small	small	ADJ
ajst-20773	23	10	cell	cell	NOUN
ajst-20773	23	11	lung	lung	NOUN
ajst-20773	23	12	cancer	cancer	NOUN
ajst-20773	23	13	provides	provide	VERB
ajst-20773	23	14	a	a	DET
ajst-20773	23	15	good	good	ADJ
ajst-20773	23	16	prognosis	prognosis	NOUN
ajst-20773	23	17	,	,	PUNCT
ajst-20773	23	18	with	with	ADP
ajst-20773	23	19	a	a	DET
ajst-20773	23	20	5	5	NUM
ajst-20773	23	21	-	-	PUNCT
ajst-20773	23	22	year	year	NOUN
ajst-20773	23	23	survival	survival	NOUN
ajst-20773	23	24	rate	rate	NOUN
ajst-20773	23	25	of	of	ADP
ajst-20773	23	26	70	70	NUM
ajst-20773	23	27	-	-	SYM
ajst-20773	23	28	90	90	NUM
ajst-20773	23	29	%	%	NOUN
ajst-20773	23	30	(	(	PUNCT
ajst-20773	23	31	stage	stage	NOUN
ajst-20773	23	32	i	i	PROPN
ajst-20773	23	33	)	)	PUNCT
ajst-20773	23	34	.	.	PUNCT
ajst-20773	24	1	however	however	ADV
ajst-20773	24	2	,	,	PUNCT
ajst-20773	24	3	most	most	ADJ
ajst-20773	24	4	patients	patient	NOUN
ajst-20773	24	5	(	(	PUNCT
ajst-20773	24	6	about	about	ADV
ajst-20773	24	7	75	75	NUM
ajst-20773	24	8	%	%	NOUN
ajst-20773	24	9	)	)	PUNCT
ajst-20773	24	10	are	be	AUX
ajst-20773	24	11	diagnosed	diagnose	VERB
ajst-20773	24	12	at	at	ADP
ajst-20773	24	13	a	a	DET
ajst-20773	24	14	late	late	ADJ
ajst-20773	24	15	stage	stage	NOUN
ajst-20773	24	16	(	(	PUNCT
ajst-20773	24	17	stage	stage	NOUN
ajst-20773	24	18	iii	iii	SYM
ajst-20773	24	19	/	/	SYM
ajst-20773	24	20	iv	iv	NUM
ajst-20773	24	21	)	)	PUNCT
ajst-20773	24	22	,	,	PUNCT
ajst-20773	24	23	and	and	CCONJ
ajst-20773	24	24	their	their	PRON
ajst-20773	24	25	survival	survival	NOUN
ajst-20773	24	26	rates	rate	NOUN
ajst-20773	24	27	are	be	AUX
ajst-20773	24	28	very	very	ADV
ajst-20773	24	29	low	low	ADJ
ajst-20773	24	30	(	(	PUNCT
ajst-20773	24	31	miranda	miranda	NOUN
ajst-20773	24	32	-	-	PUNCT
ajst-20773	24	33	filho	filho	PROPN
ajst-20773	24	34	et	et	PROPN
ajst-20773	24	35	al	al	PROPN
ajst-20773	24	36	.	.	PROPN
ajst-20773	24	37	,	,	PUNCT
ajst-20773	24	38	2019	2019	NUM
ajst-20773	24	39	)	)	PUNCT
ajst-20773	24	40	.	.	PUNCT
ajst-20773	25	1	long	long	ADJ
ajst-20773	25	2	non	non	ADJ
ajst-20773	25	3	-	-	ADJ
ajst-20773	25	4	coding	coding	ADJ
ajst-20773	25	5	rnas	rna	NOUN
ajst-20773	25	6	(	(	PUNCT
ajst-20773	25	7	lncrnas	lncrna	NOUN
ajst-20773	25	8	)	)	PUNCT
ajst-20773	25	9	are	be	AUX
ajst-20773	25	10	rna	rna	NOUN
ajst-20773	25	11	molecules	molecule	NOUN
ajst-20773	25	12	longer	long	ADV
ajst-20773	25	13	than	than	ADP
ajst-20773	25	14	200	200	NUM
ajst-20773	25	15	nucleotides	nucleotide	NOUN
ajst-20773	25	16	that	that	PRON
ajst-20773	25	17	do	do	AUX
ajst-20773	25	18	not	not	PART
ajst-20773	25	19	have	have	VERB
ajst-20773	25	20	the	the	DET
ajst-20773	25	21	capacity	capacity	NOUN
ajst-20773	25	22	to	to	PART
ajst-20773	25	23	encode	encode	VERB
ajst-20773	25	24	proteins	protein	NOUN
ajst-20773	25	25	.	.	PUNCT
ajst-20773	26	1	initially	initially	ADV
ajst-20773	26	2	,	,	PUNCT
ajst-20773	26	3	lncrnas	lncrnas	PROPN
ajst-20773	26	4	were	be	AUX
ajst-20773	26	5	considered	consider	VERB
ajst-20773	26	6	byproducts	byproduct	NOUN
ajst-20773	26	7	of	of	ADP
ajst-20773	26	8	the	the	DET
ajst-20773	26	9	transcription	transcription	NOUN
ajst-20773	26	10	process	process	NOUN
ajst-20773	26	11	and	and	CCONJ
ajst-20773	26	12	were	be	AUX
ajst-20773	26	13	thought	think	VERB
ajst-20773	26	14	to	to	PART
ajst-20773	26	15	lack	lack	VERB
ajst-20773	26	16	practical	practical	ADJ
ajst-20773	26	17	biological	biological	ADJ
ajst-20773	26	18	functions	function	NOUN
ajst-20773	26	19	,	,	PUNCT
ajst-20773	26	20	hence	hence	ADV
ajst-20773	26	21	they	they	PRON
ajst-20773	26	22	were	be	AUX
ajst-20773	26	23	not	not	PART
ajst-20773	26	24	given	give	VERB
ajst-20773	26	25	much	much	ADJ
ajst-20773	26	26	attention	attention	NOUN
ajst-20773	26	27	.	.	PUNCT
ajst-20773	27	1	however	however	ADV
ajst-20773	27	2	,	,	PUNCT
ajst-20773	27	3	advances	advance	NOUN
ajst-20773	27	4	in	in	ADP
ajst-20773	27	5	chip	chip	NOUN
ajst-20773	27	6	technology	technology	NOUN
ajst-20773	27	7	and	and	CCONJ
ajst-20773	27	8	bioinformatics	bioinformatics	NOUN
ajst-20773	27	9	have	have	AUX
ajst-20773	27	10	led	lead	VERB
ajst-20773	27	11	to	to	ADP
ajst-20773	27	12	the	the	DET
ajst-20773	27	13	recognition	recognition	NOUN
ajst-20773	27	14	of	of	ADP
ajst-20773	27	15	the	the	DET
ajst-20773	27	16	significant	significant	ADJ
ajst-20773	27	17	roles	role	NOUN
ajst-20773	27	18	lncrnas	lncrna	NOUN
ajst-20773	27	19	play	play	VERB
ajst-20773	27	20	in	in	ADP
ajst-20773	27	21	biological	biological	ADJ
ajst-20773	27	22	processes	process	NOUN
ajst-20773	27	23	,	,	PUNCT
ajst-20773	27	24	particularly	particularly	ADV
ajst-20773	27	25	in	in	ADP
ajst-20773	27	26	pre	pre	ADJ
ajst-20773	27	27	-	-	ADJ
ajst-20773	27	28	transcriptional	transcriptional	ADJ
ajst-20773	27	29	regulation	regulation	NOUN
ajst-20773	27	30	,	,	PUNCT
ajst-20773	27	31	post	post	ADJ
ajst-20773	27	32	-	-	ADJ
ajst-20773	27	33	transcriptional	transcriptional	ADJ
ajst-20773	27	34	regulation	regulation	NOUN
ajst-20773	27	35	,	,	PUNCT
ajst-20773	27	36	and	and	CCONJ
ajst-20773	27	37	epigenetic	epigenetic	ADJ
ajst-20773	27	38	regulation	regulation	NOUN
ajst-20773	27	39	(	(	PUNCT
ajst-20773	27	40	serviss	serviss	VERB
ajst-20773	27	41	et	et	PROPN
ajst-20773	27	42	al	al	PROPN
ajst-20773	27	43	.	.	PROPN
ajst-20773	27	44	,	,	PUNCT
ajst-20773	27	45	2014	2014	NUM
ajst-20773	27	46	;	;	PUNCT
ajst-20773	27	47	zhang	zhang	PROPN
ajst-20773	27	48	et	et	PROPN
ajst-20773	27	49	al	al	PROPN
ajst-20773	27	50	.	.	PROPN
ajst-20773	27	51	,	,	PUNCT
ajst-20773	27	52	2020	2020	NUM
ajst-20773	27	53	)	)	PUNCT
ajst-20773	27	54	.	.	PUNCT
ajst-20773	28	1	further	further	ADJ
ajst-20773	28	2	research	research	NOUN
ajst-20773	28	3	has	have	AUX
ajst-20773	28	4	revealed	reveal	VERB
ajst-20773	28	5	a	a	DET
ajst-20773	28	6	close	close	ADJ
ajst-20773	28	7	relationship	relationship	NOUN
ajst-20773	28	8	between	between	ADP
ajst-20773	28	9	the	the	DET
ajst-20773	28	10	occurrence	occurrence	NOUN
ajst-20773	28	11	,	,	PUNCT
ajst-20773	28	12	development	development	NOUN
ajst-20773	28	13	,	,	PUNCT
ajst-20773	28	14	metastasis	metastasis	NOUN
ajst-20773	28	15	,	,	PUNCT
ajst-20773	28	16	and	and	CCONJ
ajst-20773	28	17	recurrence	recurrence	NOUN
ajst-20773	28	18	of	of	ADP
ajst-20773	28	19	tumors	tumor	NOUN
ajst-20773	28	20	and	and	CCONJ
ajst-20773	28	21	the	the	DET
ajst-20773	28	22	differential	differential	ADJ
ajst-20773	28	23	expression	expression	NOUN
ajst-20773	28	24	of	of	ADP
ajst-20773	28	25	lncrnas	lncrna	NOUN
ajst-20773	28	26	,	,	PUNCT
ajst-20773	28	27	making	make	VERB
ajst-20773	28	28	them	they	PRON
ajst-20773	28	29	a	a	DET
ajst-20773	28	30	new	new	ADJ
ajst-20773	28	31	focus	focus	NOUN
ajst-20773	28	32	in	in	ADP
ajst-20773	28	33	cancer	cancer	NOUN
ajst-20773	28	34	research	research	NOUN
ajst-20773	28	35	(	(	PUNCT
ajst-20773	28	36	silva	silva	NOUN
ajst-20773	28	37	et	et	PROPN
ajst-20773	28	38	al	al	PROPN
ajst-20773	28	39	.	.	PROPN
ajst-20773	28	40	,	,	PUNCT
ajst-20773	28	41	2015	2015	NUM
ajst-20773	28	42	)	)	PUNCT
ajst-20773	28	43	.	.	PUNCT
ajst-20773	29	1	due	due	ADP
ajst-20773	29	2	to	to	ADP
ajst-20773	29	3	their	their	PRON
ajst-20773	29	4	tissue	tissue	NOUN
ajst-20773	29	5	-	-	PUNCT
ajst-20773	29	6	specific	specific	ADJ
ajst-20773	29	7	expression	expression	NOUN
ajst-20773	29	8	,	,	PUNCT
ajst-20773	29	9	lncrnas	lncrna	NOUN
ajst-20773	29	10	have	have	VERB
ajst-20773	29	11	the	the	DET
ajst-20773	29	12	potential	potential	NOUN
ajst-20773	29	13	to	to	PART
ajst-20773	29	14	serve	serve	VERB
ajst-20773	29	15	as	as	ADP
ajst-20773	29	16	novel	novel	NOUN
ajst-20773	29	17	,	,	PUNCT
ajst-20773	29	18	specific	specific	ADJ
ajst-20773	29	19	cancer	cancer	NOUN
ajst-20773	29	20	biomarkers	biomarker	NOUN
ajst-20773	29	21	and	and	CCONJ
ajst-20773	29	22	hold	hold	VERB
ajst-20773	29	23	potential	potential	NOUN
ajst-20773	29	24	for	for	ADP
ajst-20773	29	25	use	use	NOUN
ajst-20773	29	26	in	in	ADP
ajst-20773	29	27	auxiliary	auxiliary	ADJ
ajst-20773	29	28	cancer	cancer	NOUN
ajst-20773	29	29	diagnostics	diagnostic	NOUN
ajst-20773	29	30	(	(	PUNCT
ajst-20773	29	31	do	do	VERB
ajst-20773	29	32	and	and	CCONJ
ajst-20773	29	33	kim	kim	PROPN
ajst-20773	29	34	,	,	PUNCT
ajst-20773	29	35	2018	2018	NUM
ajst-20773	29	36	)	)	PUNCT
ajst-20773	29	37	.	.	PUNCT
ajst-20773	30	1	lncrna	lncrna	NOUN
ajst-20773	30	2	detection	detection	NOUN
ajst-20773	30	3	methods	method	NOUN
ajst-20773	30	4	are	be	AUX
ajst-20773	30	5	simple	simple	ADJ
ajst-20773	30	6	and	and	CCONJ
ajst-20773	30	7	quick	quick	ADJ
ajst-20773	30	8	,	,	PUNCT
ajst-20773	30	9	effectively	effectively	ADV
ajst-20773	30	10	increasing	increase	VERB
ajst-20773	30	11	the	the	DET
ajst-20773	30	12	likelihood	likelihood	NOUN
ajst-20773	30	13	of	of	ADP
ajst-20773	30	14	detecting	detect	VERB
ajst-20773	30	15	diseases	disease	NOUN
ajst-20773	30	16	in	in	ADP
ajst-20773	30	17	patients	patient	NOUN
ajst-20773	30	18	.	.	PUNCT
ajst-20773	31	1	combined	combine	VERB
ajst-20773	31	2	with	with	ADP
ajst-20773	31	3	other	other	ADJ
ajst-20773	31	4	diagnostic	diagnostic	ADJ
ajst-20773	31	5	methods	method	NOUN
ajst-20773	31	6	,	,	PUNCT
ajst-20773	31	7	they	they	PRON
ajst-20773	31	8	can	can	AUX
ajst-20773	31	9	aid	aid	VERB
ajst-20773	31	10	in	in	ADP
ajst-20773	31	11	the	the	DET
ajst-20773	31	12	early	early	ADJ
ajst-20773	31	13	detection	detection	NOUN
ajst-20773	31	14	and	and	CCONJ
ajst-20773	31	15	treatment	treatment	NOUN
ajst-20773	31	16	of	of	ADP
ajst-20773	31	17	tumors	tumor	NOUN
ajst-20773	31	18	.	.	PUNCT
ajst-20773	32	1	given	give	VERB
ajst-20773	32	2	the	the	DET
ajst-20773	32	3	limitations	limitation	NOUN
ajst-20773	32	4	of	of	ADP
ajst-20773	32	5	traditional	traditional	ADJ
ajst-20773	32	6	cancer	cancer	NOUN
ajst-20773	32	7	diagnostic	diagnostic	ADJ
ajst-20773	32	8	methods	method	NOUN
ajst-20773	32	9	,	,	PUNCT
ajst-20773	32	10	lncrnas	lncrna	NOUN
ajst-20773	32	11	,	,	PUNCT
ajst-20773	32	12	as	as	ADP
ajst-20773	32	13	more	more	ADV
ajst-20773	32	14	specific	specific	ADJ
ajst-20773	32	15	and	and	CCONJ
ajst-20773	32	16	sensitive	sensitive	ADJ
ajst-20773	32	17	diagnostic	diagnostic	ADJ
ajst-20773	32	18	indicators	indicator	NOUN
ajst-20773	32	19	,	,	PUNCT
ajst-20773	32	20	are	be	AUX
ajst-20773	32	21	expected	expect	VERB
ajst-20773	32	22	to	to	PART
ajst-20773	32	23	significantly	significantly	ADV
ajst-20773	32	24	improve	improve	VERB
ajst-20773	32	25	the	the	DET
ajst-20773	32	26	accuracy	accuracy	NOUN
ajst-20773	32	27	of	of	ADP
ajst-20773	32	28	cancer	cancer	NOUN
ajst-20773	32	29	diagnoses	diagnosis	NOUN
ajst-20773	32	30	.	.	PUNCT
ajst-20773	33	1	lncrnas	lncrnas	PROPN
ajst-20773	33	2	have	have	AUX
ajst-20773	33	3	shown	show	VERB
ajst-20773	33	4	potential	potential	NOUN
ajst-20773	33	5	to	to	PART
ajst-20773	33	6	enhance	enhance	VERB
ajst-20773	33	7	diagnostic	diagnostic	ADJ
ajst-20773	33	8	specificity	specificity	NOUN
ajst-20773	33	9	and	and	CCONJ
ajst-20773	33	10	sensitivity	sensitivity	NOUN
ajst-20773	33	11	as	as	ADP
ajst-20773	33	12	specific	specific	ADJ
ajst-20773	33	13	tumor	tumor	NOUN
ajst-20773	33	14	biomarkers	biomarker	NOUN
ajst-20773	33	15	.	.	PUNCT
ajst-20773	34	1	abnormally	abnormally	ADV
ajst-20773	34	2	expressed	express	VERB
ajst-20773	34	3	lncrnas	lncrna	NOUN
ajst-20773	34	4	in	in	ADP
ajst-20773	34	5	the	the	DET
ajst-20773	34	6	serum	serum	NOUN
ajst-20773	34	7	,	,	PUNCT
ajst-20773	34	8	particularly	particularly	ADV
ajst-20773	34	9	those	those	PRON
ajst-20773	34	10	originating	originate	VERB
ajst-20773	34	11	from	from	ADP
ajst-20773	34	12	specific	specific	ADJ
ajst-20773	34	13	tumors	tumor	NOUN
ajst-20773	34	14	,	,	PUNCT
ajst-20773	34	15	offer	offer	VERB
ajst-20773	34	16	higher	high	ADJ
ajst-20773	34	17	diagnostic	diagnostic	ADJ
ajst-20773	34	18	accuracy	accuracy	NOUN
ajst-20773	34	19	(	(	PUNCT
ajst-20773	34	20	yuan	yuan	NOUN
ajst-20773	34	21	et	et	NOUN
ajst-20773	34	22	al	al	PROPN
ajst-20773	34	23	.	.	PROPN
ajst-20773	34	24	,	,	PUNCT
ajst-20773	34	25	2020	2020	NUM
ajst-20773	34	26	)	)	PUNCT
ajst-20773	34	27	.	.	PUNCT
ajst-20773	35	1	in	in	ADP
ajst-20773	35	2	lung	lung	NOUN
ajst-20773	35	3	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	35	4	tissues	tissue	NOUN
ajst-20773	35	5	,	,	PUNCT
ajst-20773	35	6	the	the	DET
ajst-20773	35	7	expression	expression	NOUN
ajst-20773	35	8	levels	level	NOUN
ajst-20773	35	9	of	of	ADP
ajst-20773	35	10	certain	certain	ADJ
ajst-20773	35	11	lncrnas	lncrna	NOUN
ajst-20773	35	12	are	be	AUX
ajst-20773	35	13	upregulated	upregulate	VERB
ajst-20773	35	14	;	;	PUNCT
ajst-20773	35	15	these	these	DET
ajst-20773	35	16	rna	rna	NOUN
ajst-20773	35	17	molecules	molecule	NOUN
ajst-20773	35	18	can	can	AUX
ajst-20773	35	19	act	act	VERB
ajst-20773	35	20	both	both	PRON
ajst-20773	35	21	as	as	ADP
ajst-20773	35	22	oncogenes	oncogene	NOUN
ajst-20773	35	23	and	and	CCONJ
ajst-20773	35	24	tumor	tumor	NOUN
ajst-20773	35	25	suppressor	suppressor	NOUN
ajst-20773	35	26	genes	gene	NOUN
ajst-20773	35	27	,	,	PUNCT
ajst-20773	35	28	influencing	influence	VERB
ajst-20773	35	29	the	the	DET
ajst-20773	35	30	onset	onset	NOUN
ajst-20773	35	31	,	,	PUNCT
ajst-20773	35	32	development	development	NOUN
ajst-20773	35	33	,	,	PUNCT
ajst-20773	35	34	and	and	CCONJ
ajst-20773	35	35	prognosis	prognosis	NOUN
ajst-20773	35	36	of	of	ADP
ajst-20773	35	37	the	the	DET
ajst-20773	35	38	tumor	tumor	NOUN
ajst-20773	35	39	(	(	PUNCT
ajst-20773	35	40	jin	jin	NOUN
ajst-20773	35	41	et	et	PROPN
ajst-20773	35	42	al	al	PROPN
ajst-20773	35	43	.	.	PROPN
ajst-20773	35	44	,	,	PUNCT
ajst-20773	35	45	2020	2020	NUM
ajst-20773	35	46	)	)	PUNCT
ajst-20773	35	47	.	.	PUNCT
ajst-20773	36	1	in	in	ADP
ajst-20773	36	2	-	-	PUNCT
ajst-20773	36	3	depth	depth	NOUN
ajst-20773	36	4	research	research	NOUN
ajst-20773	36	5	on	on	ADP
ajst-20773	36	6	lncrnas	lncrna	NOUN
ajst-20773	36	7	not	not	PART
ajst-20773	36	8	only	only	ADV
ajst-20773	36	9	helps	help	VERB
ajst-20773	36	10	us	we	PRON
ajst-20773	36	11	better	well	ADV
ajst-20773	36	12	understand	understand	VERB
ajst-20773	36	13	the	the	DET
ajst-20773	36	14	pathogenesis	pathogenesis	NOUN
ajst-20773	36	15	and	and	CCONJ
ajst-20773	36	16	progression	progression	NOUN
ajst-20773	36	17	of	of	ADP
ajst-20773	36	18	lung	lung	NOUN
ajst-20773	36	19	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	36	20	but	but	CCONJ
ajst-20773	36	21	also	also	ADV
ajst-20773	36	22	provides	provide	VERB
ajst-20773	36	23	vital	vital	ADJ
ajst-20773	36	24	information	information	NOUN
ajst-20773	36	25	for	for	ADP
ajst-20773	36	26	13	13	NUM
ajst-20773	36	27	developing	develop	VERB
ajst-20773	36	28	new	new	ADJ
ajst-20773	36	29	treatment	treatment	NOUN
ajst-20773	36	30	methods	method	NOUN
ajst-20773	36	31	and	and	CCONJ
ajst-20773	36	32	mechanisms	mechanism	NOUN
ajst-20773	36	33	.	.	PUNCT
ajst-20773	37	1	therefore	therefore	ADV
ajst-20773	37	2	,	,	PUNCT
ajst-20773	37	3	in	in	ADP
ajst-20773	37	4	lung	lung	NOUN
ajst-20773	37	5	adenocarcinoma	adenocarcinoma	PROPN
ajst-20773	37	6	research	research	NOUN
ajst-20773	37	7	,	,	PUNCT
ajst-20773	37	8	lncrnas	lncrnas	PROPN
ajst-20773	37	9	will	will	AUX
ajst-20773	37	10	play	play	VERB
ajst-20773	37	11	an	an	DET
ajst-20773	37	12	indispensable	indispensable	ADJ
ajst-20773	37	13	role	role	NOUN
ajst-20773	37	14	and	and	CCONJ
ajst-20773	37	15	have	have	VERB
ajst-20773	37	16	great	great	ADJ
ajst-20773	37	17	potential	potential	NOUN
ajst-20773	37	18	to	to	PART
ajst-20773	37	19	serve	serve	VERB
ajst-20773	37	20	as	as	ADP
ajst-20773	37	21	an	an	DET
ajst-20773	37	22	important	important	ADJ
ajst-20773	37	23	bridge	bridge	NOUN
ajst-20773	37	24	connecting	connect	VERB
ajst-20773	37	25	the	the	DET
ajst-20773	37	26	understanding	understanding	NOUN
ajst-20773	37	27	of	of	ADP
ajst-20773	37	28	disease	disease	NOUN
ajst-20773	37	29	mechanisms	mechanism	NOUN
ajst-20773	37	30	and	and	CCONJ
ajst-20773	37	31	the	the	DET
ajst-20773	37	32	discovery	discovery	NOUN
ajst-20773	37	33	of	of	ADP
ajst-20773	37	34	treatment	treatment	NOUN
ajst-20773	37	35	methods	method	NOUN
ajst-20773	37	36	.	.	PUNCT
ajst-20773	38	1	cellular	cellular	ADJ
ajst-20773	38	2	senescence	senescence	NOUN
ajst-20773	38	3	is	be	AUX
ajst-20773	38	4	a	a	DET
ajst-20773	38	5	stable	stable	ADJ
ajst-20773	38	6	cell	cell	NOUN
ajst-20773	38	7	cycle	cycle	NOUN
ajst-20773	38	8	arrest	arrest	NOUN
ajst-20773	38	9	program	program	NOUN
ajst-20773	38	10	,	,	PUNCT
ajst-20773	38	11	responding	respond	VERB
ajst-20773	38	12	to	to	ADP
ajst-20773	38	13	various	various	ADJ
ajst-20773	38	14	internal	internal	ADJ
ajst-20773	38	15	and	and	CCONJ
ajst-20773	38	16	external	external	ADJ
ajst-20773	38	17	stimuli	stimulus	NOUN
ajst-20773	38	18	to	to	PART
ajst-20773	38	19	eliminate	eliminate	VERB
ajst-20773	38	20	senescent	senescent	ADJ
ajst-20773	38	21	cells	cell	NOUN
ajst-20773	38	22	and	and	CCONJ
ajst-20773	38	23	maintain	maintain	VERB
ajst-20773	38	24	bodily	bodily	ADJ
ajst-20773	38	25	homeostasis	homeostasis	NOUN
ajst-20773	38	26	.	.	PUNCT
ajst-20773	39	1	cellular	cellular	ADJ
ajst-20773	39	2	senescence	senescence	NOUN
ajst-20773	39	3	is	be	AUX
ajst-20773	39	4	primarily	primarily	ADV
ajst-20773	39	5	caused	cause	VERB
ajst-20773	39	6	by	by	ADP
ajst-20773	39	7	the	the	DET
ajst-20773	39	8	gradual	gradual	ADJ
ajst-20773	39	9	shortening	shortening	NOUN
ajst-20773	39	10	of	of	ADP
ajst-20773	39	11	telomeres	telomere	NOUN
ajst-20773	39	12	,	,	PUNCT
ajst-20773	39	13	changes	change	NOUN
ajst-20773	39	14	in	in	ADP
ajst-20773	39	15	telomere	telomere	NOUN
ajst-20773	39	16	structure	structure	NOUN
ajst-20773	39	17	,	,	PUNCT
ajst-20773	39	18	mitosis	mitosis	NOUN
ajst-20773	39	19	,	,	PUNCT
ajst-20773	39	20	oncogene	oncogene	NOUN
ajst-20773	39	21	activation	activation	NOUN
ajst-20773	39	22	,	,	PUNCT
ajst-20773	39	23	ionizing	ionize	VERB
ajst-20773	39	24	radiation	radiation	NOUN
ajst-20773	39	25	,	,	PUNCT
ajst-20773	39	26	oxidation	oxidation	NOUN
ajst-20773	39	27	,	,	PUNCT
ajst-20773	39	28	genotoxic	genotoxic	ADJ
ajst-20773	39	29	stress	stress	NOUN
ajst-20773	39	30	,	,	PUNCT
ajst-20773	39	31	epigenetic	epigenetic	ADJ
ajst-20773	39	32	alterations	alteration	NOUN
ajst-20773	39	33	,	,	PUNCT
ajst-20773	39	34	chromatin	chromatin	NOUN
ajst-20773	39	35	disarray	disarray	NOUN
ajst-20773	39	36	,	,	PUNCT
ajst-20773	39	37	protein	protein	NOUN
ajst-20773	39	38	homeostasis	homeostasis	NOUN
ajst-20773	39	39	disorders	disorder	NOUN
ajst-20773	39	40	,	,	PUNCT
ajst-20773	39	41	mitochondrial	mitochondrial	ADJ
ajst-20773	39	42	dysfunction	dysfunction	NOUN
ajst-20773	39	43	,	,	PUNCT
ajst-20773	39	44	inflammation	inflammation	NOUN
ajst-20773	39	45	,	,	PUNCT
ajst-20773	39	46	tissue	tissue	NOUN
ajst-20773	39	47	damage	damage	NOUN
ajst-20773	39	48	signaling	signal	VERB
ajst-20773	39	49	,	,	PUNCT
ajst-20773	39	50	and	and	CCONJ
ajst-20773	39	51	effects	effect	NOUN
ajst-20773	39	52	of	of	ADP
ajst-20773	39	53	radiotherapy	radiotherapy	NOUN
ajst-20773	39	54	or	or	CCONJ
ajst-20773	39	55	chemotherapy	chemotherapy	NOUN
ajst-20773	39	56	(	(	PUNCT
ajst-20773	39	57	lecot	lecot	NOUN
ajst-20773	39	58	et	et	PROPN
ajst-20773	39	59	al	al	PROPN
ajst-20773	39	60	.	.	PROPN
ajst-20773	39	61	,	,	PUNCT
ajst-20773	39	62	2016	2016	NUM
ajst-20773	39	63	;	;	PUNCT
ajst-20773	39	64	schosserer	schosserer	NOUN
ajst-20773	39	65	et	et	PROPN
ajst-20773	39	66	al	al	PROPN
ajst-20773	39	67	.	.	PROPN
ajst-20773	39	68	,	,	PUNCT
ajst-20773	39	69	2017	2017	NUM
ajst-20773	39	70	)	)	PUNCT
ajst-20773	39	71	.	.	PUNCT
ajst-20773	40	1	both	both	DET
ajst-20773	40	2	cancer	cancer	NOUN
ajst-20773	40	3	and	and	CCONJ
ajst-20773	40	4	aging	aging	NOUN
ajst-20773	40	5	are	be	AUX
ajst-20773	40	6	driven	drive	VERB
ajst-20773	40	7	by	by	ADP
ajst-20773	40	8	the	the	DET
ajst-20773	40	9	accumulation	accumulation	NOUN
ajst-20773	40	10	of	of	ADP
ajst-20773	40	11	cellular	cellular	ADJ
ajst-20773	40	12	damage	damage	NOUN
ajst-20773	40	13	.	.	PUNCT
ajst-20773	41	1	previous	previous	ADJ
ajst-20773	41	2	studies	study	NOUN
ajst-20773	41	3	have	have	AUX
ajst-20773	41	4	shown	show	VERB
ajst-20773	41	5	that	that	SCONJ
ajst-20773	41	6	aging	aging	NOUN
ajst-20773	41	7	has	have	VERB
ajst-20773	41	8	both	both	DET
ajst-20773	41	9	advantages	advantage	NOUN
ajst-20773	41	10	and	and	CCONJ
ajst-20773	41	11	disadvantages	disadvantage	NOUN
ajst-20773	41	12	in	in	ADP
ajst-20773	41	13	the	the	DET
ajst-20773	41	14	process	process	NOUN
ajst-20773	41	15	of	of	ADP
ajst-20773	41	16	tumor	tumor	NOUN
ajst-20773	41	17	development	development	NOUN
ajst-20773	41	18	and	and	CCONJ
ajst-20773	41	19	is	be	AUX
ajst-20773	41	20	considered	consider	VERB
ajst-20773	41	21	an	an	DET
ajst-20773	41	22	example	example	NOUN
ajst-20773	41	23	of	of	ADP
ajst-20773	41	24	the	the	DET
ajst-20773	41	25	dichotomy	dichotomy	NOUN
ajst-20773	41	26	of	of	ADP
ajst-20773	41	27	multiple	multiple	ADJ
ajst-20773	41	28	effects	effect	NOUN
ajst-20773	41	29	in	in	ADP
ajst-20773	41	30	the	the	DET
ajst-20773	41	31	evolutionary	evolutionary	ADJ
ajst-20773	41	32	process	process	NOUN
ajst-20773	41	33	(	(	PUNCT
ajst-20773	41	34	campisi	campisi	VERB
ajst-20773	41	35	,	,	PUNCT
ajst-20773	41	36	2013	2013	NUM
ajst-20773	41	37	)	)	PUNCT
ajst-20773	41	38	.	.	PUNCT
ajst-20773	42	1	conversely	conversely	ADV
ajst-20773	42	2	,	,	PUNCT
ajst-20773	42	3	aging	age	VERB
ajst-20773	42	4	drives	drive	NOUN
ajst-20773	42	5	senescent	senescent	ADJ
ajst-20773	42	6	cells	cell	NOUN
ajst-20773	42	7	into	into	ADP
ajst-20773	42	8	a	a	DET
ajst-20773	42	9	permanent	permanent	ADJ
ajst-20773	42	10	cell	cell	NOUN
ajst-20773	42	11	cycle	cycle	NOUN
ajst-20773	42	12	arrest	arrest	NOUN
ajst-20773	42	13	to	to	PART
ajst-20773	42	14	maintain	maintain	VERB
ajst-20773	42	15	tissue	tissue	NOUN
ajst-20773	42	16	homeostasis	homeostasis	NOUN
ajst-20773	42	17	and	and	CCONJ
ajst-20773	42	18	prevent	prevent	VERB
ajst-20773	42	19	tumor	tumor	NOUN
ajst-20773	42	20	formation	formation	NOUN
ajst-20773	42	21	.	.	PUNCT
ajst-20773	43	1	however	however	ADV
ajst-20773	43	2	,	,	PUNCT
ajst-20773	43	3	when	when	SCONJ
ajst-20773	43	4	senescent	senescent	ADJ
ajst-20773	43	5	cells	cell	NOUN
ajst-20773	43	6	are	be	AUX
ajst-20773	43	7	not	not	PART
ajst-20773	43	8	cleared	clear	VERB
ajst-20773	43	9	by	by	ADP
ajst-20773	43	10	the	the	DET
ajst-20773	43	11	immune	immune	ADJ
ajst-20773	43	12	system	system	NOUN
ajst-20773	43	13	and	and	CCONJ
ajst-20773	43	14	accumulate	accumulate	VERB
ajst-20773	43	15	,	,	PUNCT
ajst-20773	43	16	cellular	cellular	ADJ
ajst-20773	43	17	senescence	senescence	NOUN
ajst-20773	43	18	can	can	AUX
ajst-20773	43	19	produce	produce	VERB
ajst-20773	43	20	harmful	harmful	ADJ
ajst-20773	43	21	outcomes	outcome	NOUN
ajst-20773	43	22	,	,	PUNCT
ajst-20773	43	23	promoting	promote	VERB
ajst-20773	43	24	tumor	tumor	NOUN
ajst-20773	43	25	occurrence	occurrence	NOUN
ajst-20773	43	26	,	,	PUNCT
ajst-20773	43	27	development	development	NOUN
ajst-20773	43	28	,	,	PUNCT
ajst-20773	43	29	invasion	invasion	NOUN
ajst-20773	43	30	,	,	PUNCT
ajst-20773	43	31	and	and	CCONJ
ajst-20773	43	32	metastasis	metastasis	NOUN
ajst-20773	43	33	through	through	ADP
ajst-20773	43	34	various	various	ADJ
ajst-20773	43	35	pathways	pathway	NOUN
ajst-20773	43	36	.	.	PUNCT
ajst-20773	44	1	the	the	DET
ajst-20773	44	2	phenotypic	phenotypic	ADJ
ajst-20773	44	3	changes	change	NOUN
ajst-20773	44	4	during	during	ADP
ajst-20773	44	5	cellular	cellular	ADJ
ajst-20773	44	6	senescence	senescence	NOUN
ajst-20773	44	7	are	be	AUX
ajst-20773	44	8	controlled	control	VERB
ajst-20773	44	9	by	by	ADP
ajst-20773	44	10	the	the	DET
ajst-20773	44	11	changes	change	NOUN
ajst-20773	44	12	in	in	ADP
ajst-20773	44	13	specific	specific	ADJ
ajst-20773	44	14	proteins	protein	NOUN
ajst-20773	44	15	expressed	express	VERB
ajst-20773	44	16	.	.	PUNCT
ajst-20773	45	1	these	these	DET
ajst-20773	45	2	processes	process	NOUN
ajst-20773	45	3	are	be	AUX
ajst-20773	45	4	mainly	mainly	ADV
ajst-20773	45	5	regulated	regulate	VERB
ajst-20773	45	6	by	by	ADP
ajst-20773	45	7	proteins	protein	NOUN
ajst-20773	45	8	that	that	PRON
ajst-20773	45	9	link	link	VERB
ajst-20773	45	10	dna	dna	NOUN
ajst-20773	45	11	and	and	CCONJ
ajst-20773	45	12	rna	rna	PROPN
ajst-20773	45	13	and	and	CCONJ
ajst-20773	45	14	various	various	ADJ
ajst-20773	45	15	non	non	ADJ
ajst-20773	45	16	-	-	ADJ
ajst-20773	45	17	coding	coding	ADJ
ajst-20773	45	18	rnas	rna	NOUN
ajst-20773	45	19	,	,	PUNCT
ajst-20773	45	20	including	include	VERB
ajst-20773	45	21	long	long	ADJ
ajst-20773	45	22	non	non	ADJ
ajst-20773	45	23	-	-	ADJ
ajst-20773	45	24	coding	coding	ADJ
ajst-20773	45	25	rnas	rna	NOUN
ajst-20773	45	26	(	(	PUNCT
ajst-20773	45	27	lncrnas	lncrnas	PROPN
ajst-20773	45	28	)	)	PUNCT
ajst-20773	45	29	.	.	PUNCT
ajst-20773	46	1	lncrna	lncrna	NOUN
ajst-20773	46	2	xist	xist	NOUN
ajst-20773	46	3	is	be	AUX
ajst-20773	46	4	downregulated	downregulate	VERB
ajst-20773	46	5	in	in	ADP
ajst-20773	46	6	aging	age	VERB
ajst-20773	46	7	cells	cell	NOUN
ajst-20773	46	8	and	and	CCONJ
ajst-20773	46	9	inhibits	inhibit	VERB
ajst-20773	46	10	the	the	DET
ajst-20773	46	11	proliferation	proliferation	NOUN
ajst-20773	46	12	and	and	CCONJ
ajst-20773	46	13	promotes	promote	VERB
ajst-20773	46	14	apoptosis	apoptosis	NOUN
ajst-20773	46	15	of	of	ADP
ajst-20773	46	16	nsclc	nsclc	NOUN
ajst-20773	46	17	cells	cell	NOUN
ajst-20773	46	18	by	by	ADP
ajst-20773	46	19	triggering	trigger	VERB
ajst-20773	46	20	cell	cell	NOUN
ajst-20773	46	21	necrosis	necrosis	NOUN
ajst-20773	46	22	mediated	mediate	VERB
ajst-20773	46	23	by	by	ADP
ajst-20773	46	24	the	the	DET
ajst-20773	46	25	mir-335	mir-335	PROPN
ajst-20773	46	26	/	/	SYM
ajst-20773	46	27	sod2	sod2	PROPN
ajst-20773	46	28	/	/	SYM
ajst-20773	46	29	ros	ros	PROPN
ajst-20773	46	30	signaling	signal	VERB
ajst-20773	46	31	pathway	pathway	NOUN
ajst-20773	46	32	,	,	PUNCT
ajst-20773	46	33	thereby	thereby	ADV
ajst-20773	46	34	inhibiting	inhibit	VERB
ajst-20773	46	35	the	the	DET
ajst-20773	46	36	progression	progression	NOUN
ajst-20773	46	37	of	of	ADP
ajst-20773	46	38	nsclc	nsclc	NOUN
ajst-20773	46	39	(	(	PUNCT
ajst-20773	46	40	xu	xu	INTJ
ajst-20773	46	41	et	et	PROPN
ajst-20773	46	42	al	al	PROPN
ajst-20773	46	43	.	.	PROPN
ajst-20773	46	44	,	,	PUNCT
ajst-20773	46	45	2020	2020	NUM
ajst-20773	46	46	)	)	PUNCT
ajst-20773	46	47	.	.	PUNCT
ajst-20773	47	1	lncrna	lncrna	NOUN
ajst-20773	47	2	h19	h19	PROPN
ajst-20773	47	3	regulates	regulate	VERB
ajst-20773	47	4	the	the	DET
ajst-20773	47	5	imprinting	imprinting	NOUN
ajst-20773	47	6	of	of	ADP
ajst-20773	47	7	the	the	DET
ajst-20773	47	8	gene	gene	NOUN
ajst-20773	47	9	cluster	cluster	NOUN
ajst-20773	47	10	containing	contain	VERB
ajst-20773	47	11	h19	h19	PROPN
ajst-20773	47	12	and	and	CCONJ
ajst-20773	47	13	insulin	insulin	NOUN
ajst-20773	47	14	-	-	PUNCT
ajst-20773	47	15	like	like	ADJ
ajst-20773	47	16	growth	growth	NOUN
ajst-20773	47	17	factor	factor	NOUN
ajst-20773	47	18	2	2	NUM
ajst-20773	47	19	(	(	PUNCT
ajst-20773	47	20	igf2	igf2	PROPN
ajst-20773	47	21	)	)	PUNCT
ajst-20773	47	22	.	.	PUNCT
ajst-20773	48	1	both	both	DET
ajst-20773	48	2	igf2	igf2	PROPN
ajst-20773	48	3	and	and	CCONJ
ajst-20773	48	4	h19	h19	PROPN
ajst-20773	48	5	are	be	AUX
ajst-20773	48	6	associated	associate	VERB
ajst-20773	48	7	with	with	ADP
ajst-20773	48	8	growth	growth	NOUN
ajst-20773	48	9	,	,	PUNCT
ajst-20773	48	10	proliferation	proliferation	NOUN
ajst-20773	48	11	,	,	PUNCT
ajst-20773	48	12	cell	cell	NOUN
ajst-20773	48	13	cycle	cycle	NOUN
ajst-20773	48	14	,	,	PUNCT
ajst-20773	48	15	apoptosis	apoptosis	NOUN
ajst-20773	48	16	,	,	PUNCT
ajst-20773	48	17	and	and	CCONJ
ajst-20773	48	18	aging	age	VERB
ajst-20773	48	19	.	.	PUNCT
ajst-20773	49	1	lncrna	lncrna	NOUN
ajst-20773	49	2	h19	h19	PROPN
ajst-20773	49	3	is	be	AUX
ajst-20773	49	4	also	also	ADV
ajst-20773	49	5	highly	highly	ADV
ajst-20773	49	6	expressed	express	VERB
ajst-20773	49	7	in	in	ADP
ajst-20773	49	8	cancer	cancer	NOUN
ajst-20773	49	9	,	,	PUNCT
ajst-20773	49	10	promoting	promote	VERB
ajst-20773	49	11	epithelialmesenchymal	epithelialmesenchymal	ADJ
ajst-20773	49	12	transition	transition	NOUN
ajst-20773	49	13	and	and	CCONJ
ajst-20773	49	14	enhancing	enhance	VERB
ajst-20773	49	15	cancer	cancer	NOUN
ajst-20773	49	16	cell	cell	NOUN
ajst-20773	49	17	proliferation	proliferation	NOUN
ajst-20773	49	18	and	and	CCONJ
ajst-20773	49	19	metastasis	metastasis	NOUN
ajst-20773	49	20	by	by	ADP
ajst-20773	49	21	inhibiting	inhibit	VERB
ajst-20773	49	22	the	the	DET
ajst-20773	49	23	function	function	NOUN
ajst-20773	49	24	of	of	ADP
ajst-20773	49	25	mir200a	mir200a	NOUN
ajst-20773	49	26	and	and	CCONJ
ajst-20773	49	27	upregulating	upregulate	VERB
ajst-20773	49	28	the	the	DET
ajst-20773	49	29	expression	expression	NOUN
ajst-20773	49	30	of	of	ADP
ajst-20773	49	31	zeb1	zeb1	PROPN
ajst-20773	49	32	and	and	CCONJ
ajst-20773	49	33	zeb2	zeb2	PROPN
ajst-20773	49	34	(	(	PUNCT
ajst-20773	49	35	shi	shi	PROPN
ajst-20773	49	36	et	et	PROPN
ajst-20773	49	37	al	al	PROPN
ajst-20773	49	38	.	.	PROPN
ajst-20773	49	39	,	,	PUNCT
ajst-20773	49	40	2020	2020	NUM
ajst-20773	49	41	)	)	PUNCT
ajst-20773	49	42	.	.	PUNCT
ajst-20773	50	1	in	in	ADP
ajst-20773	50	2	summary	summary	NOUN
ajst-20773	50	3	,	,	PUNCT
ajst-20773	50	4	lncrnas	lncrnas	PROPN
ajst-20773	50	5	can	can	AUX
ajst-20773	50	6	characterize	characterize	VERB
ajst-20773	50	7	cellular	cellular	ADJ
ajst-20773	50	8	senescence	senescence	NOUN
ajst-20773	50	9	and	and	CCONJ
ajst-20773	50	10	serve	serve	VERB
ajst-20773	50	11	as	as	ADP
ajst-20773	50	12	an	an	DET
ajst-20773	50	13	important	important	ADJ
ajst-20773	50	14	tool	tool	NOUN
ajst-20773	50	15	for	for	ADP
ajst-20773	50	16	determining	determine	VERB
ajst-20773	50	17	the	the	DET
ajst-20773	50	18	prognosis	prognosis	NOUN
ajst-20773	50	19	of	of	ADP
ajst-20773	50	20	lung	lung	NOUN
ajst-20773	50	21	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	50	22	patients	patient	NOUN
ajst-20773	50	23	.	.	PUNCT
ajst-20773	51	1	2	2	X
ajst-20773	51	2	.	.	X
ajst-20773	51	3	materials	material	NOUN
ajst-20773	51	4	and	and	CCONJ
ajst-20773	51	5	methods	method	NOUN
ajst-20773	51	6	2.1	2.1	NUM
ajst-20773	51	7	.	.	PUNCT
ajst-20773	52	1	dataset	dataset	NOUN
ajst-20773	52	2	and	and	CCONJ
ajst-20773	52	3	sample	sample	NOUN
ajst-20773	52	4	extraction	extraction	NOUN
ajst-20773	52	5	the	the	DET
ajst-20773	52	6	rna	rna	NOUN
ajst-20773	52	7	sequencing	sequencing	NOUN
ajst-20773	52	8	data	datum	NOUN
ajst-20773	52	9	,	,	PUNCT
ajst-20773	52	10	clinical	clinical	ADJ
ajst-20773	52	11	details	detail	NOUN
ajst-20773	52	12	,	,	PUNCT
ajst-20773	52	13	and	and	CCONJ
ajst-20773	52	14	mutations	mutation	NOUN
ajst-20773	52	15	for	for	ADP
ajst-20773	52	16	lung	lung	NOUN
ajst-20773	52	17	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	52	18	(	(	PUNCT
ajst-20773	52	19	luad	luad	NOUN
ajst-20773	52	20	)	)	PUNCT
ajst-20773	52	21	were	be	AUX
ajst-20773	52	22	obtained	obtain	VERB
ajst-20773	52	23	from	from	ADP
ajst-20773	52	24	the	the	DET
ajst-20773	52	25	cancer	cancer	NOUN
ajst-20773	52	26	genome	genome	NOUN
ajst-20773	52	27	atlas	atlas	PROPN
ajst-20773	52	28	lung	lung	PROPN
ajst-20773	52	29	adenocarcinoma	adenocarcinoma	PROPN
ajst-20773	52	30	(	(	PUNCT
ajst-20773	52	31	tcga	tcga	NOUN
ajst-20773	52	32	-	-	PUNCT
ajst-20773	52	33	luad	luad	NOUN
ajst-20773	52	34	)	)	PUNCT
ajst-20773	52	35	database	database	NOUN
ajst-20773	52	36	(	(	PUNCT
ajst-20773	52	37	https://portal.gdc.cancer.gov/	https://portal.gdc.cancer.gov/	NOUN
ajst-20773	52	38	)	)	PUNCT
ajst-20773	52	39	.	.	PUNCT
ajst-20773	53	1	initially	initially	ADV
ajst-20773	53	2	,	,	PUNCT
ajst-20773	53	3	data	datum	NOUN
ajst-20773	53	4	for	for	ADP
ajst-20773	53	5	539	539	NUM
ajst-20773	53	6	luad	luad	ADJ
ajst-20773	53	7	patients	patient	NOUN
ajst-20773	53	8	were	be	AUX
ajst-20773	53	9	collected	collect	VERB
ajst-20773	53	10	.	.	PUNCT
ajst-20773	54	1	patients	patient	NOUN
ajst-20773	54	2	who	who	PRON
ajst-20773	54	3	had	have	VERB
ajst-20773	54	4	incomplete	incomplete	ADJ
ajst-20773	54	5	follow	follow	VERB
ajst-20773	54	6	-	-	PUNCT
ajst-20773	54	7	up	up	ADP
ajst-20773	54	8	information	information	NOUN
ajst-20773	54	9	,	,	PUNCT
ajst-20773	54	10	a	a	DET
ajst-20773	54	11	survival	survival	NOUN
ajst-20773	54	12	time	time	NOUN
ajst-20773	54	13	of	of	ADP
ajst-20773	54	14	less	less	ADJ
ajst-20773	54	15	than	than	ADP
ajst-20773	54	16	30	30	NUM
ajst-20773	54	17	days	day	NOUN
ajst-20773	54	18	,	,	PUNCT
ajst-20773	54	19	or	or	CCONJ
ajst-20773	54	20	were	be	AUX
ajst-20773	54	21	missing	miss	VERB
ajst-20773	54	22	complete	complete	ADJ
ajst-20773	54	23	clinicopathological	clinicopathological	ADJ
ajst-20773	54	24	data	datum	NOUN
ajst-20773	54	25	were	be	AUX
ajst-20773	54	26	excluded	exclude	VERB
ajst-20773	54	27	from	from	ADP
ajst-20773	54	28	further	further	ADJ
ajst-20773	54	29	analysis	analysis	NOUN
ajst-20773	54	30	,	,	PUNCT
ajst-20773	54	31	resulting	result	VERB
ajst-20773	54	32	in	in	ADP
ajst-20773	54	33	a	a	DET
ajst-20773	54	34	final	final	ADJ
ajst-20773	54	35	cohort	cohort	NOUN
ajst-20773	54	36	of	of	ADP
ajst-20773	54	37	448	448	NUM
ajst-20773	54	38	patients	patient	NOUN
ajst-20773	54	39	.	.	PUNCT
ajst-20773	55	1	additionally	additionally	ADV
ajst-20773	55	2	,	,	PUNCT
ajst-20773	55	3	279	279	NUM
ajst-20773	55	4	senescence	senescence	NOUN
ajst-20773	55	5	-	-	PUNCT
ajst-20773	55	6	related	relate	VERB
ajst-20773	55	7	genes	gene	NOUN
ajst-20773	55	8	identified	identify	VERB
ajst-20773	55	9	through	through	ADP
ajst-20773	55	10	gene	gene	NOUN
ajst-20773	55	11	manipulation	manipulation	NOUN
ajst-20773	55	12	experiments	experiment	NOUN
ajst-20773	55	13	were	be	AUX
ajst-20773	55	14	downloaded	download	VERB
ajst-20773	55	15	from	from	ADP
ajst-20773	55	16	the	the	DET
ajst-20773	55	17	cellage	cellage	NOUN
ajst-20773	55	18	online	online	NOUN
ajst-20773	55	19	database	database	NOUN
ajst-20773	55	20	(	(	PUNCT
ajst-20773	55	21	http://genomics.senescence.info/cells	http://genomics.senescence.info/cell	NOUN
ajst-20773	55	22	)	)	PUNCT
ajst-20773	55	23	(	(	PUNCT
ajst-20773	55	24	avelar	avelar	PROPN
ajst-20773	55	25	et	et	PROPN
ajst-20773	55	26	al	al	PROPN
ajst-20773	55	27	.	.	PROPN
ajst-20773	55	28	,	,	PUNCT
ajst-20773	55	29	2020	2020	NUM
ajst-20773	55	30	)	)	PUNCT
ajst-20773	55	31	.	.	PUNCT
ajst-20773	56	1	2.2	2.2	NUM
ajst-20773	56	2	.	.	PUNCT
ajst-20773	56	3	differentially	differentially	ADV
ajst-20773	56	4	expressed	express	VERB
ajst-20773	56	5	genes	gene	NOUN
ajst-20773	56	6	(	(	PUNCT
ajst-20773	56	7	degs	deg	NOUN
ajst-20773	56	8	)	)	PUNCT
ajst-20773	56	9	of	of	ADP
ajst-20773	56	10	cellular	cellular	ADJ
ajst-20773	56	11	senescence	senescence	NOUN
ajst-20773	56	12	in	in	ADP
ajst-20773	56	13	luad	luad	NOUN
ajst-20773	56	14	and	and	CCONJ
ajst-20773	56	15	normal	normal	ADJ
ajst-20773	56	16	tissue	tissue	NOUN
ajst-20773	56	17	a	a	DET
ajst-20773	56	18	log2	log2	PROPN
ajst-20773	56	19	fold	fold	NOUN
ajst-20773	56	20	change	change	VERB
ajst-20773	56	21	absolute	absolute	ADJ
ajst-20773	56	22	value	value	NOUN
ajst-20773	56	23	greater	great	ADJ
ajst-20773	56	24	than	than	ADP
ajst-20773	56	25	1	1	NUM
ajst-20773	56	26	and	and	CCONJ
ajst-20773	56	27	a	a	DET
ajst-20773	56	28	false	false	ADJ
ajst-20773	56	29	detection	detection	NOUN
ajst-20773	56	30	rate	rate	NOUN
ajst-20773	56	31	(	(	PUNCT
ajst-20773	56	32	fdr	fdr	PROPN
ajst-20773	56	33	)	)	PUNCT
ajst-20773	56	34	of	of	ADP
ajst-20773	56	35	less	less	ADJ
ajst-20773	56	36	than	than	ADP
ajst-20773	56	37	0.05	0.05	NUM
ajst-20773	56	38	were	be	AUX
ajst-20773	56	39	criteria	criterion	NOUN
ajst-20773	56	40	set	set	VERB
ajst-20773	56	41	to	to	PART
ajst-20773	56	42	identify	identify	VERB
ajst-20773	56	43	differentially	differentially	ADV
ajst-20773	56	44	expressed	express	VERB
ajst-20773	56	45	genes	gene	NOUN
ajst-20773	56	46	(	(	PUNCT
ajst-20773	56	47	degs	deg	NOUN
ajst-20773	56	48	)	)	PUNCT
ajst-20773	56	49	between	between	ADP
ajst-20773	56	50	539	539	NUM
ajst-20773	56	51	tumor	tumor	NOUN
ajst-20773	56	52	samples	sample	NOUN
ajst-20773	56	53	and	and	CCONJ
ajst-20773	56	54	59	59	NUM
ajst-20773	56	55	normal	normal	ADJ
ajst-20773	56	56	samples	sample	NOUN
ajst-20773	56	57	.	.	PUNCT
ajst-20773	57	1	the	the	DET
ajst-20773	57	2	degs	deg	NOUN
ajst-20773	57	3	were	be	AUX
ajst-20773	57	4	visualized	visualize	VERB
ajst-20773	57	5	using	use	VERB
ajst-20773	57	6	the	the	DET
ajst-20773	57	7	r	r	NOUN
ajst-20773	57	8	package	package	NOUN
ajst-20773	57	9	limma	limma	NOUN
ajst-20773	57	10	.	.	PUNCT
ajst-20773	58	1	enrichment	enrichment	NOUN
ajst-20773	58	2	analysis	analysis	NOUN
ajst-20773	58	3	of	of	ADP
ajst-20773	58	4	these	these	DET
ajst-20773	58	5	degs	deg	NOUN
ajst-20773	58	6	was	be	AUX
ajst-20773	58	7	conducted	conduct	VERB
ajst-20773	58	8	utilizing	utilize	VERB
ajst-20773	58	9	the	the	DET
ajst-20773	58	10	kyoto	kyoto	PROPN
ajst-20773	58	11	encyclopedia	encyclopedia	NOUN
ajst-20773	58	12	of	of	ADP
ajst-20773	58	13	gene	gene	NOUN
ajst-20773	58	14	and	and	CCONJ
ajst-20773	58	15	genome	genome	NOUN
ajst-20773	58	16	(	(	PUNCT
ajst-20773	58	17	kegg	kegg	NOUN
ajst-20773	58	18	)	)	PUNCT
ajst-20773	58	19	and	and	CCONJ
ajst-20773	58	20	gene	gene	NOUN
ajst-20773	58	21	ontology	ontology	NOUN
ajst-20773	58	22	(	(	PUNCT
ajst-20773	58	23	go	go	VERB
ajst-20773	58	24	)	)	PUNCT
ajst-20773	58	25	.	.	PUNCT
ajst-20773	59	1	2.3	2.3	NUM
ajst-20773	59	2	.	.	PUNCT
ajst-20773	59	3	identification	identification	NOUN
ajst-20773	59	4	of	of	ADP
ajst-20773	59	5	a	a	DET
ajst-20773	59	6	lncrnas	lncrnas	PROPN
ajst-20773	59	7	senescence	senescence	NOUN
ajst-20773	59	8	related	relate	VERB
ajst-20773	59	9	signature	signature	NOUN
ajst-20773	59	10	(	(	PUNCT
ajst-20773	59	11	senlncsig	senlncsig	PROPN
ajst-20773	59	12	)	)	PUNCT
ajst-20773	59	13	associated	associate	VERB
ajst-20773	59	14	with	with	ADP
ajst-20773	59	15	luad	luad	ADJ
ajst-20773	59	16	prognosis	prognosis	NOUN
ajst-20773	59	17	a	a	DET
ajst-20773	59	18	gene	gene	NOUN
ajst-20773	59	19	expression	expression	NOUN
ajst-20773	59	20	network	network	NOUN
ajst-20773	59	21	involving	involve	VERB
ajst-20773	59	22	senescence	senescence	NOUN
ajst-20773	59	23	-	-	PUNCT
ajst-20773	59	24	related	relate	VERB
ajst-20773	59	25	lncrna	lncrna	NOUN
ajst-20773	59	26	-	-	PUNCT
ajst-20773	59	27	mrna	mrna	NOUN
ajst-20773	59	28	co	co	NOUN
ajst-20773	59	29	-	-	NOUN
ajst-20773	59	30	expression	expression	NOUN
ajst-20773	59	31	was	be	AUX
ajst-20773	59	32	established	establish	VERB
ajst-20773	59	33	using	use	VERB
ajst-20773	59	34	a	a	DET
ajst-20773	59	35	pearson	pearson	NOUN
ajst-20773	59	36	correlation	correlation	NOUN
ajst-20773	59	37	coefficient	coefficient	VERB
ajst-20773	59	38	absolute	absolute	ADJ
ajst-20773	59	39	value	value	NOUN
ajst-20773	59	40	greater	great	ADJ
ajst-20773	59	41	than	than	ADP
ajst-20773	59	42	0.3	0.3	NUM
ajst-20773	59	43	and	and	CCONJ
ajst-20773	59	44	a	a	DET
ajst-20773	59	45	p	p	NOUN
ajst-20773	59	46	-	-	PUNCT
ajst-20773	59	47	value	value	NOUN
ajst-20773	59	48	less	less	ADJ
ajst-20773	59	49	than	than	ADP
ajst-20773	59	50	0.001	0.001	NUM
ajst-20773	59	51	to	to	PART
ajst-20773	59	52	pinpoint	pinpoint	VERB
ajst-20773	59	53	senescence	senescence	NOUN
ajst-20773	59	54	-	-	PUNCT
ajst-20773	59	55	related	relate	VERB
ajst-20773	59	56	lncrnas	lncrna	NOUN
ajst-20773	59	57	.	.	PUNCT
ajst-20773	60	1	visualization	visualization	NOUN
ajst-20773	60	2	of	of	ADP
ajst-20773	60	3	the	the	DET
ajst-20773	60	4	lncrna	lncrna	NOUN
ajst-20773	60	5	-	-	PUNCT
ajst-20773	60	6	mrna	mrna	NOUN
ajst-20773	60	7	co	co	ADJ
ajst-20773	60	8	-	-	ADJ
ajst-20773	60	9	expression	expression	ADJ
ajst-20773	60	10	network	network	NOUN
ajst-20773	60	11	was	be	AUX
ajst-20773	60	12	achieved	achieve	VERB
ajst-20773	60	13	through	through	ADP
ajst-20773	60	14	a	a	DET
ajst-20773	60	15	sankey	sankey	ADJ
ajst-20773	60	16	diagram	diagram	NOUN
ajst-20773	60	17	created	create	VERB
ajst-20773	60	18	with	with	ADP
ajst-20773	60	19	the	the	DET
ajst-20773	60	20	r	r	NOUN
ajst-20773	60	21	package	package	NOUN
ajst-20773	60	22	ggalluvial	ggalluvial	ADJ
ajst-20773	60	23	and	and	CCONJ
ajst-20773	60	24	cytoscape	cytoscape	NOUN
ajst-20773	60	25	software	software	NOUN
ajst-20773	60	26	(	(	PUNCT
ajst-20773	60	27	version	version	NOUN
ajst-20773	60	28	3.7.2	3.7.2	NUM
ajst-20773	60	29	)	)	PUNCT
ajst-20773	60	30	.	.	PUNCT
ajst-20773	61	1	initially	initially	ADV
ajst-20773	61	2	,	,	PUNCT
ajst-20773	61	3	univariate	univariate	ADJ
ajst-20773	61	4	cox	cox	PROPN
ajst-20773	61	5	regression	regression	NOUN
ajst-20773	61	6	analysis	analysis	NOUN
ajst-20773	61	7	was	be	AUX
ajst-20773	61	8	utilized	utilize	VERB
ajst-20773	61	9	to	to	PART
ajst-20773	61	10	determine	determine	VERB
ajst-20773	61	11	lncrnas	lncrna	NOUN
ajst-20773	61	12	linked	link	VERB
ajst-20773	61	13	to	to	ADP
ajst-20773	61	14	luad	luad	ADJ
ajst-20773	61	15	prognosis	prognosis	NOUN
ajst-20773	61	16	.	.	PUNCT
ajst-20773	62	1	these	these	DET
ajst-20773	62	2	lncrnas	lncrna	NOUN
ajst-20773	62	3	were	be	AUX
ajst-20773	62	4	then	then	ADV
ajst-20773	62	5	used	use	VERB
ajst-20773	62	6	in	in	ADP
ajst-20773	62	7	a	a	DET
ajst-20773	62	8	multivariate	multivariate	NOUN
ajst-20773	62	9	cox	cox	PROPN
ajst-20773	62	10	regression	regression	VERB
ajst-20773	62	11	analysis	analysis	NOUN
ajst-20773	62	12	to	to	PART
ajst-20773	62	13	develop	develop	VERB
ajst-20773	62	14	a	a	DET
ajst-20773	62	15	prognostic	prognostic	ADJ
ajst-20773	62	16	model	model	NOUN
ajst-20773	62	17	for	for	ADP
ajst-20773	62	18	luad	luad	NOUN
ajst-20773	62	19	,	,	PUNCT
ajst-20773	62	20	which	which	PRON
ajst-20773	62	21	was	be	AUX
ajst-20773	62	22	named	name	VERB
ajst-20773	62	23	senlncsig	senlncsig	PROPN
ajst-20773	62	24	.	.	PUNCT
ajst-20773	63	1	the	the	DET
ajst-20773	63	2	risk	risk	NOUN
ajst-20773	63	3	score	score	NOUN
ajst-20773	63	4	for	for	ADP
ajst-20773	63	5	this	this	DET
ajst-20773	63	6	model	model	NOUN
ajst-20773	63	7	was	be	AUX
ajst-20773	63	8	calculated	calculate	VERB
ajst-20773	63	9	with	with	ADP
ajst-20773	63	10	the	the	DET
ajst-20773	63	11	formula	formula	NOUN
ajst-20773	63	12	:	:	PUNCT
ajst-20773	63	13	risk	risk	NOUN
ajst-20773	63	14	score	score	NOUN
ajst-20773	63	15	=	=	PUNCT
ajst-20773	63	16	explncrna1	explncrna1	PROPN
ajst-20773	63	17	×	×	PROPN
ajst-20773	63	18	coef	coef	PROPN
ajst-20773	63	19	lncrna1	lncrna1	PROPN
ajst-20773	64	1	+	+	CCONJ
ajst-20773	64	2	explncrna2	explncrna2	ADJ
ajst-20773	64	3	×	×	PROPN
ajst-20773	64	4	coef	coef	PROPN
ajst-20773	64	5	lncrna2	lncrna2	NOUN
ajst-20773	65	1	+	+	CCONJ
ajst-20773	65	2	...	...	PUNCT
ajst-20773	66	1	+	+	CCONJ
ajst-20773	66	2	explncrnai	explncrnai	ADJ
ajst-20773	66	3	×	×	PROPN
ajst-20773	66	4	coef	coef	PROPN
ajst-20773	66	5	lncrnai	lncrnai	PROPN
ajst-20773	66	6	,	,	PUNCT
ajst-20773	66	7	and	and	CCONJ
ajst-20773	66	8	patients	patient	NOUN
ajst-20773	66	9	were	be	AUX
ajst-20773	66	10	categorized	categorize	VERB
ajst-20773	66	11	into	into	ADP
ajst-20773	66	12	highand	highand	ADJ
ajst-20773	66	13	low	low	ADJ
ajst-20773	66	14	-	-	PUNCT
ajst-20773	66	15	risk	risk	NOUN
ajst-20773	66	16	groups	group	NOUN
ajst-20773	66	17	based	base	VERB
ajst-20773	66	18	on	on	ADP
ajst-20773	66	19	the	the	DET
ajst-20773	66	20	median	median	ADJ
ajst-20773	66	21	risk	risk	NOUN
ajst-20773	66	22	score	score	NOUN
ajst-20773	66	23	.	.	PUNCT
ajst-20773	67	1	to	to	PART
ajst-20773	67	2	verify	verify	VERB
ajst-20773	67	3	if	if	SCONJ
ajst-20773	67	4	the	the	DET
ajst-20773	67	5	senlncsig	senlncsig	PROPN
ajst-20773	67	6	risk	risk	NOUN
ajst-20773	67	7	score	score	NOUN
ajst-20773	67	8	served	serve	VERB
ajst-20773	67	9	as	as	ADP
ajst-20773	67	10	an	an	DET
ajst-20773	67	11	independent	independent	ADJ
ajst-20773	67	12	prognostic	prognostic	ADJ
ajst-20773	67	13	factor	factor	NOUN
ajst-20773	67	14	,	,	PUNCT
ajst-20773	67	15	clinicopathological	clinicopathological	ADJ
ajst-20773	67	16	factors	factor	NOUN
ajst-20773	67	17	were	be	AUX
ajst-20773	67	18	included	include	VERB
ajst-20773	67	19	in	in	ADP
ajst-20773	67	20	both	both	CCONJ
ajst-20773	67	21	univariate	univariate	ADJ
ajst-20773	67	22	and	and	CCONJ
ajst-20773	67	23	multivariate	multivariate	VERB
ajst-20773	67	24	cox	cox	PROPN
ajst-20773	67	25	regression	regression	PROPN
ajst-20773	67	26	analyses	analysis	NOUN
ajst-20773	67	27	.	.	PUNCT
ajst-20773	68	1	the	the	DET
ajst-20773	68	2	risk	risk	NOUN
ajst-20773	68	3	score	score	NOUN
ajst-20773	68	4	level	level	NOUN
ajst-20773	68	5	was	be	AUX
ajst-20773	68	6	employed	employ	VERB
ajst-20773	68	7	to	to	PART
ajst-20773	68	8	explore	explore	VERB
ajst-20773	68	9	the	the	DET
ajst-20773	68	10	distribution	distribution	NOUN
ajst-20773	68	11	of	of	ADP
ajst-20773	68	12	living	living	NOUN
ajst-20773	68	13	conditions	condition	NOUN
ajst-20773	68	14	.	.	PUNCT
ajst-20773	69	1	the	the	DET
ajst-20773	69	2	model	model	NOUN
ajst-20773	69	3	’s	’s	PART
ajst-20773	69	4	accuracy	accuracy	NOUN
ajst-20773	69	5	was	be	AUX
ajst-20773	69	6	evaluated	evaluate	VERB
ajst-20773	69	7	using	use	VERB
ajst-20773	69	8	the	the	DET
ajst-20773	69	9	receiver	receiver	NOUN
ajst-20773	69	10	operating	operate	VERB
ajst-20773	69	11	characteristic	characteristic	NOUN
ajst-20773	69	12	(	(	PUNCT
ajst-20773	69	13	roc	roc	PROPN
ajst-20773	69	14	)	)	PUNCT
ajst-20773	69	15	curve	curve	NOUN
ajst-20773	69	16	.	.	PUNCT
ajst-20773	70	1	clinicopathological	clinicopathological	ADJ
ajst-20773	70	2	variables	variable	NOUN
ajst-20773	70	3	for	for	ADP
ajst-20773	70	4	the	the	DET
ajst-20773	70	5	high	high	ADJ
ajst-20773	70	6	and	and	CCONJ
ajst-20773	70	7	low	low	ADJ
ajst-20773	70	8	-	-	PUNCT
ajst-20773	70	9	risk	risk	NOUN
ajst-20773	70	10	groups	group	NOUN
ajst-20773	70	11	were	be	AUX
ajst-20773	70	12	depicted	depict	VERB
ajst-20773	70	13	using	use	VERB
ajst-20773	70	14	the	the	DET
ajst-20773	70	15	r	r	NOUN
ajst-20773	70	16	package	package	NOUN
ajst-20773	70	17	pheatmap	pheatmap	NOUN
ajst-20773	70	18	,	,	PUNCT
ajst-20773	70	19	and	and	CCONJ
ajst-20773	70	20	the	the	DET
ajst-20773	70	21	distribution	distribution	NOUN
ajst-20773	70	22	of	of	ADP
ajst-20773	70	23	different	different	ADJ
ajst-20773	70	24	risk	risk	NOUN
ajst-20773	70	25	scores	score	NOUN
ajst-20773	70	26	among	among	ADP
ajst-20773	70	27	patients	patient	NOUN
ajst-20773	70	28	was	be	AUX
ajst-20773	70	29	analyzed	analyze	VERB
ajst-20773	70	30	using	use	VERB
ajst-20773	70	31	principal	principal	ADJ
ajst-20773	70	32	component	component	NOUN
ajst-20773	70	33	analysis	analysis	NOUN
ajst-20773	70	34	(	(	PUNCT
ajst-20773	70	35	pca	pca	NOUN
ajst-20773	70	36	)	)	PUNCT
ajst-20773	70	37	,	,	PUNCT
ajst-20773	70	38	with	with	ADP
ajst-20773	70	39	visualization	visualization	NOUN
ajst-20773	70	40	provided	provide	VERB
ajst-20773	70	41	by	by	ADP
ajst-20773	70	42	the	the	DET
ajst-20773	70	43	r	r	NOUN
ajst-20773	70	44	package	package	NOUN
ajst-20773	70	45	scatterplot3d	scatterplot3d	NOUN
ajst-20773	70	46	.	.	PUNCT
ajst-20773	71	1	2.4	2.4	NUM
ajst-20773	71	2	.	.	PUNCT
ajst-20773	71	3	construction	construction	NOUN
ajst-20773	71	4	of	of	ADP
ajst-20773	71	5	the	the	DET
ajst-20773	71	6	nomogram	nomogram	PROPN
ajst-20773	71	7	a	a	DET
ajst-20773	71	8	nomogram	nomogram	NOUN
ajst-20773	71	9	that	that	PRON
ajst-20773	71	10	integrates	integrate	VERB
ajst-20773	71	11	risk	risk	NOUN
ajst-20773	71	12	scores	score	NOUN
ajst-20773	71	13	and	and	CCONJ
ajst-20773	71	14	clinicopathological	clinicopathological	ADJ
ajst-20773	71	15	features	feature	NOUN
ajst-20773	71	16	was	be	AUX
ajst-20773	71	17	created	create	VERB
ajst-20773	71	18	using	use	VERB
ajst-20773	71	19	the	the	DET
ajst-20773	71	20	r	r	NOUN
ajst-20773	71	21	package	package	NOUN
ajst-20773	71	22	rms	rm	NOUN
ajst-20773	71	23	to	to	PART
ajst-20773	71	24	forecast	forecast	VERB
ajst-20773	71	25	1	1	NUM
ajst-20773	71	26	,	,	PUNCT
ajst-20773	71	27	3	3	NUM
ajst-20773	71	28	,	,	PUNCT
ajst-20773	71	29	and	and	CCONJ
ajst-20773	71	30	5	5	NUM
ajst-20773	71	31	-	-	PUNCT
ajst-20773	71	32	year	year	NOUN
ajst-20773	71	33	survival	survival	NOUN
ajst-20773	71	34	rates	rate	NOUN
ajst-20773	71	35	in	in	ADP
ajst-20773	71	36	luad	luad	ADJ
ajst-20773	71	37	patients	patient	NOUN
ajst-20773	71	38	.	.	PUNCT
ajst-20773	72	1	calibration	calibration	NOUN
ajst-20773	72	2	curves	curve	NOUN
ajst-20773	72	3	were	be	AUX
ajst-20773	72	4	utilized	utilize	VERB
ajst-20773	72	5	to	to	PART
ajst-20773	72	6	assess	assess	VERB
ajst-20773	72	7	the	the	DET
ajst-20773	72	8	accuracy	accuracy	NOUN
ajst-20773	72	9	of	of	ADP
ajst-20773	72	10	the	the	DET
ajst-20773	72	11	predicted	predict	VERB
ajst-20773	72	12	survival	survival	NOUN
ajst-20773	72	13	against	against	ADP
ajst-20773	72	14	the	the	DET
ajst-20773	72	15	actual	actual	ADJ
ajst-20773	72	16	survival	survival	NOUN
ajst-20773	72	17	outcomes	outcome	NOUN
ajst-20773	72	18	.	.	PUNCT
ajst-20773	73	1	2.5	2.5	NUM
ajst-20773	73	2	.	.	PUNCT
ajst-20773	74	1	gene	gene	NOUN
ajst-20773	74	2	set	set	VERB
ajst-20773	74	3	enrichment	enrichment	NOUN
ajst-20773	74	4	analysis	analysis	NOUN
ajst-20773	74	5	(	(	PUNCT
ajst-20773	74	6	gsea	gsea	NOUN
ajst-20773	74	7	)	)	PUNCT
ajst-20773	74	8	of	of	ADP
ajst-20773	74	9	the	the	DET
ajst-20773	74	10	senescence	senescence	NOUN
ajst-20773	74	11	-	-	PUNCT
ajst-20773	74	12	related	relate	VERB
ajst-20773	74	13	lncrna	lncrna	NOUN
ajst-20773	74	14	predictive	predictive	ADJ
ajst-20773	74	15	signature	signature	NOUN
ajst-20773	74	16	gene	gene	NOUN
ajst-20773	74	17	set	set	VERB
ajst-20773	74	18	enrichment	enrichment	NOUN
ajst-20773	74	19	analysis	analysis	NOUN
ajst-20773	74	20	(	(	PUNCT
ajst-20773	74	21	gsea	gsea	NOUN
ajst-20773	74	22	)	)	PUNCT
ajst-20773	74	23	was	be	AUX
ajst-20773	74	24	conducted	conduct	VERB
ajst-20773	74	25	on	on	ADP
ajst-20773	74	26	the	the	DET
ajst-20773	74	27	highand	highand	ADJ
ajst-20773	74	28	low	low	ADJ
ajst-20773	74	29	-	-	PUNCT
ajst-20773	74	30	risk	risk	NOUN
ajst-20773	74	31	groups	group	NOUN
ajst-20773	74	32	to	to	PART
ajst-20773	74	33	discover	discover	VERB
ajst-20773	74	34	distinct	distinct	ADJ
ajst-20773	74	35	functional	functional	ADJ
ajst-20773	74	36	enrichments	enrichment	NOUN
ajst-20773	74	37	between	between	ADP
ajst-20773	74	38	them	they	PRON
ajst-20773	74	39	.	.	PUNCT
ajst-20773	75	1	key	key	ADJ
ajst-20773	75	2	biological	biological	ADJ
ajst-20773	75	3	processes	process	NOUN
ajst-20773	75	4	and	and	CCONJ
ajst-20773	75	5	pathways	pathway	NOUN
ajst-20773	75	6	were	be	AUX
ajst-20773	75	7	identified	identify	VERB
ajst-20773	75	8	at	at	ADP
ajst-20773	75	9	significant	significant	ADJ
ajst-20773	75	10	levels	level	NOUN
ajst-20773	75	11	,	,	PUNCT
ajst-20773	75	12	with	with	ADP
ajst-20773	75	13	a	a	DET
ajst-20773	75	14	nominal	nominal	ADJ
ajst-20773	75	15	p	p	NOUN
ajst-20773	75	16	-	-	PUNCT
ajst-20773	75	17	value	value	NOUN
ajst-20773	75	18	(	(	PUNCT
ajst-20773	75	19	nom	nom	NOUN
ajst-20773	75	20	p	p	NOUN
ajst-20773	75	21	)	)	PUNCT
ajst-20773	75	22	less	less	ADJ
ajst-20773	75	23	than	than	ADP
ajst-20773	75	24	0.05	0.05	NUM
ajst-20773	75	25	and	and	CCONJ
ajst-20773	75	26	a	a	DET
ajst-20773	75	27	false	false	ADJ
ajst-20773	75	28	discovery	discovery	NOUN
ajst-20773	75	29	rate	rate	NOUN
ajst-20773	75	30	(	(	PUNCT
ajst-20773	75	31	fdr	fdr	PROPN
ajst-20773	75	32	)	)	PUNCT
ajst-20773	75	33	q	q	ADJ
ajst-20773	75	34	-	-	PUNCT
ajst-20773	75	35	value	value	NOUN
ajst-20773	75	36	less	less	ADJ
ajst-20773	75	37	than	than	ADP
ajst-20773	75	38	0.25	0.25	NUM
ajst-20773	75	39	.	.	PUNCT
ajst-20773	76	1	the	the	DET
ajst-20773	76	2	findings	finding	NOUN
ajst-20773	76	3	were	be	AUX
ajst-20773	76	4	visualized	visualize	VERB
ajst-20773	76	5	using	use	VERB
ajst-20773	76	6	the	the	DET
ajst-20773	76	7	r	r	NOUN
ajst-20773	76	8	package	package	NOUN
ajst-20773	76	9	ggplot2	ggplot2	PROPN
ajst-20773	76	10	.	.	PUNCT
ajst-20773	77	1	14	14	NUM
ajst-20773	77	2	2.6	2.6	NUM
ajst-20773	77	3	.	.	PUNCT
ajst-20773	77	4	estimation	estimation	NOUN
ajst-20773	77	5	of	of	ADP
ajst-20773	77	6	immune	immune	ADJ
ajst-20773	77	7	infiltration	infiltration	NOUN
ajst-20773	77	8	the	the	DET
ajst-20773	77	9	proportion	proportion	NOUN
ajst-20773	77	10	of	of	ADP
ajst-20773	77	11	immune	immune	ADJ
ajst-20773	77	12	cell	cell	NOUN
ajst-20773	77	13	infiltration	infiltration	NOUN
ajst-20773	77	14	and	and	CCONJ
ajst-20773	77	15	the	the	DET
ajst-20773	77	16	activity	activity	NOUN
ajst-20773	77	17	of	of	ADP
ajst-20773	77	18	immune	immune	NOUN
ajst-20773	77	19	-	-	PUNCT
ajst-20773	77	20	related	relate	VERB
ajst-20773	77	21	pathways	pathway	NOUN
ajst-20773	77	22	in	in	ADP
ajst-20773	77	23	highand	highand	ADJ
ajst-20773	77	24	low	low	ADJ
ajst-20773	77	25	-	-	PUNCT
ajst-20773	77	26	risk	risk	NOUN
ajst-20773	77	27	luad	luad	NOUN
ajst-20773	77	28	samples	sample	NOUN
ajst-20773	77	29	were	be	AUX
ajst-20773	77	30	evaluated	evaluate	VERB
ajst-20773	77	31	using	use	VERB
ajst-20773	77	32	single	single	ADJ
ajst-20773	77	33	-	-	PUNCT
ajst-20773	77	34	sample	sample	NOUN
ajst-20773	77	35	gsea	gsea	NOUN
ajst-20773	77	36	(	(	PUNCT
ajst-20773	77	37	ssgsea	ssgsea	NOUN
ajst-20773	77	38	)	)	PUNCT
ajst-20773	77	39	(	(	PUNCT
ajst-20773	77	40	rooney	rooney	NOUN
ajst-20773	77	41	et	et	PROPN
ajst-20773	77	42	al	al	PROPN
ajst-20773	77	43	.	.	PROPN
ajst-20773	77	44	,	,	PUNCT
ajst-20773	77	45	2015	2015	NUM
ajst-20773	77	46	)	)	PUNCT
ajst-20773	77	47	and	and	CCONJ
ajst-20773	77	48	verified	verify	VERB
ajst-20773	77	49	using	use	VERB
ajst-20773	77	50	the	the	DET
ajst-20773	77	51	cibersort	cibersort	NOUN
ajst-20773	77	52	algorithm	algorithm	NOUN
ajst-20773	77	53	(	(	PUNCT
ajst-20773	77	54	newman	newman	PROPN
ajst-20773	77	55	et	et	PROPN
ajst-20773	77	56	al	al	PROPN
ajst-20773	77	57	.	.	PROPN
ajst-20773	77	58	,	,	PUNCT
ajst-20773	77	59	2015	2015	NUM
ajst-20773	77	60	)	)	PUNCT
ajst-20773	77	61	as	as	ADP
ajst-20773	77	62	a	a	DET
ajst-20773	77	63	method	method	NOUN
ajst-20773	77	64	of	of	ADP
ajst-20773	77	65	crossvalidation	crossvalidation	NOUN
ajst-20773	77	66	.	.	PUNCT
ajst-20773	78	1	the	the	DET
ajst-20773	78	2	wilcoxon	wilcoxon	ADJ
ajst-20773	78	3	rank	rank	NOUN
ajst-20773	78	4	-	-	PUNCT
ajst-20773	78	5	sum	sum	NOUN
ajst-20773	78	6	test	test	NOUN
ajst-20773	78	7	was	be	AUX
ajst-20773	78	8	applied	apply	VERB
ajst-20773	78	9	to	to	PART
ajst-20773	78	10	establish	establish	VERB
ajst-20773	78	11	whether	whether	SCONJ
ajst-20773	78	12	there	there	PRON
ajst-20773	78	13	was	be	VERB
ajst-20773	78	14	a	a	DET
ajst-20773	78	15	significant	significant	ADJ
ajst-20773	78	16	difference	difference	NOUN
ajst-20773	78	17	in	in	ADP
ajst-20773	78	18	the	the	DET
ajst-20773	78	19	proportions	proportion	NOUN
ajst-20773	78	20	of	of	ADP
ajst-20773	78	21	immune	immune	ADJ
ajst-20773	78	22	cells	cell	NOUN
ajst-20773	78	23	between	between	ADP
ajst-20773	78	24	the	the	DET
ajst-20773	78	25	low	low	ADJ
ajst-20773	78	26	-	-	PUNCT
ajst-20773	78	27	risk	risk	NOUN
ajst-20773	78	28	and	and	CCONJ
ajst-20773	78	29	highrisk	highrisk	NOUN
ajst-20773	78	30	groups	group	NOUN
ajst-20773	78	31	.	.	PUNCT
ajst-20773	79	1	2.7	2.7	NUM
ajst-20773	79	2	.	.	PUNCT
ajst-20773	79	3	potential	potential	ADJ
ajst-20773	79	4	relationship	relationship	NOUN
ajst-20773	79	5	between	between	ADP
ajst-20773	79	6	the	the	DET
ajst-20773	79	7	senlncsig	senlncsig	NOUN
ajst-20773	79	8	and	and	CCONJ
ajst-20773	79	9	immunotherapy	immunotherapy	NOUN
ajst-20773	79	10	,	,	PUNCT
ajst-20773	79	11	chemotherapy	chemotherapy	NOUN
ajst-20773	79	12	,	,	PUNCT
ajst-20773	79	13	and	and	CCONJ
ajst-20773	79	14	target	target	NOUN
ajst-20773	79	15	therapy	therapy	NOUN
ajst-20773	79	16	initially	initially	ADV
ajst-20773	79	17	,	,	PUNCT
ajst-20773	79	18	the	the	DET
ajst-20773	79	19	differential	differential	ADJ
ajst-20773	79	20	expression	expression	NOUN
ajst-20773	79	21	of	of	ADP
ajst-20773	79	22	40	40	NUM
ajst-20773	79	23	immune	immune	ADJ
ajst-20773	79	24	checkpoints	checkpoint	NOUN
ajst-20773	79	25	was	be	AUX
ajst-20773	79	26	examined	examine	VERB
ajst-20773	79	27	between	between	ADP
ajst-20773	79	28	the	the	DET
ajst-20773	79	29	high	high	ADJ
ajst-20773	79	30	-	-	PUNCT
ajst-20773	79	31	risk	risk	NOUN
ajst-20773	79	32	and	and	CCONJ
ajst-20773	79	33	lowrisk	lowrisk	NOUN
ajst-20773	79	34	groups	group	NOUN
ajst-20773	79	35	(	(	PUNCT
ajst-20773	79	36	wagner	wagner	PROPN
ajst-20773	79	37	et	et	PROPN
ajst-20773	79	38	al	al	PROPN
ajst-20773	79	39	.	.	PROPN
ajst-20773	79	40	,	,	PUNCT
ajst-20773	79	41	2021	2021	NUM
ajst-20773	79	42	)	)	PUNCT
ajst-20773	79	43	.	.	PUNCT
ajst-20773	80	1	additionally	additionally	ADV
ajst-20773	80	2	,	,	PUNCT
ajst-20773	80	3	the	the	DET
ajst-20773	80	4	tumor	tumor	NOUN
ajst-20773	80	5	immune	immune	ADJ
ajst-20773	80	6	dysfunction	dysfunction	NOUN
ajst-20773	80	7	and	and	CCONJ
ajst-20773	80	8	exclusion	exclusion	NOUN
ajst-20773	80	9	(	(	PUNCT
ajst-20773	80	10	tide	tide	NOUN
ajst-20773	80	11	,	,	PUNCT
ajst-20773	80	12	http://tide.dfci.harvard.edu/	http://tide.dfci.harvard.edu/	NOUN
ajst-20773	80	13	)	)	PUNCT
ajst-20773	80	14	module	module	NOUN
ajst-20773	80	15	was	be	AUX
ajst-20773	80	16	utilized	utilize	VERB
ajst-20773	80	17	to	to	PART
ajst-20773	80	18	differentiate	differentiate	VERB
ajst-20773	80	19	potential	potential	ADJ
ajst-20773	80	20	responses	response	NOUN
ajst-20773	80	21	to	to	ADP
ajst-20773	80	22	immunotherapy	immunotherapy	NOUN
ajst-20773	80	23	between	between	ADP
ajst-20773	80	24	these	these	DET
ajst-20773	80	25	groups	group	NOUN
ajst-20773	80	26	,	,	PUNCT
ajst-20773	80	27	predicting	predict	VERB
ajst-20773	80	28	responses	response	NOUN
ajst-20773	80	29	to	to	ADP
ajst-20773	80	30	anti	anti	ADJ
ajst-20773	80	31	-	-	ADJ
ajst-20773	80	32	pd1	pd1	VERB
ajst-20773	80	33	and	and	CCONJ
ajst-20773	80	34	antictla4	antictla4	NOUN
ajst-20773	80	35	treatments	treatment	NOUN
ajst-20773	80	36	based	base	VERB
ajst-20773	80	37	on	on	ADP
ajst-20773	80	38	pre	pre	ADJ
ajst-20773	80	39	-	-	ADJ
ajst-20773	80	40	treatment	treatment	ADJ
ajst-20773	80	41	transcriptional	transcriptional	NOUN
ajst-20773	80	42	expression	expression	NOUN
ajst-20773	80	43	profiles	profile	NOUN
ajst-20773	80	44	of	of	ADP
ajst-20773	80	45	patient	patient	ADJ
ajst-20773	80	46	genomes	genome	NOUN
ajst-20773	80	47	(	(	PUNCT
ajst-20773	80	48	yi	yi	X
ajst-20773	80	49	et	et	PROPN
ajst-20773	80	50	al	al	PROPN
ajst-20773	80	51	.	.	PROPN
ajst-20773	80	52	,	,	PUNCT
ajst-20773	80	53	2021	2021	NUM
ajst-20773	80	54	)	)	PUNCT
ajst-20773	80	55	.	.	PUNCT
ajst-20773	81	1	moreover	moreover	ADV
ajst-20773	81	2	,	,	PUNCT
ajst-20773	81	3	to	to	PART
ajst-20773	81	4	further	far	ADV
ajst-20773	81	5	assess	assess	VERB
ajst-20773	81	6	the	the	DET
ajst-20773	81	7	utility	utility	NOUN
ajst-20773	81	8	of	of	ADP
ajst-20773	81	9	senlncsig	senlncsig	NOUN
ajst-20773	81	10	in	in	ADP
ajst-20773	81	11	predicting	predict	VERB
ajst-20773	81	12	luad	luad	NOUN
ajst-20773	81	13	's	's	PART
ajst-20773	81	14	response	response	NOUN
ajst-20773	81	15	to	to	ADP
ajst-20773	81	16	therapy	therapy	NOUN
ajst-20773	81	17	,	,	PUNCT
ajst-20773	81	18	the	the	DET
ajst-20773	81	19	half	half	ADJ
ajst-20773	81	20	-	-	PUNCT
ajst-20773	81	21	maximal	maximal	ADJ
ajst-20773	81	22	inhibitory	inhibitory	ADJ
ajst-20773	81	23	concentrations	concentration	NOUN
ajst-20773	81	24	(	(	PUNCT
ajst-20773	81	25	ic50	ic50	PROPN
ajst-20773	81	26	)	)	PUNCT
ajst-20773	81	27	of	of	ADP
ajst-20773	81	28	common	common	ADJ
ajst-20773	81	29	chemotherapeutic	chemotherapeutic	NOUN
ajst-20773	81	30	and	and	CCONJ
ajst-20773	81	31	targeted	target	VERB
ajst-20773	81	32	therapeutic	therapeutic	ADJ
ajst-20773	81	33	drugs	drug	NOUN
ajst-20773	81	34	were	be	AUX
ajst-20773	81	35	calculated	calculate	VERB
ajst-20773	81	36	.	.	PUNCT
ajst-20773	82	1	the	the	DET
ajst-20773	82	2	wilcoxon	wilcoxon	ADJ
ajst-20773	82	3	signed	sign	VERB
ajst-20773	82	4	-	-	PUNCT
ajst-20773	82	5	rank	rank	NOUN
ajst-20773	82	6	test	test	NOUN
ajst-20773	82	7	and	and	CCONJ
ajst-20773	82	8	the	the	DET
ajst-20773	82	9	r	r	NOUN
ajst-20773	82	10	package	package	NOUN
ajst-20773	82	11	prrophetic	prrophetic	ADJ
ajst-20773	82	12	were	be	AUX
ajst-20773	82	13	employed	employ	VERB
ajst-20773	82	14	to	to	PART
ajst-20773	82	15	analyze	analyze	VERB
ajst-20773	82	16	and	and	CCONJ
ajst-20773	82	17	display	display	VERB
ajst-20773	82	18	the	the	DET
ajst-20773	82	19	differences	difference	NOUN
ajst-20773	82	20	in	in	ADP
ajst-20773	82	21	ic50	ic50	PROPN
ajst-20773	82	22	values	value	NOUN
ajst-20773	82	23	between	between	ADP
ajst-20773	82	24	the	the	DET
ajst-20773	82	25	high	high	ADJ
ajst-20773	82	26	-	-	PUNCT
ajst-20773	82	27	risk	risk	NOUN
ajst-20773	82	28	and	and	CCONJ
ajst-20773	82	29	low	low	ADJ
ajst-20773	82	30	-	-	PUNCT
ajst-20773	82	31	risk	risk	NOUN
ajst-20773	82	32	groups	group	NOUN
ajst-20773	82	33	(	(	PUNCT
ajst-20773	82	34	liu	liu	PROPN
ajst-20773	82	35	et	et	PROPN
ajst-20773	82	36	al	al	PROPN
ajst-20773	82	37	.	.	PROPN
ajst-20773	82	38	,	,	PUNCT
ajst-20773	82	39	2020	2020	NUM
ajst-20773	82	40	)	)	PUNCT
ajst-20773	82	41	.	.	PUNCT
ajst-20773	83	1	2.8	2.8	NUM
ajst-20773	83	2	.	.	PUNCT
ajst-20773	84	1	statistical	statistical	ADJ
ajst-20773	84	2	analysis	analysis	NOUN
ajst-20773	84	3	the	the	DET
ajst-20773	84	4	wilcoxon	wilcoxon	ADJ
ajst-20773	84	5	test	test	NOUN
ajst-20773	84	6	was	be	AUX
ajst-20773	84	7	picked	pick	VERB
ajst-20773	84	8	to	to	PART
ajst-20773	84	9	analyze	analyze	VERB
ajst-20773	84	10	the	the	DET
ajst-20773	84	11	expression	expression	NOUN
ajst-20773	84	12	differences	difference	NOUN
ajst-20773	84	13	of	of	ADP
ajst-20773	84	14	senescence	senescence	NOUN
ajst-20773	84	15	-	-	PUNCT
ajst-20773	84	16	related	relate	VERB
ajst-20773	84	17	degs	deg	NOUN
ajst-20773	84	18	between	between	ADP
ajst-20773	84	19	cancer	cancer	NOUN
ajst-20773	84	20	and	and	CCONJ
ajst-20773	84	21	normal	normal	ADJ
ajst-20773	84	22	tissues	tissue	NOUN
ajst-20773	84	23	.	.	PUNCT
ajst-20773	85	1	the	the	DET
ajst-20773	85	2	kaplan	kaplan	PROPN
ajst-20773	85	3	-	-	PUNCT
ajst-20773	85	4	meier	meier	PROPN
ajst-20773	85	5	method	method	NOUN
ajst-20773	85	6	along	along	ADP
ajst-20773	85	7	with	with	ADP
ajst-20773	85	8	the	the	DET
ajst-20773	85	9	logrank	logrank	NOUN
ajst-20773	85	10	test	test	NOUN
ajst-20773	85	11	were	be	AUX
ajst-20773	85	12	used	use	VERB
ajst-20773	85	13	to	to	PART
ajst-20773	85	14	assess	assess	VERB
ajst-20773	85	15	differences	difference	NOUN
ajst-20773	85	16	in	in	ADP
ajst-20773	85	17	overall	overall	ADJ
ajst-20773	85	18	survival	survival	NOUN
ajst-20773	85	19	(	(	PUNCT
ajst-20773	85	20	os	os	NOUN
ajst-20773	85	21	)	)	PUNCT
ajst-20773	85	22	rates	rate	NOUN
ajst-20773	85	23	between	between	ADP
ajst-20773	85	24	the	the	DET
ajst-20773	85	25	high	high	ADJ
ajst-20773	85	26	-	-	PUNCT
ajst-20773	85	27	risk	risk	NOUN
ajst-20773	85	28	and	and	CCONJ
ajst-20773	85	29	low	low	ADJ
ajst-20773	85	30	-	-	PUNCT
ajst-20773	85	31	risk	risk	NOUN
ajst-20773	85	32	groups	group	NOUN
ajst-20773	85	33	(	(	PUNCT
ajst-20773	85	34	tang	tang	X
ajst-20773	85	35	et	et	PROPN
ajst-20773	85	36	al	al	PROPN
ajst-20773	85	37	.	.	PROPN
ajst-20773	85	38	,	,	PUNCT
ajst-20773	85	39	2021	2021	NUM
ajst-20773	85	40	)	)	PUNCT
ajst-20773	85	41	.	.	PUNCT
ajst-20773	86	1	the	the	DET
ajst-20773	86	2	survivalroc	survivalroc	NOUN
ajst-20773	86	3	package	package	NOUN
ajst-20773	86	4	facilitated	facilitate	VERB
ajst-20773	86	5	the	the	DET
ajst-20773	86	6	generation	generation	NOUN
ajst-20773	86	7	of	of	ADP
ajst-20773	86	8	roc	roc	PROPN
ajst-20773	86	9	curves	curve	NOUN
ajst-20773	86	10	and	and	CCONJ
ajst-20773	86	11	the	the	DET
ajst-20773	86	12	calculation	calculation	NOUN
ajst-20773	86	13	of	of	ADP
ajst-20773	86	14	the	the	DET
ajst-20773	86	15	area	area	NOUN
ajst-20773	86	16	under	under	ADP
ajst-20773	86	17	the	the	DET
ajst-20773	86	18	curve	curve	NOUN
ajst-20773	86	19	(	(	PUNCT
ajst-20773	86	20	auc	auc	NOUN
ajst-20773	86	21	)	)	PUNCT
ajst-20773	86	22	.	.	PUNCT
ajst-20773	87	1	group	group	NOUN
ajst-20773	87	2	differences	difference	NOUN
ajst-20773	87	3	were	be	AUX
ajst-20773	87	4	evaluated	evaluate	VERB
ajst-20773	87	5	using	use	VERB
ajst-20773	87	6	the	the	DET
ajst-20773	87	7	kruskal	kruskal	NOUN
ajst-20773	87	8	–	–	PUNCT
ajst-20773	87	9	wallis	wallis	PROPN
ajst-20773	87	10	test	test	NOUN
ajst-20773	87	11	.	.	PUNCT
ajst-20773	88	1	clinical	clinical	ADJ
ajst-20773	88	2	data	datum	NOUN
ajst-20773	88	3	were	be	AUX
ajst-20773	88	4	examined	examine	VERB
ajst-20773	88	5	either	either	CCONJ
ajst-20773	88	6	by	by	ADP
ajst-20773	88	7	the	the	DET
ajst-20773	88	8	chi	chi	ADJ
ajst-20773	88	9	-	-	PUNCT
ajst-20773	88	10	square	square	ADJ
ajst-20773	88	11	test	test	NOUN
ajst-20773	88	12	or	or	CCONJ
ajst-20773	88	13	fisher	fisher	PROPN
ajst-20773	88	14	’s	’s	PART
ajst-20773	88	15	exact	exact	ADJ
ajst-20773	88	16	test	test	NOUN
ajst-20773	88	17	depending	depend	VERB
ajst-20773	88	18	on	on	ADP
ajst-20773	88	19	the	the	DET
ajst-20773	88	20	data	data	NOUN
ajst-20773	88	21	characteristics	characteristic	NOUN
ajst-20773	88	22	(	(	PUNCT
ajst-20773	88	23	huo	huo	NOUN
ajst-20773	88	24	et	et	PROPN
ajst-20773	88	25	al	al	PROPN
ajst-20773	88	26	.	.	PROPN
ajst-20773	88	27	,	,	PUNCT
ajst-20773	88	28	2021	2021	NUM
ajst-20773	88	29	)	)	PUNCT
ajst-20773	88	30	.	.	PUNCT
ajst-20773	89	1	a	a	DET
ajst-20773	89	2	pearson	pearson	NOUN
ajst-20773	89	3	correlation	correlation	NOUN
ajst-20773	89	4	coefficient	coefficient	NOUN
ajst-20773	89	5	was	be	AUX
ajst-20773	89	6	utilized	utilize	VERB
ajst-20773	89	7	to	to	PART
ajst-20773	89	8	assess	assess	VERB
ajst-20773	89	9	the	the	DET
ajst-20773	89	10	association	association	NOUN
ajst-20773	89	11	between	between	ADP
ajst-20773	89	12	lncrna	lncrna	NOUN
ajst-20773	89	13	expression	expression	NOUN
ajst-20773	89	14	,	,	PUNCT
ajst-20773	89	15	immune	immune	ADJ
ajst-20773	89	16	infiltration	infiltration	NOUN
ajst-20773	89	17	,	,	PUNCT
ajst-20773	89	18	and	and	CCONJ
ajst-20773	89	19	the	the	DET
ajst-20773	89	20	expression	expression	NOUN
ajst-20773	89	21	of	of	ADP
ajst-20773	89	22	immune	immune	ADJ
ajst-20773	89	23	checkpoint	checkpoint	NOUN
ajst-20773	89	24	genes	gene	NOUN
ajst-20773	89	25	.	.	PUNCT
ajst-20773	90	1	all	all	DET
ajst-20773	90	2	statistical	statistical	ADJ
ajst-20773	90	3	evaluations	evaluation	NOUN
ajst-20773	90	4	were	be	AUX
ajst-20773	90	5	conducted	conduct	VERB
ajst-20773	90	6	using	use	VERB
ajst-20773	90	7	r	r	NOUN
ajst-20773	90	8	software	software	NOUN
ajst-20773	90	9	(	(	PUNCT
ajst-20773	90	10	version	version	NOUN
ajst-20773	90	11	4.1.2	4.1.2	NUM
ajst-20773	90	12	)	)	PUNCT
ajst-20773	90	13	.	.	PUNCT
ajst-20773	91	1	3	3	X
ajst-20773	91	2	.	.	NOUN
ajst-20773	91	3	results	result	VERB
ajst-20773	91	4	3.1	3.1	NUM
ajst-20773	91	5	.	.	PUNCT
ajst-20773	92	1	enrichment	enrichment	NOUN
ajst-20773	92	2	analysis	analysis	NOUN
ajst-20773	92	3	of	of	ADP
ajst-20773	92	4	senescence	senescence	NOUN
ajst-20773	92	5	related	relate	VERB
ajst-20773	92	6	degs	deg	NOUN
ajst-20773	92	7	in	in	ADP
ajst-20773	92	8	luad	luad	NOUN
ajst-20773	92	9	initially	initially	ADV
ajst-20773	92	10	,	,	PUNCT
ajst-20773	92	11	the	the	DET
ajst-20773	92	12	expression	expression	NOUN
ajst-20773	92	13	levels	level	NOUN
ajst-20773	92	14	of	of	ADP
ajst-20773	92	15	279	279	NUM
ajst-20773	92	16	senescence	senescence	NOUN
ajst-20773	92	17	-	-	PUNCT
ajst-20773	92	18	related	relate	VERB
ajst-20773	92	19	genes	gene	NOUN
ajst-20773	92	20	in	in	ADP
ajst-20773	92	21	both	both	DET
ajst-20773	92	22	tumor	tumor	NOUN
ajst-20773	92	23	and	and	CCONJ
ajst-20773	92	24	normal	normal	ADJ
ajst-20773	92	25	tissues	tissue	NOUN
ajst-20773	92	26	were	be	AUX
ajst-20773	92	27	analyzed	analyze	VERB
ajst-20773	92	28	to	to	PART
ajst-20773	92	29	identify	identify	VERB
ajst-20773	92	30	any	any	DET
ajst-20773	92	31	abnormal	abnormal	ADJ
ajst-20773	92	32	expressions	expression	NOUN
ajst-20773	92	33	in	in	ADP
ajst-20773	92	34	the	the	DET
ajst-20773	92	35	tumor	tumor	NOUN
ajst-20773	92	36	tissues	tissue	NOUN
ajst-20773	92	37	.	.	PUNCT
ajst-20773	93	1	within	within	ADP
ajst-20773	93	2	luad	luad	ADJ
ajst-20773	93	3	tumor	tumor	NOUN
ajst-20773	93	4	tissues	tissue	NOUN
ajst-20773	93	5	,	,	PUNCT
ajst-20773	93	6	23	23	NUM
ajst-20773	93	7	out	out	ADP
ajst-20773	93	8	of	of	ADP
ajst-20773	93	9	62	62	NUM
ajst-20773	93	10	differentially	differentially	ADV
ajst-20773	93	11	expressed	express	VERB
ajst-20773	93	12	genes	gene	NOUN
ajst-20773	93	13	were	be	AUX
ajst-20773	93	14	found	find	VERB
ajst-20773	93	15	to	to	PART
ajst-20773	93	16	be	be	AUX
ajst-20773	93	17	downregulated	downregulate	VERB
ajst-20773	93	18	,	,	PUNCT
ajst-20773	93	19	while	while	SCONJ
ajst-20773	93	20	39	39	NUM
ajst-20773	93	21	were	be	AUX
ajst-20773	93	22	upregulated	upregulate	VERB
ajst-20773	93	23	(	(	PUNCT
ajst-20773	93	24	figures	figure	NOUN
ajst-20773	93	25	1	1	NUM
ajst-20773	93	26	,	,	PUNCT
ajst-20773	93	27	2	2	NUM
ajst-20773	93	28	)	)	PUNCT
ajst-20773	93	29	.	.	PUNCT
ajst-20773	94	1	kegg	kegg	NOUN
ajst-20773	94	2	pathway	pathway	NOUN
ajst-20773	94	3	analysis	analysis	NOUN
ajst-20773	94	4	identified	identify	VERB
ajst-20773	94	5	the	the	DET
ajst-20773	94	6	top	top	ADJ
ajst-20773	94	7	five	five	NUM
ajst-20773	94	8	enriched	enriched	ADJ
ajst-20773	94	9	pathways	pathway	NOUN
ajst-20773	94	10	as	as	ADP
ajst-20773	94	11	human	human	PROPN
ajst-20773	94	12	t	t	PROPN
ajst-20773	94	13	-	-	PUNCT
ajst-20773	94	14	cell	cell	NOUN
ajst-20773	94	15	leukemia	leukemia	NOUN
ajst-20773	94	16	virus	virus	NOUN
ajst-20773	94	17	one	one	NUM
ajst-20773	94	18	infection	infection	NOUN
ajst-20773	94	19	,	,	PUNCT
ajst-20773	94	20	cellular	cellular	ADJ
ajst-20773	94	21	senescence	senescence	NOUN
ajst-20773	94	22	,	,	PUNCT
ajst-20773	94	23	cell	cell	NOUN
ajst-20773	94	24	cycle	cycle	NOUN
ajst-20773	94	25	,	,	PUNCT
ajst-20773	94	26	kaposi	kaposi	PROPN
ajst-20773	94	27	sarcoma	sarcoma	NOUN
ajst-20773	94	28	-	-	PUNCT
ajst-20773	94	29	associated	associate	VERB
ajst-20773	94	30	herpesvirus	herpesvirus	NOUN
ajst-20773	94	31	infection	infection	NOUN
ajst-20773	94	32	,	,	PUNCT
ajst-20773	94	33	and	and	CCONJ
ajst-20773	94	34	p53	p53	NOUN
ajst-20773	94	35	signaling	signal	VERB
ajst-20773	94	36	pathway	pathway	NOUN
ajst-20773	94	37	(	(	PUNCT
ajst-20773	94	38	figure	figure	NOUN
ajst-20773	94	39	3	3	NUM
ajst-20773	94	40	)	)	PUNCT
ajst-20773	94	41	.	.	PUNCT
ajst-20773	95	1	on	on	ADP
ajst-20773	95	2	the	the	DET
ajst-20773	95	3	other	other	ADJ
ajst-20773	95	4	hand	hand	NOUN
ajst-20773	95	5	,	,	PUNCT
ajst-20773	95	6	go	go	VERB
ajst-20773	95	7	analysis	analysis	NOUN
ajst-20773	95	8	highlighted	highlight	VERB
ajst-20773	95	9	the	the	DET
ajst-20773	95	10	most	most	ADV
ajst-20773	95	11	enriched	enrich	VERB
ajst-20773	95	12	categories	category	NOUN
ajst-20773	95	13	as	as	ADP
ajst-20773	95	14	cell	cell	NOUN
ajst-20773	95	15	aging	aging	NOUN
ajst-20773	95	16	,	,	PUNCT
ajst-20773	95	17	aging	aging	NOUN
ajst-20773	95	18	,	,	PUNCT
ajst-20773	95	19	mitotic	mitotic	ADJ
ajst-20773	95	20	cell	cell	NOUN
ajst-20773	95	21	cycle	cycle	NOUN
ajst-20773	95	22	phase	phase	NOUN
ajst-20773	95	23	transition	transition	NOUN
ajst-20773	95	24	,	,	PUNCT
ajst-20773	95	25	regulation	regulation	NOUN
ajst-20773	95	26	of	of	ADP
ajst-20773	95	27	mitotic	mitotic	ADJ
ajst-20773	95	28	cell	cell	NOUN
ajst-20773	95	29	cycle	cycle	NOUN
ajst-20773	95	30	phase	phase	NOUN
ajst-20773	95	31	transition	transition	NOUN
ajst-20773	95	32	,	,	PUNCT
ajst-20773	95	33	and	and	CCONJ
ajst-20773	95	34	cellular	cellular	ADJ
ajst-20773	95	35	response	response	NOUN
ajst-20773	95	36	to	to	ADP
ajst-20773	95	37	chemical	chemical	ADJ
ajst-20773	95	38	stress	stress	NOUN
ajst-20773	95	39	(	(	PUNCT
ajst-20773	95	40	figure	figure	NOUN
ajst-20773	95	41	4	4	NUM
ajst-20773	95	42	)	)	PUNCT
ajst-20773	95	43	.	.	PUNCT
ajst-20773	96	1	these	these	DET
ajst-20773	96	2	results	result	NOUN
ajst-20773	96	3	suggest	suggest	VERB
ajst-20773	96	4	that	that	SCONJ
ajst-20773	96	5	the	the	DET
ajst-20773	96	6	degs	deg	NOUN
ajst-20773	96	7	predominantly	predominantly	ADV
ajst-20773	96	8	play	play	VERB
ajst-20773	96	9	roles	role	NOUN
ajst-20773	96	10	in	in	ADP
ajst-20773	96	11	cell	cell	NOUN
ajst-20773	96	12	senescence	senescence	NOUN
ajst-20773	96	13	,	,	PUNCT
ajst-20773	96	14	the	the	DET
ajst-20773	96	15	cell	cell	NOUN
ajst-20773	96	16	cycle	cycle	NOUN
ajst-20773	96	17	,	,	PUNCT
ajst-20773	96	18	virus	virus	NOUN
ajst-20773	96	19	infection	infection	NOUN
ajst-20773	96	20	,	,	PUNCT
ajst-20773	96	21	cellular	cellular	ADJ
ajst-20773	96	22	stress	stress	NOUN
ajst-20773	96	23	,	,	PUNCT
ajst-20773	96	24	and	and	CCONJ
ajst-20773	96	25	apoptosis	apoptosis	NOUN
ajst-20773	96	26	.	.	PUNCT
ajst-20773	97	1	3.2	3.2	NUM
ajst-20773	97	2	.	.	PUNCT
ajst-20773	98	1	construction	construction	NOUN
ajst-20773	98	2	of	of	ADP
ajst-20773	98	3	the	the	DET
ajst-20773	98	4	senlncsig	senlncsig	PROPN
ajst-20773	98	5	pearson	pearson	PROPN
ajst-20773	98	6	correlation	correlation	PROPN
ajst-20773	98	7	analysis	analysis	NOUN
ajst-20773	98	8	revealed	reveal	VERB
ajst-20773	98	9	1,081	1,081	NUM
ajst-20773	98	10	lncrnas	lncrna	NOUN
ajst-20773	98	11	linked	link	VERB
ajst-20773	98	12	to	to	ADP
ajst-20773	98	13	senescence	senescence	NOUN
ajst-20773	98	14	,	,	PUNCT
ajst-20773	98	15	with	with	ADP
ajst-20773	98	16	62	62	NUM
ajst-20773	98	17	of	of	ADP
ajst-20773	98	18	these	these	PRON
ajst-20773	98	19	associated	associate	VERB
ajst-20773	98	20	with	with	ADP
ajst-20773	98	21	the	the	DET
ajst-20773	98	22	prognosis	prognosis	NOUN
ajst-20773	98	23	of	of	ADP
ajst-20773	98	24	luad	luad	NOUN
ajst-20773	98	25	(	(	PUNCT
ajst-20773	98	26	figure	figure	NOUN
ajst-20773	98	27	5	5	NUM
ajst-20773	98	28	)	)	PUNCT
ajst-20773	98	29	.	.	PUNCT
ajst-20773	99	1	furthermore	furthermore	ADV
ajst-20773	99	2	,	,	PUNCT
ajst-20773	99	3	a	a	DET
ajst-20773	99	4	set	set	NOUN
ajst-20773	99	5	of	of	ADP
ajst-20773	99	6	seven	seven	NUM
ajst-20773	99	7	senescence	senescence	NOUN
ajst-20773	99	8	-	-	PUNCT
ajst-20773	99	9	related	relate	VERB
ajst-20773	99	10	lncrnas	lncrna	NOUN
ajst-20773	99	11	—	—	PUNCT
ajst-20773	99	12	al031775.2	al031775.2	NUM
ajst-20773	99	13	,	,	PUNCT
ajst-20773	99	14	ac026355.1	ac026355.1	NUM
ajst-20773	99	15	,	,	PUNCT
ajst-20773	99	16	ac090559.1	ac090559.1	NUM
ajst-20773	99	17	,	,	PUNCT
ajst-20773	99	18	al513550.1	al513550.1	NUM
ajst-20773	99	19	,	,	PUNCT
ajst-20773	99	20	c20orf197	c20orf197	PROPN
ajst-20773	99	21	,	,	PUNCT
ajst-20773	99	22	al365181.2	al365181.2	NOUN
ajst-20773	99	23	and	and	CCONJ
ajst-20773	99	24	al606489.1	al606489.1	NUM
ajst-20773	99	25	—	—	PUNCT
ajst-20773	99	26	were	be	AUX
ajst-20773	99	27	identified	identify	VERB
ajst-20773	99	28	through	through	ADP
ajst-20773	99	29	multivariate	multivariate	NOUN
ajst-20773	99	30	cox	cox	PROPN
ajst-20773	99	31	regression	regression	VERB
ajst-20773	99	32	analysis	analysis	NOUN
ajst-20773	99	33	to	to	PART
ajst-20773	99	34	create	create	VERB
ajst-20773	99	35	the	the	DET
ajst-20773	99	36	senlncsig	senlncsig	PROPN
ajst-20773	99	37	prognostic	prognostic	PROPN
ajst-20773	99	38	signature	signature	NOUN
ajst-20773	99	39	.	.	PUNCT
ajst-20773	100	1	figure	figure	NOUN
ajst-20773	100	2	6	6	NUM
ajst-20773	100	3	shows	show	VERB
ajst-20773	100	4	a	a	DET
ajst-20773	100	5	heatmap	heatmap	NOUN
ajst-20773	100	6	illustrating	illustrate	VERB
ajst-20773	100	7	the	the	DET
ajst-20773	100	8	expression	expression	NOUN
ajst-20773	100	9	levels	level	NOUN
ajst-20773	100	10	of	of	ADP
ajst-20773	100	11	the	the	DET
ajst-20773	100	12	senlncsig	senlncsig	PROPN
ajst-20773	100	13	lncrnas	lncrnas	PROPN
ajst-20773	100	14	in	in	ADP
ajst-20773	100	15	luad	luad	ADJ
ajst-20773	100	16	patients	patient	NOUN
ajst-20773	100	17	.	.	PUNCT
ajst-20773	101	1	the	the	DET
ajst-20773	101	2	senescence	senescence	NOUN
ajst-20773	101	3	-	-	PUNCT
ajst-20773	101	4	related	relate	VERB
ajst-20773	101	5	lncrna	lncrna	NOUN
ajst-20773	101	6	-	-	PUNCT
ajst-20773	101	7	mrna	mrna	NOUN
ajst-20773	101	8	expression	expression	NOUN
ajst-20773	101	9	network	network	NOUN
ajst-20773	101	10	was	be	AUX
ajst-20773	101	11	visualized	visualize	VERB
ajst-20773	101	12	using	use	VERB
ajst-20773	101	13	cytoscape	cytoscape	NOUN
ajst-20773	101	14	software	software	NOUN
ajst-20773	101	15	(	(	PUNCT
ajst-20773	101	16	figure	figure	NOUN
ajst-20773	101	17	7	7	NUM
ajst-20773	101	18	,	,	PUNCT
ajst-20773	101	19	|r2|	|r2|	VERB
ajst-20773	101	20	>	>	X
ajst-20773	101	21	0.3	0.3	NUM
ajst-20773	101	22	,	,	PUNCT
ajst-20773	101	23	p	p	X
ajst-20773	101	24	<	<	X
ajst-20773	101	25	0.001	0.001	NUM
ajst-20773	101	26	)	)	PUNCT
ajst-20773	101	27	.	.	PUNCT
ajst-20773	102	1	based	base	VERB
ajst-20773	102	2	on	on	ADP
ajst-20773	102	3	the	the	DET
ajst-20773	102	4	sankey	sankey	PROPN
ajst-20773	102	5	diagram	diagram	NOUN
ajst-20773	102	6	in	in	ADP
ajst-20773	102	7	figure	figure	NOUN
ajst-20773	102	8	7	7	NUM
ajst-20773	102	9	,	,	PUNCT
ajst-20773	102	10	al031775.2ac026355.1	al031775.2ac026355.1	ADV
ajst-20773	102	11	,	,	PUNCT
ajst-20773	102	12	ac090559.1	ac090559.1	NUM
ajst-20773	102	13	,	,	PUNCT
ajst-20773	102	14	al513550.1	al513550.1	NUM
ajst-20773	102	15	,	,	PUNCT
ajst-20773	102	16	c20orf197	c20orf197	PROPN
ajst-20773	102	17	,	,	PUNCT
ajst-20773	102	18	al365181.2	al365181.2	NUM
ajst-20773	102	19	were	be	AUX
ajst-20773	102	20	identified	identify	VERB
ajst-20773	102	21	as	as	ADP
ajst-20773	102	22	protective	protective	ADJ
ajst-20773	102	23	factors	factor	NOUN
ajst-20773	102	24	,	,	PUNCT
ajst-20773	102	25	whereas	whereas	SCONJ
ajst-20773	102	26	al365181.2	al365181.2	NUM
ajst-20773	102	27	and	and	CCONJ
ajst-20773	102	28	al606489.1	al606489.1	NUM
ajst-20773	102	29	were	be	AUX
ajst-20773	102	30	deemed	deem	VERB
ajst-20773	102	31	risk	risk	NOUN
ajst-20773	102	32	factors	factor	NOUN
ajst-20773	102	33	.	.	PUNCT
ajst-20773	103	1	figure	figure	VERB
ajst-20773	103	2	1	1	NUM
ajst-20773	103	3	.	.	PUNCT
ajst-20773	104	1	a	a	DET
ajst-20773	104	2	heatmap	heatmap	NOUN
ajst-20773	104	3	displays	display	VERB
ajst-20773	104	4	62	62	NUM
ajst-20773	104	5	senescence	senescence	NOUN
ajst-20773	104	6	degs	deg	NOUN
ajst-20773	104	7	between	between	ADP
ajst-20773	104	8	normal	normal	ADJ
ajst-20773	104	9	and	and	CCONJ
ajst-20773	104	10	luad	luad	ADJ
ajst-20773	104	11	tumor	tumor	NOUN
ajst-20773	104	12	tissues	tissue	NOUN
ajst-20773	104	13	.	.	PUNCT
ajst-20773	105	1	15	15	NUM
ajst-20773	105	2	figure	figure	NOUN
ajst-20773	105	3	2	2	NUM
ajst-20773	105	4	.	.	PUNCT
ajst-20773	105	5	a	a	DET
ajst-20773	105	6	volcano	volcano	NOUN
ajst-20773	105	7	plot	plot	NOUN
ajst-20773	105	8	of	of	ADP
ajst-20773	105	9	senescence	senescence	NOUN
ajst-20773	105	10	-	-	PUNCT
ajst-20773	105	11	related	relate	VERB
ajst-20773	105	12	differentially	differentially	ADV
ajst-20773	105	13	expressed	express	VERB
ajst-20773	105	14	genes	gene	NOUN
ajst-20773	105	15	in	in	ADP
ajst-20773	105	16	lung	lung	NOUN
ajst-20773	105	17	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	105	18	.	.	PUNCT
ajst-20773	106	1	figure	figure	NOUN
ajst-20773	106	2	3	3	NUM
ajst-20773	106	3	.	.	PUNCT
ajst-20773	106	4	kegg	kegg	NOUN
ajst-20773	106	5	pathway	pathway	NOUN
ajst-20773	106	6	enrichment	enrichment	NOUN
ajst-20773	106	7	analysis	analysis	NOUN
ajst-20773	106	8	of	of	ADP
ajst-20773	106	9	senescence	senescence	NOUN
ajst-20773	106	10	-	-	PUNCT
ajst-20773	106	11	related	relate	VERB
ajst-20773	106	12	differentially	differentially	ADV
ajst-20773	106	13	expressed	express	VERB
ajst-20773	106	14	genes	gene	NOUN
ajst-20773	106	15	in	in	ADP
ajst-20773	106	16	lung	lung	NOUN
ajst-20773	106	17	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	106	18	.	.	PUNCT
ajst-20773	107	1	16	16	NUM
ajst-20773	107	2	figure	figure	NOUN
ajst-20773	107	3	4	4	NUM
ajst-20773	107	4	.	.	NUM
ajst-20773	107	5	go	go	VERB
ajst-20773	107	6	functional	functional	ADJ
ajst-20773	107	7	enrichment	enrichment	NOUN
ajst-20773	107	8	analysis	analysis	NOUN
ajst-20773	107	9	of	of	ADP
ajst-20773	107	10	senescence	senescence	NOUN
ajst-20773	107	11	-	-	PUNCT
ajst-20773	107	12	related	relate	VERB
ajst-20773	107	13	differentially	differentially	ADV
ajst-20773	107	14	expressed	express	VERB
ajst-20773	107	15	genes	gene	NOUN
ajst-20773	107	16	in	in	ADP
ajst-20773	107	17	lung	lung	NOUN
ajst-20773	107	18	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	107	19	.	.	PUNCT
ajst-20773	108	1	figure	figure	NOUN
ajst-20773	108	2	5	5	NUM
ajst-20773	108	3	.	.	PUNCT
ajst-20773	109	1	a	a	DET
ajst-20773	109	2	forest	forest	NOUN
ajst-20773	109	3	plot	plot	NOUN
ajst-20773	109	4	shows	show	VERB
ajst-20773	109	5	the	the	DET
ajst-20773	109	6	62	62	NUM
ajst-20773	109	7	senescence	senescence	NOUN
ajst-20773	109	8	-	-	PUNCT
ajst-20773	109	9	related	relate	VERB
ajst-20773	109	10	lncrnas	lncrna	NOUN
ajst-20773	109	11	.	.	PUNCT
ajst-20773	110	1	17	17	NUM
ajst-20773	110	2	figure	figure	NOUN
ajst-20773	110	3	6	6	NUM
ajst-20773	110	4	.	.	PUNCT
ajst-20773	110	5	expression	expression	NOUN
ajst-20773	110	6	levels	level	NOUN
ajst-20773	110	7	of	of	ADP
ajst-20773	110	8	seven	seven	NUM
ajst-20773	110	9	senescence	senescence	NOUN
ajst-20773	110	10	-	-	PUNCT
ajst-20773	110	11	related	relate	VERB
ajst-20773	110	12	lncrnas	lncrna	NOUN
ajst-20773	110	13	associated	associate	VERB
ajst-20773	110	14	with	with	ADP
ajst-20773	110	15	luad	luad	ADJ
ajst-20773	110	16	prognosis	prognosis	NOUN
ajst-20773	110	17	identified	identify	VERB
ajst-20773	110	18	through	through	ADP
ajst-20773	110	19	multivariate	multivariate	NOUN
ajst-20773	110	20	cox	cox	PROPN
ajst-20773	110	21	regression	regression	VERB
ajst-20773	110	22	analysis	analysis	NOUN
ajst-20773	110	23	.	.	PUNCT
ajst-20773	111	1	figure	figure	NOUN
ajst-20773	111	2	7	7	NUM
ajst-20773	111	3	.	.	PUNCT
ajst-20773	111	4	co	co	ADJ
ajst-20773	111	5	-	-	NOUN
ajst-20773	111	6	expression	expression	ADJ
ajst-20773	111	7	network	network	NOUN
ajst-20773	111	8	diagram	diagram	NOUN
ajst-20773	111	9	of	of	ADP
ajst-20773	111	10	12	12	NUM
ajst-20773	111	11	senescence	senescence	NOUN
ajst-20773	111	12	-	-	PUNCT
ajst-20773	111	13	related	relate	VERB
ajst-20773	111	14	mrnas	mrna	NOUN
ajst-20773	111	15	and	and	CCONJ
ajst-20773	111	16	lncrnas	lncrna	NOUN
ajst-20773	111	17	in	in	ADP
ajst-20773	111	18	lung	lung	NOUN
ajst-20773	111	19	adenocarcinoma	adenocarcinoma	PROPN
ajst-20773	111	20	.	.	PUNCT
ajst-20773	112	1	figure	figure	NOUN
ajst-20773	112	2	8	8	NUM
ajst-20773	112	3	.	.	PUNCT
ajst-20773	113	1	sankey	sankey	ADJ
ajst-20773	113	2	diagram	diagram	NOUN
ajst-20773	113	3	of	of	ADP
ajst-20773	113	4	12	12	NUM
ajst-20773	113	5	senescence	senescence	NOUN
ajst-20773	113	6	-	-	PUNCT
ajst-20773	113	7	related	relate	VERB
ajst-20773	113	8	mrnas	mrna	NOUN
ajst-20773	113	9	and	and	CCONJ
ajst-20773	113	10	lncrnas	lncrna	NOUN
ajst-20773	113	11	in	in	ADP
ajst-20773	113	12	lung	lung	NOUN
ajst-20773	113	13	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	113	14	.	.	PUNCT
ajst-20773	114	1	18	18	NUM
ajst-20773	114	2	3.3	3.3	NUM
ajst-20773	114	3	.	.	PUNCT
ajst-20773	114	4	correlation	correlation	NOUN
ajst-20773	114	5	between	between	ADP
ajst-20773	114	6	senlncsig	senlncsig	NOUN
ajst-20773	114	7	and	and	CCONJ
ajst-20773	114	8	prognosis	prognosis	NOUN
ajst-20773	114	9	of	of	ADP
ajst-20773	114	10	luad	luad	NOUN
ajst-20773	114	11	patients	patient	NOUN
ajst-20773	114	12	the	the	DET
ajst-20773	114	13	risk	risk	NOUN
ajst-20773	114	14	score	score	NOUN
ajst-20773	114	15	of	of	ADP
ajst-20773	114	16	senlncsig	senlncsig	PROPN
ajst-20773	114	17	was	be	AUX
ajst-20773	114	18	calculated	calculate	VERB
ajst-20773	114	19	as	as	SCONJ
ajst-20773	114	20	follows	follow	VERB
ajst-20773	114	21	:	:	PUNCT
ajst-20773	114	22	risk	risk	NOUN
ajst-20773	114	23	score	score	NOUN
ajst-20773	114	24	=	=	PUNCT
ajst-20773	114	25	expgene(al365181.2)*0.2587expgene(al031775.2)*0.5210expgene(ac090559.1)*0.4512+expgene(al606489.1)*0	expgene(al365181.2)*0.2587expgene(al031775.2)*0.5210expgene(ac090559.1)*0.4512+expgene(al606489.1)*0	NOUN
ajst-20773	114	26	.	.	PROPN
ajst-20773	114	27	4246	4246	NUM
ajst-20773	114	28	-	-	SYM
ajst-20773	114	29	expgene(al513550.1)*0.470expgene(c20orf197)*0.30937	expgene(al513550.1)*0.470expgene(c20orf197)*0.30937	X
ajst-20773	114	30	.	.	PUNCT
ajst-20773	115	1	the	the	DET
ajst-20773	115	2	formula	formula	NOUN
ajst-20773	115	3	was	be	AUX
ajst-20773	115	4	applied	apply	VERB
ajst-20773	115	5	to	to	PART
ajst-20773	115	6	compute	compute	VERB
ajst-20773	115	7	each	each	DET
ajst-20773	115	8	patient	patient	NOUN
ajst-20773	115	9	's	's	PART
ajst-20773	115	10	risk	risk	NOUN
ajst-20773	115	11	score	score	NOUN
ajst-20773	115	12	,	,	PUNCT
ajst-20773	115	13	and	and	CCONJ
ajst-20773	115	14	the	the	DET
ajst-20773	115	15	patients	patient	NOUN
ajst-20773	115	16	were	be	AUX
ajst-20773	115	17	categorized	categorize	VERB
ajst-20773	115	18	into	into	ADP
ajst-20773	115	19	two	two	NUM
ajst-20773	115	20	groups	group	NOUN
ajst-20773	115	21	according	accord	VERB
ajst-20773	115	22	to	to	ADP
ajst-20773	115	23	the	the	DET
ajst-20773	115	24	median	median	ADJ
ajst-20773	115	25	risk	risk	NOUN
ajst-20773	115	26	score	score	NOUN
ajst-20773	115	27	:	:	PUNCT
ajst-20773	115	28	a	a	DET
ajst-20773	115	29	high	high	ADJ
ajst-20773	115	30	-	-	PUNCT
ajst-20773	115	31	risk	risk	NOUN
ajst-20773	115	32	group	group	NOUN
ajst-20773	115	33	(	(	PUNCT
ajst-20773	115	34	n	n	NOUN
ajst-20773	115	35	=	=	SYM
ajst-20773	115	36	256	256	NUM
ajst-20773	115	37	)	)	PUNCT
ajst-20773	115	38	and	and	CCONJ
ajst-20773	115	39	a	a	DET
ajst-20773	115	40	low	low	ADJ
ajst-20773	115	41	-	-	PUNCT
ajst-20773	115	42	risk	risk	NOUN
ajst-20773	115	43	group	group	NOUN
ajst-20773	115	44	(	(	PUNCT
ajst-20773	115	45	n	n	NOUN
ajst-20773	115	46	=	=	SYM
ajst-20773	115	47	224	224	NUM
ajst-20773	115	48	)	)	PUNCT
ajst-20773	115	49	(	(	PUNCT
ajst-20773	115	50	figure	figure	NOUN
ajst-20773	115	51	9	9	NUM
ajst-20773	115	52	)	)	PUNCT
ajst-20773	115	53	.	.	PUNCT
ajst-20773	116	1	kaplan	kaplan	PROPN
ajst-20773	116	2	-	-	PUNCT
ajst-20773	116	3	meier	meier	PROPN
ajst-20773	116	4	analysis	analysis	NOUN
ajst-20773	116	5	revealed	reveal	VERB
ajst-20773	116	6	that	that	SCONJ
ajst-20773	116	7	overall	overall	ADJ
ajst-20773	116	8	survival	survival	NOUN
ajst-20773	116	9	(	(	PUNCT
ajst-20773	116	10	os	os	NOUN
ajst-20773	116	11	)	)	PUNCT
ajst-20773	116	12	was	be	AUX
ajst-20773	116	13	significantly	significantly	ADV
ajst-20773	116	14	shorter	short	ADJ
ajst-20773	116	15	in	in	ADP
ajst-20773	116	16	the	the	DET
ajst-20773	116	17	high	high	ADJ
ajst-20773	116	18	-	-	PUNCT
ajst-20773	116	19	risk	risk	NOUN
ajst-20773	116	20	group	group	NOUN
ajst-20773	116	21	compared	compare	VERB
ajst-20773	116	22	to	to	ADP
ajst-20773	116	23	the	the	DET
ajst-20773	116	24	low	low	ADJ
ajst-20773	116	25	-	-	PUNCT
ajst-20773	116	26	risk	risk	NOUN
ajst-20773	116	27	group	group	NOUN
ajst-20773	116	28	(	(	PUNCT
ajst-20773	116	29	figure	figure	NOUN
ajst-20773	116	30	9	9	NUM
ajst-20773	116	31	)	)	PUNCT
ajst-20773	116	32	.	.	PUNCT
ajst-20773	117	1	figures	figure	NOUN
ajst-20773	117	2	10	10	NUM
ajst-20773	117	3	and	and	CCONJ
ajst-20773	117	4	11	11	NUM
ajst-20773	117	5	illustrate	illustrate	VERB
ajst-20773	117	6	the	the	DET
ajst-20773	117	7	risk	risk	NOUN
ajst-20773	117	8	scores	score	NOUN
ajst-20773	117	9	and	and	CCONJ
ajst-20773	117	10	survival	survival	NOUN
ajst-20773	117	11	data	datum	NOUN
ajst-20773	117	12	for	for	ADP
ajst-20773	117	13	individual	individual	ADJ
ajst-20773	117	14	patients	patient	NOUN
ajst-20773	117	15	,	,	PUNCT
ajst-20773	117	16	showing	show	VERB
ajst-20773	117	17	a	a	DET
ajst-20773	117	18	higher	high	ADJ
ajst-20773	117	19	number	number	NOUN
ajst-20773	117	20	of	of	ADP
ajst-20773	117	21	deaths	death	NOUN
ajst-20773	117	22	as	as	SCONJ
ajst-20773	117	23	risk	risk	NOUN
ajst-20773	117	24	scores	score	NOUN
ajst-20773	117	25	increased	increase	VERB
ajst-20773	117	26	.	.	PUNCT
ajst-20773	118	1	both	both	PRON
ajst-20773	118	2	univariate	univariate	ADJ
ajst-20773	118	3	and	and	CCONJ
ajst-20773	118	4	multivariate	multivariate	VERB
ajst-20773	118	5	cox	cox	PROPN
ajst-20773	118	6	regression	regression	PROPN
ajst-20773	118	7	analyses	analysis	NOUN
ajst-20773	118	8	confirmed	confirm	VERB
ajst-20773	118	9	that	that	SCONJ
ajst-20773	118	10	the	the	DET
ajst-20773	118	11	senlncsig	senlncsig	PROPN
ajst-20773	118	12	risk	risk	NOUN
ajst-20773	118	13	score	score	NOUN
ajst-20773	118	14	was	be	AUX
ajst-20773	118	15	an	an	DET
ajst-20773	118	16	independent	independent	ADJ
ajst-20773	118	17	prognostic	prognostic	ADJ
ajst-20773	118	18	indicator	indicator	NOUN
ajst-20773	118	19	for	for	ADP
ajst-20773	118	20	luad	luad	NOUN
ajst-20773	118	21	(	(	PUNCT
ajst-20773	118	22	figures	figure	NOUN
ajst-20773	118	23	12,13	12,13	NUM
ajst-20773	118	24	)	)	PUNCT
ajst-20773	118	25	,	,	PUNCT
ajst-20773	118	26	with	with	ADP
ajst-20773	118	27	an	an	DET
ajst-20773	118	28	auc	auc	NOUN
ajst-20773	118	29	of	of	ADP
ajst-20773	118	30	0.797	0.797	NUM
ajst-20773	118	31	,	,	PUNCT
ajst-20773	118	32	making	make	VERB
ajst-20773	118	33	it	it	PRON
ajst-20773	118	34	the	the	DET
ajst-20773	118	35	strongest	strong	ADJ
ajst-20773	118	36	predictor	predictor	NOUN
ajst-20773	118	37	of	of	ADP
ajst-20773	118	38	luad	luad	ADJ
ajst-20773	118	39	prognosis	prognosis	NOUN
ajst-20773	118	40	among	among	ADP
ajst-20773	118	41	the	the	DET
ajst-20773	118	42	clinicopathological	clinicopathological	ADJ
ajst-20773	118	43	variables	variable	NOUN
ajst-20773	118	44	studied	study	VERB
ajst-20773	118	45	(	(	PUNCT
ajst-20773	118	46	figure	figure	NOUN
ajst-20773	118	47	14	14	NUM
ajst-20773	118	48	)	)	PUNCT
ajst-20773	118	49	.	.	PUNCT
ajst-20773	119	1	the	the	DET
ajst-20773	119	2	auc	auc	NOUN
ajst-20773	119	3	values	value	NOUN
ajst-20773	119	4	for	for	ADP
ajst-20773	119	5	the	the	DET
ajst-20773	119	6	1	1	NUM
ajst-20773	119	7	-	-	PUNCT
ajst-20773	119	8	year	year	NOUN
ajst-20773	119	9	,	,	PUNCT
ajst-20773	119	10	3	3	NUM
ajst-20773	119	11	-	-	PUNCT
ajst-20773	119	12	year	year	NOUN
ajst-20773	119	13	,	,	PUNCT
ajst-20773	119	14	and	and	CCONJ
ajst-20773	119	15	5	5	NUM
ajst-20773	119	16	-	-	PUNCT
ajst-20773	119	17	year	year	NOUN
ajst-20773	119	18	roc	roc	PROPN
ajst-20773	119	19	curves	curve	NOUN
ajst-20773	119	20	were	be	AUX
ajst-20773	119	21	0.731	0.731	NUM
ajst-20773	119	22	,	,	PUNCT
ajst-20773	119	23	0.705	0.705	NUM
ajst-20773	119	24	,	,	PUNCT
ajst-20773	119	25	and	and	CCONJ
ajst-20773	119	26	0.756	0.756	NUM
ajst-20773	119	27	,	,	PUNCT
ajst-20773	119	28	respectively	respectively	ADV
ajst-20773	119	29	,	,	PUNCT
ajst-20773	119	30	demonstrating	demonstrate	VERB
ajst-20773	119	31	that	that	SCONJ
ajst-20773	119	32	senlncsig	senlncsig	PROPN
ajst-20773	119	33	effectively	effectively	ADV
ajst-20773	119	34	predicts	predict	VERB
ajst-20773	119	35	luad	luad	ADJ
ajst-20773	119	36	prognosis	prognosis	NOUN
ajst-20773	119	37	(	(	PUNCT
ajst-20773	119	38	figure	figure	NOUN
ajst-20773	119	39	15	15	NUM
ajst-20773	119	40	)	)	PUNCT
ajst-20773	119	41	.	.	PUNCT
ajst-20773	120	1	figure	figure	NOUN
ajst-20773	120	2	9	9	NUM
ajst-20773	120	3	.	.	PUNCT
ajst-20773	121	1	kaplan	kaplan	PROPN
ajst-20773	121	2	-	-	PUNCT
ajst-20773	121	3	meier	meier	PROPN
ajst-20773	121	4	survival	survival	NOUN
ajst-20773	121	5	curves	curve	NOUN
ajst-20773	121	6	for	for	ADP
ajst-20773	121	7	the	the	DET
ajst-20773	121	8	high	high	ADJ
ajst-20773	121	9	-	-	PUNCT
ajst-20773	121	10	risk	risk	NOUN
ajst-20773	121	11	and	and	CCONJ
ajst-20773	121	12	low	low	ADJ
ajst-20773	121	13	-	-	PUNCT
ajst-20773	121	14	risk	risk	NOUN
ajst-20773	121	15	groups	group	NOUN
ajst-20773	121	16	based	base	VERB
ajst-20773	121	17	on	on	ADP
ajst-20773	121	18	lung	lung	NOUN
ajst-20773	121	19	adenocarcinoma	adenocarcinoma	PROPN
ajst-20773	121	20	risk	risk	NOUN
ajst-20773	121	21	scores	score	NOUN
ajst-20773	121	22	.	.	PUNCT
ajst-20773	122	1	figure	figure	NOUN
ajst-20773	122	2	10	10	NUM
ajst-20773	122	3	.	.	PUNCT
ajst-20773	123	1	risk	risk	NOUN
ajst-20773	123	2	score	score	NOUN
ajst-20773	123	3	curves	curve	NOUN
ajst-20773	123	4	for	for	ADP
ajst-20773	123	5	the	the	DET
ajst-20773	123	6	high	high	ADJ
ajst-20773	123	7	and	and	CCONJ
ajst-20773	123	8	low	low	ADJ
ajst-20773	123	9	-	-	PUNCT
ajst-20773	123	10	risk	risk	NOUN
ajst-20773	123	11	groups	group	NOUN
ajst-20773	123	12	.	.	PUNCT
ajst-20773	124	1	figure	figure	VERB
ajst-20773	124	2	11	11	NUM
ajst-20773	124	3	.	.	PUNCT
ajst-20773	125	1	survival	survival	PROPN
ajst-20773	125	2	statistics	statistic	NOUN
ajst-20773	125	3	charts	chart	NOUN
ajst-20773	125	4	for	for	ADP
ajst-20773	125	5	the	the	DET
ajst-20773	125	6	high	high	ADJ
ajst-20773	125	7	and	and	CCONJ
ajst-20773	125	8	low	low	ADJ
ajst-20773	125	9	-	-	PUNCT
ajst-20773	125	10	risk	risk	NOUN
ajst-20773	125	11	groups	group	NOUN
ajst-20773	125	12	.	.	PUNCT
ajst-20773	126	1	19	19	NUM
ajst-20773	126	2	figure	figure	NOUN
ajst-20773	126	3	12	12	NUM
ajst-20773	126	4	.	.	PUNCT
ajst-20773	127	1	forest	forest	NOUN
ajst-20773	127	2	plot	plot	NOUN
ajst-20773	127	3	of	of	ADP
ajst-20773	127	4	univariate	univariate	ADJ
ajst-20773	127	5	cox	cox	PROPN
ajst-20773	127	6	regression	regression	NOUN
ajst-20773	127	7	analysis	analysis	NOUN
ajst-20773	127	8	for	for	ADP
ajst-20773	127	9	prognostic	prognostic	ADJ
ajst-20773	127	10	factors	factor	NOUN
ajst-20773	127	11	and	and	CCONJ
ajst-20773	127	12	risk	risk	NOUN
ajst-20773	127	13	scores	score	NOUN
ajst-20773	127	14	in	in	ADP
ajst-20773	127	15	lung	lung	NOUN
ajst-20773	127	16	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	127	17	.	.	PUNCT
ajst-20773	128	1	figure	figure	NOUN
ajst-20773	128	2	13	13	NUM
ajst-20773	128	3	.	.	PUNCT
ajst-20773	129	1	forest	forest	NOUN
ajst-20773	129	2	plot	plot	NOUN
ajst-20773	129	3	of	of	ADP
ajst-20773	129	4	multivariate	multivariate	NOUN
ajst-20773	129	5	cox	cox	PROPN
ajst-20773	129	6	regression	regression	VERB
ajst-20773	129	7	analysis	analysis	NOUN
ajst-20773	129	8	for	for	ADP
ajst-20773	129	9	clinical	clinical	ADJ
ajst-20773	129	10	factors	factor	NOUN
ajst-20773	129	11	and	and	CCONJ
ajst-20773	129	12	risk	risk	NOUN
ajst-20773	129	13	scores	score	NOUN
ajst-20773	129	14	in	in	ADP
ajst-20773	129	15	lung	lung	NOUN
ajst-20773	129	16	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	129	17	prognosis	prognosis	NOUN
ajst-20773	129	18	.	.	PUNCT
ajst-20773	130	1	figure	figure	NOUN
ajst-20773	130	2	14	14	NUM
ajst-20773	130	3	.	.	PUNCT
ajst-20773	131	1	roc	roc	PROPN
ajst-20773	131	2	curve	curve	NOUN
ajst-20773	131	3	of	of	ADP
ajst-20773	131	4	risk	risk	NOUN
ajst-20773	131	5	score	score	NOUN
ajst-20773	131	6	and	and	CCONJ
ajst-20773	131	7	other	other	ADJ
ajst-20773	131	8	clinical	clinical	ADJ
ajst-20773	131	9	factors	factor	NOUN
ajst-20773	131	10	.	.	PUNCT
ajst-20773	132	1	20	20	NUM
ajst-20773	132	2	figure	figure	NOUN
ajst-20773	132	3	15	15	NUM
ajst-20773	132	4	.	.	PUNCT
ajst-20773	133	1	the	the	DET
ajst-20773	133	2	roc	roc	PROPN
ajst-20773	133	3	curves	curve	NOUN
ajst-20773	133	4	of	of	ADP
ajst-20773	133	5	the	the	DET
ajst-20773	133	6	risk	risk	NOUN
ajst-20773	133	7	score	score	NOUN
ajst-20773	133	8	at	at	ADP
ajst-20773	133	9	1	1	NUM
ajst-20773	133	10	,	,	PUNCT
ajst-20773	133	11	3	3	NUM
ajst-20773	133	12	,	,	PUNCT
ajst-20773	133	13	and	and	CCONJ
ajst-20773	133	14	5	5	NUM
ajst-20773	133	15	years	year	NOUN
ajst-20773	133	16	.	.	PUNCT
ajst-20773	134	1	figure	figure	NOUN
ajst-20773	134	2	16	16	NUM
ajst-20773	134	3	illustrates	illustrate	VERB
ajst-20773	134	4	the	the	DET
ajst-20773	134	5	levels	level	NOUN
ajst-20773	134	6	of	of	ADP
ajst-20773	134	7	expression	expression	NOUN
ajst-20773	134	8	of	of	ADP
ajst-20773	134	9	nine	nine	NUM
ajst-20773	134	10	lncrnas	lncrna	NOUN
ajst-20773	134	11	and	and	CCONJ
ajst-20773	134	12	clinicopathological	clinicopathological	ADJ
ajst-20773	134	13	factors	factor	NOUN
ajst-20773	134	14	within	within	ADP
ajst-20773	134	15	the	the	DET
ajst-20773	134	16	senlncsig	senlncsig	PROPN
ajst-20773	134	17	model	model	PROPN
ajst-20773	134	18	.	.	PUNCT
ajst-20773	135	1	principal	principal	ADJ
ajst-20773	135	2	component	component	NOUN
ajst-20773	135	3	analysis	analysis	NOUN
ajst-20773	135	4	(	(	PUNCT
ajst-20773	135	5	pca	pca	NOUN
ajst-20773	135	6	)	)	PUNCT
ajst-20773	135	7	was	be	AUX
ajst-20773	135	8	conducted	conduct	VERB
ajst-20773	135	9	on	on	ADP
ajst-20773	135	10	a	a	DET
ajst-20773	135	11	genome	genome	NOUN
ajst-20773	135	12	-	-	PUNCT
ajst-20773	135	13	wide	wide	ADJ
ajst-20773	135	14	scale	scale	NOUN
ajst-20773	135	15	,	,	PUNCT
ajst-20773	135	16	senescence	senescence	NOUN
ajst-20773	135	17	-	-	PUNCT
ajst-20773	135	18	related	relate	VERB
ajst-20773	135	19	degs	deg	NOUN
ajst-20773	135	20	,	,	PUNCT
ajst-20773	135	21	senescence	senescence	NOUN
ajst-20773	135	22	-	-	PUNCT
ajst-20773	135	23	related	relate	VERB
ajst-20773	135	24	lncrnas	lncrna	NOUN
ajst-20773	135	25	,	,	PUNCT
ajst-20773	135	26	and	and	CCONJ
ajst-20773	135	27	senlncsig	senlncsig	NOUN
ajst-20773	135	28	to	to	PART
ajst-20773	135	29	discern	discern	VERB
ajst-20773	135	30	between	between	ADP
ajst-20773	135	31	high	high	ADJ
ajst-20773	135	32	-	-	PUNCT
ajst-20773	135	33	risk	risk	NOUN
ajst-20773	135	34	and	and	CCONJ
ajst-20773	135	35	low	low	ADJ
ajst-20773	135	36	-	-	PUNCT
ajst-20773	135	37	risk	risk	NOUN
ajst-20773	135	38	patients	patient	NOUN
ajst-20773	135	39	(	(	PUNCT
ajst-20773	135	40	figures	figure	NOUN
ajst-20773	135	41	17a	17a	X
ajst-20773	135	42	–	–	PUNCT
ajst-20773	135	43	d	d	NOUN
ajst-20773	135	44	)	)	PUNCT
ajst-20773	135	45	.	.	PUNCT
ajst-20773	136	1	the	the	DET
ajst-20773	136	2	senlncsig	senlncsig	PROPN
ajst-20773	136	3	model	model	NOUN
ajst-20773	136	4	effectively	effectively	ADV
ajst-20773	136	5	differentiated	differentiate	VERB
ajst-20773	136	6	between	between	ADP
ajst-20773	136	7	lowrisk	lowrisk	PROPN
ajst-20773	136	8	and	and	CCONJ
ajst-20773	136	9	high	high	ADJ
ajst-20773	136	10	-	-	PUNCT
ajst-20773	136	11	risk	risk	NOUN
ajst-20773	136	12	groups	group	NOUN
ajst-20773	136	13	,	,	PUNCT
ajst-20773	136	14	as	as	SCONJ
ajst-20773	136	15	evidenced	evidence	VERB
ajst-20773	136	16	in	in	ADP
ajst-20773	136	17	figure	figure	NOUN
ajst-20773	136	18	17d	17d	NOUN
ajst-20773	136	19	,	,	PUNCT
ajst-20773	136	20	highlighting	highlight	VERB
ajst-20773	136	21	the	the	DET
ajst-20773	136	22	precision	precision	NOUN
ajst-20773	136	23	of	of	ADP
ajst-20773	136	24	the	the	DET
ajst-20773	136	25	model	model	NOUN
ajst-20773	136	26	.	.	PUNCT
ajst-20773	137	1	figure	figure	VERB
ajst-20773	137	2	16	16	NUM
ajst-20773	137	3	.	.	PUNCT
ajst-20773	138	1	heat	heat	NOUN
ajst-20773	138	2	map	map	NOUN
ajst-20773	138	3	of	of	ADP
ajst-20773	138	4	the	the	DET
ajst-20773	138	5	relationship	relationship	NOUN
ajst-20773	138	6	between	between	ADP
ajst-20773	138	7	risk	risk	NOUN
ajst-20773	138	8	score	score	NOUN
ajst-20773	138	9	and	and	CCONJ
ajst-20773	138	10	various	various	ADJ
ajst-20773	138	11	clinical	clinical	ADJ
ajst-20773	138	12	characteristic	characteristic	ADJ
ajst-20773	138	13	factors	factor	NOUN
ajst-20773	138	14	21	21	NUM
ajst-20773	138	15	figure	figure	NOUN
ajst-20773	138	16	17	17	NUM
ajst-20773	138	17	.	.	PUNCT
ajst-20773	139	1	pca	pca	PROPN
ajst-20773	139	2	of	of	ADP
ajst-20773	139	3	whole	whole	ADJ
ajst-20773	139	4	genome	genome	NOUN
ajst-20773	139	5	(	(	PUNCT
ajst-20773	139	6	a	a	NOUN
ajst-20773	139	7	)	)	PUNCT
ajst-20773	139	8	,	,	PUNCT
ajst-20773	139	9	cell	cell	NOUN
ajst-20773	139	10	aging	age	VERB
ajst-20773	139	11	related	relate	VERB
ajst-20773	139	12	genes	gene	NOUN
ajst-20773	139	13	(	(	PUNCT
ajst-20773	139	14	b	b	NOUN
ajst-20773	139	15	)	)	PUNCT
ajst-20773	139	16	,	,	PUNCT
ajst-20773	139	17	cell	cell	NOUN
ajst-20773	139	18	aging	age	VERB
ajst-20773	139	19	related	relate	VERB
ajst-20773	139	20	lncrna	lncrna	NOUN
ajst-20773	139	21	(	(	PUNCT
ajst-20773	139	22	c	c	NOUN
ajst-20773	139	23	)	)	PUNCT
ajst-20773	139	24	,	,	PUNCT
ajst-20773	139	25	senlncsig	senlncsig	PROPN
ajst-20773	139	26	model	model	NOUN
ajst-20773	139	27	(	(	PUNCT
ajst-20773	139	28	d	d	NOUN
ajst-20773	139	29	)	)	PUNCT
ajst-20773	139	30	figure	figure	NOUN
ajst-20773	139	31	18	18	NUM
ajst-20773	139	32	.	.	PUNCT
ajst-20773	140	1	kaplan	kaplan	PROPN
ajst-20773	140	2	–	–	PUNCT
ajst-20773	140	3	meier	meier	PROPN
ajst-20773	140	4	survival	survival	NOUN
ajst-20773	140	5	curves	curve	NOUN
ajst-20773	140	6	for	for	ADP
ajst-20773	140	7	low	low	ADJ
ajst-20773	140	8	and	and	CCONJ
ajst-20773	140	9	high	high	ADJ
ajst-20773	140	10	risk	risk	NOUN
ajst-20773	140	11	groups	group	NOUN
ajst-20773	140	12	classified	classify	VERB
ajst-20773	140	13	based	base	VERB
ajst-20773	140	14	on	on	ADP
ajst-20773	140	15	clinicopathological	clinicopathological	ADJ
ajst-20773	140	16	variables	variable	NOUN
ajst-20773	140	17	.	.	PUNCT
ajst-20773	141	1	(	(	PUNCT
ajst-20773	141	2	a	a	DET
ajst-20773	141	3	,	,	PUNCT
ajst-20773	141	4	b	b	NOUN
ajst-20773	141	5	)	)	PUNCT
ajst-20773	141	6	age	age	NOUN
ajst-20773	141	7	;	;	PUNCT
ajst-20773	141	8	(	(	PUNCT
ajst-20773	141	9	c	c	X
ajst-20773	141	10	,	,	PUNCT
ajst-20773	141	11	d	d	NOUN
ajst-20773	141	12	)	)	PUNCT
ajst-20773	141	13	sex	sex	NOUN
ajst-20773	141	14	;	;	PUNCT
ajst-20773	141	15	(	(	PUNCT
ajst-20773	141	16	e	e	NOUN
ajst-20773	141	17	,	,	PUNCT
ajst-20773	141	18	f	f	X
ajst-20773	141	19	)	)	PUNCT
ajst-20773	141	20	m	m	NOUN
ajst-20773	141	21	stage	stage	NOUN
ajst-20773	141	22	;	;	PUNCT
ajst-20773	141	23	(	(	PUNCT
ajst-20773	141	24	g	g	NOUN
ajst-20773	141	25	–	–	PUNCT
ajst-20773	141	26	i	i	NOUN
ajst-20773	141	27	)	)	PUNCT
ajst-20773	141	28	n	n	PRON
ajst-20773	141	29	stage	stage	NOUN
ajst-20773	141	30	;	;	PUNCT
ajst-20773	141	31	(	(	PUNCT
ajst-20773	141	32	j	j	PROPN
ajst-20773	141	33	–	–	PUNCT
ajst-20773	141	34	m	m	NOUN
ajst-20773	141	35	)	)	PUNCT
ajst-20773	141	36	overall	overall	ADJ
ajst-20773	141	37	stage	stage	NOUN
ajst-20773	141	38	;	;	PUNCT
ajst-20773	141	39	(	(	PUNCT
ajst-20773	141	40	n	n	CCONJ
ajst-20773	141	41	–	–	PUNCT
ajst-20773	141	42	q	q	NOUN
ajst-20773	141	43	)	)	PUNCT
ajst-20773	141	44	t	t	NOUN
ajst-20773	141	45	stage	stage	NOUN
ajst-20773	141	46	.	.	PUNCT
ajst-20773	142	1	t	t	PROPN
ajst-20773	142	2	,	,	PUNCT
ajst-20773	142	3	tumor	tumor	NOUN
ajst-20773	142	4	;	;	PUNCT
ajst-20773	142	5	n	n	CCONJ
ajst-20773	142	6	,	,	PUNCT
ajst-20773	142	7	lymph	lymph	NOUN
ajst-20773	142	8	node	node	NOUN
ajst-20773	142	9	metastasis	metastasis	NOUN
ajst-20773	142	10	;	;	PUNCT
ajst-20773	142	11	m	m	SYM
ajst-20773	142	12	,	,	PUNCT
ajst-20773	142	13	distant	distant	ADJ
ajst-20773	142	14	metastasis	metastasis	NOUN
ajst-20773	142	15	.	.	PUNCT
ajst-20773	143	1	22	22	NUM
ajst-20773	144	1	moreover	moreover	ADV
ajst-20773	144	2	,	,	PUNCT
ajst-20773	144	3	figures	figure	NOUN
ajst-20773	144	4	18a	18a	NOUN
ajst-20773	144	5	-	-	PUNCT
ajst-20773	144	6	q	q	NOUN
ajst-20773	144	7	illustrate	illustrate	VERB
ajst-20773	144	8	the	the	DET
ajst-20773	144	9	connection	connection	NOUN
ajst-20773	144	10	between	between	ADP
ajst-20773	144	11	clinical	clinical	ADJ
ajst-20773	144	12	variables	variable	NOUN
ajst-20773	144	13	and	and	CCONJ
ajst-20773	144	14	the	the	DET
ajst-20773	144	15	risk	risk	NOUN
ajst-20773	144	16	score	score	NOUN
ajst-20773	144	17	.	.	PUNCT
ajst-20773	145	1	notable	notable	ADJ
ajst-20773	145	2	associations	association	NOUN
ajst-20773	145	3	were	be	AUX
ajst-20773	145	4	found	find	VERB
ajst-20773	145	5	between	between	ADP
ajst-20773	145	6	the	the	DET
ajst-20773	145	7	risk	risk	NOUN
ajst-20773	145	8	score	score	NOUN
ajst-20773	145	9	and	and	CCONJ
ajst-20773	145	10	factors	factor	NOUN
ajst-20773	145	11	such	such	ADJ
ajst-20773	145	12	as	as	ADP
ajst-20773	145	13	age	age	NOUN
ajst-20773	145	14	(	(	PUNCT
ajst-20773	145	15	both	both	CCONJ
ajst-20773	145	16	above	above	ADP
ajst-20773	145	17	and	and	CCONJ
ajst-20773	145	18	below	below	ADP
ajst-20773	145	19	65	65	NUM
ajst-20773	145	20	years	year	NOUN
ajst-20773	145	21	,	,	PUNCT
ajst-20773	145	22	as	as	SCONJ
ajst-20773	145	23	shown	show	VERB
ajst-20773	145	24	in	in	ADP
ajst-20773	145	25	figures	figure	NOUN
ajst-20773	145	26	18a	18a	NOUN
ajst-20773	145	27	and	and	CCONJ
ajst-20773	145	28	b	b	NOUN
ajst-20773	145	29	)	)	PUNCT
ajst-20773	145	30	,	,	PUNCT
ajst-20773	145	31	gender	gender	NOUN
ajst-20773	145	32	(	(	PUNCT
ajst-20773	145	33	female	female	ADJ
ajst-20773	145	34	and	and	CCONJ
ajst-20773	145	35	male	male	NOUN
ajst-20773	145	36	,	,	PUNCT
ajst-20773	145	37	figures	figure	NOUN
ajst-20773	145	38	18c	18c	NOUN
ajst-20773	145	39	and	and	CCONJ
ajst-20773	145	40	d	d	NOUN
ajst-20773	145	41	)	)	PUNCT
ajst-20773	145	42	,	,	PUNCT
ajst-20773	145	43	m0	m0	NOUN
ajst-20773	145	44	stage	stage	NOUN
ajst-20773	145	45	(	(	PUNCT
ajst-20773	145	46	figure	figure	NOUN
ajst-20773	145	47	18e	18e	NOUN
ajst-20773	145	48	)	)	PUNCT
ajst-20773	145	49	,	,	PUNCT
ajst-20773	145	50	n0	n0	ADJ
ajst-20773	145	51	and	and	CCONJ
ajst-20773	145	52	n1	n1	ADJ
ajst-20773	145	53	stages	stage	NOUN
ajst-20773	145	54	(	(	PUNCT
ajst-20773	145	55	figures	figure	NOUN
ajst-20773	145	56	18	18	NUM
ajst-20773	145	57	g	g	NOUN
ajst-20773	145	58	and	and	CCONJ
ajst-20773	145	59	h	h	NOUN
ajst-20773	145	60	)	)	PUNCT
ajst-20773	145	61	,	,	PUNCT
ajst-20773	145	62	overall	overall	ADJ
ajst-20773	145	63	tnm	tnm	PROPN
ajst-20773	145	64	stages	stage	NOUN
ajst-20773	145	65	2	2	NUM
ajst-20773	145	66	and	and	CCONJ
ajst-20773	145	67	3	3	NUM
ajst-20773	145	68	(	(	PUNCT
ajst-20773	145	69	figures	figure	NOUN
ajst-20773	145	70	18k	18k	NOUN
ajst-20773	145	71	and	and	CCONJ
ajst-20773	145	72	l	l	NOUN
ajst-20773	145	73	)	)	PUNCT
ajst-20773	145	74	,	,	PUNCT
ajst-20773	145	75	and	and	CCONJ
ajst-20773	145	76	t2	t2	PROPN
ajst-20773	145	77	,	,	PUNCT
ajst-20773	145	78	t3	t3	PROPN
ajst-20773	145	79	,	,	PUNCT
ajst-20773	145	80	and	and	CCONJ
ajst-20773	145	81	t4	t4	PROPN
ajst-20773	145	82	stages	stage	NOUN
ajst-20773	145	83	(	(	PUNCT
ajst-20773	145	84	figures	figure	NOUN
ajst-20773	145	85	18o	18o	NOUN
ajst-20773	145	86	-	-	SYM
ajst-20773	145	87	q	q	NOUN
ajst-20773	145	88	)	)	PUNCT
ajst-20773	145	89	.	.	PUNCT
ajst-20773	146	1	the	the	DET
ajst-20773	146	2	senlncsig	senlncsig	PROPN
ajst-20773	146	3	risk	risk	NOUN
ajst-20773	146	4	score	score	NOUN
ajst-20773	146	5	was	be	AUX
ajst-20773	146	6	confirmed	confirm	VERB
ajst-20773	146	7	as	as	ADP
ajst-20773	146	8	an	an	DET
ajst-20773	146	9	independent	independent	ADJ
ajst-20773	146	10	prognostic	prognostic	ADJ
ajst-20773	146	11	risk	risk	NOUN
ajst-20773	146	12	factor	factor	NOUN
ajst-20773	146	13	for	for	ADP
ajst-20773	146	14	luad	luad	ADJ
ajst-20773	146	15	patients	patient	NOUN
ajst-20773	146	16	.	.	PUNCT
ajst-20773	147	1	3.4	3.4	NUM
ajst-20773	147	2	.	.	PUNCT
ajst-20773	147	3	construction	construction	NOUN
ajst-20773	147	4	of	of	ADP
ajst-20773	147	5	the	the	DET
ajst-20773	147	6	nomogram	nomogram	PROPN
ajst-20773	147	7	a	a	DET
ajst-20773	147	8	nomogram	nomogram	NOUN
ajst-20773	147	9	for	for	ADP
ajst-20773	147	10	clinical	clinical	ADJ
ajst-20773	147	11	prognostic	prognostic	ADJ
ajst-20773	147	12	evaluation	evaluation	NOUN
ajst-20773	147	13	was	be	AUX
ajst-20773	147	14	developed	develop	VERB
ajst-20773	147	15	using	use	VERB
ajst-20773	147	16	the	the	DET
ajst-20773	147	17	luadsenlncsig	luadsenlncsig	ADJ
ajst-20773	147	18	risk	risk	NOUN
ajst-20773	147	19	score	score	NOUN
ajst-20773	147	20	along	along	ADP
ajst-20773	147	21	with	with	ADP
ajst-20773	147	22	other	other	ADJ
ajst-20773	147	23	clinicopathological	clinicopathological	ADJ
ajst-20773	147	24	factors	factor	NOUN
ajst-20773	147	25	,	,	PUNCT
ajst-20773	147	26	aimed	aim	VERB
ajst-20773	147	27	at	at	ADP
ajst-20773	147	28	predicting	predict	VERB
ajst-20773	147	29	the	the	DET
ajst-20773	147	30	survival	survival	NOUN
ajst-20773	147	31	likelihood	likelihood	NOUN
ajst-20773	147	32	at	at	ADP
ajst-20773	147	33	1	1	NUM
ajst-20773	147	34	,	,	PUNCT
ajst-20773	147	35	3	3	NUM
ajst-20773	147	36	,	,	PUNCT
ajst-20773	147	37	and	and	CCONJ
ajst-20773	147	38	5	5	NUM
ajst-20773	147	39	years	year	NOUN
ajst-20773	147	40	for	for	ADP
ajst-20773	147	41	luad	luad	NOUN
ajst-20773	147	42	patients	patient	NOUN
ajst-20773	147	43	(	(	PUNCT
ajst-20773	147	44	figure	figure	NOUN
ajst-20773	147	45	19	19	NUM
ajst-20773	147	46	)	)	PUNCT
ajst-20773	147	47	.	.	PUNCT
ajst-20773	148	1	according	accord	VERB
ajst-20773	148	2	to	to	ADP
ajst-20773	148	3	three	three	NUM
ajst-20773	148	4	calibration	calibration	NOUN
ajst-20773	148	5	plots	plot	NOUN
ajst-20773	148	6	,	,	PUNCT
ajst-20773	148	7	the	the	DET
ajst-20773	148	8	mortality	mortality	NOUN
ajst-20773	148	9	predicted	predict	VERB
ajst-20773	148	10	by	by	ADP
ajst-20773	148	11	the	the	DET
ajst-20773	148	12	nomogram	nomogram	PROPN
ajst-20773	148	13	closely	closely	ADV
ajst-20773	148	14	matched	match	VERB
ajst-20773	148	15	the	the	DET
ajst-20773	148	16	observed	observe	VERB
ajst-20773	148	17	mortality	mortality	NOUN
ajst-20773	148	18	rates	rate	NOUN
ajst-20773	148	19	(	(	PUNCT
ajst-20773	148	20	figures	figure	NOUN
ajst-20773	148	21	20a	20a	NOUN
ajst-20773	148	22	-	-	SYM
ajst-20773	148	23	c	c	NOUN
ajst-20773	148	24	)	)	PUNCT
ajst-20773	148	25	.	.	PUNCT
ajst-20773	149	1	figure	figure	NOUN
ajst-20773	149	2	19	19	NUM
ajst-20773	149	3	.	.	PUNCT
ajst-20773	150	1	a	a	DET
ajst-20773	150	2	nomogram	nomogram	NOUN
ajst-20773	150	3	constructed	construct	VERB
ajst-20773	150	4	based	base	VERB
ajst-20773	150	5	on	on	ADP
ajst-20773	150	6	clinical	clinical	ADJ
ajst-20773	150	7	characteristic	characteristic	ADJ
ajst-20773	150	8	factors	factor	NOUN
ajst-20773	150	9	and	and	CCONJ
ajst-20773	150	10	risk	risk	NOUN
ajst-20773	150	11	scores	score	NOUN
ajst-20773	150	12	.	.	PUNCT
ajst-20773	151	1	figure	figure	NOUN
ajst-20773	151	2	20	20	NUM
ajst-20773	151	3	.	.	PUNCT
ajst-20773	152	1	calibration	calibration	NOUN
ajst-20773	152	2	plots	plot	NOUN
ajst-20773	152	3	for	for	ADP
ajst-20773	152	4	1	1	NUM
ajst-20773	152	5	,	,	PUNCT
ajst-20773	152	6	3	3	NUM
ajst-20773	152	7	,	,	PUNCT
ajst-20773	152	8	and	and	CCONJ
ajst-20773	152	9	5	5	NUM
ajst-20773	152	10	-	-	PUNCT
ajst-20773	152	11	year	year	NOUN
ajst-20773	152	12	overall	overall	ADJ
ajst-20773	152	13	survival	survival	NOUN
ajst-20773	152	14	(	(	PUNCT
ajst-20773	152	15	os	os	NOUN
ajst-20773	152	16	)	)	PUNCT
ajst-20773	152	17	of	of	ADP
ajst-20773	152	18	lung	lung	NOUN
ajst-20773	152	19	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	152	20	patients	patient	NOUN
ajst-20773	152	21	obtained	obtain	VERB
ajst-20773	152	22	from	from	ADP
ajst-20773	152	23	the	the	DET
ajst-20773	152	24	nomogram	nomogram	NOUN
ajst-20773	152	25	.	.	PUNCT
ajst-20773	153	1	3.5	3.5	NUM
ajst-20773	153	2	.	.	PUNCT
ajst-20773	154	1	internal	internal	ADJ
ajst-20773	154	2	validation	validation	NOUN
ajst-20773	154	3	of	of	ADP
ajst-20773	154	4	the	the	DET
ajst-20773	154	5	senlncsig	senlncsig	NOUN
ajst-20773	154	6	the	the	DET
ajst-20773	154	7	tcga	tcga	PROPN
ajst-20773	154	8	-	-	PUNCT
ajst-20773	154	9	luad	luad	NOUN
ajst-20773	154	10	patient	patient	NOUN
ajst-20773	154	11	group	group	NOUN
ajst-20773	154	12	,	,	PUNCT
ajst-20773	154	13	consisting	consist	VERB
ajst-20773	154	14	of	of	ADP
ajst-20773	154	15	480	480	NUM
ajst-20773	154	16	individuals	individual	NOUN
ajst-20773	154	17	,	,	PUNCT
ajst-20773	154	18	was	be	AUX
ajst-20773	154	19	split	split	VERB
ajst-20773	154	20	into	into	ADP
ajst-20773	154	21	two	two	NUM
ajst-20773	154	22	internal	internal	ADJ
ajst-20773	154	23	validation	validation	NOUN
ajst-20773	154	24	cohorts	cohort	NOUN
ajst-20773	154	25	,	,	PUNCT
ajst-20773	154	26	each	each	PRON
ajst-20773	154	27	containing	contain	VERB
ajst-20773	154	28	240	240	NUM
ajst-20773	154	29	patients	patient	NOUN
ajst-20773	154	30	,	,	PUNCT
ajst-20773	154	31	to	to	PART
ajst-20773	154	32	verify	verify	VERB
ajst-20773	154	33	the	the	DET
ajst-20773	154	34	universal	universal	ADJ
ajst-20773	154	35	applicability	applicability	NOUN
ajst-20773	154	36	of	of	ADP
ajst-20773	154	37	senlncsig	senlncsig	PROPN
ajst-20773	154	38	to	to	ADP
ajst-20773	154	39	predicting	predict	VERB
ajst-20773	154	40	overall	overall	ADJ
ajst-20773	154	41	survival	survival	NOUN
ajst-20773	154	42	(	(	PUNCT
ajst-20773	154	43	os	os	NOUN
ajst-20773	154	44	)	)	PUNCT
ajst-20773	154	45	in	in	ADP
ajst-20773	154	46	luad	luad	NOUN
ajst-20773	154	47	.	.	PUNCT
ajst-20773	155	1	the	the	DET
ajst-20773	155	2	clinical	clinical	ADJ
ajst-20773	155	3	details	detail	NOUN
ajst-20773	155	4	of	of	ADP
ajst-20773	155	5	the	the	DET
ajst-20773	155	6	sample	sample	NOUN
ajst-20773	155	7	are	be	AUX
ajst-20773	155	8	provided	provide	VERB
ajst-20773	155	9	in	in	ADP
ajst-20773	155	10	table	table	NOUN
ajst-20773	155	11	1	1	NUM
ajst-20773	155	12	.	.	PUNCT
ajst-20773	156	1	in	in	ADP
ajst-20773	156	2	both	both	CCONJ
ajst-20773	156	3	the	the	DET
ajst-20773	156	4	first	first	ADJ
ajst-20773	156	5	and	and	CCONJ
ajst-20773	156	6	second	second	ADJ
ajst-20773	156	7	internal	internal	ADJ
ajst-20773	156	8	cohorts	cohort	NOUN
ajst-20773	156	9	,	,	PUNCT
ajst-20773	156	10	patients	patient	NOUN
ajst-20773	156	11	in	in	ADP
ajst-20773	156	12	the	the	DET
ajst-20773	156	13	high	high	ADJ
ajst-20773	156	14	-	-	PUNCT
ajst-20773	156	15	risk	risk	NOUN
ajst-20773	156	16	group	group	NOUN
ajst-20773	156	17	exhibited	exhibit	VERB
ajst-20773	156	18	shorter	short	ADJ
ajst-20773	156	19	os	os	NOUN
ajst-20773	156	20	compared	compare	VERB
ajst-20773	156	21	to	to	ADP
ajst-20773	156	22	those	those	PRON
ajst-20773	156	23	in	in	ADP
ajst-20773	156	24	the	the	DET
ajst-20773	156	25	low	low	ADJ
ajst-20773	156	26	-	-	PUNCT
ajst-20773	156	27	risk	risk	NOUN
ajst-20773	156	28	group	group	NOUN
ajst-20773	156	29	(	(	PUNCT
ajst-20773	156	30	figures	figure	NOUN
ajst-20773	156	31	21a	21a	NUM
ajst-20773	156	32	,	,	PUNCT
ajst-20773	156	33	c	c	NOUN
ajst-20773	156	34	)	)	PUNCT
ajst-20773	156	35	,	,	PUNCT
ajst-20773	156	36	aligning	align	VERB
ajst-20773	156	37	with	with	ADP
ajst-20773	156	38	the	the	DET
ajst-20773	156	39	findings	finding	NOUN
ajst-20773	156	40	from	from	ADP
ajst-20773	156	41	the	the	DET
ajst-20773	156	42	broader	broad	ADJ
ajst-20773	156	43	tcga	tcga	NOUN
ajst-20773	156	44	-	-	PUNCT
ajst-20773	156	45	luad	luad	NOUN
ajst-20773	156	46	dataset	dataset	NOUN
ajst-20773	156	47	.	.	PUNCT
ajst-20773	157	1	additionally	additionally	ADV
ajst-20773	157	2	,	,	PUNCT
ajst-20773	157	3	the	the	DET
ajst-20773	157	4	area	area	NOUN
ajst-20773	157	5	under	under	ADP
ajst-20773	157	6	the	the	DET
ajst-20773	157	7	curve	curve	NOUN
ajst-20773	157	8	(	(	PUNCT
ajst-20773	157	9	auc	auc	NOUN
ajst-20773	157	10	)	)	PUNCT
ajst-20773	157	11	for	for	ADP
ajst-20773	157	12	1	1	NUM
ajst-20773	157	13	-	-	PUNCT
ajst-20773	157	14	year	year	NOUN
ajst-20773	157	15	,	,	PUNCT
ajst-20773	157	16	3	3	NUM
ajst-20773	157	17	-	-	PUNCT
ajst-20773	157	18	year	year	NOUN
ajst-20773	157	19	,	,	PUNCT
ajst-20773	157	20	and	and	CCONJ
ajst-20773	157	21	5	5	NUM
ajst-20773	157	22	-	-	PUNCT
ajst-20773	157	23	year	year	NOUN
ajst-20773	157	24	survival	survival	NOUN
ajst-20773	157	25	was	be	AUX
ajst-20773	157	26	0.77	0.77	NUM
ajst-20773	157	27	,	,	PUNCT
ajst-20773	157	28	0.733	0.733	NUM
ajst-20773	157	29	,	,	PUNCT
ajst-20773	157	30	and	and	CCONJ
ajst-20773	157	31	0.777	0.777	NUM
ajst-20773	157	32	in	in	ADP
ajst-20773	157	33	the	the	DET
ajst-20773	157	34	first	first	ADJ
ajst-20773	157	35	internal	internal	ADJ
ajst-20773	157	36	cohort	cohort	NOUN
ajst-20773	157	37	(	(	PUNCT
ajst-20773	157	38	figure	figure	NOUN
ajst-20773	157	39	21b	21b	NOUN
ajst-20773	157	40	)	)	PUNCT
ajst-20773	157	41	and	and	CCONJ
ajst-20773	157	42	0.697	0.697	NUM
ajst-20773	157	43	,	,	PUNCT
ajst-20773	157	44	0.678	0.678	NUM
ajst-20773	157	45	,	,	PUNCT
ajst-20773	157	46	and	and	CCONJ
ajst-20773	157	47	0.735	0.735	NUM
ajst-20773	157	48	in	in	ADP
ajst-20773	157	49	the	the	DET
ajst-20773	157	50	second	second	ADJ
ajst-20773	157	51	internal	internal	ADJ
ajst-20773	157	52	cohort	cohort	NOUN
ajst-20773	157	53	(	(	PUNCT
ajst-20773	157	54	figure	figure	NOUN
ajst-20773	157	55	21d	21d	NOUN
ajst-20773	157	56	)	)	PUNCT
ajst-20773	157	57	,	,	PUNCT
ajst-20773	157	58	respectively	respectively	ADV
ajst-20773	157	59	.	.	PUNCT
ajst-20773	158	1	these	these	DET
ajst-20773	158	2	outcomes	outcome	NOUN
ajst-20773	158	3	affirm	affirm	VERB
ajst-20773	158	4	the	the	DET
ajst-20773	158	5	effectiveness	effectiveness	NOUN
ajst-20773	158	6	of	of	ADP
ajst-20773	158	7	senlncsig	senlncsig	NOUN
ajst-20773	158	8	across	across	ADP
ajst-20773	158	9	both	both	DET
ajst-20773	158	10	validation	validation	NOUN
ajst-20773	158	11	cohorts	cohort	NOUN
ajst-20773	158	12	,	,	PUNCT
ajst-20773	158	13	underscoring	underscore	VERB
ajst-20773	158	14	the	the	DET
ajst-20773	158	15	reliability	reliability	NOUN
ajst-20773	158	16	of	of	ADP
ajst-20773	158	17	the	the	DET
ajst-20773	158	18	predictive	predictive	ADJ
ajst-20773	158	19	model	model	NOUN
ajst-20773	158	20	.	.	PUNCT
ajst-20773	159	1	23	23	NUM
ajst-20773	159	2	figure	figure	NOUN
ajst-20773	159	3	21	21	NUM
ajst-20773	159	4	.	.	PUNCT
ajst-20773	160	1	kaplan	kaplan	PROPN
ajst-20773	160	2	-	-	PUNCT
ajst-20773	160	3	meier	meier	PROPN
ajst-20773	160	4	curves	curve	NOUN
ajst-20773	160	5	and	and	CCONJ
ajst-20773	160	6	roc	roc	PROPN
ajst-20773	160	7	curves	curve	NOUN
ajst-20773	160	8	for	for	ADP
ajst-20773	160	9	the	the	DET
ajst-20773	160	10	two	two	NUM
ajst-20773	160	11	validation	validation	NOUN
ajst-20773	160	12	cohorts	cohort	NOUN
ajst-20773	160	13	.	.	PUNCT
ajst-20773	161	1	3.6	3.6	NUM
ajst-20773	161	2	.	.	PUNCT
ajst-20773	161	3	identification	identification	NOUN
ajst-20773	161	4	of	of	ADP
ajst-20773	161	5	biological	biological	ADJ
ajst-20773	161	6	pathways	pathway	NOUN
ajst-20773	161	7	associated	associate	VERB
ajst-20773	161	8	with	with	ADP
ajst-20773	161	9	senlncsig	senlncsig	PROPN
ajst-20773	161	10	single	single	ADJ
ajst-20773	161	11	gsea	gsea	NOUN
ajst-20773	161	12	enrichment	enrichment	NOUN
ajst-20773	161	13	analysis	analysis	NOUN
ajst-20773	161	14	of	of	ADP
ajst-20773	161	15	the	the	DET
ajst-20773	161	16	high	high	ADJ
ajst-20773	161	17	-	-	PUNCT
ajst-20773	161	18	risk	risk	NOUN
ajst-20773	161	19	and	and	CCONJ
ajst-20773	161	20	lowrisk	lowrisk	NOUN
ajst-20773	161	21	groups	group	NOUN
ajst-20773	161	22	,	,	PUNCT
ajst-20773	161	23	as	as	SCONJ
ajst-20773	161	24	distinguished	distinguish	VERB
ajst-20773	161	25	by	by	ADP
ajst-20773	161	26	the	the	DET
ajst-20773	161	27	model	model	NOUN
ajst-20773	161	28	's	's	PART
ajst-20773	161	29	risk	risk	NOUN
ajst-20773	161	30	scores	score	NOUN
ajst-20773	161	31	,	,	PUNCT
ajst-20773	161	32	showed	show	VERB
ajst-20773	161	33	differential	differential	ADJ
ajst-20773	161	34	enrichment	enrichment	NOUN
ajst-20773	161	35	in	in	ADP
ajst-20773	161	36	kegg	kegg	NOUN
ajst-20773	161	37	signaling	signal	VERB
ajst-20773	161	38	pathways	pathway	NOUN
ajst-20773	161	39	and	and	CCONJ
ajst-20773	161	40	go	go	VERB
ajst-20773	161	41	functions	function	NOUN
ajst-20773	161	42	related	relate	VERB
ajst-20773	161	43	to	to	ADP
ajst-20773	161	44	the	the	DET
ajst-20773	161	45	expression	expression	NOUN
ajst-20773	161	46	of	of	ADP
ajst-20773	161	47	agingassociated	agingassociated	ADJ
ajst-20773	161	48	lncrnas	lncrna	NOUN
ajst-20773	161	49	.	.	PUNCT
ajst-20773	162	1	for	for	ADP
ajst-20773	162	2	kegg	kegg	NOUN
ajst-20773	162	3	signaling	signal	VERB
ajst-20773	162	4	pathways	pathway	NOUN
ajst-20773	162	5	,	,	PUNCT
ajst-20773	162	6	the	the	DET
ajst-20773	162	7	high	high	ADJ
ajst-20773	162	8	-	-	PUNCT
ajst-20773	162	9	risk	risk	NOUN
ajst-20773	162	10	group	group	NOUN
ajst-20773	162	11	showed	show	VERB
ajst-20773	162	12	significant	significant	ADJ
ajst-20773	162	13	enrichment	enrichment	NOUN
ajst-20773	162	14	in	in	ADP
ajst-20773	162	15	five	five	NUM
ajst-20773	162	16	pathways	pathway	NOUN
ajst-20773	162	17	:	:	PUNCT
ajst-20773	162	18	the	the	DET
ajst-20773	162	19	cell	cell	NOUN
ajst-20773	162	20	cycle	cycle	NOUN
ajst-20773	162	21	pathway	pathway	NOUN
ajst-20773	162	22	(	(	PUNCT
ajst-20773	162	23	nes=2.15	nes=2.15	PROPN
ajst-20773	162	24	,	,	PUNCT
ajst-20773	162	25	nom	nom	PROPN
ajst-20773	162	26	p<0.001	p<0.001	PROPN
ajst-20773	162	27	,	,	PUNCT
ajst-20773	162	28	fdr	fdr	PROPN
ajst-20773	162	29	q=0.008	q=0.008	PROPN
ajst-20773	162	30	)	)	PUNCT
ajst-20773	162	31	,	,	PUNCT
ajst-20773	162	32	oocyte	oocyte	ADJ
ajst-20773	162	33	meiosis	meiosis	NOUN
ajst-20773	162	34	pathway	pathway	NOUN
ajst-20773	162	35	(	(	PUNCT
ajst-20773	162	36	nes=2.12	nes=2.12	PROPN
ajst-20773	162	37	,	,	PUNCT
ajst-20773	162	38	nom	nom	PROPN
ajst-20773	162	39	p<0.001	p<0.001	PROPN
ajst-20773	162	40	,	,	PUNCT
ajst-20773	162	41	fdr	fdr	PROPN
ajst-20773	162	42	q=0.006	q=0.006	NUM
ajst-20773	162	43	)	)	PUNCT
ajst-20773	162	44	,	,	PUNCT
ajst-20773	162	45	pentose	pentose	NOUN
ajst-20773	162	46	phosphate	phosphate	NOUN
ajst-20773	162	47	pathway	pathway	NOUN
ajst-20773	162	48	(	(	PUNCT
ajst-20773	162	49	nes=1.96	nes=1.96	PROPN
ajst-20773	162	50	,	,	PUNCT
ajst-20773	162	51	nom	nom	PROPN
ajst-20773	162	52	p<0.001	p<0.001	PROPN
ajst-20773	162	53	,	,	PUNCT
ajst-20773	162	54	fdr	fdr	PROPN
ajst-20773	162	55	q=0.051	q=0.051	PROPN
ajst-20773	162	56	)	)	PUNCT
ajst-20773	162	57	,	,	PUNCT
ajst-20773	162	58	mismatch	mismatch	ADJ
ajst-20773	162	59	repair	repair	NOUN
ajst-20773	162	60	pathway	pathway	NOUN
ajst-20773	162	61	(	(	PUNCT
ajst-20773	162	62	nes=1.95	nes=1.95	PROPN
ajst-20773	162	63	,	,	PUNCT
ajst-20773	162	64	nom	nom	PROPN
ajst-20773	162	65	p<0.001	p<0.001	PROPN
ajst-20773	162	66	,	,	PUNCT
ajst-20773	162	67	fdr	fdr	PROPN
ajst-20773	162	68	q=0.041	q=0.041	NOUN
ajst-20773	162	69	)	)	PUNCT
ajst-20773	162	70	,	,	PUNCT
ajst-20773	162	71	and	and	CCONJ
ajst-20773	162	72	dna	dna	NOUN
ajst-20773	162	73	replication	replication	NOUN
ajst-20773	162	74	pathway	pathway	NOUN
ajst-20773	162	75	(	(	PUNCT
ajst-20773	162	76	nes=1.95	nes=1.95	PROPN
ajst-20773	162	77	,	,	PUNCT
ajst-20773	162	78	nom	nom	PROPN
ajst-20773	162	79	p<0.001	p<0.001	PROPN
ajst-20773	162	80	,	,	PUNCT
ajst-20773	162	81	fdr	fdr	PROPN
ajst-20773	162	82	q=0.035	q=0.035	ADV
ajst-20773	162	83	)	)	PUNCT
ajst-20773	162	84	.	.	PUNCT
ajst-20773	163	1	in	in	ADP
ajst-20773	163	2	the	the	DET
ajst-20773	163	3	low	low	ADJ
ajst-20773	163	4	-	-	PUNCT
ajst-20773	163	5	risk	risk	NOUN
ajst-20773	163	6	group	group	NOUN
ajst-20773	163	7	,	,	PUNCT
ajst-20773	163	8	the	the	DET
ajst-20773	163	9	most	most	ADV
ajst-20773	163	10	enriched	enriched	ADJ
ajst-20773	163	11	pathways	pathway	NOUN
ajst-20773	163	12	included	include	VERB
ajst-20773	163	13	hematopoietic	hematopoietic	ADJ
ajst-20773	163	14	cell	cell	NOUN
ajst-20773	163	15	lineage	lineage	NOUN
ajst-20773	163	16	(	(	PUNCT
ajst-20773	163	17	nes=-1.89	nes=-1.89	PROPN
ajst-20773	163	18	,	,	PUNCT
ajst-20773	163	19	nom	nom	PROPN
ajst-20773	163	20	p=0.002	p=0.002	PROPN
ajst-20773	163	21	,	,	PUNCT
ajst-20773	163	22	fdr	fdr	PROPN
ajst-20773	163	23	q=0.152	q=0.152	NOUN
ajst-20773	163	24	)	)	PUNCT
ajst-20773	163	25	,	,	PUNCT
ajst-20773	163	26	autoimmune	autoimmune	ADJ
ajst-20773	163	27	thyroid	thyroid	NOUN
ajst-20773	163	28	disease	disease	NOUN
ajst-20773	163	29	(	(	PUNCT
ajst-20773	163	30	nes=1.87	nes=1.87	PROPN
ajst-20773	163	31	,	,	PUNCT
ajst-20773	163	32	nom	nom	PROPN
ajst-20773	163	33	p=0.006	p=0.006	PROPN
ajst-20773	163	34	,	,	PUNCT
ajst-20773	163	35	fdr	fdr	PROPN
ajst-20773	163	36	q=0.096	q=0.096	X
ajst-20773	163	37	)	)	PUNCT
ajst-20773	163	38	,	,	PUNCT
ajst-20773	163	39	intestinal	intestinal	ADJ
ajst-20773	163	40	immune	immune	ADJ
ajst-20773	163	41	network	network	NOUN
ajst-20773	163	42	for	for	ADP
ajst-20773	163	43	iga	iga	PROPN
ajst-20773	163	44	production	production	NOUN
ajst-20773	163	45	(	(	PUNCT
ajst-20773	163	46	nes=-1.86	nes=-1.86	PROPN
ajst-20773	163	47	,	,	PUNCT
ajst-20773	163	48	nom	nom	PROPN
ajst-20773	163	49	p=0.008	p=0.008	PROPN
ajst-20773	163	50	,	,	PUNCT
ajst-20773	163	51	fdr	fdr	PROPN
ajst-20773	163	52	q=0.065	q=0.065	PROPN
ajst-20773	163	53	)	)	PUNCT
ajst-20773	163	54	,	,	PUNCT
ajst-20773	163	55	allograft	allograft	NOUN
ajst-20773	163	56	rejection	rejection	NOUN
ajst-20773	163	57	(	(	PUNCT
ajst-20773	163	58	nes=-1.85	nes=-1.85	PROPN
ajst-20773	163	59	,	,	PUNCT
ajst-20773	163	60	nom	nom	PROPN
ajst-20773	163	61	p=0.004	p=0.004	PROPN
ajst-20773	163	62	,	,	PUNCT
ajst-20773	163	63	fdr	fdr	PROPN
ajst-20773	163	64	q=0.056	q=0.056	NUM
ajst-20773	163	65	)	)	PUNCT
ajst-20773	163	66	,	,	PUNCT
ajst-20773	163	67	and	and	CCONJ
ajst-20773	163	68	asthma	asthma	NOUN
ajst-20773	163	69	(	(	PUNCT
ajst-20773	163	70	nes=-1.83	nes=-1.83	PROPN
ajst-20773	163	71	,	,	PUNCT
ajst-20773	163	72	nom	nom	PROPN
ajst-20773	163	73	p=0.014	p=0.014	PROPN
ajst-20773	163	74	,	,	PUNCT
ajst-20773	163	75	fdr	fdr	PROPN
ajst-20773	163	76	q=0.055	q=0.055	NUM
ajst-20773	163	77	)	)	PUNCT
ajst-20773	163	78	(	(	PUNCT
ajst-20773	163	79	figure	figure	NOUN
ajst-20773	163	80	22	22	NUM
ajst-20773	163	81	)	)	PUNCT
ajst-20773	163	82	.	.	PUNCT
ajst-20773	164	1	figure	figure	NOUN
ajst-20773	164	2	22	22	NUM
ajst-20773	164	3	.	.	PUNCT
ajst-20773	165	1	kegg_gsea	kegg_gsea	PROPN
ajst-20773	165	2	enrichment	enrichment	NOUN
ajst-20773	165	3	analysis	analysis	NOUN
ajst-20773	165	4	between	between	ADP
ajst-20773	165	5	high	high	ADJ
ajst-20773	165	6	and	and	CCONJ
ajst-20773	165	7	low	low	ADJ
ajst-20773	165	8	-	-	PUNCT
ajst-20773	165	9	risk	risk	NOUN
ajst-20773	165	10	groups	group	NOUN
ajst-20773	165	11	.	.	PUNCT
ajst-20773	166	1	24	24	NUM
ajst-20773	166	2	for	for	ADP
ajst-20773	166	3	go	go	NOUN
ajst-20773	166	4	functions	function	NOUN
ajst-20773	166	5	,	,	PUNCT
ajst-20773	166	6	in	in	ADP
ajst-20773	166	7	the	the	DET
ajst-20773	166	8	high	high	ADJ
ajst-20773	166	9	-	-	PUNCT
ajst-20773	166	10	risk	risk	NOUN
ajst-20773	166	11	group	group	NOUN
ajst-20773	166	12	,	,	PUNCT
ajst-20773	166	13	the	the	DET
ajst-20773	166	14	most	most	ADV
ajst-20773	166	15	enriched	enrich	VERB
ajst-20773	166	16	functions	function	NOUN
ajst-20773	166	17	and	and	CCONJ
ajst-20773	166	18	biological	biological	ADJ
ajst-20773	166	19	processes	process	NOUN
ajst-20773	166	20	include	include	VERB
ajst-20773	166	21	cadherin	cadherin	NOUN
ajst-20773	166	22	binding	bind	VERB
ajst-20773	166	23	(	(	PUNCT
ajst-20773	166	24	nes=2.48	nes=2.48	PROPN
ajst-20773	166	25	,	,	PUNCT
ajst-20773	166	26	nom	nom	PROPN
ajst-20773	166	27	p<0.001	p<0.001	PROPN
ajst-20773	166	28	,	,	PUNCT
ajst-20773	166	29	fdr	fdr	PROPN
ajst-20773	166	30	q<0.001	q<0.001	NOUN
ajst-20773	166	31	)	)	PUNCT
ajst-20773	166	32	,	,	PUNCT
ajst-20773	166	33	metaphase	metaphase	NOUN
ajst-20773	166	34	plate	plate	NOUN
ajst-20773	166	35	congression	congression	NOUN
ajst-20773	166	36	(	(	PUNCT
ajst-20773	166	37	nes=2.37	nes=2.37	PROPN
ajst-20773	166	38	,	,	PUNCT
ajst-20773	166	39	nom	nom	PROPN
ajst-20773	166	40	p<0.001	p<0.001	PROPN
ajst-20773	166	41	,	,	PUNCT
ajst-20773	166	42	fdr	fdr	PROPN
ajst-20773	166	43	q<0.001	q<0.001	NOUN
ajst-20773	166	44	)	)	PUNCT
ajst-20773	166	45	,	,	PUNCT
ajst-20773	166	46	chromosome	chromosome	NOUN
ajst-20773	166	47	localization	localization	NOUN
ajst-20773	166	48	(	(	PUNCT
ajst-20773	166	49	nes=2.35	nes=2.35	PROPN
ajst-20773	166	50	,	,	PUNCT
ajst-20773	166	51	nom	nom	PROPN
ajst-20773	166	52	p<0.001	p<0.001	PROPN
ajst-20773	166	53	,	,	PUNCT
ajst-20773	166	54	fdr	fdr	PROPN
ajst-20773	166	55	q<0.001	q<0.001	NOUN
ajst-20773	166	56	)	)	PUNCT
ajst-20773	166	57	,	,	PUNCT
ajst-20773	166	58	mitotic	mitotic	ADJ
ajst-20773	166	59	metaphase	metaphase	NOUN
ajst-20773	166	60	plate	plate	NOUN
ajst-20773	166	61	congression	congression	NOUN
ajst-20773	166	62	(	(	PUNCT
ajst-20773	166	63	nes=2.32	nes=2.32	PROPN
ajst-20773	166	64	,	,	PUNCT
ajst-20773	166	65	nom	nom	PROPN
ajst-20773	166	66	p<0.001	p<0.001	PROPN
ajst-20773	166	67	,	,	PUNCT
ajst-20773	166	68	fdr	fdr	PROPN
ajst-20773	166	69	q=0.001	q=0.001	NOUN
ajst-20773	166	70	)	)	PUNCT
ajst-20773	166	71	,	,	PUNCT
ajst-20773	166	72	and	and	CCONJ
ajst-20773	166	73	microtubule	microtubule	NOUN
ajst-20773	166	74	cytoskeleton	cytoskeleton	PROPN
ajst-20773	166	75	organization	organization	NOUN
ajst-20773	166	76	involved	involve	VERB
ajst-20773	166	77	in	in	ADP
ajst-20773	166	78	mitosis	mitosis	NOUN
ajst-20773	166	79	(	(	PUNCT
ajst-20773	166	80	nes=2.31	nes=2.31	PROPN
ajst-20773	166	81	,	,	PUNCT
ajst-20773	166	82	nom	nom	PROPN
ajst-20773	166	83	p<0.001	p<0.001	PROPN
ajst-20773	166	84	,	,	PUNCT
ajst-20773	166	85	fdr	fdr	PROPN
ajst-20773	166	86	q=0.001	q=0.001	NOUN
ajst-20773	166	87	)	)	PUNCT
ajst-20773	166	88	.	.	PUNCT
ajst-20773	167	1	in	in	ADP
ajst-20773	167	2	the	the	DET
ajst-20773	167	3	low	low	ADJ
ajst-20773	167	4	-	-	PUNCT
ajst-20773	167	5	risk	risk	NOUN
ajst-20773	167	6	group	group	NOUN
ajst-20773	167	7	,	,	PUNCT
ajst-20773	167	8	the	the	DET
ajst-20773	167	9	most	most	ADV
ajst-20773	167	10	enriched	enrich	VERB
ajst-20773	167	11	include	include	VERB
ajst-20773	167	12	the	the	DET
ajst-20773	167	13	mhc	mhc	PROPN
ajst-20773	167	14	class	class	PROPN
ajst-20773	167	15	ii	ii	PROPN
ajst-20773	167	16	biosynthetic	biosynthetic	ADJ
ajst-20773	167	17	process	process	NOUN
ajst-20773	167	18	(	(	PUNCT
ajst-20773	167	19	nes=-2.02	nes=-2.02	PROPN
ajst-20773	167	20	,	,	PUNCT
ajst-20773	167	21	nom	nom	PROPN
ajst-20773	167	22	p<0.001	p<0.001	PROPN
ajst-20773	167	23	,	,	PUNCT
ajst-20773	167	24	fdr	fdr	PROPN
ajst-20773	167	25	q=0.998	q=0.998	NUM
ajst-20773	167	26	)	)	PUNCT
ajst-20773	167	27	,	,	PUNCT
ajst-20773	167	28	peptidase	peptidase	NOUN
ajst-20773	167	29	activator	activator	NOUN
ajst-20773	167	30	activity	activity	NOUN
ajst-20773	167	31	involved	involve	VERB
ajst-20773	167	32	in	in	ADP
ajst-20773	167	33	the	the	DET
ajst-20773	167	34	apoptotic	apoptotic	ADJ
ajst-20773	167	35	process	process	NOUN
ajst-20773	167	36	(	(	PUNCT
ajst-20773	167	37	nes=-1.97	nes=-1.97	PROPN
ajst-20773	167	38	,	,	PUNCT
ajst-20773	167	39	nom	nom	PROPN
ajst-20773	167	40	p<0.001	p<0.001	PROPN
ajst-20773	167	41	,	,	PUNCT
ajst-20773	167	42	fdr	fdr	PROPN
ajst-20773	167	43	q=1.0	q=1.0	NOUN
ajst-20773	167	44	)	)	PUNCT
ajst-20773	167	45	,	,	PUNCT
ajst-20773	167	46	regulation	regulation	NOUN
ajst-20773	167	47	of	of	ADP
ajst-20773	167	48	b	b	NOUN
ajst-20773	167	49	cell	cell	NOUN
ajst-20773	167	50	receptor	receptor	NOUN
ajst-20773	167	51	signaling	signal	VERB
ajst-20773	167	52	pathway	pathway	NOUN
ajst-20773	167	53	(	(	PUNCT
ajst-20773	167	54	nes=-1.97	nes=-1.97	PROPN
ajst-20773	167	55	,	,	PUNCT
ajst-20773	167	56	nom	nom	PROPN
ajst-20773	167	57	p=0.002	p=0.002	PROPN
ajst-20773	167	58	,	,	PUNCT
ajst-20773	167	59	fdr	fdr	PROPN
ajst-20773	167	60	q=0.690	q=0.690	NOUN
ajst-20773	167	61	)	)	PUNCT
ajst-20773	167	62	,	,	PUNCT
ajst-20773	167	63	negative	negative	ADJ
ajst-20773	167	64	regulation	regulation	NOUN
ajst-20773	167	65	of	of	ADP
ajst-20773	167	66	tor	tor	NOUN
ajst-20773	167	67	signaling	signal	VERB
ajst-20773	167	68	(	(	PUNCT
ajst-20773	167	69	nes=-1.96	nes=-1.96	PROPN
ajst-20773	167	70	,	,	PUNCT
ajst-20773	167	71	nom	nom	PROPN
ajst-20773	167	72	p<0.001	p<0.001	PROPN
ajst-20773	167	73	,	,	PUNCT
ajst-20773	167	74	fdr	fdr	PROPN
ajst-20773	167	75	q=0.585	q=0.585	NUM
ajst-20773	167	76	)	)	PUNCT
ajst-20773	167	77	,	,	PUNCT
ajst-20773	167	78	and	and	CCONJ
ajst-20773	167	79	negative	negative	ADJ
ajst-20773	167	80	regulation	regulation	NOUN
ajst-20773	167	81	of	of	ADP
ajst-20773	167	82	phosphatidylinositol	phosphatidylinositol	NOUN
ajst-20773	167	83	3	3	NUM
ajst-20773	167	84	-	-	PUNCT
ajst-20773	167	85	kinase	kinase	NOUN
ajst-20773	167	86	signaling	signal	VERB
ajst-20773	167	87	(	(	PUNCT
ajst-20773	167	88	nes=-1.94	nes=-1.94	PROPN
ajst-20773	167	89	,	,	PUNCT
ajst-20773	167	90	nom	nom	PROPN
ajst-20773	167	91	p<0.001	p<0.001	PROPN
ajst-20773	167	92	,	,	PUNCT
ajst-20773	167	93	fdr	fdr	PROPN
ajst-20773	167	94	q=0.542	q=0.542	NUM
ajst-20773	167	95	)	)	PUNCT
ajst-20773	167	96	(	(	PUNCT
ajst-20773	167	97	figure	figure	NOUN
ajst-20773	167	98	23	23	NUM
ajst-20773	167	99	)	)	PUNCT
ajst-20773	167	100	.	.	PUNCT
ajst-20773	168	1	figure	figure	VERB
ajst-20773	168	2	23	23	NUM
ajst-20773	168	3	.	.	PUNCT
ajst-20773	169	1	go_gsea	go_gsea	X
ajst-20773	169	2	enrichment	enrichment	NOUN
ajst-20773	169	3	analysis	analysis	NOUN
ajst-20773	169	4	between	between	ADP
ajst-20773	169	5	high	high	ADJ
ajst-20773	169	6	and	and	CCONJ
ajst-20773	169	7	low	low	ADJ
ajst-20773	169	8	-	-	PUNCT
ajst-20773	169	9	risk	risk	NOUN
ajst-20773	169	10	groups	group	NOUN
ajst-20773	169	11	.	.	PUNCT
ajst-20773	170	1	3.7	3.7	NUM
ajst-20773	170	2	.	.	PUNCT
ajst-20773	170	3	differential	differential	ADJ
ajst-20773	170	4	analysis	analysis	NOUN
ajst-20773	170	5	of	of	ADP
ajst-20773	170	6	immune	immune	ADJ
ajst-20773	170	7	infiltration	infiltration	NOUN
ajst-20773	170	8	between	between	ADP
ajst-20773	170	9	high	high	ADJ
ajst-20773	170	10	and	and	CCONJ
ajst-20773	170	11	low	low	ADJ
ajst-20773	170	12	-	-	PUNCT
ajst-20773	170	13	risk	risk	NOUN
ajst-20773	170	14	groups	group	NOUN
ajst-20773	170	15	.	.	PUNCT
ajst-20773	171	1	to	to	PART
ajst-20773	171	2	explore	explore	VERB
ajst-20773	171	3	the	the	DET
ajst-20773	171	4	impact	impact	NOUN
ajst-20773	171	5	of	of	ADP
ajst-20773	171	6	the	the	DET
ajst-20773	171	7	quantity	quantity	NOUN
ajst-20773	171	8	of	of	ADP
ajst-20773	171	9	immune	immune	ADJ
ajst-20773	171	10	cells	cell	NOUN
ajst-20773	171	11	in	in	ADP
ajst-20773	171	12	the	the	DET
ajst-20773	171	13	tumor	tumor	NOUN
ajst-20773	171	14	microenvironment	microenvironment	NOUN
ajst-20773	171	15	on	on	ADP
ajst-20773	171	16	lung	lung	NOUN
ajst-20773	171	17	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	171	18	,	,	PUNCT
ajst-20773	171	19	we	we	PRON
ajst-20773	171	20	performed	perform	VERB
ajst-20773	171	21	a	a	DET
ajst-20773	171	22	differential	differential	ADJ
ajst-20773	171	23	analysis	analysis	NOUN
ajst-20773	171	24	of	of	ADP
ajst-20773	171	25	immune	immune	ADJ
ajst-20773	171	26	infiltration	infiltration	NOUN
ajst-20773	171	27	using	use	VERB
ajst-20773	171	28	the	the	DET
ajst-20773	171	29	ssgsea	ssgsea	NOUN
ajst-20773	171	30	method	method	NOUN
ajst-20773	171	31	on	on	ADP
ajst-20773	171	32	the	the	DET
ajst-20773	171	33	marker	marker	NOUN
ajst-20773	171	34	genes	gene	NOUN
ajst-20773	171	35	of	of	ADP
ajst-20773	171	36	most	most	ADJ
ajst-20773	171	37	types	type	NOUN
ajst-20773	171	38	of	of	ADP
ajst-20773	171	39	immune	immune	ADJ
ajst-20773	171	40	cells	cell	NOUN
ajst-20773	171	41	in	in	ADP
ajst-20773	171	42	high	high	ADJ
ajst-20773	171	43	and	and	CCONJ
ajst-20773	171	44	low	low	ADJ
ajst-20773	171	45	-	-	PUNCT
ajst-20773	171	46	risk	risk	NOUN
ajst-20773	171	47	groups	group	NOUN
ajst-20773	171	48	.	.	PUNCT
ajst-20773	172	1	the	the	DET
ajst-20773	172	2	differential	differential	ADJ
ajst-20773	172	3	analysis	analysis	NOUN
ajst-20773	172	4	of	of	ADP
ajst-20773	172	5	immune	immune	ADJ
ajst-20773	172	6	cell	cell	NOUN
ajst-20773	172	7	quantities	quantity	NOUN
ajst-20773	172	8	showed	show	VERB
ajst-20773	172	9	that	that	SCONJ
ajst-20773	172	10	the	the	DET
ajst-20773	172	11	low	low	ADJ
ajst-20773	172	12	-	-	PUNCT
ajst-20773	172	13	risk	risk	NOUN
ajst-20773	172	14	group	group	NOUN
ajst-20773	172	15	had	have	VERB
ajst-20773	172	16	significantly	significantly	ADV
ajst-20773	172	17	higher	high	ADJ
ajst-20773	172	18	numbers	number	NOUN
ajst-20773	172	19	of	of	ADP
ajst-20773	172	20	anti	anti	ADJ
ajst-20773	172	21	-	-	ADJ
ajst-20773	172	22	tumor	tumor	ADJ
ajst-20773	172	23	immune	immune	ADJ
ajst-20773	172	24	cells	cell	NOUN
ajst-20773	172	25	such	such	ADJ
ajst-20773	172	26	as	as	ADP
ajst-20773	172	27	immature	immature	ADJ
ajst-20773	172	28	dendritic	dendritic	ADJ
ajst-20773	172	29	cells	cell	NOUN
ajst-20773	172	30	(	(	PUNCT
ajst-20773	172	31	idcs	idcs	ADJ
ajst-20773	172	32	)	)	PUNCT
ajst-20773	172	33	,	,	PUNCT
ajst-20773	172	34	mast	mast	NOUN
ajst-20773	172	35	cells	cell	NOUN
ajst-20773	172	36	,	,	PUNCT
ajst-20773	172	37	and	and	CCONJ
ajst-20773	172	38	helper	helper	NOUN
ajst-20773	172	39	t	t	NOUN
ajst-20773	172	40	cells	cell	NOUN
ajst-20773	172	41	compared	compare	VERB
ajst-20773	172	42	to	to	ADP
ajst-20773	172	43	the	the	DET
ajst-20773	172	44	high	high	ADJ
ajst-20773	172	45	-	-	PUNCT
ajst-20773	172	46	risk	risk	NOUN
ajst-20773	172	47	group	group	NOUN
ajst-20773	172	48	(	(	PUNCT
ajst-20773	172	49	figure	figure	NOUN
ajst-20773	172	50	24	24	NUM
ajst-20773	172	51	)	)	PUNCT
ajst-20773	172	52	.	.	PUNCT
ajst-20773	173	1	an	an	DET
ajst-20773	173	2	analysis	analysis	NOUN
ajst-20773	173	3	of	of	ADP
ajst-20773	173	4	the	the	DET
ajst-20773	173	5	differences	difference	NOUN
ajst-20773	173	6	in	in	ADP
ajst-20773	173	7	immune	immune	ADJ
ajst-20773	173	8	functions	function	NOUN
ajst-20773	173	9	between	between	ADP
ajst-20773	173	10	the	the	DET
ajst-20773	173	11	high	high	ADJ
ajst-20773	173	12	and	and	CCONJ
ajst-20773	173	13	low	low	ADJ
ajst-20773	173	14	-	-	PUNCT
ajst-20773	173	15	risk	risk	NOUN
ajst-20773	173	16	groups	group	NOUN
ajst-20773	173	17	revealed	reveal	VERB
ajst-20773	173	18	that	that	SCONJ
ajst-20773	173	19	scores	score	NOUN
ajst-20773	173	20	for	for	ADP
ajst-20773	173	21	antitumor	antitumor	PROPN
ajst-20773	173	22	immune	immune	ADJ
ajst-20773	173	23	functions	function	NOUN
ajst-20773	173	24	,	,	PUNCT
ajst-20773	173	25	including	include	VERB
ajst-20773	173	26	checkpoints	checkpoint	NOUN
ajst-20773	173	27	,	,	PUNCT
ajst-20773	173	28	human	human	ADJ
ajst-20773	173	29	leukocyte	leukocyte	NOUN
ajst-20773	173	30	antigens	antigen	NOUN
ajst-20773	173	31	(	(	PUNCT
ajst-20773	173	32	hla	hla	NOUN
ajst-20773	173	33	)	)	PUNCT
ajst-20773	173	34	,	,	PUNCT
ajst-20773	173	35	t	t	PROPN
ajst-20773	173	36	cell	cell	NOUN
ajst-20773	173	37	co	co	NOUN
ajst-20773	173	38	-	-	NOUN
ajst-20773	173	39	inhibition	inhibition	NOUN
ajst-20773	173	40	,	,	PUNCT
ajst-20773	173	41	and	and	CCONJ
ajst-20773	173	42	t	t	PROPN
ajst-20773	173	43	cell	cell	NOUN
ajst-20773	173	44	costimulation	costimulation	NOUN
ajst-20773	173	45	,	,	PUNCT
ajst-20773	173	46	were	be	AUX
ajst-20773	173	47	significantly	significantly	ADV
ajst-20773	173	48	higher	high	ADJ
ajst-20773	173	49	in	in	ADP
ajst-20773	173	50	the	the	DET
ajst-20773	173	51	low	low	ADJ
ajst-20773	173	52	-	-	PUNCT
ajst-20773	173	53	risk	risk	NOUN
ajst-20773	173	54	group	group	NOUN
ajst-20773	173	55	(	(	PUNCT
ajst-20773	173	56	figure	figure	NOUN
ajst-20773	173	57	25	25	NUM
ajst-20773	173	58	)	)	PUNCT
ajst-20773	173	59	.	.	PUNCT
ajst-20773	174	1	these	these	DET
ajst-20773	174	2	results	result	NOUN
ajst-20773	174	3	suggest	suggest	VERB
ajst-20773	174	4	that	that	SCONJ
ajst-20773	174	5	the	the	DET
ajst-20773	174	6	tumor	tumor	NOUN
ajst-20773	174	7	microenvironment	microenvironment	NOUN
ajst-20773	174	8	of	of	ADP
ajst-20773	174	9	lung	lung	NOUN
ajst-20773	174	10	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	174	11	patients	patient	NOUN
ajst-20773	174	12	in	in	ADP
ajst-20773	174	13	the	the	DET
ajst-20773	174	14	low	low	ADJ
ajst-20773	174	15	-	-	PUNCT
ajst-20773	174	16	risk	risk	NOUN
ajst-20773	174	17	group	group	NOUN
ajst-20773	174	18	exhibits	exhibit	VERB
ajst-20773	174	19	a	a	DET
ajst-20773	174	20	stronger	strong	ADJ
ajst-20773	174	21	anti	anti	ADJ
ajst-20773	174	22	-	-	ADJ
ajst-20773	174	23	tumor	tumor	ADJ
ajst-20773	174	24	immune	immune	ADJ
ajst-20773	174	25	response	response	NOUN
ajst-20773	174	26	compared	compare	VERB
ajst-20773	174	27	to	to	ADP
ajst-20773	174	28	those	those	PRON
ajst-20773	174	29	in	in	ADP
ajst-20773	174	30	the	the	DET
ajst-20773	174	31	high	high	ADJ
ajst-20773	174	32	-	-	PUNCT
ajst-20773	174	33	risk	risk	NOUN
ajst-20773	174	34	group	group	NOUN
ajst-20773	174	35	.	.	PUNCT
ajst-20773	175	1	figure	figure	NOUN
ajst-20773	175	2	24	24	NUM
ajst-20773	175	3	.	.	NOUN
ajst-20773	175	4	immune	immune	ADJ
ajst-20773	175	5	cell	cell	NOUN
ajst-20773	175	6	count	count	NOUN
ajst-20773	175	7	scores	score	NOUN
ajst-20773	175	8	for	for	ADP
ajst-20773	175	9	high	high	ADJ
ajst-20773	175	10	and	and	CCONJ
ajst-20773	175	11	low	low	ADJ
ajst-20773	175	12	-	-	PUNCT
ajst-20773	175	13	risk	risk	NOUN
ajst-20773	175	14	groups	group	NOUN
ajst-20773	175	15	.	.	PUNCT
ajst-20773	176	1	25	25	NUM
ajst-20773	176	2	figure	figure	NOUN
ajst-20773	176	3	25	25	NUM
ajst-20773	176	4	.	.	NOUN
ajst-20773	176	5	immune	immune	ADJ
ajst-20773	176	6	function	function	NOUN
ajst-20773	176	7	scores	score	NOUN
ajst-20773	176	8	for	for	ADP
ajst-20773	176	9	high	high	ADJ
ajst-20773	176	10	and	and	CCONJ
ajst-20773	176	11	low	low	ADJ
ajst-20773	176	12	-	-	PUNCT
ajst-20773	176	13	risk	risk	NOUN
ajst-20773	176	14	groups	group	NOUN
ajst-20773	176	15	.	.	PUNCT
ajst-20773	177	1	to	to	PART
ajst-20773	177	2	further	far	ADV
ajst-20773	177	3	validate	validate	VERB
ajst-20773	177	4	the	the	DET
ajst-20773	177	5	conclusions	conclusion	NOUN
ajst-20773	177	6	,	,	PUNCT
ajst-20773	177	7	we	we	PRON
ajst-20773	177	8	utilized	utilize	VERB
ajst-20773	177	9	the	the	DET
ajst-20773	177	10	cibersort	cibersort	NOUN
ajst-20773	177	11	algorithm	algorithm	NOUN
ajst-20773	177	12	to	to	PART
ajst-20773	177	13	analyze	analyze	VERB
ajst-20773	177	14	and	and	CCONJ
ajst-20773	177	15	visualize	visualize	VERB
ajst-20773	177	16	the	the	DET
ajst-20773	177	17	immune	immune	ADJ
ajst-20773	177	18	infiltration	infiltration	NOUN
ajst-20773	177	19	in	in	ADP
ajst-20773	177	20	the	the	DET
ajst-20773	177	21	high	high	ADJ
ajst-20773	177	22	and	and	CCONJ
ajst-20773	177	23	low	low	ADJ
ajst-20773	177	24	-	-	PUNCT
ajst-20773	177	25	risk	risk	NOUN
ajst-20773	177	26	groups	group	NOUN
ajst-20773	177	27	.	.	PUNCT
ajst-20773	178	1	the	the	DET
ajst-20773	178	2	analysis	analysis	NOUN
ajst-20773	178	3	of	of	ADP
ajst-20773	178	4	immune	immune	ADJ
ajst-20773	178	5	infiltration	infiltration	NOUN
ajst-20773	178	6	in	in	ADP
ajst-20773	178	7	the	the	DET
ajst-20773	178	8	high	high	ADJ
ajst-20773	178	9	and	and	CCONJ
ajst-20773	178	10	low	low	ADJ
ajst-20773	178	11	-	-	PUNCT
ajst-20773	178	12	risk	risk	NOUN
ajst-20773	178	13	groups	group	NOUN
ajst-20773	178	14	provided	provide	VERB
ajst-20773	178	15	the	the	DET
ajst-20773	178	16	content	content	NOUN
ajst-20773	178	17	of	of	ADP
ajst-20773	178	18	immune	immune	ADJ
ajst-20773	178	19	cells	cell	NOUN
ajst-20773	178	20	in	in	ADP
ajst-20773	178	21	each	each	DET
ajst-20773	178	22	sample	sample	NOUN
ajst-20773	178	23	(	(	PUNCT
ajst-20773	178	24	figures	figure	NOUN
ajst-20773	178	25	26	26	NUM
ajst-20773	178	26	and	and	CCONJ
ajst-20773	178	27	27	27	NUM
ajst-20773	178	28	)	)	PUNCT
ajst-20773	178	29	.	.	PUNCT
ajst-20773	179	1	subsequently	subsequently	ADV
ajst-20773	179	2	,	,	PUNCT
ajst-20773	179	3	we	we	PRON
ajst-20773	179	4	performed	perform	VERB
ajst-20773	179	5	a	a	DET
ajst-20773	179	6	differential	differential	ADJ
ajst-20773	179	7	analysis	analysis	NOUN
ajst-20773	179	8	of	of	ADP
ajst-20773	179	9	immune	immune	ADJ
ajst-20773	179	10	infiltration	infiltration	NOUN
ajst-20773	179	11	based	base	VERB
ajst-20773	179	12	on	on	ADP
ajst-20773	179	13	these	these	DET
ajst-20773	179	14	results	result	NOUN
ajst-20773	179	15	(	(	PUNCT
ajst-20773	179	16	figure	figure	NOUN
ajst-20773	179	17	28	28	NUM
ajst-20773	179	18	)	)	PUNCT
ajst-20773	179	19	,	,	PUNCT
ajst-20773	179	20	which	which	PRON
ajst-20773	179	21	showed	show	VERB
ajst-20773	179	22	that	that	SCONJ
ajst-20773	179	23	the	the	DET
ajst-20773	179	24	quantities	quantity	NOUN
ajst-20773	179	25	of	of	ADP
ajst-20773	179	26	cd+8	cd+8	NUM
ajst-20773	179	27	t	t	NOUN
ajst-20773	179	28	cells	cell	NOUN
ajst-20773	179	29	,	,	PUNCT
ajst-20773	179	30	m0	m0	NOUN
ajst-20773	179	31	macrophages	macrophage	NOUN
ajst-20773	179	32	,	,	PUNCT
ajst-20773	179	33	and	and	CCONJ
ajst-20773	179	34	dendritic	dendritic	ADJ
ajst-20773	179	35	cells	cell	NOUN
ajst-20773	179	36	were	be	AUX
ajst-20773	179	37	significantly	significantly	ADV
ajst-20773	179	38	higher	high	ADJ
ajst-20773	179	39	in	in	ADP
ajst-20773	179	40	the	the	DET
ajst-20773	179	41	low	low	ADJ
ajst-20773	179	42	-	-	PUNCT
ajst-20773	179	43	risk	risk	NOUN
ajst-20773	179	44	group	group	NOUN
ajst-20773	179	45	compared	compare	VERB
ajst-20773	179	46	to	to	ADP
ajst-20773	179	47	the	the	DET
ajst-20773	179	48	high	high	ADJ
ajst-20773	179	49	-	-	PUNCT
ajst-20773	179	50	risk	risk	NOUN
ajst-20773	179	51	group	group	NOUN
ajst-20773	179	52	.	.	PUNCT
ajst-20773	180	1	this	this	PRON
ajst-20773	180	2	confirmed	confirm	VERB
ajst-20773	180	3	the	the	DET
ajst-20773	180	4	results	result	NOUN
ajst-20773	180	5	of	of	ADP
ajst-20773	180	6	the	the	DET
ajst-20773	180	7	ssgsea	ssgsea	NOUN
ajst-20773	180	8	analysis	analysis	NOUN
ajst-20773	180	9	and	and	CCONJ
ajst-20773	180	10	also	also	ADV
ajst-20773	180	11	indicated	indicate	VERB
ajst-20773	180	12	that	that	SCONJ
ajst-20773	180	13	both	both	CCONJ
ajst-20773	180	14	specific	specific	ADJ
ajst-20773	180	15	and	and	CCONJ
ajst-20773	180	16	non	non	ADJ
ajst-20773	180	17	-	-	ADJ
ajst-20773	180	18	specific	specific	ADJ
ajst-20773	180	19	immunity	immunity	NOUN
ajst-20773	180	20	are	be	AUX
ajst-20773	180	21	suppressed	suppress	VERB
ajst-20773	180	22	in	in	ADP
ajst-20773	180	23	the	the	DET
ajst-20773	180	24	high	high	ADJ
ajst-20773	180	25	-	-	PUNCT
ajst-20773	180	26	risk	risk	NOUN
ajst-20773	180	27	group	group	NOUN
ajst-20773	180	28	compared	compare	VERB
ajst-20773	180	29	to	to	ADP
ajst-20773	180	30	the	the	DET
ajst-20773	180	31	low	low	ADJ
ajst-20773	180	32	-	-	PUNCT
ajst-20773	180	33	risk	risk	NOUN
ajst-20773	180	34	group	group	NOUN
ajst-20773	180	35	.	.	PUNCT
ajst-20773	181	1	figure	figure	VERB
ajst-20773	181	2	26	26	NUM
ajst-20773	181	3	.	.	PUNCT
ajst-20773	182	1	proportion	proportion	NOUN
ajst-20773	182	2	of	of	ADP
ajst-20773	182	3	various	various	ADJ
ajst-20773	182	4	immune	immune	ADJ
ajst-20773	182	5	cells	cell	NOUN
ajst-20773	182	6	in	in	ADP
ajst-20773	182	7	high	high	ADJ
ajst-20773	182	8	and	and	CCONJ
ajst-20773	182	9	low	low	ADJ
ajst-20773	182	10	-	-	PUNCT
ajst-20773	182	11	risk	risk	NOUN
ajst-20773	182	12	groups	group	NOUN
ajst-20773	182	13	.	.	PUNCT
ajst-20773	183	1	figure	figure	VERB
ajst-20773	183	2	27	27	NUM
ajst-20773	183	3	.	.	PUNCT
ajst-20773	184	1	heatmap	heatmap	NOUN
ajst-20773	184	2	of	of	ADP
ajst-20773	184	3	various	various	ADJ
ajst-20773	184	4	immune	immune	ADJ
ajst-20773	184	5	cell	cell	NOUN
ajst-20773	184	6	expressions	expression	NOUN
ajst-20773	184	7	in	in	ADP
ajst-20773	184	8	high	high	ADJ
ajst-20773	184	9	and	and	CCONJ
ajst-20773	184	10	low	low	ADJ
ajst-20773	184	11	-	-	PUNCT
ajst-20773	184	12	risk	risk	NOUN
ajst-20773	184	13	groups	group	NOUN
ajst-20773	184	14	.	.	PUNCT
ajst-20773	185	1	26	26	NUM
ajst-20773	185	2	figure	figure	NOUN
ajst-20773	185	3	28	28	NUM
ajst-20773	185	4	.	.	PUNCT
ajst-20773	186	1	differential	differential	ADJ
ajst-20773	186	2	analysis	analysis	NOUN
ajst-20773	186	3	of	of	ADP
ajst-20773	186	4	immune	immune	ADJ
ajst-20773	186	5	infiltration	infiltration	NOUN
ajst-20773	186	6	between	between	ADP
ajst-20773	186	7	high	high	ADJ
ajst-20773	186	8	and	and	CCONJ
ajst-20773	186	9	low	low	ADJ
ajst-20773	186	10	-	-	PUNCT
ajst-20773	186	11	risk	risk	NOUN
ajst-20773	186	12	groups	group	NOUN
ajst-20773	186	13	3.8	3.8	NUM
ajst-20773	186	14	.	.	PUNCT
ajst-20773	187	1	differential	differential	ADJ
ajst-20773	187	2	analysis	analysis	NOUN
ajst-20773	187	3	of	of	ADP
ajst-20773	187	4	immune	immune	ADJ
ajst-20773	187	5	checkpoint	checkpoint	NOUN
ajst-20773	187	6	expression	expression	NOUN
ajst-20773	187	7	between	between	ADP
ajst-20773	187	8	high	high	ADJ
ajst-20773	187	9	and	and	CCONJ
ajst-20773	187	10	low	low	ADJ
ajst-20773	187	11	-	-	PUNCT
ajst-20773	187	12	risk	risk	NOUN
ajst-20773	187	13	groups	group	NOUN
ajst-20773	187	14	next	next	ADV
ajst-20773	187	15	,	,	PUNCT
ajst-20773	187	16	we	we	PRON
ajst-20773	187	17	compared	compare	VERB
ajst-20773	187	18	the	the	DET
ajst-20773	187	19	expression	expression	NOUN
ajst-20773	187	20	levels	level	NOUN
ajst-20773	187	21	of	of	ADP
ajst-20773	187	22	32	32	NUM
ajst-20773	187	23	immune	immune	ADJ
ajst-20773	187	24	checkpoints	checkpoint	NOUN
ajst-20773	187	25	in	in	ADP
ajst-20773	187	26	the	the	DET
ajst-20773	187	27	high	high	ADJ
ajst-20773	187	28	-	-	PUNCT
ajst-20773	187	29	risk	risk	NOUN
ajst-20773	187	30	and	and	CCONJ
ajst-20773	187	31	low	low	ADJ
ajst-20773	187	32	-	-	PUNCT
ajst-20773	187	33	risk	risk	NOUN
ajst-20773	187	34	groups	group	NOUN
ajst-20773	187	35	of	of	ADP
ajst-20773	187	36	the	the	DET
ajst-20773	187	37	senlncsig	senlncsig	PROPN
ajst-20773	187	38	model	model	NOUN
ajst-20773	187	39	and	and	CCONJ
ajst-20773	187	40	identified	identify	VERB
ajst-20773	187	41	significant	significant	ADJ
ajst-20773	187	42	differences	difference	NOUN
ajst-20773	187	43	.	.	PUNCT
ajst-20773	188	1	the	the	DET
ajst-20773	188	2	expression	expression	NOUN
ajst-20773	188	3	of	of	ADP
ajst-20773	188	4	immune	immune	ADJ
ajst-20773	188	5	therapy	therapy	NOUN
ajst-20773	188	6	checkpoints	checkpoint	NOUN
ajst-20773	188	7	currently	currently	ADV
ajst-20773	188	8	widely	widely	ADV
ajst-20773	188	9	used	use	VERB
ajst-20773	188	10	in	in	ADP
ajst-20773	188	11	clinical	clinical	ADJ
ajst-20773	188	12	treatment	treatment	NOUN
ajst-20773	188	13	and	and	CCONJ
ajst-20773	188	14	experimental	experimental	ADJ
ajst-20773	188	15	exploration	exploration	NOUN
ajst-20773	188	16	,	,	PUNCT
ajst-20773	188	17	such	such	ADJ
ajst-20773	188	18	as	as	ADP
ajst-20773	188	19	cd40	cd40	PROPN
ajst-20773	188	20	,	,	PUNCT
ajst-20773	188	21	havcr2	havcr2	PROPN
ajst-20773	188	22	,	,	PUNCT
ajst-20773	188	23	cd27	cd27	PROPN
ajst-20773	188	24	,	,	PUNCT
ajst-20773	188	25	and	and	CCONJ
ajst-20773	188	26	btla	btla	NOUN
ajst-20773	188	27	,	,	PUNCT
ajst-20773	188	28	was	be	AUX
ajst-20773	188	29	significantly	significantly	ADV
ajst-20773	188	30	higher	high	ADJ
ajst-20773	188	31	in	in	ADP
ajst-20773	188	32	the	the	DET
ajst-20773	188	33	low	low	ADJ
ajst-20773	188	34	-	-	PUNCT
ajst-20773	188	35	risk	risk	NOUN
ajst-20773	188	36	group	group	NOUN
ajst-20773	188	37	(	(	PUNCT
ajst-20773	188	38	figure	figure	NOUN
ajst-20773	188	39	29	29	NUM
ajst-20773	188	40	)	)	PUNCT
ajst-20773	188	41	.	.	PUNCT
ajst-20773	189	1	the	the	DET
ajst-20773	189	2	results	result	NOUN
ajst-20773	189	3	also	also	ADV
ajst-20773	189	4	show	show	VERB
ajst-20773	189	5	that	that	SCONJ
ajst-20773	189	6	the	the	DET
ajst-20773	189	7	immune	immune	ADJ
ajst-20773	189	8	checkpoint	checkpoint	NOUN
ajst-20773	189	9	expression	expression	NOUN
ajst-20773	189	10	levels	level	NOUN
ajst-20773	189	11	are	be	AUX
ajst-20773	189	12	generally	generally	ADV
ajst-20773	189	13	higher	high	ADJ
ajst-20773	189	14	in	in	ADP
ajst-20773	189	15	the	the	DET
ajst-20773	189	16	low	low	ADJ
ajst-20773	189	17	-	-	PUNCT
ajst-20773	189	18	risk	risk	NOUN
ajst-20773	189	19	group	group	NOUN
ajst-20773	189	20	compared	compare	VERB
ajst-20773	189	21	to	to	ADP
ajst-20773	189	22	the	the	DET
ajst-20773	189	23	highrisk	highrisk	NOUN
ajst-20773	189	24	group	group	NOUN
ajst-20773	189	25	.	.	PUNCT
ajst-20773	190	1	this	this	PRON
ajst-20773	190	2	may	may	AUX
ajst-20773	190	3	indicate	indicate	VERB
ajst-20773	190	4	that	that	SCONJ
ajst-20773	190	5	these	these	DET
ajst-20773	190	6	patients	patient	NOUN
ajst-20773	190	7	have	have	VERB
ajst-20773	190	8	a	a	DET
ajst-20773	190	9	more	more	ADV
ajst-20773	190	10	active	active	ADJ
ajst-20773	190	11	immune	immune	ADJ
ajst-20773	190	12	response	response	NOUN
ajst-20773	190	13	,	,	PUNCT
ajst-20773	190	14	enabling	enable	VERB
ajst-20773	190	15	their	their	PRON
ajst-20773	190	16	immune	immune	ADJ
ajst-20773	190	17	system	system	NOUN
ajst-20773	190	18	to	to	PART
ajst-20773	190	19	more	more	ADV
ajst-20773	190	20	effectively	effectively	ADV
ajst-20773	190	21	recognize	recognize	VERB
ajst-20773	190	22	and	and	CCONJ
ajst-20773	190	23	eliminate	eliminate	VERB
ajst-20773	190	24	tumor	tumor	NOUN
ajst-20773	190	25	cells	cell	NOUN
ajst-20773	190	26	,	,	PUNCT
ajst-20773	190	27	thereby	thereby	ADV
ajst-20773	190	28	inhibiting	inhibit	VERB
ajst-20773	190	29	tumor	tumor	NOUN
ajst-20773	190	30	growth	growth	NOUN
ajst-20773	190	31	and	and	CCONJ
ajst-20773	190	32	spread	spread	VERB
ajst-20773	190	33	.	.	PUNCT
ajst-20773	191	1	this	this	DET
ajst-20773	191	2	enhanced	enhance	VERB
ajst-20773	191	3	immune	immune	ADJ
ajst-20773	191	4	surveillance	surveillance	NOUN
ajst-20773	191	5	could	could	AUX
ajst-20773	191	6	be	be	AUX
ajst-20773	191	7	one	one	NUM
ajst-20773	191	8	reason	reason	NOUN
ajst-20773	191	9	for	for	ADP
ajst-20773	191	10	the	the	DET
ajst-20773	191	11	better	well	ADJ
ajst-20773	191	12	prognosis	prognosis	NOUN
ajst-20773	191	13	observed	observe	VERB
ajst-20773	191	14	in	in	ADP
ajst-20773	191	15	low	low	ADJ
ajst-20773	191	16	-	-	PUNCT
ajst-20773	191	17	risk	risk	NOUN
ajst-20773	191	18	patients	patient	NOUN
ajst-20773	191	19	.	.	PUNCT
ajst-20773	192	1	it	it	PRON
ajst-20773	192	2	may	may	AUX
ajst-20773	192	3	also	also	ADV
ajst-20773	192	4	suggest	suggest	VERB
ajst-20773	192	5	that	that	SCONJ
ajst-20773	192	6	lowrisk	lowrisk	PROPN
ajst-20773	192	7	group	group	NOUN
ajst-20773	192	8	patients	patient	NOUN
ajst-20773	192	9	have	have	VERB
ajst-20773	192	10	more	more	ADJ
ajst-20773	192	11	immune	immune	ADJ
ajst-20773	192	12	cell	cell	NOUN
ajst-20773	192	13	infiltration	infiltration	NOUN
ajst-20773	192	14	and	and	CCONJ
ajst-20773	192	15	a	a	DET
ajst-20773	192	16	more	more	ADV
ajst-20773	192	17	active	active	ADJ
ajst-20773	192	18	immune	immune	ADJ
ajst-20773	192	19	microenvironment	microenvironment	NOUN
ajst-20773	192	20	,	,	PUNCT
ajst-20773	192	21	potentially	potentially	ADV
ajst-20773	192	22	responding	respond	VERB
ajst-20773	192	23	better	well	ADV
ajst-20773	192	24	to	to	ADP
ajst-20773	192	25	immune	immune	ADJ
ajst-20773	192	26	checkpoint	checkpoint	NOUN
ajst-20773	192	27	inhibitors	inhibitor	NOUN
ajst-20773	192	28	such	such	ADJ
ajst-20773	192	29	as	as	ADP
ajst-20773	192	30	pd-1	pd-1	ADJ
ajst-20773	192	31	,	,	PUNCT
ajst-20773	192	32	pd	pd	PROPN
ajst-20773	192	33	-	-	PROPN
ajst-20773	192	34	l1	l1	PROPN
ajst-20773	192	35	,	,	PUNCT
ajst-20773	192	36	and	and	CCONJ
ajst-20773	192	37	ctla-4	ctla-4	NOUN
ajst-20773	192	38	inhibitors	inhibitor	NOUN
ajst-20773	192	39	.	.	PUNCT
ajst-20773	193	1	figure	figure	NOUN
ajst-20773	193	2	29	29	NUM
ajst-20773	193	3	.	.	PUNCT
ajst-20773	194	1	expression	expression	NOUN
ajst-20773	194	2	levels	level	NOUN
ajst-20773	194	3	of	of	ADP
ajst-20773	194	4	immune	immune	ADJ
ajst-20773	194	5	checkpoints	checkpoint	NOUN
ajst-20773	194	6	in	in	ADP
ajst-20773	194	7	high	high	ADJ
ajst-20773	194	8	and	and	CCONJ
ajst-20773	194	9	low	low	ADJ
ajst-20773	194	10	-	-	PUNCT
ajst-20773	194	11	risk	risk	NOUN
ajst-20773	194	12	groups	group	NOUN
ajst-20773	194	13	.	.	PUNCT
ajst-20773	195	1	3.9	3.9	NUM
ajst-20773	195	2	.	.	PUNCT
ajst-20773	195	3	analysis	analysis	NOUN
ajst-20773	195	4	of	of	ADP
ajst-20773	195	5	the	the	DET
ajst-20773	195	6	correlation	correlation	NOUN
ajst-20773	195	7	between	between	ADP
ajst-20773	195	8	the	the	DET
ajst-20773	195	9	senlncsig	senlncsig	PROPN
ajst-20773	195	10	model	model	NOUN
ajst-20773	195	11	and	and	CCONJ
ajst-20773	195	12	the	the	DET
ajst-20773	195	13	tumor	tumor	NOUN
ajst-20773	195	14	microenvironment	microenvironment	NOUN
ajst-20773	195	15	.	.	PUNCT
ajst-20773	196	1	to	to	PART
ajst-20773	196	2	determine	determine	VERB
ajst-20773	196	3	if	if	SCONJ
ajst-20773	196	4	the	the	DET
ajst-20773	196	5	risk	risk	NOUN
ajst-20773	196	6	scores	score	NOUN
ajst-20773	196	7	of	of	ADP
ajst-20773	196	8	our	our	PRON
ajst-20773	196	9	constructed	construct	VERB
ajst-20773	196	10	model	model	NOUN
ajst-20773	196	11	are	be	AUX
ajst-20773	196	12	correlated	correlate	VERB
ajst-20773	196	13	with	with	ADP
ajst-20773	196	14	the	the	DET
ajst-20773	196	15	tumor	tumor	NOUN
ajst-20773	196	16	microenvironment	microenvironment	NOUN
ajst-20773	196	17	,	,	PUNCT
ajst-20773	196	18	we	we	PRON
ajst-20773	196	19	used	use	VERB
ajst-20773	196	20	the	the	DET
ajst-20773	196	21	estimate	estimate	NOUN
ajst-20773	196	22	algorithm	algorithm	NOUN
ajst-20773	196	23	in	in	ADP
ajst-20773	196	24	r	r	NOUN
ajst-20773	196	25	to	to	PART
ajst-20773	196	26	score	score	VERB
ajst-20773	196	27	immune	immune	ADJ
ajst-20773	196	28	infiltration	infiltration	NOUN
ajst-20773	196	29	for	for	ADP
ajst-20773	196	30	high	high	ADJ
ajst-20773	196	31	and	and	CCONJ
ajst-20773	196	32	low	low	ADJ
ajst-20773	196	33	-	-	PUNCT
ajst-20773	196	34	risk	risk	NOUN
ajst-20773	196	35	groups	group	NOUN
ajst-20773	196	36	distinguished	distinguish	VERB
ajst-20773	196	37	by	by	ADP
ajst-20773	196	38	risk	risk	NOUN
ajst-20773	196	39	scores	score	NOUN
ajst-20773	196	40	,	,	PUNCT
ajst-20773	196	41	and	and	CCONJ
ajst-20773	196	42	visualized	visualize	VERB
ajst-20773	196	43	the	the	DET
ajst-20773	196	44	results	result	NOUN
ajst-20773	196	45	(	(	PUNCT
ajst-20773	196	46	figure	figure	NOUN
ajst-20773	196	47	30	30	NUM
ajst-20773	196	48	)	)	PUNCT
ajst-20773	196	49	.	.	PUNCT
ajst-20773	197	1	the	the	DET
ajst-20773	197	2	figure	figure	NOUN
ajst-20773	197	3	shows	show	VERB
ajst-20773	197	4	that	that	SCONJ
ajst-20773	197	5	the	the	DET
ajst-20773	197	6	low	low	ADJ
ajst-20773	197	7	-	-	PUNCT
ajst-20773	197	8	risk	risk	NOUN
ajst-20773	197	9	group	group	NOUN
ajst-20773	197	10	has	have	VERB
ajst-20773	197	11	higher	high	ADJ
ajst-20773	197	12	stromal	stromal	ADJ
ajst-20773	197	13	scores	score	NOUN
ajst-20773	197	14	,	,	PUNCT
ajst-20773	197	15	immune	immune	ADJ
ajst-20773	197	16	scores	score	NOUN
ajst-20773	197	17	,	,	PUNCT
ajst-20773	197	18	and	and	CCONJ
ajst-20773	197	19	the	the	DET
ajst-20773	197	20	combined	combine	VERB
ajst-20773	197	21	estimate	estimate	NOUN
ajst-20773	197	22	scores	score	NOUN
ajst-20773	197	23	than	than	ADP
ajst-20773	197	24	the	the	DET
ajst-20773	197	25	high	high	ADJ
ajst-20773	197	26	-	-	PUNCT
ajst-20773	197	27	risk	risk	NOUN
ajst-20773	197	28	group	group	NOUN
ajst-20773	197	29	,	,	PUNCT
ajst-20773	197	30	27	27	NUM
ajst-20773	197	31	indicating	indicate	VERB
ajst-20773	197	32	that	that	SCONJ
ajst-20773	197	33	the	the	DET
ajst-20773	197	34	prognosis	prognosis	NOUN
ajst-20773	197	35	of	of	ADP
ajst-20773	197	36	the	the	DET
ajst-20773	197	37	low	low	ADJ
ajst-20773	197	38	-	-	PUNCT
ajst-20773	197	39	risk	risk	NOUN
ajst-20773	197	40	group	group	NOUN
ajst-20773	197	41	is	be	AUX
ajst-20773	197	42	better	well	ADJ
ajst-20773	197	43	than	than	ADP
ajst-20773	197	44	that	that	PRON
ajst-20773	197	45	of	of	ADP
ajst-20773	197	46	the	the	DET
ajst-20773	197	47	high	high	ADJ
ajst-20773	197	48	-	-	PUNCT
ajst-20773	197	49	risk	risk	NOUN
ajst-20773	197	50	group	group	NOUN
ajst-20773	197	51	,	,	PUNCT
ajst-20773	197	52	which	which	PRON
ajst-20773	197	53	is	be	AUX
ajst-20773	197	54	consistent	consistent	ADJ
ajst-20773	197	55	with	with	ADP
ajst-20773	197	56	actual	actual	ADJ
ajst-20773	197	57	observations	observation	NOUN
ajst-20773	197	58	.	.	PUNCT
ajst-20773	198	1	figure	figure	VERB
ajst-20773	198	2	30	30	NUM
ajst-20773	198	3	.	.	PUNCT
ajst-20773	199	1	estimate	estimate	NOUN
ajst-20773	199	2	algorithm	algorithm	PROPN
ajst-20773	199	3	immune	immune	ADJ
ajst-20773	199	4	infiltration	infiltration	NOUN
ajst-20773	199	5	scores	score	NOUN
ajst-20773	199	6	for	for	ADP
ajst-20773	199	7	high	high	ADJ
ajst-20773	199	8	and	and	CCONJ
ajst-20773	199	9	low	low	ADJ
ajst-20773	199	10	-	-	PUNCT
ajst-20773	199	11	risk	risk	NOUN
ajst-20773	199	12	groups	group	NOUN
ajst-20773	199	13	.	.	PUNCT
ajst-20773	200	1	3.10	3.10	NUM
ajst-20773	200	2	.	.	PUNCT
ajst-20773	201	1	the	the	DET
ajst-20773	201	2	relationship	relationship	NOUN
ajst-20773	201	3	between	between	ADP
ajst-20773	201	4	senlncsig	senlncsig	PROPN
ajst-20773	201	5	risk	risk	NOUN
ajst-20773	201	6	scores	score	NOUN
ajst-20773	201	7	and	and	CCONJ
ajst-20773	201	8	the	the	DET
ajst-20773	201	9	efficacy	efficacy	NOUN
ajst-20773	201	10	of	of	ADP
ajst-20773	201	11	chemotherapy	chemotherapy	NOUN
ajst-20773	201	12	and	and	CCONJ
ajst-20773	201	13	targeted	target	VERB
ajst-20773	201	14	therapy	therapy	NOUN
ajst-20773	201	15	for	for	ADP
ajst-20773	201	16	lung	lung	NOUN
ajst-20773	201	17	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	201	18	.	.	PUNCT
ajst-20773	202	1	finally	finally	ADV
ajst-20773	202	2	,	,	PUNCT
ajst-20773	202	3	to	to	PART
ajst-20773	202	4	help	help	VERB
ajst-20773	202	5	clinicians	clinician	NOUN
ajst-20773	202	6	devise	devise	VERB
ajst-20773	202	7	more	more	ADV
ajst-20773	202	8	precise	precise	ADJ
ajst-20773	202	9	treatment	treatment	NOUN
ajst-20773	202	10	plans	plan	NOUN
ajst-20773	202	11	for	for	ADP
ajst-20773	202	12	patients	patient	NOUN
ajst-20773	202	13	,	,	PUNCT
ajst-20773	202	14	we	we	PRON
ajst-20773	202	15	analyzed	analyze	VERB
ajst-20773	202	16	the	the	DET
ajst-20773	202	17	relationship	relationship	NOUN
ajst-20773	202	18	between	between	ADP
ajst-20773	202	19	senlncsig	senlncsig	PROPN
ajst-20773	202	20	risk	risk	NOUN
ajst-20773	202	21	scores	score	NOUN
ajst-20773	202	22	and	and	CCONJ
ajst-20773	202	23	the	the	DET
ajst-20773	202	24	efficacy	efficacy	NOUN
ajst-20773	202	25	of	of	ADP
ajst-20773	202	26	chemotherapy	chemotherapy	NOUN
ajst-20773	202	27	and	and	CCONJ
ajst-20773	202	28	targeted	target	VERB
ajst-20773	202	29	therapy	therapy	NOUN
ajst-20773	202	30	for	for	ADP
ajst-20773	202	31	lung	lung	NOUN
ajst-20773	202	32	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	202	33	,	,	PUNCT
ajst-20773	202	34	examining	examine	VERB
ajst-20773	202	35	drug	drug	NOUN
ajst-20773	202	36	sensitivity	sensitivity	NOUN
ajst-20773	202	37	in	in	ADP
ajst-20773	202	38	high	high	ADJ
ajst-20773	202	39	and	and	CCONJ
ajst-20773	202	40	low	low	ADJ
ajst-20773	202	41	-	-	PUNCT
ajst-20773	202	42	risk	risk	NOUN
ajst-20773	202	43	groups	group	NOUN
ajst-20773	202	44	.	.	PUNCT
ajst-20773	203	1	based	base	VERB
ajst-20773	203	2	on	on	ADP
ajst-20773	203	3	the	the	DET
ajst-20773	203	4	results	result	NOUN
ajst-20773	203	5	,	,	PUNCT
ajst-20773	203	6	and	and	CCONJ
ajst-20773	203	7	existing	exist	VERB
ajst-20773	203	8	experiments	experiment	NOUN
ajst-20773	203	9	and	and	CCONJ
ajst-20773	203	10	studies	study	NOUN
ajst-20773	203	11	on	on	ADP
ajst-20773	203	12	drugs	drug	NOUN
ajst-20773	203	13	,	,	PUNCT
ajst-20773	203	14	we	we	PRON
ajst-20773	203	15	found	find	VERB
ajst-20773	203	16	that	that	SCONJ
ajst-20773	203	17	the	the	DET
ajst-20773	203	18	targeted	target	VERB
ajst-20773	203	19	drug	drug	NOUN
ajst-20773	203	20	epidermal	epidermal	ADJ
ajst-20773	203	21	growth	growth	NOUN
ajst-20773	203	22	factor	factor	NOUN
ajst-20773	203	23	receptor	receptor	NOUN
ajst-20773	203	24	(	(	PUNCT
ajst-20773	203	25	egfr	egfr	X
ajst-20773	203	26	)	)	PUNCT
ajst-20773	203	27	inhibitor	inhibitor	NOUN
ajst-20773	203	28	erlotinib	erlotinib	NOUN
ajst-20773	203	29	(	(	PUNCT
ajst-20773	203	30	figure	figure	NOUN
ajst-20773	203	31	31a	31a	NUM
ajst-20773	203	32	)	)	PUNCT
ajst-20773	203	33	;	;	PUNCT
ajst-20773	203	34	paclitaxel	paclitaxel	PROPN
ajst-20773	203	35	(	(	PUNCT
ajst-20773	203	36	figure	figure	NOUN
ajst-20773	203	37	31b	31b	NUM
ajst-20773	203	38	)	)	PUNCT
ajst-20773	203	39	;	;	PUNCT
ajst-20773	203	40	the	the	DET
ajst-20773	203	41	experimental	experimental	ADJ
ajst-20773	203	42	drug	drug	NOUN
ajst-20773	203	43	sgk1	sgk1	PROPN
ajst-20773	203	44	inhibitor	inhibitor	NOUN
ajst-20773	203	45	gsk650394	gsk650394	NOUN
ajst-20773	203	46	(	(	PUNCT
ajst-20773	203	47	figure	figure	NOUN
ajst-20773	203	48	31c	31c	NUM
ajst-20773	203	49	)	)	PUNCT
ajst-20773	203	50	;	;	PUNCT
ajst-20773	203	51	and	and	CCONJ
ajst-20773	203	52	the	the	DET
ajst-20773	203	53	natural	natural	ADJ
ajst-20773	203	54	plant	plant	NOUN
ajst-20773	203	55	extract	extract	NOUN
ajst-20773	203	56	parthenolide	parthenolide	ADV
ajst-20773	203	57	(	(	PUNCT
ajst-20773	203	58	figure	figure	NOUN
ajst-20773	203	59	31d	31d	NOUN
ajst-20773	203	60	)	)	PUNCT
ajst-20773	203	61	are	be	AUX
ajst-20773	203	62	more	more	ADV
ajst-20773	203	63	sensitive	sensitive	ADJ
ajst-20773	203	64	in	in	ADP
ajst-20773	203	65	the	the	DET
ajst-20773	203	66	low	low	ADJ
ajst-20773	203	67	-	-	PUNCT
ajst-20773	203	68	risk	risk	NOUN
ajst-20773	203	69	group	group	NOUN
ajst-20773	203	70	with	with	ADP
ajst-20773	203	71	relatively	relatively	ADV
ajst-20773	203	72	lower	low	ADJ
ajst-20773	203	73	ic50	ic50	PROPN
ajst-20773	203	74	values	value	NOUN
ajst-20773	203	75	,	,	PUNCT
ajst-20773	203	76	indicating	indicate	VERB
ajst-20773	203	77	these	these	DET
ajst-20773	203	78	drugs	drug	NOUN
ajst-20773	203	79	would	would	AUX
ajst-20773	203	80	achieve	achieve	VERB
ajst-20773	203	81	better	well	ADJ
ajst-20773	203	82	efficacy	efficacy	NOUN
ajst-20773	203	83	in	in	ADP
ajst-20773	203	84	this	this	DET
ajst-20773	203	85	group	group	NOUN
ajst-20773	203	86	.	.	PUNCT
ajst-20773	204	1	meanwhile	meanwhile	ADV
ajst-20773	204	2	,	,	PUNCT
ajst-20773	204	3	the	the	DET
ajst-20773	204	4	chemotherapy	chemotherapy	NOUN
ajst-20773	204	5	drug	drug	NOUN
ajst-20773	204	6	methotrexate	methotrexate	NOUN
ajst-20773	204	7	(	(	PUNCT
ajst-20773	204	8	figure	figure	NOUN
ajst-20773	204	9	32a	32a	NOUN
ajst-20773	204	10	)	)	PUNCT
ajst-20773	204	11	;	;	PUNCT
ajst-20773	204	12	the	the	DET
ajst-20773	204	13	broad	broad	ADJ
ajst-20773	204	14	-	-	PUNCT
ajst-20773	204	15	spectrum	spectrum	NOUN
ajst-20773	204	16	anticancer	anticancer	NOUN
ajst-20773	204	17	drug	drug	NOUN
ajst-20773	204	18	pac-1	pac-1	PUNCT
ajst-20773	204	19	(	(	PUNCT
ajst-20773	204	20	figure	figure	NOUN
ajst-20773	204	21	32b	32b	NOUN
ajst-20773	204	22	)	)	PUNCT
ajst-20773	204	23	;	;	PUNCT
ajst-20773	204	24	akt	akt	PROPN
ajst-20773	204	25	inhibitor	inhibitor	PROPN
ajst-20773	204	26	mk2206	mk2206	PROPN
ajst-20773	204	27	(	(	PUNCT
ajst-20773	204	28	figure	figure	NOUN
ajst-20773	204	29	32c	32c	NOUN
ajst-20773	204	30	)	)	PUNCT
ajst-20773	204	31	;	;	PUNCT
ajst-20773	204	32	and	and	CCONJ
ajst-20773	204	33	the	the	DET
ajst-20773	204	34	multi	multi	ADJ
ajst-20773	204	35	-	-	ADJ
ajst-20773	204	36	target	target	ADJ
ajst-20773	204	37	tyrosine	tyrosine	NOUN
ajst-20773	204	38	kinase	kinase	PROPN
ajst-20773	204	39	inhibitor	inhibitor	PROPN
ajst-20773	204	40	ponatinib	ponatinib	NOUN
ajst-20773	204	41	(	(	PUNCT
ajst-20773	204	42	ap.24534	ap.24534	PROPN
ajst-20773	204	43	)	)	PUNCT
ajst-20773	204	44	(	(	PUNCT
ajst-20773	204	45	figure	figure	NOUN
ajst-20773	204	46	32d	32d	NUM
ajst-20773	204	47	)	)	PUNCT
ajst-20773	204	48	,	,	PUNCT
ajst-20773	204	49	are	be	AUX
ajst-20773	204	50	more	more	ADV
ajst-20773	204	51	sensitive	sensitive	ADJ
ajst-20773	204	52	in	in	ADP
ajst-20773	204	53	the	the	DET
ajst-20773	204	54	high	high	ADJ
ajst-20773	204	55	-	-	PUNCT
ajst-20773	204	56	risk	risk	NOUN
ajst-20773	204	57	group	group	NOUN
ajst-20773	204	58	,	,	PUNCT
ajst-20773	204	59	suggesting	suggest	VERB
ajst-20773	204	60	these	these	DET
ajst-20773	204	61	drugs	drug	NOUN
ajst-20773	204	62	may	may	AUX
ajst-20773	204	63	be	be	AUX
ajst-20773	204	64	more	more	ADV
ajst-20773	204	65	suitable	suitable	ADJ
ajst-20773	204	66	for	for	ADP
ajst-20773	204	67	use	use	NOUN
ajst-20773	204	68	in	in	ADP
ajst-20773	204	69	high	high	ADJ
ajst-20773	204	70	-	-	PUNCT
ajst-20773	204	71	risk	risk	NOUN
ajst-20773	204	72	patients	patient	NOUN
ajst-20773	204	73	.	.	PUNCT
ajst-20773	205	1	figure	figure	NOUN
ajst-20773	205	2	31	31	NUM
ajst-20773	205	3	.	.	PUNCT
ajst-20773	206	1	ic50	ic50	PROPN
ajst-20773	206	2	values	value	NOUN
ajst-20773	206	3	of	of	ADP
ajst-20773	206	4	various	various	ADJ
ajst-20773	206	5	targeted	target	VERB
ajst-20773	206	6	therapy	therapy	NOUN
ajst-20773	206	7	drugs	drug	NOUN
ajst-20773	206	8	in	in	ADP
ajst-20773	206	9	high	high	ADJ
ajst-20773	206	10	and	and	CCONJ
ajst-20773	206	11	low	low	ADJ
ajst-20773	206	12	-	-	PUNCT
ajst-20773	206	13	risk	risk	NOUN
ajst-20773	206	14	patient	patient	NOUN
ajst-20773	206	15	groups	group	NOUN
ajst-20773	206	16	.	.	PUNCT
ajst-20773	207	1	28	28	NUM
ajst-20773	207	2	figure	figure	NOUN
ajst-20773	207	3	32	32	NUM
ajst-20773	207	4	.	.	PUNCT
ajst-20773	208	1	ic50	ic50	PROPN
ajst-20773	208	2	values	value	NOUN
ajst-20773	208	3	of	of	ADP
ajst-20773	208	4	various	various	ADJ
ajst-20773	208	5	targeted	target	VERB
ajst-20773	208	6	therapy	therapy	NOUN
ajst-20773	208	7	drugs	drug	NOUN
ajst-20773	208	8	in	in	ADP
ajst-20773	208	9	high	high	ADJ
ajst-20773	208	10	and	and	CCONJ
ajst-20773	208	11	low	low	ADJ
ajst-20773	208	12	-	-	PUNCT
ajst-20773	208	13	risk	risk	NOUN
ajst-20773	208	14	patient	patient	NOUN
ajst-20773	208	15	groups	group	NOUN
ajst-20773	208	16	.	.	PUNCT
ajst-20773	209	1	4	4	X
ajst-20773	209	2	.	.	X
ajst-20773	209	3	discussion	discussion	NOUN
ajst-20773	209	4	lung	lung	NOUN
ajst-20773	209	5	cancer	cancer	NOUN
ajst-20773	209	6	is	be	AUX
ajst-20773	209	7	the	the	DET
ajst-20773	209	8	leading	lead	VERB
ajst-20773	209	9	cause	cause	NOUN
ajst-20773	209	10	of	of	ADP
ajst-20773	209	11	cancer	cancer	NOUN
ajst-20773	209	12	-	-	PUNCT
ajst-20773	209	13	related	relate	VERB
ajst-20773	209	14	deaths	death	NOUN
ajst-20773	209	15	worldwide	worldwide	ADV
ajst-20773	209	16	.	.	PUNCT
ajst-20773	210	1	the	the	DET
ajst-20773	210	2	tumor	tumor	NOUN
ajst-20773	210	3	microenvironment	microenvironment	NOUN
ajst-20773	210	4	(	(	PUNCT
ajst-20773	210	5	tme	tme	NOUN
ajst-20773	210	6	)	)	PUNCT
ajst-20773	210	7	refers	refer	VERB
ajst-20773	210	8	to	to	ADP
ajst-20773	210	9	the	the	DET
ajst-20773	210	10	local	local	ADJ
ajst-20773	210	11	environment	environment	NOUN
ajst-20773	210	12	surrounding	surround	VERB
ajst-20773	210	13	tumor	tumor	NOUN
ajst-20773	210	14	cells	cell	NOUN
ajst-20773	210	15	,	,	PUNCT
ajst-20773	210	16	including	include	VERB
ajst-20773	210	17	non	non	ADJ
ajst-20773	210	18	-	-	ADJ
ajst-20773	210	19	tumor	tumor	ADJ
ajst-20773	210	20	cells	cell	NOUN
ajst-20773	210	21	,	,	PUNCT
ajst-20773	210	22	the	the	DET
ajst-20773	210	23	extracellular	extracellular	ADJ
ajst-20773	210	24	matrix	matrix	NOUN
ajst-20773	210	25	(	(	PUNCT
ajst-20773	210	26	ecm	ecm	PROPN
ajst-20773	210	27	)	)	PUNCT
ajst-20773	210	28	,	,	PUNCT
ajst-20773	210	29	the	the	DET
ajst-20773	210	30	vascular	vascular	ADJ
ajst-20773	210	31	system	system	NOUN
ajst-20773	210	32	,	,	PUNCT
ajst-20773	210	33	immune	immune	ADJ
ajst-20773	210	34	cells	cell	NOUN
ajst-20773	210	35	,	,	PUNCT
ajst-20773	210	36	and	and	CCONJ
ajst-20773	210	37	various	various	ADJ
ajst-20773	210	38	cytokines	cytokine	NOUN
ajst-20773	210	39	and	and	CCONJ
ajst-20773	210	40	chemical	chemical	NOUN
ajst-20773	210	41	signals	signal	NOUN
ajst-20773	210	42	.	.	PUNCT
ajst-20773	211	1	the	the	DET
ajst-20773	211	2	tumor	tumor	NOUN
ajst-20773	211	3	microenvironment	microenvironment	NOUN
ajst-20773	211	4	plays	play	VERB
ajst-20773	211	5	a	a	DET
ajst-20773	211	6	crucial	crucial	ADJ
ajst-20773	211	7	role	role	NOUN
ajst-20773	211	8	in	in	ADP
ajst-20773	211	9	the	the	DET
ajst-20773	211	10	occurrence	occurrence	NOUN
ajst-20773	211	11	,	,	PUNCT
ajst-20773	211	12	development	development	NOUN
ajst-20773	211	13	,	,	PUNCT
ajst-20773	211	14	metastasis	metastasis	NOUN
ajst-20773	211	15	,	,	PUNCT
ajst-20773	211	16	and	and	CCONJ
ajst-20773	211	17	response	response	NOUN
ajst-20773	211	18	to	to	ADP
ajst-20773	211	19	treatment	treatment	NOUN
ajst-20773	211	20	of	of	ADP
ajst-20773	211	21	tumors	tumor	NOUN
ajst-20773	211	22	(	(	PUNCT
ajst-20773	211	23	genova	genova	X
ajst-20773	211	24	et	et	PROPN
ajst-20773	211	25	al	al	PROPN
ajst-20773	211	26	.	.	PROPN
ajst-20773	211	27	,	,	PUNCT
ajst-20773	211	28	2022	2022	NUM
ajst-20773	211	29	;	;	PUNCT
ajst-20773	211	30	bonanno	bonanno	PROPN
ajst-20773	211	31	et	et	PROPN
ajst-20773	211	32	al	al	PROPN
ajst-20773	211	33	.	.	PROPN
ajst-20773	211	34	,	,	PUNCT
ajst-20773	211	35	2018	2018	NUM
ajst-20773	211	36	)	)	PUNCT
ajst-20773	211	37	.	.	PUNCT
ajst-20773	212	1	the	the	DET
ajst-20773	212	2	level	level	NOUN
ajst-20773	212	3	of	of	ADP
ajst-20773	212	4	immune	immune	ADJ
ajst-20773	212	5	infiltration	infiltration	NOUN
ajst-20773	212	6	in	in	ADP
ajst-20773	212	7	the	the	DET
ajst-20773	212	8	tme	tme	NOUN
ajst-20773	212	9	refers	refer	VERB
ajst-20773	212	10	to	to	ADP
ajst-20773	212	11	the	the	DET
ajst-20773	212	12	degree	degree	NOUN
ajst-20773	212	13	to	to	PART
ajst-20773	212	14	which	which	PRON
ajst-20773	212	15	immune	immune	ADJ
ajst-20773	212	16	cells	cell	NOUN
ajst-20773	212	17	enter	enter	VERB
ajst-20773	212	18	and	and	CCONJ
ajst-20773	212	19	exist	exist	VERB
ajst-20773	212	20	within	within	ADP
ajst-20773	212	21	the	the	DET
ajst-20773	212	22	tumor	tumor	NOUN
ajst-20773	212	23	tissue	tissue	NOUN
ajst-20773	212	24	.	.	PUNCT
ajst-20773	213	1	the	the	DET
ajst-20773	213	2	tme	tme	PROPN
ajst-20773	213	3	is	be	AUX
ajst-20773	213	4	a	a	DET
ajst-20773	213	5	complex	complex	ADJ
ajst-20773	213	6	ecosystem	ecosystem	NOUN
ajst-20773	213	7	that	that	PRON
ajst-20773	213	8	includes	include	VERB
ajst-20773	213	9	tumor	tumor	NOUN
ajst-20773	213	10	cells	cell	NOUN
ajst-20773	213	11	,	,	PUNCT
ajst-20773	213	12	immune	immune	ADJ
ajst-20773	213	13	cells	cell	NOUN
ajst-20773	213	14	,	,	PUNCT
ajst-20773	213	15	blood	blood	NOUN
ajst-20773	213	16	vessels	vessel	NOUN
ajst-20773	213	17	,	,	PUNCT
ajst-20773	213	18	extracellular	extracellular	ADJ
ajst-20773	213	19	matrix	matrix	NOUN
ajst-20773	213	20	,	,	PUNCT
ajst-20773	213	21	and	and	CCONJ
ajst-20773	213	22	other	other	ADJ
ajst-20773	213	23	cell	cell	NOUN
ajst-20773	213	24	types	type	NOUN
ajst-20773	213	25	.	.	PUNCT
ajst-20773	214	1	within	within	ADP
ajst-20773	214	2	this	this	DET
ajst-20773	214	3	environment	environment	NOUN
ajst-20773	214	4	,	,	PUNCT
ajst-20773	214	5	various	various	ADJ
ajst-20773	214	6	components	component	NOUN
ajst-20773	214	7	of	of	ADP
ajst-20773	214	8	the	the	DET
ajst-20773	214	9	immune	immune	ADJ
ajst-20773	214	10	system	system	NOUN
ajst-20773	214	11	,	,	PUNCT
ajst-20773	214	12	such	such	ADJ
ajst-20773	214	13	as	as	ADP
ajst-20773	214	14	t	t	PROPN
ajst-20773	214	15	cells	cell	NOUN
ajst-20773	214	16	,	,	PUNCT
ajst-20773	214	17	b	b	NOUN
ajst-20773	214	18	cells	cell	NOUN
ajst-20773	214	19	,	,	PUNCT
ajst-20773	214	20	natural	natural	ADJ
ajst-20773	214	21	killer	killer	NOUN
ajst-20773	214	22	(	(	PUNCT
ajst-20773	214	23	nk	nk	PROPN
ajst-20773	214	24	)	)	PUNCT
ajst-20773	214	25	cells	cell	NOUN
ajst-20773	214	26	,	,	PUNCT
ajst-20773	214	27	macrophages	macrophage	NOUN
ajst-20773	214	28	,	,	PUNCT
ajst-20773	214	29	and	and	CCONJ
ajst-20773	214	30	dendritic	dendritic	ADJ
ajst-20773	214	31	cells	cell	NOUN
ajst-20773	214	32	,	,	PUNCT
ajst-20773	214	33	can	can	AUX
ajst-20773	214	34	penetrate	penetrate	VERB
ajst-20773	214	35	the	the	DET
ajst-20773	214	36	tumor	tumor	NOUN
ajst-20773	214	37	tissue	tissue	NOUN
ajst-20773	214	38	,	,	PUNCT
ajst-20773	214	39	forming	form	VERB
ajst-20773	214	40	immune	immune	ADJ
ajst-20773	214	41	infiltration	infiltration	NOUN
ajst-20773	214	42	.	.	PUNCT
ajst-20773	215	1	the	the	DET
ajst-20773	215	2	level	level	NOUN
ajst-20773	215	3	of	of	ADP
ajst-20773	215	4	immune	immune	ADJ
ajst-20773	215	5	infiltration	infiltration	NOUN
ajst-20773	215	6	is	be	AUX
ajst-20773	215	7	an	an	DET
ajst-20773	215	8	important	important	ADJ
ajst-20773	215	9	indicator	indicator	NOUN
ajst-20773	215	10	for	for	ADP
ajst-20773	215	11	assessing	assess	VERB
ajst-20773	215	12	the	the	DET
ajst-20773	215	13	immune	immune	ADJ
ajst-20773	215	14	response	response	NOUN
ajst-20773	215	15	status	status	NOUN
ajst-20773	215	16	of	of	ADP
ajst-20773	215	17	tumors	tumor	NOUN
ajst-20773	215	18	,	,	PUNCT
ajst-20773	215	19	which	which	PRON
ajst-20773	215	20	has	have	VERB
ajst-20773	215	21	significant	significant	ADJ
ajst-20773	215	22	implications	implication	NOUN
ajst-20773	215	23	for	for	ADP
ajst-20773	215	24	cancer	cancer	NOUN
ajst-20773	215	25	treatment	treatment	NOUN
ajst-20773	215	26	and	and	CCONJ
ajst-20773	215	27	prognosis	prognosis	NOUN
ajst-20773	215	28	(	(	PUNCT
ajst-20773	215	29	peng	peng	PROPN
ajst-20773	215	30	et	et	PROPN
ajst-20773	215	31	al	al	PROPN
ajst-20773	215	32	.	.	PROPN
ajst-20773	215	33	,	,	PUNCT
ajst-20773	215	34	2021	2021	NUM
ajst-20773	215	35	;	;	PUNCT
ajst-20773	215	36	wen	wen	PROPN
ajst-20773	215	37	et	et	PROPN
ajst-20773	215	38	al	al	PROPN
ajst-20773	215	39	.	.	PROPN
ajst-20773	215	40	,	,	PUNCT
ajst-20773	215	41	2022	2022	NUM
ajst-20773	215	42	)	)	PUNCT
ajst-20773	215	43	.	.	PUNCT
ajst-20773	216	1	although	although	SCONJ
ajst-20773	216	2	chemotherapy	chemotherapy	NOUN
ajst-20773	216	3	and	and	CCONJ
ajst-20773	216	4	radiation	radiation	NOUN
ajst-20773	216	5	therapy	therapy	NOUN
ajst-20773	216	6	remain	remain	VERB
ajst-20773	216	7	mainstream	mainstream	ADJ
ajst-20773	216	8	methods	method	NOUN
ajst-20773	216	9	for	for	ADP
ajst-20773	216	10	many	many	ADJ
ajst-20773	216	11	malignant	malignant	ADJ
ajst-20773	216	12	tumors	tumor	NOUN
ajst-20773	216	13	,	,	PUNCT
ajst-20773	216	14	immune	immune	ADJ
ajst-20773	216	15	checkpoint	checkpoint	NOUN
ajst-20773	216	16	inhibitors	inhibitor	NOUN
ajst-20773	216	17	(	(	PUNCT
ajst-20773	216	18	icis	icis	NOUN
ajst-20773	216	19	)	)	PUNCT
ajst-20773	216	20	have	have	AUX
ajst-20773	216	21	now	now	ADV
ajst-20773	216	22	become	become	VERB
ajst-20773	216	23	indispensable	indispensable	ADJ
ajst-20773	216	24	in	in	ADP
ajst-20773	216	25	the	the	DET
ajst-20773	216	26	treatment	treatment	NOUN
ajst-20773	216	27	of	of	ADP
ajst-20773	216	28	various	various	ADJ
ajst-20773	216	29	malignancies	malignancy	NOUN
ajst-20773	216	30	.	.	PUNCT
ajst-20773	217	1	during	during	ADP
ajst-20773	217	2	the	the	DET
ajst-20773	217	3	progression	progression	NOUN
ajst-20773	217	4	of	of	ADP
ajst-20773	217	5	malignant	malignant	ADJ
ajst-20773	217	6	tumors	tumor	NOUN
ajst-20773	217	7	,	,	PUNCT
ajst-20773	217	8	the	the	DET
ajst-20773	217	9	tumor	tumor	NOUN
ajst-20773	217	10	immune	immune	ADJ
ajst-20773	217	11	response	response	NOUN
ajst-20773	217	12	is	be	AUX
ajst-20773	217	13	often	often	ADV
ajst-20773	217	14	suppressed	suppress	VERB
ajst-20773	217	15	,	,	PUNCT
ajst-20773	217	16	and	and	CCONJ
ajst-20773	217	17	the	the	DET
ajst-20773	217	18	core	core	NOUN
ajst-20773	217	19	mechanism	mechanism	NOUN
ajst-20773	217	20	of	of	ADP
ajst-20773	217	21	icis	icis	NOUN
ajst-20773	217	22	is	be	AUX
ajst-20773	217	23	to	to	PART
ajst-20773	217	24	lift	lift	VERB
ajst-20773	217	25	the	the	DET
ajst-20773	217	26	suppression	suppression	NOUN
ajst-20773	217	27	on	on	ADP
ajst-20773	217	28	t	t	NOUN
ajst-20773	217	29	cells	cell	NOUN
ajst-20773	217	30	,	,	PUNCT
ajst-20773	217	31	thereby	thereby	ADV
ajst-20773	217	32	activating	activate	VERB
ajst-20773	217	33	an	an	DET
ajst-20773	217	34	immune	immune	ADJ
ajst-20773	217	35	response	response	NOUN
ajst-20773	217	36	against	against	ADP
ajst-20773	217	37	the	the	DET
ajst-20773	217	38	tumor	tumor	NOUN
ajst-20773	217	39	(	(	PUNCT
ajst-20773	217	40	topalian	topalian	NOUN
ajst-20773	217	41	et	et	PROPN
ajst-20773	217	42	al	al	PROPN
ajst-20773	217	43	.	.	PROPN
ajst-20773	217	44	,	,	PUNCT
ajst-20773	217	45	2016	2016	NUM
ajst-20773	217	46	)	)	PUNCT
ajst-20773	217	47	.	.	PUNCT
ajst-20773	218	1	additionally	additionally	ADV
ajst-20773	218	2	,	,	PUNCT
ajst-20773	218	3	icis	icis	PROPN
ajst-20773	218	4	also	also	ADV
ajst-20773	218	5	promote	promote	VERB
ajst-20773	218	6	the	the	DET
ajst-20773	218	7	activation	activation	NOUN
ajst-20773	218	8	of	of	ADP
ajst-20773	218	9	other	other	ADJ
ajst-20773	218	10	cells	cell	NOUN
ajst-20773	218	11	in	in	ADP
ajst-20773	218	12	both	both	CCONJ
ajst-20773	218	13	the	the	DET
ajst-20773	218	14	innate	innate	ADJ
ajst-20773	218	15	and	and	CCONJ
ajst-20773	218	16	adaptive	adaptive	ADJ
ajst-20773	218	17	immune	immune	ADJ
ajst-20773	218	18	systems	system	NOUN
ajst-20773	218	19	,	,	PUNCT
ajst-20773	218	20	which	which	PRON
ajst-20773	218	21	work	work	VERB
ajst-20773	218	22	together	together	ADV
ajst-20773	218	23	to	to	PART
ajst-20773	218	24	exert	exert	VERB
ajst-20773	218	25	an	an	DET
ajst-20773	218	26	anti	anti	ADJ
ajst-20773	218	27	-	-	ADJ
ajst-20773	218	28	tumor	tumor	ADJ
ajst-20773	218	29	effect	effect	NOUN
ajst-20773	218	30	(	(	PUNCT
ajst-20773	218	31	wei	wei	PROPN
ajst-20773	218	32	et	et	PROPN
ajst-20773	218	33	al	al	PROPN
ajst-20773	218	34	.	.	PROPN
ajst-20773	218	35	,	,	PUNCT
ajst-20773	218	36	2018	2018	NUM
ajst-20773	218	37	)	)	PUNCT
ajst-20773	218	38	.	.	PUNCT
ajst-20773	219	1	changes	change	NOUN
ajst-20773	219	2	in	in	ADP
ajst-20773	219	3	the	the	DET
ajst-20773	219	4	immune	immune	ADJ
ajst-20773	219	5	response	response	NOUN
ajst-20773	219	6	induced	induce	VERB
ajst-20773	219	7	by	by	ADP
ajst-20773	219	8	icis	icis	PROPN
ajst-20773	219	9	can	can	AUX
ajst-20773	219	10	be	be	AUX
ajst-20773	219	11	observed	observe	VERB
ajst-20773	219	12	not	not	PART
ajst-20773	219	13	only	only	ADV
ajst-20773	219	14	in	in	ADP
ajst-20773	219	15	the	the	DET
ajst-20773	219	16	tumor	tumor	NOUN
ajst-20773	219	17	itself	itself	PRON
ajst-20773	219	18	,	,	PUNCT
ajst-20773	219	19	nearby	nearby	ADJ
ajst-20773	219	20	tissues	tissue	NOUN
ajst-20773	219	21	,	,	PUNCT
ajst-20773	219	22	or	or	CCONJ
ajst-20773	219	23	distant	distant	ADJ
ajst-20773	219	24	organs	organ	NOUN
ajst-20773	219	25	such	such	ADJ
ajst-20773	219	26	as	as	ADP
ajst-20773	219	27	draining	drain	VERB
ajst-20773	219	28	lymph	lymph	NOUN
ajst-20773	219	29	nodes	node	NOUN
ajst-20773	219	30	and	and	CCONJ
ajst-20773	219	31	the	the	DET
ajst-20773	219	32	circulatory	circulatory	ADJ
ajst-20773	219	33	system	system	NOUN
ajst-20773	219	34	.	.	PUNCT
ajst-20773	220	1	this	this	DET
ajst-20773	220	2	peripheral	peripheral	ADJ
ajst-20773	220	3	immune	immune	ADJ
ajst-20773	220	4	response	response	NOUN
ajst-20773	220	5	is	be	AUX
ajst-20773	220	6	extremely	extremely	ADV
ajst-20773	220	7	critical	critical	ADJ
ajst-20773	220	8	for	for	ADP
ajst-20773	220	9	achieving	achieve	VERB
ajst-20773	220	10	positive	positive	ADJ
ajst-20773	220	11	clinical	clinical	ADJ
ajst-20773	220	12	outcomes	outcome	NOUN
ajst-20773	220	13	.	.	PUNCT
ajst-20773	221	1	currently	currently	ADV
ajst-20773	221	2	,	,	PUNCT
ajst-20773	221	3	three	three	NUM
ajst-20773	221	4	types	type	NOUN
ajst-20773	221	5	of	of	ADP
ajst-20773	221	6	icis	icis	NOUN
ajst-20773	221	7	targeting	target	VERB
ajst-20773	221	8	different	different	ADJ
ajst-20773	221	9	points	point	NOUN
ajst-20773	221	10	have	have	AUX
ajst-20773	221	11	been	be	AUX
ajst-20773	221	12	clinically	clinically	ADV
ajst-20773	221	13	approved	approve	VERB
ajst-20773	221	14	:	:	PUNCT
ajst-20773	221	15	pd-1	pd-1	ADP
ajst-20773	221	16	inhibitors	inhibitor	NOUN
ajst-20773	221	17	,	,	PUNCT
ajst-20773	221	18	pd	pd	PROPN
ajst-20773	221	19	-	-	PUNCT
ajst-20773	221	20	l1	l1	PROPN
ajst-20773	221	21	inhibitors	inhibitor	NOUN
ajst-20773	221	22	,	,	PUNCT
ajst-20773	221	23	and	and	CCONJ
ajst-20773	221	24	ctla-4	ctla-4	NOUN
ajst-20773	221	25	inhibitors	inhibitor	NOUN
ajst-20773	221	26	.	.	PUNCT
ajst-20773	222	1	pd-1	pd-1	ADJ
ajst-20773	222	2	is	be	AUX
ajst-20773	222	3	a	a	DET
ajst-20773	222	4	protein	protein	NOUN
ajst-20773	222	5	on	on	ADP
ajst-20773	222	6	the	the	DET
ajst-20773	222	7	surface	surface	NOUN
ajst-20773	222	8	of	of	ADP
ajst-20773	222	9	t	t	NOUN
ajst-20773	222	10	cells	cell	NOUN
ajst-20773	222	11	,	,	PUNCT
ajst-20773	222	12	while	while	SCONJ
ajst-20773	222	13	pd	pd	PROPN
ajst-20773	222	14	-	-	PROPN
ajst-20773	222	15	l1	l1	PROPN
ajst-20773	222	16	is	be	AUX
ajst-20773	222	17	a	a	DET
ajst-20773	222	18	protein	protein	NOUN
ajst-20773	222	19	on	on	ADP
ajst-20773	222	20	the	the	DET
ajst-20773	222	21	surface	surface	NOUN
ajst-20773	222	22	of	of	ADP
ajst-20773	222	23	cancer	cancer	NOUN
ajst-20773	222	24	cells	cell	NOUN
ajst-20773	222	25	.	.	PUNCT
ajst-20773	223	1	their	their	PRON
ajst-20773	223	2	interaction	interaction	NOUN
ajst-20773	223	3	can	can	AUX
ajst-20773	223	4	inhibit	inhibit	VERB
ajst-20773	223	5	the	the	DET
ajst-20773	223	6	activity	activity	NOUN
ajst-20773	223	7	of	of	ADP
ajst-20773	223	8	t	t	NOUN
ajst-20773	223	9	cells	cell	NOUN
ajst-20773	223	10	.	.	PUNCT
ajst-20773	224	1	by	by	ADP
ajst-20773	224	2	using	use	VERB
ajst-20773	224	3	inhibitors	inhibitor	NOUN
ajst-20773	224	4	targeting	target	VERB
ajst-20773	224	5	pd-1	pd-1	ADP
ajst-20773	224	6	(	(	PUNCT
ajst-20773	224	7	such	such	ADJ
ajst-20773	224	8	as	as	ADP
ajst-20773	224	9	nivolumab	nivolumab	NOUN
ajst-20773	224	10	and	and	CCONJ
ajst-20773	224	11	pembrolizumab	pembrolizumab	NOUN
ajst-20773	224	12	)	)	PUNCT
ajst-20773	224	13	or	or	CCONJ
ajst-20773	224	14	pd	pd	PROPN
ajst-20773	224	15	-	-	PROPN
ajst-20773	224	16	l1	l1	PROPN
ajst-20773	224	17	(	(	PUNCT
ajst-20773	224	18	such	such	ADJ
ajst-20773	224	19	as	as	ADP
ajst-20773	224	20	atezolizumab	atezolizumab	NOUN
ajst-20773	224	21	and	and	CCONJ
ajst-20773	224	22	durvalumab	durvalumab	NOUN
ajst-20773	224	23	)	)	PUNCT
ajst-20773	224	24	,	,	PUNCT
ajst-20773	224	25	this	this	DET
ajst-20773	224	26	interaction	interaction	NOUN
ajst-20773	224	27	can	can	AUX
ajst-20773	224	28	be	be	AUX
ajst-20773	224	29	blocked	block	VERB
ajst-20773	224	30	,	,	PUNCT
ajst-20773	224	31	enhancing	enhance	VERB
ajst-20773	224	32	the	the	DET
ajst-20773	224	33	immune	immune	ADJ
ajst-20773	224	34	system	system	NOUN
ajst-20773	224	35	's	's	PART
ajst-20773	224	36	attack	attack	NOUN
ajst-20773	224	37	on	on	ADP
ajst-20773	224	38	cancer	cancer	NOUN
ajst-20773	224	39	cells	cell	NOUN
ajst-20773	224	40	(	(	PUNCT
ajst-20773	224	41	jenkins	jenkin	NOUN
ajst-20773	224	42	et	et	PROPN
ajst-20773	224	43	al	al	PROPN
ajst-20773	224	44	.	.	PROPN
ajst-20773	224	45	,	,	PUNCT
ajst-20773	224	46	2018	2018	NUM
ajst-20773	224	47	)	)	PUNCT
ajst-20773	224	48	.	.	PUNCT
ajst-20773	225	1	ctla-4	ctla-4	NUM
ajst-20773	225	2	is	be	AUX
ajst-20773	225	3	another	another	DET
ajst-20773	225	4	protein	protein	NOUN
ajst-20773	225	5	on	on	ADP
ajst-20773	225	6	the	the	DET
ajst-20773	225	7	surface	surface	NOUN
ajst-20773	225	8	of	of	ADP
ajst-20773	225	9	t	t	NOUN
ajst-20773	225	10	cells	cell	NOUN
ajst-20773	225	11	that	that	PRON
ajst-20773	225	12	can	can	AUX
ajst-20773	225	13	inhibit	inhibit	VERB
ajst-20773	225	14	t	t	NOUN
ajst-20773	225	15	cell	cell	NOUN
ajst-20773	225	16	activation	activation	NOUN
ajst-20773	225	17	.	.	PUNCT
ajst-20773	226	1	inhibitors	inhibitor	NOUN
ajst-20773	226	2	targeting	target	VERB
ajst-20773	226	3	ctla-4	ctla-4	NOUN
ajst-20773	226	4	(	(	PUNCT
ajst-20773	226	5	such	such	ADJ
ajst-20773	226	6	as	as	ADP
ajst-20773	226	7	ipilimumab	ipilimumab	NOUN
ajst-20773	226	8	)	)	PUNCT
ajst-20773	226	9	can	can	AUX
ajst-20773	226	10	prevent	prevent	VERB
ajst-20773	226	11	this	this	DET
ajst-20773	226	12	inhibitory	inhibitory	ADJ
ajst-20773	226	13	effect	effect	NOUN
ajst-20773	226	14	and	and	CCONJ
ajst-20773	226	15	promote	promote	VERB
ajst-20773	226	16	the	the	DET
ajst-20773	226	17	activity	activity	NOUN
ajst-20773	226	18	of	of	ADP
ajst-20773	226	19	the	the	DET
ajst-20773	226	20	immune	immune	ADJ
ajst-20773	226	21	system	system	NOUN
ajst-20773	226	22	(	(	PUNCT
ajst-20773	226	23	pennock	pennock	NOUN
ajst-20773	226	24	&	&	CCONJ
ajst-20773	226	25	chow	chow	PROPN
ajst-20773	226	26	,	,	PUNCT
ajst-20773	226	27	2015	2015	NUM
ajst-20773	226	28	)	)	PUNCT
ajst-20773	226	29	.	.	PUNCT
ajst-20773	227	1	although	although	SCONJ
ajst-20773	227	2	icis	icis	PROPN
ajst-20773	227	3	represent	represent	VERB
ajst-20773	227	4	the	the	DET
ajst-20773	227	5	most	most	ADV
ajst-20773	227	6	profound	profound	ADJ
ajst-20773	227	7	and	and	CCONJ
ajst-20773	227	8	advanced	advanced	ADJ
ajst-20773	227	9	treatment	treatment	NOUN
ajst-20773	227	10	mechanisms	mechanism	NOUN
ajst-20773	227	11	at	at	ADP
ajst-20773	227	12	this	this	DET
ajst-20773	227	13	stage	stage	NOUN
ajst-20773	227	14	,	,	PUNCT
ajst-20773	227	15	they	they	PRON
ajst-20773	227	16	are	be	AUX
ajst-20773	227	17	limited	limit	VERB
ajst-20773	227	18	by	by	ADP
ajst-20773	227	19	the	the	DET
ajst-20773	227	20	possibility	possibility	NOUN
ajst-20773	227	21	of	of	ADP
ajst-20773	227	22	over	over	ADV
ajst-20773	227	23	-	-	PUNCT
ajst-20773	227	24	activating	activate	VERB
ajst-20773	227	25	the	the	DET
ajst-20773	227	26	immune	immune	ADJ
ajst-20773	227	27	system	system	NOUN
ajst-20773	227	28	,	,	PUNCT
ajst-20773	227	29	which	which	PRON
ajst-20773	227	30	may	may	AUX
ajst-20773	227	31	attack	attack	VERB
ajst-20773	227	32	the	the	DET
ajst-20773	227	33	body	body	NOUN
ajst-20773	227	34	's	's	PART
ajst-20773	227	35	own	own	ADJ
ajst-20773	227	36	tissues	tissue	NOUN
ajst-20773	227	37	,	,	PUNCT
ajst-20773	227	38	leading	lead	VERB
ajst-20773	227	39	to	to	ADP
ajst-20773	227	40	the	the	DET
ajst-20773	227	41	occurrence	occurrence	NOUN
ajst-20773	227	42	of	of	ADP
ajst-20773	227	43	immune	immune	NOUN
ajst-20773	227	44	-	-	PUNCT
ajst-20773	227	45	related	relate	VERB
ajst-20773	227	46	side	side	NOUN
ajst-20773	227	47	effects	effect	NOUN
ajst-20773	227	48	.	.	PUNCT
ajst-20773	228	1	therefore	therefore	ADV
ajst-20773	228	2	,	,	PUNCT
ajst-20773	228	3	only	only	ADV
ajst-20773	228	4	a	a	DET
ajst-20773	228	5	small	small	ADJ
ajst-20773	228	6	portion	portion	NOUN
ajst-20773	228	7	of	of	ADP
ajst-20773	228	8	patients	patient	NOUN
ajst-20773	228	9	benefit	benefit	VERB
ajst-20773	228	10	from	from	ADP
ajst-20773	228	11	ici	ici	PROPN
ajst-20773	228	12	treatments	treatment	NOUN
ajst-20773	228	13	,	,	PUNCT
ajst-20773	228	14	and	and	CCONJ
ajst-20773	228	15	the	the	DET
ajst-20773	228	16	overall	overall	ADJ
ajst-20773	228	17	efficacy	efficacy	NOUN
ajst-20773	228	18	rate	rate	NOUN
ajst-20773	228	19	is	be	AUX
ajst-20773	228	20	less	less	ADJ
ajst-20773	228	21	than	than	ADP
ajst-20773	228	22	20	20	NUM
ajst-20773	228	23	%	%	NOUN
ajst-20773	228	24	.	.	PUNCT
ajst-20773	229	1	thus	thus	ADV
ajst-20773	229	2	,	,	PUNCT
ajst-20773	229	3	fully	fully	ADV
ajst-20773	229	4	assessing	assess	VERB
ajst-20773	229	5	whether	whether	SCONJ
ajst-20773	229	6	patients	patient	NOUN
ajst-20773	229	7	can	can	AUX
ajst-20773	229	8	benefit	benefit	VERB
ajst-20773	229	9	from	from	ADP
ajst-20773	229	10	ici	ici	NOUN
ajst-20773	229	11	treatment	treatment	NOUN
ajst-20773	229	12	is	be	AUX
ajst-20773	229	13	the	the	DET
ajst-20773	229	14	first	first	ADJ
ajst-20773	229	15	step	step	NOUN
ajst-20773	229	16	in	in	ADP
ajst-20773	229	17	formulating	formulate	VERB
ajst-20773	229	18	a	a	DET
ajst-20773	229	19	clinical	clinical	ADJ
ajst-20773	229	20	treatment	treatment	NOUN
ajst-20773	229	21	plan	plan	NOUN
ajst-20773	229	22	for	for	ADP
ajst-20773	229	23	patients	patient	NOUN
ajst-20773	229	24	.	.	PUNCT
ajst-20773	230	1	recently	recently	ADV
ajst-20773	230	2	,	,	PUNCT
ajst-20773	230	3	the	the	DET
ajst-20773	230	4	u.s	u.s	PROPN
ajst-20773	230	5	.	.	PROPN
ajst-20773	230	6	food	food	PROPN
ajst-20773	230	7	and	and	CCONJ
ajst-20773	230	8	drug	drug	PROPN
ajst-20773	230	9	administration	administration	PROPN
ajst-20773	230	10	(	(	PUNCT
ajst-20773	230	11	fda	fda	PROPN
ajst-20773	230	12	)	)	PUNCT
ajst-20773	230	13	approved	approve	VERB
ajst-20773	230	14	immune	immune	ADJ
ajst-20773	230	15	checkpoint	checkpoint	NOUN
ajst-20773	230	16	inhibitors	inhibitor	NOUN
ajst-20773	230	17	(	(	PUNCT
ajst-20773	230	18	icis	icis	PROPN
ajst-20773	230	19	)	)	PUNCT
ajst-20773	230	20	for	for	ADP
ajst-20773	230	21	the	the	DET
ajst-20773	230	22	treatment	treatment	NOUN
ajst-20773	230	23	of	of	ADP
ajst-20773	230	24	lung	lung	NOUN
ajst-20773	230	25	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	230	26	,	,	PUNCT
ajst-20773	230	27	changing	change	VERB
ajst-20773	230	28	the	the	DET
ajst-20773	230	29	selection	selection	NOUN
ajst-20773	230	30	of	of	ADP
ajst-20773	230	31	clinical	clinical	ADJ
ajst-20773	230	32	treatment	treatment	NOUN
ajst-20773	230	33	methods	method	NOUN
ajst-20773	230	34	(	(	PUNCT
ajst-20773	230	35	wu	wu	PROPN
ajst-20773	230	36	et	et	PROPN
ajst-20773	230	37	al	al	PROPN
ajst-20773	230	38	.	.	PROPN
ajst-20773	230	39	,	,	PUNCT
ajst-20773	230	40	2022	2022	NUM
ajst-20773	230	41	)	)	PUNCT
ajst-20773	230	42	.	.	PUNCT
ajst-20773	231	1	however	however	ADV
ajst-20773	231	2	,	,	PUNCT
ajst-20773	231	3	the	the	DET
ajst-20773	231	4	overall	overall	ADJ
ajst-20773	231	5	efficacy	efficacy	NOUN
ajst-20773	231	6	rate	rate	NOUN
ajst-20773	231	7	of	of	ADP
ajst-20773	231	8	icis	icis	NOUN
ajst-20773	231	9	is	be	AUX
ajst-20773	231	10	less	less	ADJ
ajst-20773	231	11	than	than	ADP
ajst-20773	231	12	20	20	NUM
ajst-20773	231	13	%	%	NOUN
ajst-20773	231	14	,	,	PUNCT
ajst-20773	231	15	with	with	ADP
ajst-20773	231	16	only	only	ADV
ajst-20773	231	17	a	a	DET
ajst-20773	231	18	minority	minority	NOUN
ajst-20773	231	19	of	of	ADP
ajst-20773	231	20	lung	lung	NOUN
ajst-20773	231	21	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	231	22	patients	patient	NOUN
ajst-20773	231	23	benefiting	benefit	VERB
ajst-20773	231	24	from	from	ADP
ajst-20773	231	25	ici	ici	NOUN
ajst-20773	231	26	therapy	therapy	NOUN
ajst-20773	231	27	.	.	PUNCT
ajst-20773	232	1	therefore	therefore	ADV
ajst-20773	232	2	,	,	PUNCT
ajst-20773	232	3	a	a	DET
ajst-20773	232	4	comprehensive	comprehensive	ADJ
ajst-20773	232	5	assessment	assessment	NOUN
ajst-20773	232	6	of	of	ADP
ajst-20773	232	7	whether	whether	SCONJ
ajst-20773	232	8	patients	patient	NOUN
ajst-20773	232	9	benefit	benefit	VERB
ajst-20773	232	10	from	from	ADP
ajst-20773	232	11	ici	ici	NOUN
ajst-20773	232	12	treatment	treatment	NOUN
ajst-20773	232	13	is	be	AUX
ajst-20773	232	14	crucial	crucial	ADJ
ajst-20773	232	15	.	.	PUNCT
ajst-20773	233	1	biomarkers	biomarker	NOUN
ajst-20773	233	2	provide	provide	VERB
ajst-20773	233	3	decision	decision	NOUN
ajst-20773	233	4	-	-	PUNCT
ajst-20773	233	5	making	make	VERB
ajst-20773	233	6	information	information	NOUN
ajst-20773	233	7	for	for	ADP
ajst-20773	233	8	this	this	DET
ajst-20773	233	9	treatment	treatment	NOUN
ajst-20773	233	10	,	,	PUNCT
ajst-20773	233	11	but	but	CCONJ
ajst-20773	233	12	currently	currently	ADV
ajst-20773	233	13	,	,	PUNCT
ajst-20773	233	14	there	there	PRON
ajst-20773	233	15	are	be	VERB
ajst-20773	233	16	no	no	DET
ajst-20773	233	17	effective	effective	ADJ
ajst-20773	233	18	biomarkers	biomarker	NOUN
ajst-20773	233	19	for	for	ADP
ajst-20773	233	20	predicting	predict	VERB
ajst-20773	233	21	29	29	NUM
ajst-20773	233	22	clinical	clinical	ADJ
ajst-20773	233	23	efficacy	efficacy	NOUN
ajst-20773	233	24	.	.	PUNCT
ajst-20773	234	1	pd	pd	PROPN
ajst-20773	234	2	-	-	PROPN
ajst-20773	234	3	l1	l1	PROPN
ajst-20773	234	4	detected	detect	VERB
ajst-20773	234	5	by	by	ADP
ajst-20773	234	6	tumor	tumor	NOUN
ajst-20773	234	7	cell	cell	NOUN
ajst-20773	234	8	immunohistochemistry	immunohistochemistry	NOUN
ajst-20773	234	9	(	(	PUNCT
ajst-20773	234	10	ihc	ihc	PROPN
ajst-20773	234	11	)	)	PUNCT
ajst-20773	234	12	is	be	AUX
ajst-20773	234	13	the	the	DET
ajst-20773	234	14	standard	standard	ADJ
ajst-20773	234	15	biomarker	biomarker	NOUN
ajst-20773	234	16	for	for	ADP
ajst-20773	234	17	predicting	predict	VERB
ajst-20773	234	18	the	the	DET
ajst-20773	234	19	effectiveness	effectiveness	NOUN
ajst-20773	234	20	of	of	ADP
ajst-20773	234	21	ici	ici	NOUN
ajst-20773	234	22	therapy	therapy	NOUN
ajst-20773	234	23	.	.	PUNCT
ajst-20773	235	1	in	in	ADP
ajst-20773	235	2	patients	patient	NOUN
ajst-20773	235	3	with	with	ADP
ajst-20773	235	4	advanced	advanced	ADJ
ajst-20773	235	5	non	non	ADJ
ajst-20773	235	6	-	-	ADJ
ajst-20773	235	7	small	small	ADJ
ajst-20773	235	8	cell	cell	NOUN
ajst-20773	235	9	lung	lung	NOUN
ajst-20773	235	10	cancer	cancer	NOUN
ajst-20773	235	11	(	(	PUNCT
ajst-20773	235	12	nsclc	nsclc	NOUN
ajst-20773	235	13	)	)	PUNCT
ajst-20773	235	14	,	,	PUNCT
ajst-20773	235	15	pembrolizumab	pembrolizumab	NOUN
ajst-20773	235	16	has	have	AUX
ajst-20773	235	17	been	be	AUX
ajst-20773	235	18	used	use	VERB
ajst-20773	235	19	as	as	ADP
ajst-20773	235	20	a	a	DET
ajst-20773	235	21	first	first	ADJ
ajst-20773	235	22	-	-	PUNCT
ajst-20773	235	23	line	line	NOUN
ajst-20773	235	24	treatment	treatment	NOUN
ajst-20773	235	25	,	,	PUNCT
ajst-20773	235	26	with	with	ADP
ajst-20773	235	27	a	a	DET
ajst-20773	235	28	pd	pd	ADJ
ajst-20773	235	29	-	-	PUNCT
ajst-20773	235	30	l1	l1	PROPN
ajst-20773	235	31	expression	expression	NOUN
ajst-20773	235	32	threshold	threshold	NOUN
ajst-20773	235	33	of	of	ADP
ajst-20773	235	34	50	50	NUM
ajst-20773	235	35	%	%	NOUN
ajst-20773	235	36	(	(	PUNCT
ajst-20773	235	37	shiravand	shiravand	NOUN
ajst-20773	235	38	et	et	PROPN
ajst-20773	235	39	al	al	PROPN
ajst-20773	235	40	.	.	PROPN
ajst-20773	235	41	,	,	PUNCT
ajst-20773	235	42	2022	2022	NUM
ajst-20773	235	43	)	)	PUNCT
ajst-20773	235	44	.	.	PUNCT
ajst-20773	236	1	however	however	ADV
ajst-20773	236	2	,	,	PUNCT
ajst-20773	236	3	pd	pd	PROPN
ajst-20773	236	4	-	-	PUNCT
ajst-20773	236	5	l1	l1	PROPN
ajst-20773	236	6	expression	expression	NOUN
ajst-20773	236	7	is	be	AUX
ajst-20773	236	8	low	low	ADJ
ajst-20773	236	9	in	in	ADP
ajst-20773	236	10	some	some	DET
ajst-20773	236	11	patients	patient	NOUN
ajst-20773	236	12	and	and	CCONJ
ajst-20773	236	13	there	there	PRON
ajst-20773	236	14	are	be	VERB
ajst-20773	236	15	false	false	ADJ
ajst-20773	236	16	-	-	PUNCT
ajst-20773	236	17	negative	negative	ADJ
ajst-20773	236	18	results	result	NOUN
ajst-20773	236	19	,	,	PUNCT
ajst-20773	236	20	as	as	ADV
ajst-20773	236	21	well	well	ADV
ajst-20773	236	22	as	as	ADP
ajst-20773	236	23	spatial	spatial	ADJ
ajst-20773	236	24	differences	difference	NOUN
ajst-20773	236	25	within	within	ADP
ajst-20773	236	26	and	and	CCONJ
ajst-20773	236	27	outside	outside	ADP
ajst-20773	236	28	the	the	DET
ajst-20773	236	29	tumor	tumor	NOUN
ajst-20773	236	30	.	.	PUNCT
ajst-20773	237	1	moreover	moreover	ADV
ajst-20773	237	2	,	,	PUNCT
ajst-20773	237	3	compared	compare	VERB
ajst-20773	237	4	to	to	ADP
ajst-20773	237	5	a	a	DET
ajst-20773	237	6	single	single	ADJ
ajst-20773	237	7	clinical	clinical	ADJ
ajst-20773	237	8	biomarker	biomarker	NOUN
ajst-20773	237	9	,	,	PUNCT
ajst-20773	237	10	combining	combine	VERB
ajst-20773	237	11	multiple	multiple	ADJ
ajst-20773	237	12	biomarkers	biomarker	NOUN
ajst-20773	237	13	into	into	ADP
ajst-20773	237	14	a	a	DET
ajst-20773	237	15	single	single	ADJ
ajst-20773	237	16	model	model	NOUN
ajst-20773	237	17	can	can	AUX
ajst-20773	237	18	improve	improve	VERB
ajst-20773	237	19	predictive	predictive	ADJ
ajst-20773	237	20	accuracy	accuracy	NOUN
ajst-20773	237	21	,	,	PUNCT
ajst-20773	237	22	helping	help	VERB
ajst-20773	237	23	to	to	PART
ajst-20773	237	24	tailor	tailor	VERB
ajst-20773	237	25	precise	precise	ADJ
ajst-20773	237	26	individual	individual	ADJ
ajst-20773	237	27	treatment	treatment	NOUN
ajst-20773	237	28	plans	plan	NOUN
ajst-20773	237	29	(	(	PUNCT
ajst-20773	237	30	twomey	twomey	PROPN
ajst-20773	237	31	&	&	CCONJ
ajst-20773	237	32	zhang	zhang	PROPN
ajst-20773	237	33	,	,	PUNCT
ajst-20773	237	34	2021	2021	NUM
ajst-20773	237	35	)	)	PUNCT
ajst-20773	237	36	.	.	PUNCT
ajst-20773	238	1	cellular	cellular	ADJ
ajst-20773	238	2	senescence	senescence	NOUN
ajst-20773	238	3	has	have	AUX
ajst-20773	238	4	recently	recently	ADV
ajst-20773	238	5	been	be	AUX
ajst-20773	238	6	identified	identify	VERB
ajst-20773	238	7	as	as	ADP
ajst-20773	238	8	an	an	DET
ajst-20773	238	9	important	important	ADJ
ajst-20773	238	10	cellular	cellular	ADJ
ajst-20773	238	11	function	function	NOUN
ajst-20773	238	12	type	type	NOUN
ajst-20773	238	13	within	within	ADP
ajst-20773	238	14	the	the	DET
ajst-20773	238	15	tumor	tumor	NOUN
ajst-20773	238	16	microenvironment	microenvironment	NOUN
ajst-20773	238	17	,	,	PUNCT
ajst-20773	238	18	including	include	VERB
ajst-20773	238	19	in	in	ADP
ajst-20773	238	20	lung	lung	NOUN
ajst-20773	238	21	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	238	22	.	.	PUNCT
ajst-20773	239	1	recently	recently	ADV
ajst-20773	239	2	,	,	PUNCT
ajst-20773	239	3	it	it	PRON
ajst-20773	239	4	has	have	AUX
ajst-20773	239	5	been	be	AUX
ajst-20773	239	6	discovered	discover	VERB
ajst-20773	239	7	that	that	SCONJ
ajst-20773	239	8	some	some	DET
ajst-20773	239	9	lncrnas	lncrna	NOUN
ajst-20773	239	10	are	be	AUX
ajst-20773	239	11	involved	involve	VERB
ajst-20773	239	12	in	in	ADP
ajst-20773	239	13	the	the	DET
ajst-20773	239	14	regulation	regulation	NOUN
ajst-20773	239	15	of	of	ADP
ajst-20773	239	16	cellular	cellular	ADJ
ajst-20773	239	17	senescence	senescence	NOUN
ajst-20773	239	18	in	in	ADP
ajst-20773	239	19	lung	lung	NOUN
ajst-20773	239	20	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	239	21	patients	patient	NOUN
ajst-20773	239	22	;	;	PUNCT
ajst-20773	239	23	however	however	ADV
ajst-20773	239	24	,	,	PUNCT
ajst-20773	239	25	the	the	DET
ajst-20773	239	26	overall	overall	ADJ
ajst-20773	239	27	pattern	pattern	NOUN
ajst-20773	239	28	of	of	ADP
ajst-20773	239	29	luad	luad	ADJ
ajst-20773	239	30	cellular	cellular	ADJ
ajst-20773	239	31	senescence	senescence	NOUN
ajst-20773	239	32	regulation	regulation	NOUN
ajst-20773	239	33	networks	network	NOUN
ajst-20773	239	34	remains	remain	VERB
ajst-20773	239	35	largely	largely	ADV
ajst-20773	239	36	unknown	unknown	ADJ
ajst-20773	239	37	(	(	PUNCT
ajst-20773	239	38	liu	liu	PROPN
ajst-20773	239	39	et	et	PROPN
ajst-20773	239	40	al	al	PROPN
ajst-20773	239	41	.	.	PROPN
ajst-20773	239	42	,	,	PUNCT
ajst-20773	239	43	2023	2023	NUM
ajst-20773	239	44	)	)	PUNCT
ajst-20773	239	45	.	.	PUNCT
ajst-20773	240	1	therefore	therefore	ADV
ajst-20773	240	2	,	,	PUNCT
ajst-20773	240	3	we	we	PRON
ajst-20773	240	4	developed	develop	VERB
ajst-20773	240	5	a	a	DET
ajst-20773	240	6	senlncsig	senlncsig	NOUN
ajst-20773	240	7	signature	signature	NOUN
ajst-20773	240	8	to	to	PART
ajst-20773	240	9	predict	predict	VERB
ajst-20773	240	10	aging	aging	NOUN
ajst-20773	240	11	and	and	CCONJ
ajst-20773	240	12	prognosis	prognosis	NOUN
ajst-20773	240	13	in	in	ADP
ajst-20773	240	14	lung	lung	NOUN
ajst-20773	240	15	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	240	16	.	.	PUNCT
ajst-20773	241	1	validated	validate	VERB
ajst-20773	241	2	and	and	CCONJ
ajst-20773	241	3	assessed	assess	VERB
ajst-20773	241	4	,	,	PUNCT
ajst-20773	241	5	the	the	DET
ajst-20773	241	6	senlncsig	senlncsig	PROPN
ajst-20773	241	7	model	model	NOUN
ajst-20773	241	8	developed	develop	VERB
ajst-20773	241	9	in	in	ADP
ajst-20773	241	10	this	this	DET
ajst-20773	241	11	study	study	NOUN
ajst-20773	241	12	has	have	VERB
ajst-20773	241	13	good	good	ADJ
ajst-20773	241	14	predictive	predictive	ADJ
ajst-20773	241	15	performance	performance	NOUN
ajst-20773	241	16	for	for	ADP
ajst-20773	241	17	the	the	DET
ajst-20773	241	18	prognosis	prognosis	NOUN
ajst-20773	241	19	of	of	ADP
ajst-20773	241	20	tcga	tcga	NOUN
ajst-20773	241	21	-	-	PUNCT
ajst-20773	241	22	luad	luad	NOUN
ajst-20773	241	23	samples	sample	NOUN
ajst-20773	241	24	.	.	PUNCT
ajst-20773	242	1	additionally	additionally	ADV
ajst-20773	242	2	,	,	PUNCT
ajst-20773	242	3	including	include	VERB
ajst-20773	242	4	the	the	DET
ajst-20773	242	5	senlncsig	senlncsig	PROPN
ajst-20773	242	6	risk	risk	NOUN
ajst-20773	242	7	score	score	NOUN
ajst-20773	242	8	,	,	PUNCT
ajst-20773	242	9	a	a	DET
ajst-20773	242	10	nomogram	nomogram	NOUN
ajst-20773	242	11	could	could	AUX
ajst-20773	242	12	potentially	potentially	ADV
ajst-20773	242	13	guide	guide	VERB
ajst-20773	242	14	clinical	clinical	ADJ
ajst-20773	242	15	decision	decision	NOUN
ajst-20773	242	16	-	-	PUNCT
ajst-20773	242	17	making	making	NOUN
ajst-20773	242	18	.	.	PUNCT
ajst-20773	243	1	notably	notably	ADV
ajst-20773	243	2	,	,	PUNCT
ajst-20773	243	3	senlncsig	senlncsig	PROPN
ajst-20773	243	4	can	can	AUX
ajst-20773	243	5	stratify	stratify	VERB
ajst-20773	243	6	luad	luad	ADJ
ajst-20773	243	7	patients	patient	NOUN
ajst-20773	243	8	based	base	VERB
ajst-20773	243	9	on	on	ADP
ajst-20773	243	10	the	the	DET
ajst-20773	243	11	expression	expression	NOUN
ajst-20773	243	12	levels	level	NOUN
ajst-20773	243	13	of	of	ADP
ajst-20773	243	14	immune	immune	ADJ
ajst-20773	243	15	checkpoint	checkpoint	NOUN
ajst-20773	243	16	genes	gene	NOUN
ajst-20773	243	17	,	,	PUNCT
ajst-20773	243	18	which	which	PRON
ajst-20773	243	19	is	be	AUX
ajst-20773	243	20	very	very	ADV
ajst-20773	243	21	important	important	ADJ
ajst-20773	243	22	for	for	ADP
ajst-20773	243	23	helping	help	VERB
ajst-20773	243	24	patients	patient	NOUN
ajst-20773	243	25	select	select	VERB
ajst-20773	243	26	drugs	drug	NOUN
ajst-20773	243	27	and	and	CCONJ
ajst-20773	243	28	therapies	therapy	NOUN
ajst-20773	243	29	that	that	PRON
ajst-20773	243	30	may	may	AUX
ajst-20773	243	31	benefit	benefit	VERB
ajst-20773	243	32	them	they	PRON
ajst-20773	243	33	(	(	PUNCT
ajst-20773	243	34	degirmenci	degirmenci	PROPN
ajst-20773	243	35	&	&	CCONJ
ajst-20773	243	36	lei	lei	PROPN
ajst-20773	243	37	,	,	PUNCT
ajst-20773	243	38	2016	2016	NUM
ajst-20773	243	39	)	)	PUNCT
ajst-20773	243	40	.	.	PUNCT
ajst-20773	244	1	this	this	DET
ajst-20773	244	2	study	study	NOUN
ajst-20773	244	3	is	be	AUX
ajst-20773	244	4	notable	notable	ADJ
ajst-20773	244	5	for	for	ADP
ajst-20773	244	6	exploring	explore	VERB
ajst-20773	244	7	the	the	DET
ajst-20773	244	8	association	association	NOUN
ajst-20773	244	9	between	between	ADP
ajst-20773	244	10	cellular	cellular	ADJ
ajst-20773	244	11	senescence	senescence	NOUN
ajst-20773	244	12	and	and	CCONJ
ajst-20773	244	13	the	the	DET
ajst-20773	244	14	prognosis	prognosis	NOUN
ajst-20773	244	15	of	of	ADP
ajst-20773	244	16	lung	lung	NOUN
ajst-20773	244	17	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	244	18	and	and	CCONJ
ajst-20773	244	19	the	the	DET
ajst-20773	244	20	tumor	tumor	NOUN
ajst-20773	244	21	microenvironment	microenvironment	NOUN
ajst-20773	244	22	(	(	PUNCT
ajst-20773	244	23	lin	lin	PROPN
ajst-20773	244	24	et	et	PROPN
ajst-20773	244	25	al	al	PROPN
ajst-20773	244	26	.	.	PROPN
ajst-20773	244	27	,	,	PUNCT
ajst-20773	244	28	2021	2021	NUM
ajst-20773	244	29	)	)	PUNCT
ajst-20773	244	30	.	.	PUNCT
ajst-20773	245	1	currently	currently	ADV
ajst-20773	245	2	,	,	PUNCT
ajst-20773	245	3	the	the	DET
ajst-20773	245	4	role	role	NOUN
ajst-20773	245	5	of	of	ADP
ajst-20773	245	6	cellular	cellular	ADJ
ajst-20773	245	7	senescence	senescence	NOUN
ajst-20773	245	8	and	and	CCONJ
ajst-20773	245	9	the	the	DET
ajst-20773	245	10	tumor	tumor	NOUN
ajst-20773	245	11	microenvironment	microenvironment	NOUN
ajst-20773	245	12	combined	combine	VERB
ajst-20773	245	13	in	in	ADP
ajst-20773	245	14	tumors	tumor	NOUN
ajst-20773	245	15	is	be	AUX
ajst-20773	245	16	often	often	ADV
ajst-20773	245	17	overlooked	overlook	VERB
ajst-20773	245	18	in	in	ADP
ajst-20773	245	19	preclinical	preclinical	ADJ
ajst-20773	245	20	studies	study	NOUN
ajst-20773	245	21	,	,	PUNCT
ajst-20773	245	22	which	which	PRON
ajst-20773	245	23	are	be	AUX
ajst-20773	245	24	usually	usually	ADV
ajst-20773	245	25	designed	design	VERB
ajst-20773	245	26	for	for	ADP
ajst-20773	245	27	young	young	ADJ
ajst-20773	245	28	mice	mouse	NOUN
ajst-20773	245	29	rather	rather	ADV
ajst-20773	245	30	than	than	ADP
ajst-20773	245	31	old	old	ADJ
ajst-20773	245	32	mice	mouse	NOUN
ajst-20773	245	33	.	.	PUNCT
ajst-20773	246	1	this	this	PRON
ajst-20773	246	2	might	might	AUX
ajst-20773	246	3	help	help	VERB
ajst-20773	246	4	explain	explain	VERB
ajst-20773	246	5	why	why	SCONJ
ajst-20773	246	6	many	many	ADJ
ajst-20773	246	7	successful	successful	ADJ
ajst-20773	246	8	preclinical	preclinical	ADJ
ajst-20773	246	9	responses	response	NOUN
ajst-20773	246	10	fail	fail	VERB
ajst-20773	246	11	to	to	PART
ajst-20773	246	12	replicate	replicate	VERB
ajst-20773	246	13	when	when	SCONJ
ajst-20773	246	14	entering	enter	VERB
ajst-20773	246	15	actual	actual	ADJ
ajst-20773	246	16	clinical	clinical	ADJ
ajst-20773	246	17	trials	trial	NOUN
ajst-20773	246	18	.	.	PUNCT
ajst-20773	247	1	when	when	SCONJ
ajst-20773	247	2	considering	consider	VERB
ajst-20773	247	3	the	the	DET
ajst-20773	247	4	roles	role	NOUN
ajst-20773	247	5	and	and	CCONJ
ajst-20773	247	6	mechanisms	mechanism	NOUN
ajst-20773	247	7	of	of	ADP
ajst-20773	247	8	network	network	NOUN
ajst-20773	247	9	-	-	PUNCT
ajst-20773	247	10	related	relate	VERB
ajst-20773	247	11	genes	gene	NOUN
ajst-20773	247	12	in	in	ADP
ajst-20773	247	13	lung	lung	NOUN
ajst-20773	247	14	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	247	15	tissue	tissue	NOUN
ajst-20773	247	16	in	in	ADP
ajst-20773	247	17	comprehensive	comprehensive	ADJ
ajst-20773	247	18	cancer	cancer	NOUN
ajst-20773	247	19	treatment	treatment	NOUN
ajst-20773	247	20	,	,	PUNCT
ajst-20773	247	21	cellular	cellular	ADJ
ajst-20773	247	22	senescence	senescence	NOUN
ajst-20773	247	23	should	should	AUX
ajst-20773	247	24	be	be	AUX
ajst-20773	247	25	considered	consider	VERB
ajst-20773	247	26	a	a	DET
ajst-20773	247	27	parameter	parameter	NOUN
ajst-20773	247	28	(	(	PUNCT
ajst-20773	247	29	liu	liu	PROPN
ajst-20773	247	30	et	et	PROPN
ajst-20773	247	31	al	al	PROPN
ajst-20773	247	32	.	.	PROPN
ajst-20773	247	33	,	,	PUNCT
ajst-20773	247	34	2022	2022	NUM
ajst-20773	247	35	)	)	PUNCT
ajst-20773	247	36	.	.	PUNCT
ajst-20773	248	1	in	in	ADP
ajst-20773	248	2	this	this	DET
ajst-20773	248	3	study	study	NOUN
ajst-20773	248	4	,	,	PUNCT
ajst-20773	248	5	we	we	PRON
ajst-20773	248	6	also	also	ADV
ajst-20773	248	7	identified	identify	VERB
ajst-20773	248	8	the	the	DET
ajst-20773	248	9	relationship	relationship	NOUN
ajst-20773	248	10	between	between	ADP
ajst-20773	248	11	the	the	DET
ajst-20773	248	12	senlncsig	senlncsig	PROPN
ajst-20773	248	13	model	model	NOUN
ajst-20773	248	14	derived	derive	VERB
ajst-20773	248	15	from	from	ADP
ajst-20773	248	16	aging	age	VERB
ajst-20773	248	17	genes	gene	NOUN
ajst-20773	248	18	and	and	CCONJ
ajst-20773	248	19	the	the	DET
ajst-20773	248	20	potential	potential	ADJ
ajst-20773	248	21	efficacy	efficacy	NOUN
ajst-20773	248	22	in	in	ADP
ajst-20773	248	23	lung	lung	NOUN
ajst-20773	248	24	adenocarcinoma	adenocarcinoma	PROPN
ajst-20773	248	25	.	.	PUNCT
ajst-20773	249	1	based	base	VERB
ajst-20773	249	2	on	on	ADP
ajst-20773	249	3	the	the	DET
ajst-20773	249	4	stratification	stratification	NOUN
ajst-20773	249	5	of	of	ADP
ajst-20773	249	6	lung	lung	PROPN
ajst-20773	249	7	adenocarcinoma	adenocarcinoma	PROPN
ajst-20773	249	8	senlncsig	senlncsig	PROPN
ajst-20773	249	9	,	,	PUNCT
ajst-20773	249	10	the	the	DET
ajst-20773	249	11	expression	expression	NOUN
ajst-20773	249	12	of	of	ADP
ajst-20773	249	13	most	most	ADJ
ajst-20773	249	14	immune	immune	ADJ
ajst-20773	249	15	checkpoints	checkpoint	NOUN
ajst-20773	249	16	,	,	PUNCT
ajst-20773	249	17	immune	immune	ADJ
ajst-20773	249	18	pathway	pathway	NOUN
ajst-20773	249	19	activation	activation	NOUN
ajst-20773	249	20	,	,	PUNCT
ajst-20773	249	21	and	and	CCONJ
ajst-20773	249	22	anti	anti	ADJ
ajst-20773	249	23	-	-	ADJ
ajst-20773	249	24	tumor	tumor	ADJ
ajst-20773	249	25	immune	immune	ADJ
ajst-20773	249	26	cell	cell	NOUN
ajst-20773	249	27	infiltration	infiltration	NOUN
ajst-20773	249	28	are	be	AUX
ajst-20773	249	29	all	all	ADV
ajst-20773	249	30	higher	high	ADJ
ajst-20773	249	31	in	in	ADP
ajst-20773	249	32	the	the	DET
ajst-20773	249	33	low	low	ADJ
ajst-20773	249	34	-	-	PUNCT
ajst-20773	249	35	risk	risk	NOUN
ajst-20773	249	36	group	group	NOUN
ajst-20773	249	37	,	,	PUNCT
ajst-20773	249	38	suggesting	suggest	VERB
ajst-20773	249	39	that	that	SCONJ
ajst-20773	249	40	low	low	ADJ
ajst-20773	249	41	-	-	PUNCT
ajst-20773	249	42	risk	risk	NOUN
ajst-20773	249	43	patients	patient	NOUN
ajst-20773	249	44	may	may	AUX
ajst-20773	249	45	benefit	benefit	VERB
ajst-20773	249	46	more	more	ADV
ajst-20773	249	47	from	from	ADP
ajst-20773	249	48	immunotherapy	immunotherapy	NOUN
ajst-20773	249	49	(	(	PUNCT
ajst-20773	249	50	montes	montes	PROPN
ajst-20773	249	51	et	et	PROPN
ajst-20773	249	52	al	al	PROPN
ajst-20773	249	53	.	.	PROPN
ajst-20773	249	54	,	,	PUNCT
ajst-20773	249	55	2021	2021	NUM
ajst-20773	249	56	)	)	PUNCT
ajst-20773	249	57	.	.	PUNCT
ajst-20773	250	1	moreover	moreover	ADV
ajst-20773	250	2	,	,	PUNCT
ajst-20773	250	3	compared	compare	VERB
ajst-20773	250	4	to	to	ADP
ajst-20773	250	5	other	other	ADJ
ajst-20773	250	6	studies	study	NOUN
ajst-20773	250	7	that	that	PRON
ajst-20773	250	8	used	use	VERB
ajst-20773	250	9	the	the	DET
ajst-20773	250	10	tcga	tcga	PROPN
ajst-20773	250	11	database	database	NOUN
ajst-20773	250	12	to	to	PART
ajst-20773	250	13	develop	develop	VERB
ajst-20773	250	14	lncrna	lncrna	NOUN
ajst-20773	250	15	prognostic	prognostic	ADJ
ajst-20773	250	16	models	model	NOUN
ajst-20773	250	17	,	,	PUNCT
ajst-20773	250	18	our	our	PRON
ajst-20773	250	19	senlncsig	senlncsig	NOUN
ajst-20773	250	20	model	model	NOUN
ajst-20773	250	21	has	have	VERB
ajst-20773	250	22	higher	high	ADJ
ajst-20773	250	23	reliability	reliability	NOUN
ajst-20773	250	24	.	.	PUNCT
ajst-20773	251	1	this	this	PRON
ajst-20773	251	2	suggests	suggest	VERB
ajst-20773	251	3	that	that	SCONJ
ajst-20773	251	4	senescent	senescent	ADJ
ajst-20773	251	5	cells	cell	NOUN
ajst-20773	251	6	in	in	ADP
ajst-20773	251	7	the	the	DET
ajst-20773	251	8	tumor	tumor	NOUN
ajst-20773	251	9	microenvironment	microenvironment	NOUN
ajst-20773	251	10	,	,	PUNCT
ajst-20773	251	11	along	along	ADP
ajst-20773	251	12	with	with	ADP
ajst-20773	251	13	other	other	ADJ
ajst-20773	251	14	biomarkers	biomarker	NOUN
ajst-20773	251	15	,	,	PUNCT
ajst-20773	251	16	are	be	AUX
ajst-20773	251	17	equally	equally	ADV
ajst-20773	251	18	important	important	ADJ
ajst-20773	251	19	in	in	ADP
ajst-20773	251	20	predicting	predict	VERB
ajst-20773	251	21	the	the	DET
ajst-20773	251	22	prognosis	prognosis	NOUN
ajst-20773	251	23	of	of	ADP
ajst-20773	251	24	lung	lung	NOUN
ajst-20773	251	25	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	251	26	and	and	CCONJ
ajst-20773	251	27	assessing	assess	VERB
ajst-20773	251	28	the	the	DET
ajst-20773	251	29	effectiveness	effectiveness	NOUN
ajst-20773	251	30	of	of	ADP
ajst-20773	251	31	immune	immune	ADJ
ajst-20773	251	32	therapy	therapy	NOUN
ajst-20773	251	33	.	.	PUNCT
ajst-20773	252	1	interestingly	interestingly	ADV
ajst-20773	252	2	,	,	PUNCT
ajst-20773	252	3	other	other	ADJ
ajst-20773	252	4	studies	study	NOUN
ajst-20773	252	5	have	have	AUX
ajst-20773	252	6	also	also	ADV
ajst-20773	252	7	focused	focus	VERB
ajst-20773	252	8	on	on	ADP
ajst-20773	252	9	the	the	DET
ajst-20773	252	10	role	role	NOUN
ajst-20773	252	11	of	of	ADP
ajst-20773	252	12	senescence	senescence	NOUN
ajst-20773	252	13	-	-	PUNCT
ajst-20773	252	14	associated	associate	VERB
ajst-20773	252	15	long	long	ADJ
ajst-20773	252	16	non	non	ADJ
ajst-20773	252	17	-	-	ADJ
ajst-20773	252	18	coding	coding	ADJ
ajst-20773	252	19	rnas	rna	NOUN
ajst-20773	252	20	in	in	ADP
ajst-20773	252	21	different	different	ADJ
ajst-20773	252	22	cancers	cancer	NOUN
ajst-20773	252	23	,	,	PUNCT
ajst-20773	252	24	including	include	VERB
ajst-20773	252	25	liver	liver	NOUN
ajst-20773	252	26	cancer	cancer	NOUN
ajst-20773	252	27	,	,	PUNCT
ajst-20773	252	28	colorectal	colorectal	ADJ
ajst-20773	252	29	cancer	cancer	NOUN
ajst-20773	252	30	,	,	PUNCT
ajst-20773	252	31	and	and	CCONJ
ajst-20773	252	32	gastric	gastric	ADJ
ajst-20773	252	33	cancer	cancer	NOUN
ajst-20773	252	34	(	(	PUNCT
ajst-20773	252	35	peng	peng	PROPN
ajst-20773	252	36	et	et	PROPN
ajst-20773	252	37	al	al	PROPN
ajst-20773	252	38	.	.	PROPN
ajst-20773	252	39	,	,	PUNCT
ajst-20773	252	40	2017	2017	NUM
ajst-20773	252	41	;	;	PUNCT
ajst-20773	252	42	kim	kim	PROPN
ajst-20773	252	43	et	et	PROPN
ajst-20773	252	44	al	al	PROPN
ajst-20773	252	45	.	.	PROPN
ajst-20773	252	46	,	,	PUNCT
ajst-20773	252	47	2017	2017	NUM
ajst-20773	252	48	)	)	PUNCT
ajst-20773	252	49	.	.	PUNCT
ajst-20773	253	1	these	these	DET
ajst-20773	253	2	studies	study	NOUN
ajst-20773	253	3	'	'	PART
ajst-20773	253	4	auc	auc	NOUN
ajst-20773	253	5	values	value	NOUN
ajst-20773	253	6	are	be	AUX
ajst-20773	253	7	similar	similar	ADJ
ajst-20773	253	8	to	to	ADP
ajst-20773	253	9	the	the	DET
ajst-20773	253	10	time	time	NOUN
ajst-20773	253	11	-	-	PUNCT
ajst-20773	253	12	dependent	dependent	ADJ
ajst-20773	253	13	roc	roc	PROPN
ajst-20773	253	14	curves	curve	NOUN
ajst-20773	253	15	of	of	ADP
ajst-20773	253	16	our	our	PRON
ajst-20773	253	17	model	model	NOUN
ajst-20773	253	18	and	and	CCONJ
ajst-20773	253	19	specifically	specifically	ADV
ajst-20773	253	20	highlight	highlight	VERB
ajst-20773	253	21	the	the	DET
ajst-20773	253	22	significant	significant	ADJ
ajst-20773	253	23	contribution	contribution	NOUN
ajst-20773	253	24	of	of	ADP
ajst-20773	253	25	senescent	senescent	ADJ
ajst-20773	253	26	cells	cell	NOUN
ajst-20773	253	27	to	to	ADP
ajst-20773	253	28	the	the	DET
ajst-20773	253	29	tumor	tumor	NOUN
ajst-20773	253	30	microenvironment	microenvironment	NOUN
ajst-20773	253	31	.	.	PUNCT
ajst-20773	254	1	it	it	PRON
ajst-20773	254	2	must	must	AUX
ajst-20773	254	3	be	be	AUX
ajst-20773	254	4	admitted	admit	VERB
ajst-20773	254	5	that	that	SCONJ
ajst-20773	254	6	this	this	DET
ajst-20773	254	7	study	study	NOUN
ajst-20773	254	8	still	still	ADV
ajst-20773	254	9	has	have	VERB
ajst-20773	254	10	some	some	DET
ajst-20773	254	11	areas	area	NOUN
ajst-20773	254	12	where	where	SCONJ
ajst-20773	254	13	it	it	PRON
ajst-20773	254	14	is	be	AUX
ajst-20773	254	15	not	not	PART
ajst-20773	254	16	rigorous	rigorous	ADJ
ajst-20773	254	17	enough	enough	ADV
ajst-20773	254	18	from	from	ADP
ajst-20773	254	19	design	design	NOUN
ajst-20773	254	20	to	to	ADP
ajst-20773	254	21	execution	execution	NOUN
ajst-20773	254	22	.	.	PUNCT
ajst-20773	255	1	first	first	ADV
ajst-20773	255	2	,	,	PUNCT
ajst-20773	255	3	there	there	PRON
ajst-20773	255	4	is	be	VERB
ajst-20773	255	5	a	a	DET
ajst-20773	255	6	need	need	NOUN
ajst-20773	255	7	to	to	PART
ajst-20773	255	8	consider	consider	VERB
ajst-20773	255	9	using	use	VERB
ajst-20773	255	10	more	more	ADJ
ajst-20773	255	11	external	external	ADJ
ajst-20773	255	12	data	datum	NOUN
ajst-20773	255	13	to	to	PART
ajst-20773	255	14	assess	assess	VERB
ajst-20773	255	15	whether	whether	SCONJ
ajst-20773	255	16	the	the	DET
ajst-20773	255	17	senlncsig	senlncsig	PROPN
ajst-20773	255	18	model	model	NOUN
ajst-20773	255	19	fully	fully	ADV
ajst-20773	255	20	matches	match	VERB
ajst-20773	255	21	other	other	ADJ
ajst-20773	255	22	datasets	dataset	NOUN
ajst-20773	255	23	.	.	PUNCT
ajst-20773	256	1	second	second	ADJ
ajst-20773	256	2	,	,	PUNCT
ajst-20773	256	3	the	the	DET
ajst-20773	256	4	lack	lack	NOUN
ajst-20773	256	5	of	of	ADP
ajst-20773	256	6	some	some	DET
ajst-20773	256	7	key	key	ADJ
ajst-20773	256	8	data	data	NOUN
ajst-20773	256	9	points	point	NOUN
ajst-20773	256	10	,	,	PUNCT
ajst-20773	256	11	such	such	ADJ
ajst-20773	256	12	as	as	ADP
ajst-20773	256	13	the	the	DET
ajst-20773	256	14	situation	situation	NOUN
ajst-20773	256	15	of	of	ADP
ajst-20773	256	16	patients	patient	NOUN
ajst-20773	256	17	who	who	PRON
ajst-20773	256	18	have	have	AUX
ajst-20773	256	19	received	receive	VERB
ajst-20773	256	20	second	second	ADJ
ajst-20773	256	21	-	-	PUNCT
ajst-20773	256	22	line	line	NOUN
ajst-20773	256	23	treatment	treatment	NOUN
ajst-20773	256	24	,	,	PUNCT
ajst-20773	256	25	which	which	PRON
ajst-20773	256	26	can	can	AUX
ajst-20773	256	27	not	not	PART
ajst-20773	256	28	be	be	AUX
ajst-20773	256	29	included	include	VERB
ajst-20773	256	30	in	in	ADP
ajst-20773	256	31	the	the	DET
ajst-20773	256	32	diagnostic	diagnostic	ADJ
ajst-20773	256	33	charts	chart	NOUN
ajst-20773	256	34	,	,	PUNCT
ajst-20773	256	35	might	might	AUX
ajst-20773	256	36	affect	affect	VERB
ajst-20773	256	37	the	the	DET
ajst-20773	256	38	accuracy	accuracy	NOUN
ajst-20773	256	39	of	of	ADP
ajst-20773	256	40	the	the	DET
ajst-20773	256	41	model	model	NOUN
ajst-20773	256	42	.	.	PUNCT
ajst-20773	257	1	third	third	ADJ
ajst-20773	257	2	,	,	PUNCT
ajst-20773	257	3	functional	functional	ADJ
ajst-20773	257	4	studies	study	NOUN
ajst-20773	257	5	are	be	AUX
ajst-20773	257	6	needed	need	VERB
ajst-20773	257	7	to	to	PART
ajst-20773	257	8	better	well	ADV
ajst-20773	257	9	understand	understand	VERB
ajst-20773	257	10	the	the	DET
ajst-20773	257	11	molecular	molecular	ADJ
ajst-20773	257	12	mechanisms	mechanism	NOUN
ajst-20773	257	13	of	of	ADP
ajst-20773	257	14	effects	effect	NOUN
ajst-20773	257	15	related	relate	VERB
ajst-20773	257	16	to	to	ADP
ajst-20773	257	17	senescence	senescence	NOUN
ajst-20773	257	18	-	-	PUNCT
ajst-20773	257	19	associated	associate	VERB
ajst-20773	257	20	lncrnas	lncrna	NOUN
ajst-20773	257	21	.	.	PUNCT
ajst-20773	258	1	in	in	ADP
ajst-20773	258	2	summary	summary	NOUN
ajst-20773	258	3	,	,	PUNCT
ajst-20773	258	4	we	we	PRON
ajst-20773	258	5	have	have	AUX
ajst-20773	258	6	developed	develop	VERB
ajst-20773	258	7	a	a	DET
ajst-20773	258	8	lncrna	lncrna	NOUN
ajst-20773	258	9	risk	risk	NOUN
ajst-20773	258	10	score	score	NOUN
ajst-20773	258	11	model	model	NOUN
ajst-20773	258	12	named	name	VERB
ajst-20773	258	13	senlncsig	senlncsig	PROPN
ajst-20773	258	14	,	,	PUNCT
ajst-20773	258	15	which	which	PRON
ajst-20773	258	16	can	can	AUX
ajst-20773	258	17	be	be	AUX
ajst-20773	258	18	used	use	VERB
ajst-20773	258	19	to	to	PART
ajst-20773	258	20	predict	predict	VERB
ajst-20773	258	21	the	the	DET
ajst-20773	258	22	prognosis	prognosis	NOUN
ajst-20773	258	23	of	of	ADP
ajst-20773	258	24	lung	lung	NOUN
ajst-20773	258	25	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	258	26	.	.	PUNCT
ajst-20773	259	1	notably	notably	ADV
ajst-20773	259	2	,	,	PUNCT
ajst-20773	259	3	senlncsig	senlncsig	PROPN
ajst-20773	259	4	is	be	AUX
ajst-20773	259	5	associated	associate	VERB
ajst-20773	259	6	with	with	ADP
ajst-20773	259	7	levels	level	NOUN
ajst-20773	259	8	of	of	ADP
ajst-20773	259	9	immune	immune	ADJ
ajst-20773	259	10	cell	cell	NOUN
ajst-20773	259	11	infiltration	infiltration	NOUN
ajst-20773	259	12	and	and	CCONJ
ajst-20773	259	13	the	the	DET
ajst-20773	259	14	potential	potential	ADJ
ajst-20773	259	15	effects	effect	NOUN
ajst-20773	259	16	of	of	ADP
ajst-20773	259	17	tumor	tumor	NOUN
ajst-20773	259	18	immunotherapy	immunotherapy	NOUN
ajst-20773	259	19	.	.	PUNCT
ajst-20773	260	1	these	these	DET
ajst-20773	260	2	results	result	NOUN
ajst-20773	260	3	highlight	highlight	VERB
ajst-20773	260	4	the	the	DET
ajst-20773	260	5	potential	potential	ADJ
ajst-20773	260	6	future	future	ADJ
ajst-20773	260	7	direction	direction	NOUN
ajst-20773	260	8	of	of	ADP
ajst-20773	260	9	tumor	tumor	NOUN
ajst-20773	260	10	immunotherapy	immunotherapy	NOUN
ajst-20773	260	11	focused	focus	VERB
ajst-20773	260	12	on	on	ADP
ajst-20773	260	13	cellular	cellular	ADJ
ajst-20773	260	14	senescence	senescence	NOUN
ajst-20773	260	15	.	.	PUNCT
ajst-20773	261	1	moreover	moreover	ADV
ajst-20773	261	2	,	,	PUNCT
ajst-20773	261	3	as	as	SCONJ
ajst-20773	261	4	sequencing	sequencing	NOUN
ajst-20773	261	5	technologies	technology	NOUN
ajst-20773	261	6	become	become	VERB
ajst-20773	261	7	more	more	ADV
ajst-20773	261	8	widely	widely	ADV
ajst-20773	261	9	available	available	ADJ
ajst-20773	261	10	and	and	CCONJ
ajst-20773	261	11	cost	cost	NOUN
ajst-20773	261	12	-	-	PUNCT
ajst-20773	261	13	effective	effective	ADJ
ajst-20773	261	14	,	,	PUNCT
ajst-20773	261	15	bulk	bulk	ADJ
ajst-20773	261	16	sequencing	sequencing	NOUN
ajst-20773	261	17	as	as	ADP
ajst-20773	261	18	a	a	DET
ajst-20773	261	19	technique	technique	NOUN
ajst-20773	261	20	may	may	AUX
ajst-20773	261	21	be	be	AUX
ajst-20773	261	22	more	more	ADV
ajst-20773	261	23	readily	readily	ADV
ajst-20773	261	24	introduced	introduce	VERB
ajst-20773	261	25	into	into	ADP
ajst-20773	261	26	clinical	clinical	ADJ
ajst-20773	261	27	practice	practice	NOUN
ajst-20773	261	28	and	and	CCONJ
ajst-20773	261	29	become	become	VERB
ajst-20773	261	30	a	a	DET
ajst-20773	261	31	standard	standard	ADJ
ajst-20773	261	32	management	management	NOUN
ajst-20773	261	33	approach	approach	NOUN
ajst-20773	261	34	.	.	PUNCT
ajst-20773	262	1	5	5	X
ajst-20773	262	2	.	.	X
ajst-20773	262	3	data	datum	NOUN
ajst-20773	262	4	availability	availability	NOUN
ajst-20773	262	5	statement	statement	NOUN
ajst-20773	262	6	the	the	DET
ajst-20773	262	7	study	study	NOUN
ajst-20773	262	8	's	's	PART
ajst-20773	262	9	original	original	ADJ
ajst-20773	262	10	contributions	contribution	NOUN
ajst-20773	262	11	are	be	AUX
ajst-20773	262	12	detailed	detail	VERB
ajst-20773	262	13	in	in	ADP
ajst-20773	262	14	the	the	DET
ajst-20773	262	15	article	article	NOUN
ajst-20773	262	16	and	and	CCONJ
ajst-20773	262	17	supplementary	supplementary	ADJ
ajst-20773	262	18	material	material	NOUN
ajst-20773	262	19	.	.	PUNCT
ajst-20773	263	1	for	for	ADP
ajst-20773	263	2	additional	additional	ADJ
ajst-20773	263	3	questions	question	NOUN
ajst-20773	263	4	,	,	PUNCT
ajst-20773	263	5	please	please	INTJ
ajst-20773	263	6	contact	contact	VERB
ajst-20773	263	7	the	the	DET
ajst-20773	263	8	corresponding	corresponding	ADJ
ajst-20773	263	9	author	author	NOUN
ajst-20773	263	10	.	.	PUNCT
ajst-20773	264	1	6	6	X
ajst-20773	264	2	.	.	PUNCT
ajst-20773	264	3	author	author	NOUN
ajst-20773	264	4	contributions	contribution	NOUN
ajst-20773	264	5	yk	yk	PROPN
ajst-20773	264	6	and	and	CCONJ
ajst-20773	264	7	ly	ly	PROPN
ajst-20773	264	8	initiated	initiate	VERB
ajst-20773	264	9	the	the	DET
ajst-20773	264	10	study	study	NOUN
ajst-20773	264	11	and	and	CCONJ
ajst-20773	264	12	its	its	PRON
ajst-20773	264	13	design	design	NOUN
ajst-20773	264	14	,	,	PUNCT
ajst-20773	264	15	also	also	ADV
ajst-20773	264	16	offering	offer	VERB
ajst-20773	264	17	administrative	administrative	ADJ
ajst-20773	264	18	assistance	assistance	NOUN
ajst-20773	264	19	.	.	PUNCT
ajst-20773	265	1	yk	yk	PROPN
ajst-20773	265	2	were	be	AUX
ajst-20773	265	3	involved	involve	VERB
ajst-20773	265	4	in	in	ADP
ajst-20773	265	5	data	datum	NOUN
ajst-20773	265	6	analysis	analysis	NOUN
ajst-20773	265	7	,	,	PUNCT
ajst-20773	265	8	and	and	CCONJ
ajst-20773	265	9	they	they	PRON
ajst-20773	265	10	wrote	write	VERB
ajst-20773	265	11	,	,	PUNCT
ajst-20773	265	12	reviewed	review	VERB
ajst-20773	265	13	,	,	PUNCT
ajst-20773	265	14	and	and	CCONJ
ajst-20773	265	15	edited	edit	VERB
ajst-20773	265	16	the	the	DET
ajst-20773	265	17	manuscript	manuscript	NOUN
ajst-20773	265	18	.	.	PUNCT
ajst-20773	266	1	yk	yk	PROPN
ajst-20773	266	2	and	and	CCONJ
ajst-20773	266	3	lb	lb	NUM
ajst-20773	266	4	aided	aid	VERB
ajst-20773	266	5	in	in	ADP
ajst-20773	266	6	analyzing	analyze	VERB
ajst-20773	266	7	data	datum	NOUN
ajst-20773	266	8	and	and	CCONJ
ajst-20773	266	9	reviewed	review	VERB
ajst-20773	266	10	the	the	DET
ajst-20773	266	11	manuscript	manuscript	NOUN
ajst-20773	266	12	.	.	PUNCT
ajst-20773	267	1	all	all	DET
ajst-20773	267	2	authors	author	NOUN
ajst-20773	267	3	have	have	AUX
ajst-20773	267	4	read	read	VERB
ajst-20773	267	5	and	and	CCONJ
ajst-20773	267	6	given	give	VERB
ajst-20773	267	7	their	their	PRON
ajst-20773	267	8	approval	approval	NOUN
ajst-20773	267	9	to	to	ADP
ajst-20773	267	10	the	the	DET
ajst-20773	267	11	final	final	ADJ
ajst-20773	267	12	manuscript	manuscript	NOUN
ajst-20773	267	13	.	.	PUNCT
ajst-20773	268	1	every	every	DET
ajst-20773	268	2	author	author	NOUN
ajst-20773	268	3	contributed	contribute	VERB
ajst-20773	268	4	to	to	ADP
ajst-20773	268	5	the	the	DET
ajst-20773	268	6	article	article	NOUN
ajst-20773	268	7	and	and	CCONJ
ajst-20773	268	8	agreed	agree	VERB
ajst-20773	268	9	on	on	ADP
ajst-20773	268	10	the	the	DET
ajst-20773	268	11	version	version	NOUN
ajst-20773	268	12	submitted	submit	VERB
ajst-20773	268	13	for	for	ADP
ajst-20773	268	14	publication	publication	NOUN
ajst-20773	268	15	.	.	PUNCT
ajst-20773	269	1	acknowledgment	acknowledgment	NOUN
ajst-20773	269	2	the	the	DET
ajst-20773	269	3	authors	author	NOUN
ajst-20773	269	4	express	express	VERB
ajst-20773	269	5	their	their	PRON
ajst-20773	269	6	appreciation	appreciation	NOUN
ajst-20773	269	7	to	to	ADP
ajst-20773	269	8	the	the	DET
ajst-20773	269	9	cancer	cancer	NOUN
ajst-20773	269	10	genome	genome	NOUN
ajst-20773	269	11	atlas	atlas	PROPN
ajst-20773	269	12	(	(	PUNCT
ajst-20773	269	13	tcga	tcga	PROPN
ajst-20773	269	14	)	)	PUNCT
ajst-20773	269	15	for	for	ADP
ajst-20773	269	16	providing	provide	VERB
ajst-20773	269	17	valuable	valuable	ADJ
ajst-20773	269	18	rna	rna	NOUN
ajst-20773	269	19	sequence	sequence	NOUN
ajst-20773	269	20	data	datum	NOUN
ajst-20773	269	21	complete	complete	ADJ
ajst-20773	269	22	with	with	ADP
ajst-20773	269	23	detailed	detailed	ADJ
ajst-20773	269	24	clinical	clinical	ADJ
ajst-20773	269	25	information	information	NOUN
ajst-20773	269	26	(	(	PUNCT
ajst-20773	269	27	https://tcgadata.nci.nih.gov/tcga/	https://tcgadata.nci.nih.gov/tcga/	NOUN
ajst-20773	269	28	)	)	PUNCT
ajst-20773	269	29	.	.	PUNCT
ajst-20773	270	1	they	they	PRON
ajst-20773	270	2	also	also	ADV
ajst-20773	270	3	extend	extend	VERB
ajst-20773	270	4	their	their	PRON
ajst-20773	270	5	gratitude	gratitude	NOUN
ajst-20773	270	6	to	to	PART
ajst-20773	270	7	biomed	biome	VERB
ajst-20773	270	8	proofreading	proofreading	NOUN
ajst-20773	270	9	®	®	PROPN
ajst-20773	270	10	llc	llc	PROPN
ajst-20773	270	11	co.	co.	PROPN
ajst-20773	270	12	,	,	PUNCT
ajst-20773	270	13	ltd	ltd	PROPN
ajst-20773	270	14	.	.	PROPN
ajst-20773	270	15	and	and	CCONJ
ajst-20773	270	16	the	the	DET
ajst-20773	270	17	developers	developer	NOUN
ajst-20773	270	18	of	of	ADP
ajst-20773	270	19	the	the	DET
ajst-20773	270	20	r	r	NOUN
ajst-20773	270	21	language	language	NOUN
ajst-20773	270	22	for	for	ADP
ajst-20773	270	23	their	their	PRON
ajst-20773	270	24	contributions	contribution	NOUN
ajst-20773	270	25	to	to	ADP
ajst-20773	270	26	building	build	VERB
ajst-20773	270	27	bioinformatics	bioinformatics	NOUN
ajst-20773	270	28	analysis	analysis	NOUN
ajst-20773	270	29	techniques	technique	NOUN
ajst-20773	270	30	,	,	PUNCT
ajst-20773	270	31	which	which	PRON
ajst-20773	270	32	serve	serve	VERB
ajst-20773	270	33	as	as	ADP
ajst-20773	270	34	fundamental	fundamental	ADJ
ajst-20773	270	35	tools	tool	NOUN
ajst-20773	270	36	for	for	ADP
ajst-20773	270	37	conducting	conduct	VERB
ajst-20773	270	38	bioinformatics	bioinformatics	NOUN
ajst-20773	270	39	analysis	analysis	NOUN
ajst-20773	270	40	.	.	PUNCT
ajst-20773	271	1	references	reference	NOUN
ajst-20773	271	2	[	[	X
ajst-20773	271	3	1	1	NUM
ajst-20773	271	4	]	]	X
ajst-20773	271	5	avelar	avelar	PROPN
ajst-20773	271	6	,	,	PUNCT
ajst-20773	271	7	r.	r.	PROPN
ajst-20773	271	8	a.	a.	PROPN
ajst-20773	271	9	,	,	PUNCT
ajst-20773	271	10	ortega	ortega	PROPN
ajst-20773	271	11	,	,	PUNCT
ajst-20773	271	12	j.	j.	PROPN
ajst-20773	271	13	g.	g.	PROPN
ajst-20773	271	14	,	,	PUNCT
ajst-20773	271	15	tacutu	tacutu	PROPN
ajst-20773	271	16	,	,	PUNCT
ajst-20773	271	17	r.	r.	PROPN
ajst-20773	271	18	,	,	PUNCT
ajst-20773	271	19	tyler	tyler	PROPN
ajst-20773	271	20	,	,	PUNCT
ajst-20773	271	21	e.	e.	PROPN
ajst-20773	271	22	j.	j.	PROPN
ajst-20773	271	23	,	,	PUNCT
ajst-20773	271	24	bennett	bennett	PROPN
ajst-20773	271	25	,	,	PUNCT
ajst-20773	271	26	d.	d.	PROPN
ajst-20773	271	27	,	,	PUNCT
ajst-20773	271	28	&	&	CCONJ
ajst-20773	271	29	binetti	binetti	VERB
ajst-20773	271	30	,	,	PUNCT
ajst-20773	271	31	p.	p.	NOUN
ajst-20773	271	32	(	(	PUNCT
ajst-20773	271	33	2020	2020	NUM
ajst-20773	271	34	)	)	PUNCT
ajst-20773	271	35	.	.	PUNCT
ajst-20773	272	1	a	a	DET
ajst-20773	272	2	multidimensional	multidimensional	ADJ
ajst-20773	272	3	systems	system	NOUN
ajst-20773	272	4	biology	biology	NOUN
ajst-20773	272	5	analysis	analysis	NOUN
ajst-20773	272	6	of	of	ADP
ajst-20773	272	7	cellular	cellular	ADJ
ajst-20773	272	8	senescence	senescence	NOUN
ajst-20773	272	9	in	in	ADP
ajst-20773	272	10	aging	aging	NOUN
ajst-20773	272	11	and	and	CCONJ
ajst-20773	272	12	disease	disease	NOUN
ajst-20773	272	13	.	.	PUNCT
ajst-20773	273	1	genome	genome	NOUN
ajst-20773	273	2	biology	biology	NOUN
ajst-20773	273	3	,	,	PUNCT
ajst-20773	273	4	21	21	NUM
ajst-20773	273	5	,	,	PUNCT
ajst-20773	273	6	91	91	NUM
ajst-20773	273	7	.	.	PUNCT
ajst-20773	274	1	[	[	X
ajst-20773	274	2	2	2	NUM
ajst-20773	274	3	]	]	X
ajst-20773	274	4	bonanno	bonanno	ADJ
ajst-20773	274	5	,	,	PUNCT
ajst-20773	274	6	l.	l.	PROPN
ajst-20773	274	7	,	,	PUNCT
ajst-20773	274	8	pavan	pavan	PROPN
ajst-20773	274	9	,	,	PUNCT
ajst-20773	274	10	a.	a.	PROPN
ajst-20773	274	11	,	,	PUNCT
ajst-20773	274	12	dieci	dieci	PROPN
ajst-20773	274	13	,	,	PUNCT
ajst-20773	274	14	m.	m.	NOUN
ajst-20773	274	15	v.	v.	PROPN
ajst-20773	274	16	,	,	PUNCT
ajst-20773	274	17	di	di	X
ajst-20773	274	18	liso	liso	PROPN
ajst-20773	274	19	,	,	PUNCT
ajst-20773	274	20	e.	e.	PROPN
ajst-20773	274	21	,	,	PUNCT
ajst-20773	274	22	et	et	PROPN
ajst-20773	274	23	al	al	PROPN
ajst-20773	274	24	.	.	PUNCT
ajst-20773	275	1	(	(	PUNCT
ajst-20773	275	2	2018	2018	NUM
ajst-20773	275	3	)	)	PUNCT
ajst-20773	275	4	.	.	PUNCT
ajst-20773	276	1	the	the	DET
ajst-20773	276	2	role	role	NOUN
ajst-20773	276	3	of	of	ADP
ajst-20773	276	4	immune	immune	ADJ
ajst-20773	276	5	microenvironment	microenvironment	NOUN
ajst-20773	276	6	in	in	ADP
ajst-20773	276	7	small	small	ADJ
ajst-20773	276	8	-	-	PUNCT
ajst-20773	276	9	cell	cell	NOUN
ajst-20773	276	10	lung	lung	NOUN
ajst-20773	276	11	cancer	cancer	NOUN
ajst-20773	276	12	:	:	PUNCT
ajst-20773	276	13	distribution	distribution	NOUN
ajst-20773	276	14	of	of	ADP
ajst-20773	276	15	pd	pd	PROPN
ajst-20773	276	16	-	-	PROPN
ajst-20773	276	17	l1	l1	PROPN
ajst-20773	276	18	expression	expression	NOUN
ajst-20773	276	19	and	and	CCONJ
ajst-20773	276	20	prognostic	prognostic	ADJ
ajst-20773	276	21	role	role	NOUN
ajst-20773	276	22	of	of	ADP
ajst-20773	276	23	foxp3	foxp3	NOUN
ajst-20773	276	24	-	-	PUNCT
ajst-20773	276	25	positive	positive	ADJ
ajst-20773	276	26	tumour	tumour	NOUN
ajst-20773	276	27	infiltrating	infiltrate	VERB
ajst-20773	276	28	lymphocytes	lymphocyte	NOUN
ajst-20773	276	29	.	.	PUNCT
ajst-20773	277	1	european	european	PROPN
ajst-20773	277	2	journal	journal	PROPN
ajst-20773	277	3	of	of	ADP
ajst-20773	277	4	cancer	cancer	NOUN
ajst-20773	277	5	.	.	PUNCT
ajst-20773	278	1	[	[	X
ajst-20773	278	2	3	3	NUM
ajst-20773	278	3	]	]	X
ajst-20773	278	4	bray	bray	NOUN
ajst-20773	278	5	,	,	PUNCT
ajst-20773	278	6	f.	f.	PROPN
ajst-20773	278	7	,	,	PUNCT
ajst-20773	278	8	ferlay	ferlay	PROPN
ajst-20773	278	9	,	,	PUNCT
ajst-20773	278	10	j.	j.	PROPN
ajst-20773	278	11	,	,	PUNCT
ajst-20773	278	12	soerjomataram	soerjomataram	PROPN
ajst-20773	278	13	,	,	PUNCT
ajst-20773	278	14	i.	i.	PROPN
ajst-20773	278	15	,	,	PUNCT
ajst-20773	278	16	siegel	siegel	PROPN
ajst-20773	278	17	,	,	PUNCT
ajst-20773	278	18	r.	r.	PROPN
ajst-20773	278	19	l.	l.	PROPN
ajst-20773	278	20	,	,	PUNCT
ajst-20773	278	21	torre	torre	PROPN
ajst-20773	278	22	,	,	PUNCT
ajst-20773	278	23	l.	l.	PROPN
ajst-20773	278	24	a.	a.	PROPN
ajst-20773	278	25	,	,	PUNCT
ajst-20773	278	26	&	&	CCONJ
ajst-20773	278	27	jemal	jemal	ADJ
ajst-20773	278	28	,	,	PUNCT
ajst-20773	278	29	a.	a.	NOUN
ajst-20773	278	30	(	(	PUNCT
ajst-20773	278	31	2018	2018	NUM
ajst-20773	278	32	)	)	PUNCT
ajst-20773	278	33	.	.	PUNCT
ajst-20773	279	1	global	global	ADJ
ajst-20773	279	2	cancer	cancer	NOUN
ajst-20773	279	3	statistics	statistic	NOUN
ajst-20773	279	4	2018	2018	NUM
ajst-20773	279	5	:	:	PUNCT
ajst-20773	279	6	globocan	globocan	PROPN
ajst-20773	279	7	estimates	estimate	NOUN
ajst-20773	279	8	of	of	ADP
ajst-20773	279	9	incidence	incidence	NOUN
ajst-20773	279	10	and	and	CCONJ
ajst-20773	279	11	mortality	mortality	NOUN
ajst-20773	279	12	worldwide	worldwide	ADV
ajst-20773	279	13	for	for	ADP
ajst-20773	279	14	36	36	NUM
ajst-20773	279	15	cancers	cancer	NOUN
ajst-20773	279	16	in	in	ADP
ajst-20773	279	17	185	185	NUM
ajst-20773	279	18	countries	country	NOUN
ajst-20773	279	19	.	.	PUNCT
ajst-20773	280	1	ca	can	AUX
ajst-20773	280	2	:	:	PUNCT
ajst-20773	280	3	a	a	DET
ajst-20773	280	4	cancer	cancer	NOUN
ajst-20773	280	5	journal	journal	NOUN
ajst-20773	280	6	for	for	ADP
ajst-20773	280	7	clinicians	clinician	NOUN
ajst-20773	280	8	,	,	PUNCT
ajst-20773	280	9	68(6	68(6	NOUN
ajst-20773	280	10	)	)	PUNCT
ajst-20773	280	11	,	,	PUNCT
ajst-20773	280	12	394	394	NUM
ajst-20773	280	13	-	-	SYM
ajst-20773	280	14	424	424	NUM
ajst-20773	280	15	.	.	NOUN
ajst-20773	280	16	30	30	NUM
ajst-20773	281	1	[	[	SYM
ajst-20773	281	2	4	4	NUM
ajst-20773	281	3	]	]	X
ajst-20773	281	4	campisi	campisi	PROPN
ajst-20773	281	5	,	,	PUNCT
ajst-20773	281	6	j.	j.	PROPN
ajst-20773	281	7	(	(	PUNCT
ajst-20773	281	8	2013	2013	NUM
ajst-20773	281	9	)	)	PUNCT
ajst-20773	281	10	.	.	PUNCT
ajst-20773	282	1	aging	age	VERB
ajst-20773	282	2	,	,	PUNCT
ajst-20773	282	3	cellular	cellular	ADJ
ajst-20773	282	4	senescence	senescence	NOUN
ajst-20773	282	5	,	,	PUNCT
ajst-20773	282	6	and	and	CCONJ
ajst-20773	282	7	cancer	cancer	NOUN
ajst-20773	282	8	.	.	PUNCT
ajst-20773	283	1	annual	annual	ADJ
ajst-20773	283	2	review	review	NOUN
ajst-20773	283	3	of	of	ADP
ajst-20773	283	4	physiology	physiology	NOUN
ajst-20773	283	5	,	,	PUNCT
ajst-20773	283	6	75	75	NUM
ajst-20773	283	7	,	,	PUNCT
ajst-20773	283	8	685	685	NUM
ajst-20773	283	9	-	-	SYM
ajst-20773	283	10	705	705	NUM
ajst-20773	283	11	.	.	PUNCT
ajst-20773	284	1	[	[	X
ajst-20773	284	2	5	5	NUM
ajst-20773	284	3	]	]	X
ajst-20773	284	4	degirmenci	degirmenci	PROPN
ajst-20773	284	5	,	,	PUNCT
ajst-20773	284	6	u.	u.	PROPN
ajst-20773	284	7	,	,	PUNCT
ajst-20773	284	8	lei	lei	PROPN
ajst-20773	284	9	,	,	PUNCT
ajst-20773	284	10	s.	s.	PROPN
ajst-20773	284	11	(	(	PUNCT
ajst-20773	284	12	2016	2016	NUM
ajst-20773	284	13	)	)	PUNCT
ajst-20773	284	14	.	.	PUNCT
ajst-20773	285	1	role	role	NOUN
ajst-20773	285	2	of	of	ADP
ajst-20773	285	3	lncrnas	lncrna	NOUN
ajst-20773	285	4	in	in	ADP
ajst-20773	285	5	cellular	cellular	ADJ
ajst-20773	285	6	aging	aging	NOUN
ajst-20773	285	7	.	.	PUNCT
ajst-20773	286	1	frontiers	frontier	NOUN
ajst-20773	286	2	in	in	ADP
ajst-20773	286	3	endocrinology	endocrinology	NOUN
ajst-20773	286	4	.	.	PUNCT
ajst-20773	287	1	[	[	X
ajst-20773	287	2	6	6	NUM
ajst-20773	287	3	]	]	PUNCT
ajst-20773	287	4	do	do	VERB
ajst-20773	287	5	,	,	PUNCT
ajst-20773	287	6	h.	h.	PROPN
ajst-20773	287	7	,	,	PUNCT
ajst-20773	287	8	&	&	CCONJ
ajst-20773	287	9	kim	kim	PROPN
ajst-20773	287	10	,	,	PUNCT
ajst-20773	287	11	w.	w.	PROPN
ajst-20773	287	12	(	(	PUNCT
ajst-20773	287	13	2018	2018	NUM
ajst-20773	287	14	)	)	PUNCT
ajst-20773	287	15	.	.	PUNCT
ajst-20773	288	1	roles	role	NOUN
ajst-20773	288	2	of	of	ADP
ajst-20773	288	3	oncogenic	oncogenic	ADJ
ajst-20773	288	4	long	long	ADJ
ajst-20773	288	5	non	non	ADJ
ajst-20773	288	6	-	-	ADJ
ajst-20773	288	7	coding	coding	ADJ
ajst-20773	288	8	rnas	rna	NOUN
ajst-20773	288	9	in	in	ADP
ajst-20773	288	10	cancer	cancer	NOUN
ajst-20773	288	11	development	development	NOUN
ajst-20773	288	12	.	.	PUNCT
ajst-20773	289	1	genomics	genomic	NOUN
ajst-20773	289	2	&	&	CCONJ
ajst-20773	289	3	informatics	informatics	PROPN
ajst-20773	289	4	,	,	PUNCT
ajst-20773	289	5	16(1	16(1	NUM
ajst-20773	289	6	)	)	PUNCT
ajst-20773	289	7	,	,	PUNCT
ajst-20773	289	8	e18	e18	PROPN
ajst-20773	289	9	.	.	PUNCT
ajst-20773	290	1	[	[	X
ajst-20773	290	2	7	7	NUM
ajst-20773	290	3	]	]	SYM
ajst-20773	290	4	genova	genova	PROPN
ajst-20773	290	5	,	,	PUNCT
ajst-20773	290	6	c.	c.	PROPN
ajst-20773	290	7	,	,	PUNCT
ajst-20773	290	8	dellepiane	dellepiane	PROPN
ajst-20773	290	9	,	,	PUNCT
ajst-20773	290	10	c.	c.	PROPN
ajst-20773	290	11	,	,	PUNCT
ajst-20773	290	12	carrega	carrega	PROPN
ajst-20773	290	13	,	,	PUNCT
ajst-20773	290	14	p.	p.	PROPN
ajst-20773	290	15	,	,	PUNCT
ajst-20773	290	16	et	et	PROPN
ajst-20773	290	17	al	al	PROPN
ajst-20773	290	18	.	.	PROPN
ajst-20773	290	19	(	(	PUNCT
ajst-20773	290	20	2022	2022	NUM
ajst-20773	290	21	)	)	PUNCT
ajst-20773	290	22	.	.	PUNCT
ajst-20773	291	1	therapeutic	therapeutic	ADJ
ajst-20773	291	2	implications	implication	NOUN
ajst-20773	291	3	of	of	ADP
ajst-20773	291	4	tumor	tumor	NOUN
ajst-20773	291	5	microenvironment	microenvironment	NOUN
ajst-20773	291	6	in	in	ADP
ajst-20773	291	7	lung	lung	NOUN
ajst-20773	291	8	cancer	cancer	NOUN
ajst-20773	291	9	:	:	PUNCT
ajst-20773	291	10	focus	focus	VERB
ajst-20773	291	11	on	on	ADP
ajst-20773	291	12	immune	immune	ADJ
ajst-20773	291	13	checkpoint	checkpoint	NOUN
ajst-20773	291	14	blockade	blockade	NOUN
ajst-20773	291	15	.	.	PUNCT
ajst-20773	292	1	frontiers	frontier	NOUN
ajst-20773	292	2	in	in	ADP
ajst-20773	292	3	immunology	immunology	NOUN
ajst-20773	292	4	.	.	PUNCT
ajst-20773	293	1	[	[	X
ajst-20773	293	2	8	8	NUM
ajst-20773	293	3	]	]	X
ajst-20773	293	4	hoang	hoang	PROPN
ajst-20773	293	5	,	,	PUNCT
ajst-20773	293	6	p.	p.	PROPN
ajst-20773	293	7	h.	h.	PROPN
ajst-20773	293	8	,	,	PUNCT
ajst-20773	293	9	&	&	CCONJ
ajst-20773	293	10	landi	landi	PROPN
ajst-20773	293	11	,	,	PUNCT
ajst-20773	293	12	m.	m.	NOUN
ajst-20773	293	13	t.	t.	PROPN
ajst-20773	293	14	(	(	PUNCT
ajst-20773	293	15	2022	2022	NUM
ajst-20773	293	16	)	)	PUNCT
ajst-20773	293	17	.	.	PUNCT
ajst-20773	294	1	dna	dna	PROPN
ajst-20773	294	2	methylation	methylation	NOUN
ajst-20773	294	3	in	in	ADP
ajst-20773	294	4	lung	lung	NOUN
ajst-20773	294	5	cancer	cancer	NOUN
ajst-20773	294	6	:	:	PUNCT
ajst-20773	294	7	mechanisms	mechanism	NOUN
ajst-20773	294	8	and	and	CCONJ
ajst-20773	294	9	associations	association	NOUN
ajst-20773	294	10	with	with	ADP
ajst-20773	294	11	histological	histological	ADJ
ajst-20773	294	12	subtypes	subtype	NOUN
ajst-20773	294	13	,	,	PUNCT
ajst-20773	294	14	molecular	molecular	ADJ
ajst-20773	294	15	alterations	alteration	NOUN
ajst-20773	294	16	,	,	PUNCT
ajst-20773	294	17	and	and	CCONJ
ajst-20773	294	18	major	major	ADJ
ajst-20773	294	19	epidemiological	epidemiological	ADJ
ajst-20773	294	20	factors	factor	NOUN
ajst-20773	294	21	.	.	PUNCT
ajst-20773	295	1	cancers	cancer	NOUN
ajst-20773	295	2	,	,	PUNCT
ajst-20773	295	3	14(4	14(4	NUM
ajst-20773	295	4	)	)	PUNCT
ajst-20773	295	5	,	,	PUNCT
ajst-20773	295	6	961	961	NUM
ajst-20773	295	7	.	.	PUNCT
ajst-20773	296	1	[	[	X
ajst-20773	296	2	9	9	NUM
ajst-20773	296	3	]	]	PUNCT
ajst-20773	296	4	huo	huo	NOUN
ajst-20773	296	5	,	,	PUNCT
ajst-20773	296	6	j.	j.	PROPN
ajst-20773	296	7	,	,	PUNCT
ajst-20773	296	8	wu	wu	PROPN
ajst-20773	296	9	,	,	PUNCT
ajst-20773	296	10	l.	l.	PROPN
ajst-20773	296	11	,	,	PUNCT
ajst-20773	296	12	zang	zang	PROPN
ajst-20773	296	13	,	,	PUNCT
ajst-20773	296	14	y.	y.	PROPN
ajst-20773	296	15	,	,	PUNCT
ajst-20773	296	16	dong	dong	PROPN
ajst-20773	296	17	,	,	PUNCT
ajst-20773	296	18	h.	h.	PROPN
ajst-20773	296	19	,	,	PUNCT
ajst-20773	296	20	liu	liu	PROPN
ajst-20773	296	21	,	,	PUNCT
ajst-20773	296	22	x.	x.	PROPN
ajst-20773	296	23	,	,	PUNCT
ajst-20773	296	24	he	he	PRON
ajst-20773	296	25	,	,	PUNCT
ajst-20773	296	26	f.	f.	PROPN
ajst-20773	296	27	,	,	PUNCT
ajst-20773	296	28	&	&	CCONJ
ajst-20773	296	29	zhang	zhang	PROPN
ajst-20773	296	30	,	,	PUNCT
ajst-20773	296	31	x.	x.	NOUN
ajst-20773	296	32	(	(	PUNCT
ajst-20773	296	33	2021	2021	NUM
ajst-20773	296	34	)	)	PUNCT
ajst-20773	296	35	.	.	PUNCT
ajst-20773	297	1	eight	eight	NUM
ajst-20773	297	2	-	-	PUNCT
ajst-20773	297	3	gene	gene	NOUN
ajst-20773	297	4	metabolic	metabolic	NOUN
ajst-20773	297	5	signature	signature	NOUN
ajst-20773	297	6	related	relate	VERB
ajst-20773	297	7	with	with	ADP
ajst-20773	297	8	tumorassociated	tumorassociate	VERB
ajst-20773	297	9	macrophages	macrophage	NOUN
ajst-20773	297	10	predicting	predict	VERB
ajst-20773	297	11	overall	overall	ADJ
ajst-20773	297	12	survival	survival	NOUN
ajst-20773	297	13	for	for	ADP
ajst-20773	297	14	hepatocellular	hepatocellular	ADJ
ajst-20773	297	15	carcinoma	carcinoma	NOUN
ajst-20773	297	16	.	.	PUNCT
ajst-20773	298	1	bmc	bmc	ADJ
ajst-20773	298	2	cancer	cancer	NOUN
ajst-20773	298	3	,	,	PUNCT
ajst-20773	298	4	21	21	NUM
ajst-20773	298	5	,	,	PUNCT
ajst-20773	298	6	77	77	NUM
ajst-20773	298	7	.	.	PUNCT
ajst-20773	299	1	[	[	X
ajst-20773	299	2	10	10	NUM
ajst-20773	299	3	]	]	X
ajst-20773	299	4	jenkins	jenkins	PROPN
ajst-20773	299	5	,	,	PUNCT
ajst-20773	299	6	r.	r.	PROPN
ajst-20773	299	7	w.	w.	PROPN
ajst-20773	299	8	,	,	PUNCT
ajst-20773	299	9	barbie	barbie	PROPN
ajst-20773	299	10	,	,	PUNCT
ajst-20773	299	11	d.	d.	PROPN
ajst-20773	299	12	a.	a.	PROPN
ajst-20773	299	13	,	,	PUNCT
ajst-20773	299	14	flaherty	flaherty	PROPN
ajst-20773	299	15	,	,	PUNCT
ajst-20773	299	16	k.	k.	PROPN
ajst-20773	299	17	t.	t.	PROPN
ajst-20773	299	18	(	(	PUNCT
ajst-20773	299	19	2018	2018	NUM
ajst-20773	299	20	)	)	PUNCT
ajst-20773	299	21	.	.	PUNCT
ajst-20773	299	22	mechanisms	mechanism	NOUN
ajst-20773	299	23	of	of	ADP
ajst-20773	299	24	resistance	resistance	NOUN
ajst-20773	299	25	to	to	ADP
ajst-20773	299	26	immune	immune	ADJ
ajst-20773	299	27	checkpoint	checkpoint	NOUN
ajst-20773	299	28	inhibitors	inhibitor	NOUN
ajst-20773	299	29	.	.	PUNCT
ajst-20773	300	1	british	british	ADJ
ajst-20773	300	2	journal	journal	PROPN
ajst-20773	300	3	of	of	ADP
ajst-20773	300	4	cancer	cancer	NOUN
ajst-20773	300	5	.	.	PUNCT
ajst-20773	301	1	[	[	X
ajst-20773	301	2	11	11	NUM
ajst-20773	301	3	]	]	X
ajst-20773	301	4	jin	jin	PROPN
ajst-20773	301	5	,	,	PUNCT
ajst-20773	301	6	d.	d.	PROPN
ajst-20773	301	7	,	,	PUNCT
ajst-20773	301	8	song	song	NOUN
ajst-20773	301	9	,	,	PUNCT
ajst-20773	301	10	y.	y.	PROPN
ajst-20773	301	11	,	,	PUNCT
ajst-20773	301	12	chen	chen	PROPN
ajst-20773	301	13	,	,	PUNCT
ajst-20773	301	14	y.	y.	PROPN
ajst-20773	301	15	,	,	PUNCT
ajst-20773	301	16	&	&	CCONJ
ajst-20773	301	17	zhang	zhang	PROPN
ajst-20773	301	18	,	,	PUNCT
ajst-20773	301	19	p.	p.	PROPN
ajst-20773	301	20	(	(	PUNCT
ajst-20773	301	21	2020	2020	NUM
ajst-20773	301	22	)	)	PUNCT
ajst-20773	301	23	.	.	PUNCT
ajst-20773	302	1	identification	identification	NOUN
ajst-20773	302	2	of	of	ADP
ajst-20773	302	3	three	three	NUM
ajst-20773	302	4	lncrnas	lncrna	NOUN
ajst-20773	302	5	as	as	ADP
ajst-20773	302	6	potential	potential	ADJ
ajst-20773	302	7	predictive	predictive	ADJ
ajst-20773	302	8	biomarkers	biomarker	NOUN
ajst-20773	302	9	of	of	ADP
ajst-20773	302	10	lung	lung	NOUN
ajst-20773	302	11	adenocarcinoma	adenocarcinoma	PROPN
ajst-20773	302	12	.	.	PUNCT
ajst-20773	302	13	biomed	biome	VERB
ajst-20773	302	14	research	research	NOUN
ajst-20773	302	15	international	international	PROPN
ajst-20773	302	16	,	,	PUNCT
ajst-20773	302	17	2020	2020	NUM
ajst-20773	302	18	,	,	PUNCT
ajst-20773	302	19	article	article	NOUN
ajst-20773	302	20	7573689	7573689	NUM
ajst-20773	302	21	.	.	PUNCT
ajst-20773	303	1	[	[	X
ajst-20773	303	2	12	12	NUM
ajst-20773	303	3	]	]	X
ajst-20773	303	4	kim	kim	PROPN
ajst-20773	303	5	,	,	PUNCT
ajst-20773	303	6	c.	c.	PROPN
ajst-20773	303	7	,	,	PUNCT
ajst-20773	303	8	kang	kang	PROPN
ajst-20773	303	9	,	,	PUNCT
ajst-20773	303	10	d.	d.	PROPN
ajst-20773	303	11	,	,	PUNCT
ajst-20773	303	12	lee	lee	PROPN
ajst-20773	303	13	,	,	PUNCT
ajst-20773	303	14	e.	e.	PROPN
ajst-20773	303	15	k.	k.	PROPN
ajst-20773	303	16	,	,	PUNCT
ajst-20773	303	17	lee	lee	PROPN
ajst-20773	303	18	,	,	PUNCT
ajst-20773	303	19	j.	j.	PROPN
ajst-20773	303	20	s.	s.	PROPN
ajst-20773	303	21	(	(	PUNCT
ajst-20773	303	22	2017	2017	NUM
ajst-20773	303	23	)	)	PUNCT
ajst-20773	303	24	.	.	PUNCT
ajst-20773	304	1	long	long	ADJ
ajst-20773	304	2	noncoding	noncoding	ADJ
ajst-20773	304	3	rnas	rna	NOUN
ajst-20773	304	4	and	and	CCONJ
ajst-20773	304	5	rna	rna	NOUN
ajst-20773	304	6	-	-	PUNCT
ajst-20773	304	7	binding	bind	VERB
ajst-20773	304	8	proteins	protein	NOUN
ajst-20773	304	9	in	in	ADP
ajst-20773	304	10	oxidative	oxidative	ADJ
ajst-20773	304	11	stress	stress	NOUN
ajst-20773	304	12	,	,	PUNCT
ajst-20773	304	13	cellular	cellular	ADJ
ajst-20773	304	14	senescence	senescence	NOUN
ajst-20773	304	15	,	,	PUNCT
ajst-20773	304	16	and	and	CCONJ
ajst-20773	304	17	age	age	NOUN
ajst-20773	304	18	-	-	PUNCT
ajst-20773	304	19	related	relate	VERB
ajst-20773	304	20	diseases	disease	NOUN
ajst-20773	304	21	.	.	PUNCT
ajst-20773	305	1	oxidative	oxidative	ADJ
ajst-20773	305	2	medicine	medicine	NOUN
ajst-20773	305	3	and	and	CCONJ
ajst-20773	305	4	cellular	cellular	ADJ
ajst-20773	305	5	longevity	longevity	NOUN
ajst-20773	305	6	.	.	PUNCT
ajst-20773	306	1	[	[	X
ajst-20773	306	2	13	13	NUM
ajst-20773	306	3	]	]	X
ajst-20773	306	4	lecot	lecot	NOUN
ajst-20773	306	5	,	,	PUNCT
ajst-20773	306	6	p.	p.	NOUN
ajst-20773	306	7	,	,	PUNCT
ajst-20773	306	8	alimirah	alimirah	PROPN
ajst-20773	306	9	,	,	PUNCT
ajst-20773	306	10	f.	f.	PROPN
ajst-20773	306	11	,	,	PUNCT
ajst-20773	306	12	desprez	desprez	NOUN
ajst-20773	306	13	,	,	PUNCT
ajst-20773	306	14	p.	p.	PROPN
ajst-20773	306	15	y.	y.	PROPN
ajst-20773	306	16	,	,	PUNCT
ajst-20773	306	17	campisi	campisi	PROPN
ajst-20773	306	18	,	,	PUNCT
ajst-20773	306	19	j.	j.	PROPN
ajst-20773	306	20	,	,	PUNCT
ajst-20773	306	21	&	&	CCONJ
ajst-20773	306	22	wiley	wiley	PROPN
ajst-20773	306	23	,	,	PUNCT
ajst-20773	306	24	c.	c.	PROPN
ajst-20773	306	25	d.	d.	PROPN
ajst-20773	306	26	(	(	PUNCT
ajst-20773	306	27	2016	2016	NUM
ajst-20773	306	28	)	)	PUNCT
ajst-20773	306	29	.	.	PUNCT
ajst-20773	307	1	context	context	NOUN
ajst-20773	307	2	-	-	PUNCT
ajst-20773	307	3	dependent	dependent	ADJ
ajst-20773	307	4	effects	effect	NOUN
ajst-20773	307	5	of	of	ADP
ajst-20773	307	6	cellular	cellular	ADJ
ajst-20773	307	7	senescence	senescence	NOUN
ajst-20773	307	8	in	in	ADP
ajst-20773	307	9	cancer	cancer	NOUN
ajst-20773	307	10	development	development	NOUN
ajst-20773	307	11	.	.	PUNCT
ajst-20773	308	1	british	british	ADJ
ajst-20773	308	2	journal	journal	PROPN
ajst-20773	308	3	of	of	ADP
ajst-20773	308	4	cancer	cancer	NOUN
ajst-20773	308	5	,	,	PUNCT
ajst-20773	308	6	114(11	114(11	NUM
ajst-20773	308	7	)	)	PUNCT
ajst-20773	308	8	,	,	PUNCT
ajst-20773	308	9	1180	1180	NUM
ajst-20773	308	10	-	-	SYM
ajst-20773	308	11	1184	1184	NUM
ajst-20773	308	12	.	.	PUNCT
ajst-20773	309	1	[	[	X
ajst-20773	309	2	14	14	NUM
ajst-20773	309	3	]	]	X
ajst-20773	309	4	lin	lin	PROPN
ajst-20773	309	5	,	,	PUNCT
ajst-20773	309	6	w.	w.	PROPN
ajst-20773	309	7	,	,	PUNCT
ajst-20773	309	8	wang	wang	PROPN
ajst-20773	309	9	,	,	PUNCT
ajst-20773	309	10	x.	x.	PROPN
ajst-20773	309	11	,	,	PUNCT
ajst-20773	309	12	xu	xu	PROPN
ajst-20773	309	13	,	,	PUNCT
ajst-20773	309	14	z.	z.	PROPN
ajst-20773	309	15	,	,	PUNCT
ajst-20773	309	16	wang	wang	PROPN
ajst-20773	309	17	,	,	PUNCT
ajst-20773	309	18	z.	z.	PROPN
ajst-20773	309	19	,	,	PUNCT
ajst-20773	309	20	liu	liu	PROPN
ajst-20773	309	21	,	,	PUNCT
ajst-20773	309	22	t.	t.	PROPN
ajst-20773	309	23	,	,	PUNCT
ajst-20773	309	24	cao	cao	PROPN
ajst-20773	309	25	,	,	PUNCT
ajst-20773	309	26	z.	z.	PROPN
ajst-20773	309	27	,	,	PUNCT
ajst-20773	309	28	et	et	PROPN
ajst-20773	309	29	al	al	PROPN
ajst-20773	309	30	.	.	PROPN
ajst-20773	309	31	(	(	PUNCT
ajst-20773	309	32	2021	2021	NUM
ajst-20773	309	33	)	)	PUNCT
ajst-20773	309	34	.	.	PUNCT
ajst-20773	310	1	identification	identification	NOUN
ajst-20773	310	2	and	and	CCONJ
ajst-20773	310	3	validation	validation	NOUN
ajst-20773	310	4	of	of	ADP
ajst-20773	310	5	cellular	cellular	ADJ
ajst-20773	310	6	senescence	senescence	NOUN
ajst-20773	310	7	patterns	pattern	NOUN
ajst-20773	310	8	to	to	PART
ajst-20773	310	9	predict	predict	VERB
ajst-20773	310	10	clinical	clinical	ADJ
ajst-20773	310	11	outcomes	outcome	NOUN
ajst-20773	310	12	and	and	CCONJ
ajst-20773	310	13	immunotherapeutic	immunotherapeutic	ADJ
ajst-20773	310	14	responses	response	NOUN
ajst-20773	310	15	in	in	ADP
ajst-20773	310	16	lung	lung	NOUN
ajst-20773	310	17	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	310	18	.	.	PUNCT
ajst-20773	311	1	cancer	cancer	NOUN
ajst-20773	311	2	cell	cell	NOUN
ajst-20773	311	3	international	international	PROPN
ajst-20773	311	4	.	.	PUNCT
ajst-20773	312	1	[	[	X
ajst-20773	312	2	15	15	NUM
ajst-20773	312	3	]	]	X
ajst-20773	312	4	liu	liu	PROPN
ajst-20773	312	5	,	,	PUNCT
ajst-20773	312	6	a.	a.	PROPN
ajst-20773	312	7	,	,	PUNCT
ajst-20773	312	8	wang	wang	PROPN
ajst-20773	312	9	,	,	PUNCT
ajst-20773	312	10	x.	x.	PROPN
ajst-20773	312	11	,	,	PUNCT
ajst-20773	312	12	hu	hu	PROPN
ajst-20773	312	13	,	,	PUNCT
ajst-20773	312	14	l.	l.	PROPN
ajst-20773	312	15	,	,	PUNCT
ajst-20773	312	16	yan	yan	PROPN
ajst-20773	312	17	,	,	PUNCT
ajst-20773	312	18	d.	d.	PROPN
ajst-20773	312	19	,	,	PUNCT
ajst-20773	312	20	yin	yin	PROPN
ajst-20773	312	21	,	,	PUNCT
ajst-20773	312	22	y.	y.	PROPN
ajst-20773	312	23	,	,	PUNCT
ajst-20773	312	24	zheng	zheng	PROPN
ajst-20773	312	25	,	,	PUNCT
ajst-20773	312	26	h.	h.	PROPN
ajst-20773	312	27	,	,	PUNCT
ajst-20773	312	28	liu	liu	PROPN
ajst-20773	312	29	,	,	PUNCT
ajst-20773	312	30	g.	g.	PROPN
ajst-20773	312	31	et	et	PROPN
ajst-20773	312	32	al	al	PROPN
ajst-20773	312	33	.	.	PROPN
ajst-20773	312	34	(	(	PUNCT
ajst-20773	312	35	2023	2023	NUM
ajst-20773	312	36	)	)	PUNCT
ajst-20773	312	37	.	.	PUNCT
ajst-20773	313	1	a	a	DET
ajst-20773	313	2	predictive	predictive	ADJ
ajst-20773	313	3	molecular	molecular	ADJ
ajst-20773	313	4	signature	signature	NOUN
ajst-20773	313	5	consisting	consist	VERB
ajst-20773	313	6	of	of	ADP
ajst-20773	313	7	lncrnas	lncrna	NOUN
ajst-20773	313	8	associated	associate	VERB
ajst-20773	313	9	with	with	ADP
ajst-20773	313	10	cellular	cellular	ADJ
ajst-20773	313	11	senescence	senescence	NOUN
ajst-20773	313	12	for	for	ADP
ajst-20773	313	13	the	the	DET
ajst-20773	313	14	prognosis	prognosis	NOUN
ajst-20773	313	15	of	of	ADP
ajst-20773	313	16	lung	lung	NOUN
ajst-20773	313	17	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	313	18	.	.	PUNCT
ajst-20773	314	1	plos	plos	PROPN
ajst-20773	314	2	one	one	NUM
ajst-20773	314	3	.	.	PUNCT
ajst-20773	315	1	[	[	X
ajst-20773	315	2	16	16	NUM
ajst-20773	315	3	]	]	X
ajst-20773	315	4	liu	liu	PROPN
ajst-20773	315	5	,	,	PUNCT
ajst-20773	315	6	h.	h.	PROPN
ajst-20773	315	7	,	,	PUNCT
ajst-20773	315	8	zhao	zhao	PROPN
ajst-20773	315	9	,	,	PUNCT
ajst-20773	315	10	h.	h.	PROPN
ajst-20773	315	11	,	,	PUNCT
ajst-20773	315	12	sun	sun	PROPN
ajst-20773	315	13	,	,	PUNCT
ajst-20773	315	14	y.	y.	PROPN
ajst-20773	315	15	(	(	PUNCT
ajst-20773	315	16	2022	2022	NUM
ajst-20773	315	17	)	)	PUNCT
ajst-20773	315	18	.	.	PUNCT
ajst-20773	316	1	tumor	tumor	NOUN
ajst-20773	316	2	microenvironment	microenvironment	NOUN
ajst-20773	316	3	and	and	CCONJ
ajst-20773	316	4	cellular	cellular	ADJ
ajst-20773	316	5	senescence	senescence	NOUN
ajst-20773	316	6	:	:	PUNCT
ajst-20773	316	7	understanding	understand	VERB
ajst-20773	316	8	therapeutic	therapeutic	ADJ
ajst-20773	316	9	resistance	resistance	NOUN
ajst-20773	316	10	and	and	CCONJ
ajst-20773	316	11	harnessing	harness	VERB
ajst-20773	316	12	strategies	strategy	NOUN
ajst-20773	316	13	.	.	PUNCT
ajst-20773	317	1	seminars	seminar	NOUN
ajst-20773	317	2	in	in	ADP
ajst-20773	317	3	cancer	cancer	NOUN
ajst-20773	317	4	biology	biology	NOUN
ajst-20773	317	5	.	.	PUNCT
ajst-20773	318	1	[	[	X
ajst-20773	318	2	17	17	NUM
ajst-20773	318	3	]	]	X
ajst-20773	318	4	liu	liu	PROPN
ajst-20773	318	5	,	,	PUNCT
ajst-20773	318	6	j.	j.	PROPN
ajst-20773	318	7	,	,	PUNCT
ajst-20773	318	8	nie	nie	PROPN
ajst-20773	318	9	,	,	PUNCT
ajst-20773	318	10	s.	s.	PROPN
ajst-20773	318	11	,	,	PUNCT
ajst-20773	318	12	wu	wu	PROPN
ajst-20773	318	13	,	,	PUNCT
ajst-20773	318	14	z.	z.	PROPN
ajst-20773	318	15	,	,	PUNCT
ajst-20773	318	16	jiang	jiang	PROPN
ajst-20773	318	17	,	,	PUNCT
ajst-20773	318	18	y.	y.	PROPN
ajst-20773	318	19	,	,	PUNCT
ajst-20773	318	20	wan	wan	PROPN
ajst-20773	318	21	,	,	PUNCT
ajst-20773	318	22	s.	s.	PROPN
ajst-20773	318	23	,	,	PUNCT
ajst-20773	318	24	li	li	PROPN
ajst-20773	318	25	,	,	PUNCT
ajst-20773	318	26	s.	s.	PROPN
ajst-20773	318	27	,	,	PUNCT
ajst-20773	318	28	meng	meng	PROPN
ajst-20773	318	29	,	,	PUNCT
ajst-20773	318	30	h.	h.	PROPN
ajst-20773	318	31	(	(	PUNCT
ajst-20773	318	32	2020	2020	NUM
ajst-20773	318	33	)	)	PUNCT
ajst-20773	318	34	.	.	PUNCT
ajst-20773	319	1	exploration	exploration	NOUN
ajst-20773	319	2	of	of	ADP
ajst-20773	319	3	a	a	DET
ajst-20773	319	4	novel	novel	ADJ
ajst-20773	319	5	prognostic	prognostic	ADJ
ajst-20773	319	6	risk	risk	NOUN
ajst-20773	319	7	signatures	signature	NOUN
ajst-20773	319	8	and	and	CCONJ
ajst-20773	319	9	immune	immune	ADJ
ajst-20773	319	10	checkpoint	checkpoint	NOUN
ajst-20773	319	11	molecules	molecule	NOUN
ajst-20773	319	12	in	in	ADP
ajst-20773	319	13	endometrial	endometrial	ADJ
ajst-20773	319	14	carcinoma	carcinoma	NOUN
ajst-20773	319	15	microenvironment	microenvironment	NOUN
ajst-20773	319	16	.	.	PUNCT
ajst-20773	320	1	genomics	genomic	NOUN
ajst-20773	320	2	.	.	PUNCT
ajst-20773	321	1	[	[	X
ajst-20773	321	2	18	18	NUM
ajst-20773	321	3	]	]	X
ajst-20773	321	4	miranda	miranda	NOUN
ajst-20773	321	5	-	-	PUNCT
ajst-20773	321	6	filho	filho	PROPN
ajst-20773	321	7	,	,	PUNCT
ajst-20773	321	8	a.	a.	NOUN
ajst-20773	321	9	,	,	PUNCT
ajst-20773	321	10	piñeros	piñero	NOUN
ajst-20773	321	11	,	,	PUNCT
ajst-20773	321	12	m.	m.	NOUN
ajst-20773	321	13	,	,	PUNCT
ajst-20773	321	14	ferlay	ferlay	NOUN
ajst-20773	321	15	,	,	PUNCT
ajst-20773	321	16	j.	j.	PROPN
ajst-20773	321	17	,	,	PUNCT
ajst-20773	321	18	soerjomataram	soerjomataram	PROPN
ajst-20773	321	19	,	,	PUNCT
ajst-20773	321	20	i.	i.	NOUN
ajst-20773	321	21	,	,	PUNCT
ajst-20773	321	22	monnereau	monnereau	NOUN
ajst-20773	321	23	,	,	PUNCT
ajst-20773	321	24	a.	a.	PROPN
ajst-20773	321	25	,	,	PUNCT
ajst-20773	321	26	&	&	CCONJ
ajst-20773	321	27	bray	bray	PROPN
ajst-20773	321	28	,	,	PUNCT
ajst-20773	321	29	f.	f.	PROPN
ajst-20773	321	30	(	(	PUNCT
ajst-20773	321	31	2019	2019	NUM
ajst-20773	321	32	)	)	PUNCT
ajst-20773	321	33	.	.	PUNCT
ajst-20773	322	1	epidemiology	epidemiology	NOUN
ajst-20773	322	2	and	and	CCONJ
ajst-20773	322	3	patterns	pattern	NOUN
ajst-20773	322	4	of	of	ADP
ajst-20773	322	5	care	care	NOUN
ajst-20773	322	6	for	for	ADP
ajst-20773	322	7	invasive	invasive	ADJ
ajst-20773	322	8	breast	breast	NOUN
ajst-20773	322	9	and	and	CCONJ
ajst-20773	322	10	cervical	cervical	ADJ
ajst-20773	322	11	cancer	cancer	NOUN
ajst-20773	322	12	in	in	ADP
ajst-20773	322	13	57	57	NUM
ajst-20773	322	14	lowand	lowand	ADJ
ajst-20773	322	15	middle	middle	ADJ
ajst-20773	322	16	-	-	PUNCT
ajst-20773	322	17	income	income	NOUN
ajst-20773	322	18	countries	country	NOUN
ajst-20773	322	19	:	:	PUNCT
ajst-20773	322	20	a	a	DET
ajst-20773	322	21	population	population	NOUN
ajst-20773	322	22	-	-	PUNCT
ajst-20773	322	23	based	base	VERB
ajst-20773	322	24	study	study	NOUN
ajst-20773	322	25	.	.	PUNCT
ajst-20773	323	1	the	the	DET
ajst-20773	323	2	lancet	lancet	PROPN
ajst-20773	323	3	global	global	PROPN
ajst-20773	323	4	health	health	NOUN
ajst-20773	323	5	,	,	PUNCT
ajst-20773	323	6	7(7	7(7	NUM
ajst-20773	323	7	)	)	PUNCT
ajst-20773	323	8	,	,	PUNCT
ajst-20773	323	9	e951	e951	PROPN
ajst-20773	323	10	-	-	PUNCT
ajst-20773	323	11	e961	e961	PROPN
ajst-20773	323	12	.	.	PUNCT
ajst-20773	324	1	[	[	X
ajst-20773	324	2	19	19	NUM
ajst-20773	324	3	]	]	X
ajst-20773	324	4	montes	montes	PROPN
ajst-20773	324	5	,	,	PUNCT
ajst-20773	324	6	m.	m.	NOUN
ajst-20773	324	7	,	,	PUNCT
ajst-20773	324	8	lubas	lubas	ADV
ajst-20773	324	9	,	,	PUNCT
ajst-20773	324	10	m.	m.	NOUN
ajst-20773	324	11	,	,	PUNCT
ajst-20773	324	12	arendrup	arendrup	PROPN
ajst-20773	324	13	,	,	PUNCT
ajst-20773	324	14	f.	f.	PROPN
ajst-20773	324	15	s.	s.	PROPN
ajst-20773	324	16	,	,	PUNCT
ajst-20773	324	17	mentz	mentz	PROPN
ajst-20773	324	18	,	,	PUNCT
ajst-20773	324	19	b.	b.	PROPN
ajst-20773	324	20	,	,	PUNCT
ajst-20773	324	21	et	et	PROPN
ajst-20773	324	22	al	al	PROPN
ajst-20773	324	23	.	.	PROPN
ajst-20773	324	24	(	(	PUNCT
ajst-20773	324	25	2021	2021	NUM
ajst-20773	324	26	)	)	PUNCT
ajst-20773	324	27	.	.	PUNCT
ajst-20773	325	1	the	the	DET
ajst-20773	325	2	long	long	ADJ
ajst-20773	325	3	non	non	ADJ
ajst-20773	325	4	-	-	ADJ
ajst-20773	325	5	coding	coding	ADJ
ajst-20773	325	6	rna	rna	NOUN
ajst-20773	325	7	mir31hg	mir31hg	NOUN
ajst-20773	325	8	regulates	regulate	VERB
ajst-20773	325	9	the	the	DET
ajst-20773	325	10	senescence	senescence	NOUN
ajst-20773	325	11	associated	associate	VERB
ajst-20773	325	12	secretory	secretory	ADJ
ajst-20773	325	13	phenotype	phenotype	NOUN
ajst-20773	325	14	.	.	PUNCT
ajst-20773	326	1	nature	nature	NOUN
ajst-20773	326	2	communications	communication	NOUN
ajst-20773	326	3	.	.	PUNCT
ajst-20773	327	1	[	[	X
ajst-20773	327	2	20	20	NUM
ajst-20773	327	3	]	]	X
ajst-20773	327	4	muppa	muppa	ADJ
ajst-20773	327	5	,	,	PUNCT
ajst-20773	327	6	p.	p.	NOUN
ajst-20773	327	7	,	,	PUNCT
ajst-20773	327	8	terra	terra	X
ajst-20773	327	9	,	,	PUNCT
ajst-20773	327	10	s.	s.	PROPN
ajst-20773	327	11	b.	b.	PROPN
ajst-20773	327	12	s.	s.	PROPN
ajst-20773	327	13	p.	p.	PROPN
ajst-20773	327	14	,	,	PUNCT
ajst-20773	327	15	sharma	sharma	PROPN
ajst-20773	327	16	,	,	PUNCT
ajst-20773	327	17	a.	a.	PROPN
ajst-20773	327	18	,	,	PUNCT
ajst-20773	327	19	mansfield	mansfield	PROPN
ajst-20773	327	20	,	,	PUNCT
ajst-20773	327	21	a.	a.	PROPN
ajst-20773	327	22	s.	s.	PROPN
ajst-20773	327	23	,	,	PUNCT
ajst-20773	327	24	et	et	PROPN
ajst-20773	327	25	al	al	PROPN
ajst-20773	327	26	.	.	PROPN
ajst-20773	328	1	(	(	PUNCT
ajst-20773	328	2	2019	2019	NUM
ajst-20773	328	3	)	)	PUNCT
ajst-20773	328	4	.	.	PUNCT
ajst-20773	329	1	immune	immune	ADJ
ajst-20773	329	2	cell	cell	NOUN
ajst-20773	329	3	infiltration	infiltration	NOUN
ajst-20773	329	4	may	may	AUX
ajst-20773	329	5	be	be	AUX
ajst-20773	329	6	a	a	DET
ajst-20773	329	7	key	key	ADJ
ajst-20773	329	8	determinant	determinant	NOUN
ajst-20773	329	9	of	of	ADP
ajst-20773	329	10	long	long	ADJ
ajst-20773	329	11	-	-	PUNCT
ajst-20773	329	12	term	term	NOUN
ajst-20773	329	13	survival	survival	NOUN
ajst-20773	329	14	in	in	ADP
ajst-20773	329	15	small	small	ADJ
ajst-20773	329	16	cell	cell	NOUN
ajst-20773	329	17	lung	lung	NOUN
ajst-20773	329	18	cancer	cancer	NOUN
ajst-20773	329	19	.	.	PUNCT
ajst-20773	330	1	journal	journal	PROPN
ajst-20773	330	2	of	of	ADP
ajst-20773	330	3	thoracic	thoracic	NOUN
ajst-20773	330	4	oncology	oncology	NOUN
ajst-20773	330	5	.	.	PUNCT
ajst-20773	331	1	[	[	X
ajst-20773	331	2	21	21	NUM
ajst-20773	331	3	]	]	X
ajst-20773	331	4	newman	newman	PROPN
ajst-20773	331	5	,	,	PUNCT
ajst-20773	331	6	a.	a.	NOUN
ajst-20773	331	7	m.	m.	NOUN
ajst-20773	331	8	,	,	PUNCT
ajst-20773	331	9	liu	liu	PROPN
ajst-20773	331	10	,	,	PUNCT
ajst-20773	331	11	c.	c.	PROPN
ajst-20773	331	12	l.	l.	PROPN
ajst-20773	331	13	,	,	PUNCT
ajst-20773	331	14	green	green	NOUN
ajst-20773	331	15	,	,	PUNCT
ajst-20773	331	16	m.	m.	NOUN
ajst-20773	331	17	r.	r.	PROPN
ajst-20773	331	18	,	,	PUNCT
ajst-20773	331	19	gentles	gentle	NOUN
ajst-20773	331	20	,	,	PUNCT
ajst-20773	331	21	a.	a.	PROPN
ajst-20773	331	22	j.	j.	PROPN
ajst-20773	331	23	,	,	PUNCT
ajst-20773	331	24	feng	feng	PROPN
ajst-20773	331	25	,	,	PUNCT
ajst-20773	331	26	w.	w.	PROPN
ajst-20773	331	27	,	,	PUNCT
ajst-20773	331	28	xu	xu	PROPN
ajst-20773	331	29	,	,	PUNCT
ajst-20773	331	30	y.	y.	PROPN
ajst-20773	331	31	,	,	PUNCT
ajst-20773	331	32	...	...	PUNCT
ajst-20773	331	33	&	&	CCONJ
ajst-20773	331	34	alizadeh	alizadeh	PROPN
ajst-20773	331	35	,	,	PUNCT
ajst-20773	331	36	a.	a.	NOUN
ajst-20773	331	37	a.	a.	NOUN
ajst-20773	331	38	(	(	PUNCT
ajst-20773	331	39	2015	2015	NUM
ajst-20773	331	40	)	)	PUNCT
ajst-20773	331	41	.	.	PUNCT
ajst-20773	332	1	robust	robust	ADJ
ajst-20773	332	2	enumeration	enumeration	NOUN
ajst-20773	332	3	of	of	ADP
ajst-20773	332	4	cell	cell	NOUN
ajst-20773	332	5	subsets	subset	NOUN
ajst-20773	332	6	from	from	ADP
ajst-20773	332	7	tissue	tissue	NOUN
ajst-20773	332	8	expression	expression	NOUN
ajst-20773	332	9	profiles	profile	NOUN
ajst-20773	332	10	.	.	PUNCT
ajst-20773	333	1	nature	nature	NOUN
ajst-20773	333	2	methods	method	NOUN
ajst-20773	333	3	,	,	PUNCT
ajst-20773	333	4	12(5	12(5	NUM
ajst-20773	333	5	)	)	PUNCT
ajst-20773	333	6	,	,	PUNCT
ajst-20773	333	7	453	453	NUM
ajst-20773	333	8	-	-	SYM
ajst-20773	333	9	457	457	NUM
ajst-20773	333	10	.	.	PUNCT
ajst-20773	334	1	[	[	X
ajst-20773	334	2	22	22	NUM
ajst-20773	334	3	]	]	X
ajst-20773	334	4	peng	peng	PROPN
ajst-20773	334	5	,	,	PUNCT
ajst-20773	334	6	c.	c.	PROPN
ajst-20773	334	7	,	,	PUNCT
ajst-20773	334	8	hu	hu	PROPN
ajst-20773	334	9	,	,	PUNCT
ajst-20773	334	10	w.	w.	PROPN
ajst-20773	334	11	,	,	PUNCT
ajst-20773	334	12	weng	weng	PROPN
ajst-20773	334	13	,	,	PUNCT
ajst-20773	334	14	x.	x.	PROPN
ajst-20773	334	15	,	,	PUNCT
ajst-20773	334	16	tong	tong	PROPN
ajst-20773	334	17	,	,	PUNCT
ajst-20773	334	18	r.	r.	PROPN
ajst-20773	334	19	,	,	PUNCT
ajst-20773	334	20	cheng	cheng	PROPN
ajst-20773	334	21	,	,	PUNCT
ajst-20773	334	22	s.	s.	PROPN
ajst-20773	334	23	,	,	PUNCT
ajst-20773	334	24	ding	ding	NOUN
ajst-20773	334	25	,	,	PUNCT
ajst-20773	334	26	c.	c.	PROPN
ajst-20773	334	27	,	,	PUNCT
ajst-20773	334	28	et	et	PROPN
ajst-20773	334	29	al	al	PROPN
ajst-20773	334	30	.	.	PUNCT
ajst-20773	335	1	(	(	PUNCT
ajst-20773	335	2	2017	2017	NUM
ajst-20773	335	3	)	)	PUNCT
ajst-20773	335	4	.	.	PUNCT
ajst-20773	336	1	over	over	ADP
ajst-20773	336	2	expression	expression	NOUN
ajst-20773	336	3	of	of	ADP
ajst-20773	336	4	long	long	ADJ
ajst-20773	336	5	non	non	ADJ
ajst-20773	336	6	-	-	ADJ
ajst-20773	336	7	coding	coding	ADJ
ajst-20773	336	8	rna	rna	NOUN
ajst-20773	336	9	panda	panda	NOUN
ajst-20773	336	10	promotes	promote	VERB
ajst-20773	336	11	hepatocellular	hepatocellular	ADJ
ajst-20773	336	12	carcinoma	carcinoma	NOUN
ajst-20773	336	13	by	by	ADP
ajst-20773	336	14	inhibiting	inhibit	VERB
ajst-20773	336	15	senescence	senescence	NOUN
ajst-20773	336	16	associated	associate	VERB
ajst-20773	336	17	inflammatory	inflammatory	ADJ
ajst-20773	336	18	factor	factor	NOUN
ajst-20773	336	19	il8	il8	PROPN
ajst-20773	336	20	.	.	PUNCT
ajst-20773	337	1	scientific	scientific	ADJ
ajst-20773	337	2	reports	report	NOUN
ajst-20773	337	3	.	.	PUNCT
ajst-20773	338	1	[	[	X
ajst-20773	338	2	23	23	NUM
ajst-20773	338	3	]	]	X
ajst-20773	338	4	peng	peng	PROPN
ajst-20773	338	5	,	,	PUNCT
ajst-20773	338	6	h.	h.	PROPN
ajst-20773	338	7	,	,	PUNCT
ajst-20773	338	8	wu	wu	PROPN
ajst-20773	338	9	,	,	PUNCT
ajst-20773	338	10	x.	x.	PROPN
ajst-20773	338	11	,	,	PUNCT
ajst-20773	338	12	zhong	zhong	PROPN
ajst-20773	338	13	,	,	PUNCT
ajst-20773	338	14	r.	r.	PROPN
ajst-20773	338	15	,	,	PUNCT
ajst-20773	338	16	yu	yu	PROPN
ajst-20773	338	17	,	,	PUNCT
ajst-20773	338	18	t.	t.	PROPN
ajst-20773	338	19	,	,	PUNCT
ajst-20773	338	20	cai	cai	PROPN
ajst-20773	338	21	,	,	PUNCT
ajst-20773	338	22	x.	x.	PROPN
ajst-20773	338	23	,	,	PUNCT
ajst-20773	338	24	liu	liu	PROPN
ajst-20773	338	25	,	,	PUNCT
ajst-20773	338	26	j.	j.	PROPN
ajst-20773	338	27	,	,	PUNCT
ajst-20773	338	28	et	et	PROPN
ajst-20773	338	29	al	al	PROPN
ajst-20773	338	30	.	.	PROPN
ajst-20773	338	31	(	(	PUNCT
ajst-20773	338	32	2021	2021	NUM
ajst-20773	338	33	)	)	PUNCT
ajst-20773	338	34	.	.	PUNCT
ajst-20773	339	1	profiling	profile	VERB
ajst-20773	339	2	tumor	tumor	NOUN
ajst-20773	339	3	immune	immune	ADJ
ajst-20773	339	4	microenvironment	microenvironment	NOUN
ajst-20773	339	5	of	of	ADP
ajst-20773	339	6	nonsmall	nonsmall	NOUN
ajst-20773	339	7	cell	cell	NOUN
ajst-20773	339	8	lung	lung	NOUN
ajst-20773	339	9	cancer	cancer	NOUN
ajst-20773	339	10	using	use	VERB
ajst-20773	339	11	multiplex	multiplex	PROPN
ajst-20773	339	12	immunofluorescence	immunofluorescence	NOUN
ajst-20773	339	13	.	.	PUNCT
ajst-20773	340	1	frontiers	frontier	NOUN
ajst-20773	340	2	in	in	ADP
ajst-20773	340	3	immunology	immunology	NOUN
ajst-20773	340	4	.	.	PUNCT
ajst-20773	341	1	[	[	X
ajst-20773	341	2	24	24	NUM
ajst-20773	341	3	]	]	PUNCT
ajst-20773	341	4	pennock	pennock	NOUN
ajst-20773	341	5	,	,	PUNCT
ajst-20773	341	6	g.	g.	PROPN
ajst-20773	341	7	k.	k.	PROPN
ajst-20773	341	8	,	,	PUNCT
ajst-20773	341	9	chow	chow	PROPN
ajst-20773	341	10	,	,	PUNCT
ajst-20773	341	11	l.	l.	PROPN
ajst-20773	341	12	q.	q.	PROPN
ajst-20773	341	13	m.	m.	PROPN
ajst-20773	341	14	(	(	PUNCT
ajst-20773	341	15	2015	2015	NUM
ajst-20773	341	16	)	)	PUNCT
ajst-20773	341	17	.	.	PUNCT
ajst-20773	342	1	the	the	DET
ajst-20773	342	2	evolving	evolve	VERB
ajst-20773	342	3	role	role	NOUN
ajst-20773	342	4	of	of	ADP
ajst-20773	342	5	immune	immune	ADJ
ajst-20773	342	6	checkpoint	checkpoint	NOUN
ajst-20773	342	7	inhibitors	inhibitor	NOUN
ajst-20773	342	8	in	in	ADP
ajst-20773	342	9	cancer	cancer	NOUN
ajst-20773	342	10	treatment	treatment	NOUN
ajst-20773	342	11	.	.	PUNCT
ajst-20773	343	1	the	the	DET
ajst-20773	343	2	oncologist	oncologist	NOUN
ajst-20773	343	3	.	.	PUNCT
ajst-20773	344	1	[	[	X
ajst-20773	344	2	25	25	NUM
ajst-20773	344	3	]	]	X
ajst-20773	344	4	rooney	rooney	NOUN
ajst-20773	344	5	,	,	PUNCT
ajst-20773	344	6	m.	m.	NOUN
ajst-20773	344	7	s.	s.	PROPN
ajst-20773	344	8	,	,	PUNCT
ajst-20773	344	9	shukla	shukla	PROPN
ajst-20773	344	10	,	,	PUNCT
ajst-20773	344	11	s.	s.	PROPN
ajst-20773	344	12	a.	a.	PROPN
ajst-20773	344	13	,	,	PUNCT
ajst-20773	344	14	wu	wu	PROPN
ajst-20773	344	15	,	,	PUNCT
ajst-20773	344	16	c.	c.	PROPN
ajst-20773	344	17	j.	j.	PROPN
ajst-20773	344	18	,	,	PUNCT
ajst-20773	344	19	getz	getz	PROPN
ajst-20773	344	20	,	,	PUNCT
ajst-20773	344	21	g.	g.	PROPN
ajst-20773	344	22	,	,	PUNCT
ajst-20773	344	23	&	&	CCONJ
ajst-20773	344	24	hacohen	hacohen	PROPN
ajst-20773	344	25	,	,	PUNCT
ajst-20773	344	26	n.	n.	PROPN
ajst-20773	344	27	(	(	PUNCT
ajst-20773	344	28	2015	2015	NUM
ajst-20773	344	29	)	)	PUNCT
ajst-20773	344	30	.	.	PUNCT
ajst-20773	345	1	molecular	molecular	ADJ
ajst-20773	345	2	and	and	CCONJ
ajst-20773	345	3	genetic	genetic	ADJ
ajst-20773	345	4	properties	property	NOUN
ajst-20773	345	5	of	of	ADP
ajst-20773	345	6	tumors	tumor	NOUN
ajst-20773	345	7	associated	associate	VERB
ajst-20773	345	8	with	with	ADP
ajst-20773	345	9	local	local	ADJ
ajst-20773	345	10	immune	immune	ADJ
ajst-20773	345	11	cytolytic	cytolytic	ADJ
ajst-20773	345	12	activity	activity	NOUN
ajst-20773	345	13	.	.	PUNCT
ajst-20773	346	1	cell	cell	NOUN
ajst-20773	346	2	,	,	PUNCT
ajst-20773	346	3	160(1	160(1	NUM
ajst-20773	346	4	-	-	SYM
ajst-20773	346	5	2	2	NUM
ajst-20773	346	6	)	)	PUNCT
ajst-20773	346	7	,	,	PUNCT
ajst-20773	346	8	48	48	NUM
ajst-20773	346	9	-	-	SYM
ajst-20773	346	10	61	61	NUM
ajst-20773	346	11	.	.	PUNCT
ajst-20773	347	1	[	[	X
ajst-20773	347	2	26	26	NUM
ajst-20773	347	3	]	]	X
ajst-20773	347	4	schosserer	schosserer	NOUN
ajst-20773	347	5	,	,	PUNCT
ajst-20773	347	6	m.	m.	NOUN
ajst-20773	347	7	,	,	PUNCT
ajst-20773	347	8	grillari	grillari	PROPN
ajst-20773	347	9	,	,	PUNCT
ajst-20773	347	10	j.	j.	PROPN
ajst-20773	347	11	,	,	PUNCT
ajst-20773	347	12	&	&	CCONJ
ajst-20773	347	13	breitenbach	breitenbach	PROPN
ajst-20773	347	14	,	,	PUNCT
ajst-20773	347	15	m.	m.	NOUN
ajst-20773	347	16	(	(	PUNCT
ajst-20773	347	17	2017	2017	NUM
ajst-20773	347	18	)	)	PUNCT
ajst-20773	347	19	.	.	PUNCT
ajst-20773	348	1	the	the	DET
ajst-20773	348	2	dual	dual	ADJ
ajst-20773	348	3	role	role	NOUN
ajst-20773	348	4	of	of	ADP
ajst-20773	348	5	cellular	cellular	ADJ
ajst-20773	348	6	senescence	senescence	NOUN
ajst-20773	348	7	in	in	ADP
ajst-20773	348	8	developing	develop	VERB
ajst-20773	348	9	tumors	tumor	NOUN
ajst-20773	348	10	and	and	CCONJ
ajst-20773	348	11	their	their	PRON
ajst-20773	348	12	response	response	NOUN
ajst-20773	348	13	to	to	ADP
ajst-20773	348	14	cancer	cancer	NOUN
ajst-20773	348	15	therapy	therapy	NOUN
ajst-20773	348	16	.	.	PUNCT
ajst-20773	349	1	frontiers	frontier	NOUN
ajst-20773	349	2	in	in	ADP
ajst-20773	349	3	oncology	oncology	NOUN
ajst-20773	349	4	,	,	PUNCT
ajst-20773	349	5	7	7	NUM
ajst-20773	349	6	,	,	PUNCT
ajst-20773	349	7	278	278	NUM
ajst-20773	349	8	.	.	PUNCT
ajst-20773	350	1	[	[	X
ajst-20773	350	2	27	27	NUM
ajst-20773	350	3	]	]	SYM
ajst-20773	350	4	serviss	serviss	NOUN
ajst-20773	350	5	,	,	PUNCT
ajst-20773	350	6	j.	j.	PROPN
ajst-20773	350	7	t.	t.	PROPN
ajst-20773	350	8	,	,	PUNCT
ajst-20773	350	9	johnsson	johnsson	PROPN
ajst-20773	350	10	,	,	PUNCT
ajst-20773	350	11	p.	p.	PROPN
ajst-20773	350	12	,	,	PUNCT
ajst-20773	350	13	&	&	CCONJ
ajst-20773	350	14	grandér	grandér	PROPN
ajst-20773	350	15	,	,	PUNCT
ajst-20773	350	16	d.	d.	PROPN
ajst-20773	350	17	(	(	PUNCT
ajst-20773	350	18	2014	2014	NUM
ajst-20773	350	19	)	)	PUNCT
ajst-20773	350	20	.	.	PUNCT
ajst-20773	351	1	an	an	DET
ajst-20773	351	2	emerging	emerge	VERB
ajst-20773	351	3	role	role	NOUN
ajst-20773	351	4	for	for	ADP
ajst-20773	351	5	long	long	ADJ
ajst-20773	351	6	non	non	ADJ
ajst-20773	351	7	-	-	ADJ
ajst-20773	351	8	coding	coding	ADJ
ajst-20773	351	9	rnas	rna	NOUN
ajst-20773	351	10	in	in	ADP
ajst-20773	351	11	cancer	cancer	NOUN
ajst-20773	351	12	metastasis	metastasis	NOUN
ajst-20773	351	13	.	.	PUNCT
ajst-20773	352	1	frontiers	frontier	NOUN
ajst-20773	352	2	in	in	ADP
ajst-20773	352	3	genetics	genetic	NOUN
ajst-20773	352	4	,	,	PUNCT
ajst-20773	352	5	5	5	NUM
ajst-20773	352	6	,	,	PUNCT
ajst-20773	352	7	234	234	NUM
ajst-20773	352	8	.	.	PUNCT
ajst-20773	353	1	[	[	X
ajst-20773	353	2	28	28	NUM
ajst-20773	353	3	]	]	X
ajst-20773	353	4	shi	shi	PROPN
ajst-20773	353	5	,	,	PUNCT
ajst-20773	353	6	l.	l.	PROPN
ajst-20773	353	7	,	,	PUNCT
ajst-20773	353	8	ginn	ginn	PROPN
ajst-20773	353	9	,	,	PUNCT
ajst-20773	353	10	l.	l.	PROPN
ajst-20773	353	11	,	,	PUNCT
ajst-20773	353	12	la	la	PROPN
ajst-20773	353	13	montagna	montagna	PROPN
ajst-20773	353	14	,	,	PUNCT
ajst-20773	353	15	m.	m.	NOUN
ajst-20773	353	16	,	,	PUNCT
ajst-20773	353	17	&	&	CCONJ
ajst-20773	353	18	garofalo	garofalo	PROPN
ajst-20773	353	19	,	,	PUNCT
ajst-20773	353	20	m.	m.	NOUN
ajst-20773	353	21	(	(	PUNCT
ajst-20773	353	22	2020	2020	NUM
ajst-20773	353	23	)	)	PUNCT
ajst-20773	353	24	.	.	PUNCT
ajst-20773	354	1	lncrnas	lncrnas	PROPN
ajst-20773	354	2	in	in	ADP
ajst-20773	354	3	non	non	ADJ
ajst-20773	354	4	-	-	ADJ
ajst-20773	354	5	small	small	ADJ
ajst-20773	354	6	-	-	PUNCT
ajst-20773	354	7	cell	cell	NOUN
ajst-20773	354	8	lung	lung	NOUN
ajst-20773	354	9	cancer	cancer	NOUN
ajst-20773	354	10	.	.	PUNCT
ajst-20773	355	1	non	non	ADJ
ajst-20773	355	2	-	-	ADJ
ajst-20773	355	3	coding	code	VERB
ajst-20773	355	4	rna	rna	NOUN
ajst-20773	355	5	,	,	PUNCT
ajst-20773	355	6	6(3	6(3	NUM
ajst-20773	355	7	)	)	PUNCT
ajst-20773	355	8	,	,	PUNCT
ajst-20773	355	9	25	25	NUM
ajst-20773	355	10	.	.	PUNCT
ajst-20773	356	1	[	[	X
ajst-20773	356	2	29	29	NUM
ajst-20773	356	3	]	]	X
ajst-20773	356	4	shiravand	shiravand	NOUN
ajst-20773	356	5	,	,	PUNCT
ajst-20773	356	6	y.	y.	PROPN
ajst-20773	356	7	,	,	PUNCT
ajst-20773	356	8	khodadadi	khodadadi	PROPN
ajst-20773	356	9	,	,	PUNCT
ajst-20773	356	10	f.	f.	PROPN
ajst-20773	356	11	,	,	PUNCT
ajst-20773	356	12	kashani	kashani	PROPN
ajst-20773	356	13	,	,	PUNCT
ajst-20773	356	14	s.m.a	s.m.a	PROPN
ajst-20773	356	15	.	.	PUNCT
ajst-20773	356	16	(	(	PUNCT
ajst-20773	356	17	2022	2022	NUM
ajst-20773	356	18	)	)	PUNCT
ajst-20773	356	19	.	.	PUNCT
ajst-20773	357	1	immune	immune	ADJ
ajst-20773	357	2	checkpoint	checkpoint	NOUN
ajst-20773	357	3	inhibitors	inhibitor	NOUN
ajst-20773	357	4	in	in	ADP
ajst-20773	357	5	cancer	cancer	NOUN
ajst-20773	357	6	therapy	therapy	NOUN
ajst-20773	357	7	.	.	PUNCT
ajst-20773	358	1	current	current	ADJ
ajst-20773	358	2	oncology	oncology	NOUN
ajst-20773	358	3	reports	report	VERB
ajst-20773	358	4	.	.	PUNCT
ajst-20773	359	1	[	[	X
ajst-20773	359	2	30	30	NUM
ajst-20773	359	3	]	]	X
ajst-20773	359	4	silva	silva	PROPN
ajst-20773	359	5	,	,	PUNCT
ajst-20773	359	6	a.	a.	NOUN
ajst-20773	359	7	,	,	PUNCT
ajst-20773	359	8	bullock	bullock	NOUN
ajst-20773	359	9	,	,	PUNCT
ajst-20773	359	10	m.	m.	NOUN
ajst-20773	359	11	,	,	PUNCT
ajst-20773	359	12	&	&	CCONJ
ajst-20773	359	13	calin	calin	PROPN
ajst-20773	359	14	,	,	PUNCT
ajst-20773	359	15	g.	g.	PROPN
ajst-20773	359	16	(	(	PUNCT
ajst-20773	359	17	2015	2015	NUM
ajst-20773	359	18	)	)	PUNCT
ajst-20773	359	19	.	.	PUNCT
ajst-20773	360	1	the	the	DET
ajst-20773	360	2	clinical	clinical	ADJ
ajst-20773	360	3	relevance	relevance	NOUN
ajst-20773	360	4	of	of	ADP
ajst-20773	360	5	long	long	ADJ
ajst-20773	360	6	non	non	ADJ
ajst-20773	360	7	-	-	ADJ
ajst-20773	360	8	coding	coding	ADJ
ajst-20773	360	9	rnas	rna	NOUN
ajst-20773	360	10	in	in	ADP
ajst-20773	360	11	cancer	cancer	NOUN
ajst-20773	360	12	.	.	PUNCT
ajst-20773	361	1	cancers	cancer	NOUN
ajst-20773	361	2	,	,	PUNCT
ajst-20773	361	3	7(4	7(4	NUM
ajst-20773	361	4	)	)	PUNCT
ajst-20773	361	5	,	,	PUNCT
ajst-20773	361	6	884	884	NUM
ajst-20773	361	7	.	.	PUNCT
ajst-20773	362	1	[	[	X
ajst-20773	362	2	31	31	NUM
ajst-20773	362	3	]	]	PUNCT
ajst-20773	362	4	tang	tang	NOUN
ajst-20773	362	5	,	,	PUNCT
ajst-20773	362	6	p.	p.	NOUN
ajst-20773	362	7	,	,	PUNCT
ajst-20773	362	8	qu	qu	PROPN
ajst-20773	362	9	,	,	PUNCT
ajst-20773	362	10	w.	w.	PROPN
ajst-20773	362	11	,	,	PUNCT
ajst-20773	362	12	wang	wang	PROPN
ajst-20773	362	13	,	,	PUNCT
ajst-20773	362	14	t.	t.	PROPN
ajst-20773	362	15	,	,	PUNCT
ajst-20773	362	16	liu	liu	PROPN
ajst-20773	362	17	,	,	PUNCT
ajst-20773	362	18	m.	m.	NOUN
ajst-20773	362	19	,	,	PUNCT
ajst-20773	362	20	wu	wu	PROPN
ajst-20773	362	21	,	,	PUNCT
ajst-20773	362	22	d.	d.	PROPN
ajst-20773	362	23	,	,	PUNCT
ajst-20773	362	24	&	&	CCONJ
ajst-20773	362	25	tan	tan	PROPN
ajst-20773	362	26	,	,	PUNCT
ajst-20773	362	27	l.	l.	PROPN
ajst-20773	362	28	(	(	PUNCT
ajst-20773	362	29	2021	2021	NUM
ajst-20773	362	30	)	)	PUNCT
ajst-20773	362	31	.	.	PUNCT
ajst-20773	363	1	identifying	identify	VERB
ajst-20773	363	2	a	a	DET
ajst-20773	363	3	hypoxia	hypoxia	NOUN
ajst-20773	363	4	-	-	PUNCT
ajst-20773	363	5	related	relate	VERB
ajst-20773	363	6	long	long	ADJ
ajst-20773	363	7	non	non	ADJ
ajst-20773	363	8	-	-	ADJ
ajst-20773	363	9	coding	coding	ADJ
ajst-20773	363	10	rnas	rna	NOUN
ajst-20773	363	11	signature	signature	NOUN
ajst-20773	363	12	to	to	PART
ajst-20773	363	13	improve	improve	VERB
ajst-20773	363	14	the	the	DET
ajst-20773	363	15	prediction	prediction	NOUN
ajst-20773	363	16	of	of	ADP
ajst-20773	363	17	prognosis	prognosis	NOUN
ajst-20773	363	18	and	and	CCONJ
ajst-20773	363	19	immunotherapy	immunotherapy	NOUN
ajst-20773	363	20	response	response	NOUN
ajst-20773	363	21	in	in	ADP
ajst-20773	363	22	hepatocellular	hepatocellular	ADJ
ajst-20773	363	23	carcinoma	carcinoma	NOUN
ajst-20773	363	24	.	.	PUNCT
ajst-20773	364	1	frontiers	frontier	NOUN
ajst-20773	364	2	in	in	ADP
ajst-20773	364	3	genetics	genetic	NOUN
ajst-20773	364	4	,	,	PUNCT
ajst-20773	364	5	12	12	NUM
ajst-20773	364	6	,	,	PUNCT
ajst-20773	364	7	785185	785185	NUM
ajst-20773	364	8	.	.	PUNCT
ajst-20773	365	1	[	[	X
ajst-20773	365	2	32	32	NUM
ajst-20773	365	3	]	]	SYM
ajst-20773	365	4	topalian	topalian	NOUN
ajst-20773	365	5	,	,	PUNCT
ajst-20773	365	6	s.	s.	PROPN
ajst-20773	365	7	l.	l.	PROPN
ajst-20773	365	8	,	,	PUNCT
ajst-20773	365	9	taube	taube	PROPN
ajst-20773	365	10	,	,	PUNCT
ajst-20773	365	11	j.	j.	PROPN
ajst-20773	365	12	m.	m.	PROPN
ajst-20773	365	13	,	,	PUNCT
ajst-20773	365	14	anders	ander	NOUN
ajst-20773	365	15	,	,	PUNCT
ajst-20773	365	16	r.	r.	PROPN
ajst-20773	365	17	a.	a.	PROPN
ajst-20773	365	18	,	,	PUNCT
ajst-20773	365	19	et	et	PROPN
ajst-20773	365	20	al	al	PROPN
ajst-20773	365	21	.	.	PUNCT
ajst-20773	366	1	(	(	PUNCT
ajst-20773	366	2	2016	2016	NUM
ajst-20773	366	3	)	)	PUNCT
ajst-20773	366	4	.	.	PUNCT
ajst-20773	367	1	mechanism	mechanism	NOUN
ajst-20773	367	2	-	-	PUNCT
ajst-20773	367	3	driven	drive	VERB
ajst-20773	367	4	biomarkers	biomarker	NOUN
ajst-20773	367	5	to	to	PART
ajst-20773	367	6	guide	guide	VERB
ajst-20773	367	7	immune	immune	ADJ
ajst-20773	367	8	checkpoint	checkpoint	NOUN
ajst-20773	367	9	blockade	blockade	NOUN
ajst-20773	367	10	in	in	ADP
ajst-20773	367	11	cancer	cancer	NOUN
ajst-20773	367	12	therapy	therapy	NOUN
ajst-20773	367	13	.	.	PUNCT
ajst-20773	368	1	nature	nature	NOUN
ajst-20773	368	2	reviews	review	VERB
ajst-20773	368	3	cancer	cancer	NOUN
ajst-20773	368	4	.	.	PUNCT
ajst-20773	369	1	[	[	X
ajst-20773	369	2	33	33	NUM
ajst-20773	369	3	]	]	X
ajst-20773	369	4	twomey	twomey	NOUN
ajst-20773	369	5	,	,	PUNCT
ajst-20773	369	6	j.d	j.d	PROPN
ajst-20773	369	7	.	.	PROPN
ajst-20773	369	8	,	,	PUNCT
ajst-20773	369	9	zhang	zhang	PROPN
ajst-20773	369	10	,	,	PUNCT
ajst-20773	369	11	b.	b.	PROPN
ajst-20773	369	12	(	(	PUNCT
ajst-20773	369	13	2021	2021	NUM
ajst-20773	369	14	)	)	PUNCT
ajst-20773	369	15	.	.	PUNCT
ajst-20773	370	1	cancer	cancer	NOUN
ajst-20773	370	2	immunotherapy	immunotherapy	NOUN
ajst-20773	370	3	update	update	NOUN
ajst-20773	370	4	:	:	PUNCT
ajst-20773	370	5	fda	fda	PROPN
ajst-20773	370	6	-	-	PUNCT
ajst-20773	370	7	approved	approve	VERB
ajst-20773	370	8	checkpoint	checkpoint	NOUN
ajst-20773	370	9	inhibitors	inhibitor	NOUN
ajst-20773	370	10	and	and	CCONJ
ajst-20773	370	11	companion	companion	NOUN
ajst-20773	370	12	diagnostics	diagnostic	NOUN
ajst-20773	370	13	.	.	PUNCT
ajst-20773	371	1	the	the	DET
ajst-20773	371	2	aaps	aaps	PROPN
ajst-20773	371	3	journal	journal	NOUN
ajst-20773	371	4	.	.	PUNCT
ajst-20773	372	1	[	[	X
ajst-20773	372	2	34	34	NUM
ajst-20773	372	3	]	]	SYM
ajst-20773	372	4	wagner	wagner	PROPN
ajst-20773	372	5	,	,	PUNCT
ajst-20773	372	6	m.	m.	NOUN
ajst-20773	372	7	,	,	PUNCT
ajst-20773	372	8	jasek	jasek	PROPN
ajst-20773	372	9	,	,	PUNCT
ajst-20773	372	10	m.	m.	NOUN
ajst-20773	372	11	,	,	PUNCT
ajst-20773	372	12	karabon	karabon	PROPN
ajst-20773	372	13	,	,	PUNCT
ajst-20773	372	14	l.	l.	PROPN
ajst-20773	372	15	(	(	PUNCT
ajst-20773	372	16	2021	2021	NUM
ajst-20773	372	17	)	)	PUNCT
ajst-20773	372	18	.	.	PUNCT
ajst-20773	373	1	immune	immune	ADJ
ajst-20773	373	2	checkpoint	checkpoint	NOUN
ajst-20773	373	3	molecules	molecule	NOUN
ajst-20773	373	4	—	—	PUNCT
ajst-20773	373	5	inherited	inherit	VERB
ajst-20773	373	6	variations	variation	NOUN
ajst-20773	373	7	as	as	ADP
ajst-20773	373	8	markers	marker	NOUN
ajst-20773	373	9	for	for	ADP
ajst-20773	373	10	cancer	cancer	NOUN
ajst-20773	373	11	risk	risk	NOUN
ajst-20773	373	12	.	.	PUNCT
ajst-20773	374	1	frontiers	frontier	NOUN
ajst-20773	374	2	in	in	ADP
ajst-20773	374	3	immunology	immunology	NOUN
ajst-20773	374	4	.	.	PUNCT
ajst-20773	375	1	[	[	X
ajst-20773	375	2	35	35	NUM
ajst-20773	375	3	]	]	X
ajst-20773	375	4	wei	wei	PROPN
ajst-20773	375	5	,	,	PUNCT
ajst-20773	375	6	s.	s.	PROPN
ajst-20773	375	7	c.	c.	PROPN
ajst-20773	375	8	,	,	PUNCT
ajst-20773	375	9	duffy	duffy	PROPN
ajst-20773	375	10	,	,	PUNCT
ajst-20773	375	11	c.	c.	PROPN
ajst-20773	375	12	r.	r.	PROPN
ajst-20773	375	13	,	,	PUNCT
ajst-20773	375	14	allison	allison	PROPN
ajst-20773	375	15	,	,	PUNCT
ajst-20773	375	16	j.	j.	PROPN
ajst-20773	375	17	p.	p.	PROPN
ajst-20773	375	18	(	(	PUNCT
ajst-20773	375	19	2018	2018	NUM
ajst-20773	375	20	)	)	PUNCT
ajst-20773	375	21	.	.	PUNCT
ajst-20773	376	1	fundamental	fundamental	ADJ
ajst-20773	376	2	mechanisms	mechanism	NOUN
ajst-20773	376	3	of	of	ADP
ajst-20773	376	4	immune	immune	ADJ
ajst-20773	376	5	checkpoint	checkpoint	NOUN
ajst-20773	376	6	blockade	blockade	NOUN
ajst-20773	376	7	therapy	therapy	NOUN
ajst-20773	376	8	.	.	PUNCT
ajst-20773	377	1	cancer	cancer	NOUN
ajst-20773	377	2	discovery	discovery	NOUN
ajst-20773	377	3	.	.	PUNCT
ajst-20773	378	1	[	[	X
ajst-20773	378	2	36	36	NUM
ajst-20773	378	3	]	]	X
ajst-20773	378	4	wen	wen	PROPN
ajst-20773	378	5	,	,	PUNCT
ajst-20773	378	6	s.	s.	PROPN
ajst-20773	378	7	,	,	PUNCT
ajst-20773	378	8	peng	peng	PROPN
ajst-20773	378	9	,	,	PUNCT
ajst-20773	378	10	w.	w.	PROPN
ajst-20773	378	11	,	,	PUNCT
ajst-20773	378	12	chen	chen	PROPN
ajst-20773	378	13	,	,	PUNCT
ajst-20773	378	14	y.	y.	PROPN
ajst-20773	378	15	,	,	PUNCT
ajst-20773	378	16	du	du	PROPN
ajst-20773	378	17	,	,	PUNCT
ajst-20773	378	18	x.	x.	PROPN
ajst-20773	378	19	,	,	PUNCT
ajst-20773	378	20	xia	xia	PROPN
ajst-20773	378	21	,	,	PUNCT
ajst-20773	378	22	j.	j.	PROPN
ajst-20773	378	23	,	,	PUNCT
ajst-20773	378	24	shen	shen	PROPN
ajst-20773	378	25	,	,	PUNCT
ajst-20773	378	26	b.	b.	PROPN
ajst-20773	378	27	,	,	PUNCT
ajst-20773	378	28	zhou	zhou	PROPN
ajst-20773	378	29	,	,	PUNCT
ajst-20773	378	30	g.	g.	PROPN
ajst-20773	378	31	(	(	PUNCT
ajst-20773	378	32	2022	2022	NUM
ajst-20773	378	33	)	)	PUNCT
ajst-20773	378	34	.	.	PUNCT
ajst-20773	379	1	four	four	NUM
ajst-20773	379	2	differentially	differentially	ADV
ajst-20773	379	3	expressed	express	VERB
ajst-20773	379	4	genes	gene	NOUN
ajst-20773	379	5	can	can	AUX
ajst-20773	379	6	predict	predict	VERB
ajst-20773	379	7	prognosis	prognosis	NOUN
ajst-20773	379	8	and	and	CCONJ
ajst-20773	379	9	microenvironment	microenvironment	ADJ
ajst-20773	379	10	immune	immune	ADJ
ajst-20773	379	11	infiltration	infiltration	NOUN
ajst-20773	379	12	in	in	ADP
ajst-20773	379	13	lung	lung	NOUN
ajst-20773	379	14	cancer	cancer	NOUN
ajst-20773	379	15	:	:	PUNCT
ajst-20773	379	16	a	a	DET
ajst-20773	379	17	study	study	NOUN
ajst-20773	379	18	based	base	VERB
ajst-20773	379	19	on	on	ADP
ajst-20773	379	20	data	datum	NOUN
ajst-20773	379	21	from	from	ADP
ajst-20773	379	22	the	the	DET
ajst-20773	379	23	geo	geo	PROPN
ajst-20773	379	24	.	.	PROPN
ajst-20773	379	25	bmc	bmc	PROPN
ajst-20773	379	26	cancer	cancer	NOUN
ajst-20773	379	27	.	.	PUNCT
ajst-20773	380	1	[	[	X
ajst-20773	380	2	37	37	NUM
ajst-20773	380	3	]	]	X
ajst-20773	380	4	west	west	PROPN
ajst-20773	380	5	,	,	PUNCT
ajst-20773	380	6	l.	l.	PROPN
ajst-20773	380	7	,	,	PUNCT
ajst-20773	380	8	vidwans	vidwan	NOUN
ajst-20773	380	9	,	,	PUNCT
ajst-20773	380	10	s.	s.	PROPN
ajst-20773	380	11	j.	j.	PROPN
ajst-20773	380	12	,	,	PUNCT
ajst-20773	380	13	campbell	campbell	PROPN
ajst-20773	380	14	,	,	PUNCT
ajst-20773	380	15	n.	n.	PROPN
ajst-20773	380	16	p.	p.	PROPN
ajst-20773	380	17	,	,	PUNCT
ajst-20773	380	18	shrager	shrager	NOUN
ajst-20773	380	19	,	,	PUNCT
ajst-20773	380	20	j.	j.	PROPN
ajst-20773	380	21	,	,	PUNCT
ajst-20773	380	22	simon	simon	PROPN
ajst-20773	380	23	,	,	PUNCT
ajst-20773	380	24	g.	g.	PROPN
ajst-20773	380	25	r.	r.	PROPN
ajst-20773	380	26	,	,	PUNCT
ajst-20773	380	27	bueno	bueno	PROPN
ajst-20773	380	28	,	,	PUNCT
ajst-20773	380	29	r.	r.	PROPN
ajst-20773	380	30	,	,	PUNCT
ajst-20773	380	31	...	...	PUNCT
ajst-20773	380	32	&	&	CCONJ
ajst-20773	380	33	chen	chen	PROPN
ajst-20773	380	34	,	,	PUNCT
ajst-20773	380	35	h.	h.	PROPN
ajst-20773	380	36	(	(	PUNCT
ajst-20773	380	37	2012	2012	NUM
ajst-20773	380	38	)	)	PUNCT
ajst-20773	380	39	.	.	PUNCT
ajst-20773	381	1	a	a	DET
ajst-20773	381	2	novel	novel	ADJ
ajst-20773	381	3	classification	classification	NOUN
ajst-20773	381	4	of	of	ADP
ajst-20773	381	5	lung	lung	NOUN
ajst-20773	381	6	cancer	cancer	NOUN
ajst-20773	381	7	into	into	ADP
ajst-20773	381	8	molecular	molecular	ADJ
ajst-20773	381	9	subtypes	subtype	NOUN
ajst-20773	381	10	.	.	PUNCT
ajst-20773	382	1	plos	plos	PROPN
ajst-20773	382	2	one	one	NUM
ajst-20773	382	3	,	,	PUNCT
ajst-20773	382	4	7(2	7(2	NUM
ajst-20773	382	5	)	)	PUNCT
ajst-20773	382	6	,	,	PUNCT
ajst-20773	382	7	e31906	e31906	PROPN
ajst-20773	382	8	.	.	PUNCT
ajst-20773	383	1	[	[	X
ajst-20773	383	2	38	38	NUM
ajst-20773	383	3	]	]	SYM
ajst-20773	383	4	wu	wu	PROPN
ajst-20773	383	5	,	,	PUNCT
ajst-20773	383	6	q.	q.	PROPN
ajst-20773	383	7	,	,	PUNCT
ajst-20773	383	8	qian	qian	PROPN
ajst-20773	383	9	,	,	PUNCT
ajst-20773	383	10	w.	w.	PROPN
ajst-20773	383	11	,	,	PUNCT
ajst-20773	383	12	sun	sun	PROPN
ajst-20773	383	13	,	,	PUNCT
ajst-20773	383	14	x.	x.	PROPN
ajst-20773	383	15	,	,	PUNCT
ajst-20773	383	16	jiang	jiang	PROPN
ajst-20773	383	17	,	,	PUNCT
ajst-20773	383	18	s.	s.	PROPN
ajst-20773	383	19	(	(	PUNCT
ajst-20773	383	20	2022	2022	NUM
ajst-20773	383	21	)	)	PUNCT
ajst-20773	383	22	.	.	PUNCT
ajst-20773	384	1	small	small	ADJ
ajst-20773	384	2	-	-	PUNCT
ajst-20773	384	3	molecule	molecule	NOUN
ajst-20773	384	4	inhibitors	inhibitor	NOUN
ajst-20773	384	5	,	,	PUNCT
ajst-20773	384	6	immune	immune	ADJ
ajst-20773	384	7	checkpoint	checkpoint	NOUN
ajst-20773	384	8	inhibitors	inhibitor	NOUN
ajst-20773	384	9	,	,	PUNCT
ajst-20773	384	10	and	and	CCONJ
ajst-20773	384	11	more	more	ADV
ajst-20773	384	12	:	:	PUNCT
ajst-20773	384	13	fdaapproved	fdaapprove	VERB
ajst-20773	384	14	novel	novel	ADJ
ajst-20773	384	15	therapeutic	therapeutic	ADJ
ajst-20773	384	16	drugs	drug	NOUN
ajst-20773	384	17	for	for	ADP
ajst-20773	384	18	solid	solid	ADJ
ajst-20773	384	19	tumors	tumor	NOUN
ajst-20773	384	20	from	from	ADP
ajst-20773	384	21	1991	1991	NUM
ajst-20773	384	22	to	to	ADP
ajst-20773	384	23	2021	2021	NUM
ajst-20773	384	24	.	.	PUNCT
ajst-20773	385	1	journal	journal	NOUN
ajst-20773	385	2	of	of	ADP
ajst-20773	385	3	hematology	hematology	PROPN
ajst-20773	385	4	&	&	CCONJ
ajst-20773	385	5	oncology	oncology	NOUN
ajst-20773	385	6	.	.	PUNCT
ajst-20773	386	1	[	[	X
ajst-20773	386	2	39	39	NUM
ajst-20773	386	3	]	]	PUNCT
ajst-20773	386	4	xu	xu	PROPN
ajst-20773	386	5	,	,	PUNCT
ajst-20773	386	6	x.	x.	PROPN
ajst-20773	386	7	,	,	PUNCT
ajst-20773	386	8	zhou	zhou	PROPN
ajst-20773	386	9	,	,	PUNCT
ajst-20773	386	10	x.	x.	PROPN
ajst-20773	386	11	,	,	PUNCT
ajst-20773	386	12	chen	chen	PROPN
ajst-20773	386	13	,	,	PUNCT
ajst-20773	386	14	z.	z.	PROPN
ajst-20773	386	15	,	,	PUNCT
ajst-20773	386	16	gao	gao	PROPN
ajst-20773	386	17	,	,	PUNCT
ajst-20773	386	18	c.	c.	PROPN
ajst-20773	386	19	,	,	PUNCT
ajst-20773	386	20	zhao	zhao	PROPN
ajst-20773	386	21	,	,	PUNCT
ajst-20773	386	22	l.	l.	PROPN
ajst-20773	386	23	,	,	PUNCT
ajst-20773	386	24	&	&	CCONJ
ajst-20773	386	25	cui	cui	PROPN
ajst-20773	386	26	,	,	PUNCT
ajst-20773	386	27	y.	y.	PROPN
ajst-20773	386	28	(	(	PUNCT
ajst-20773	386	29	2020	2020	NUM
ajst-20773	386	30	)	)	PUNCT
ajst-20773	386	31	.	.	PUNCT
ajst-20773	387	1	silencing	silence	VERB
ajst-20773	387	2	of	of	ADP
ajst-20773	387	3	lncrna	lncrna	NOUN
ajst-20773	387	4	xist	xist	NOUN
ajst-20773	387	5	inhibits	inhibit	VERB
ajst-20773	387	6	non	non	ADJ
ajst-20773	387	7	-	-	ADJ
ajst-20773	387	8	small	small	ADJ
ajst-20773	387	9	cell	cell	NOUN
ajst-20773	387	10	lung	lung	NOUN
ajst-20773	387	11	cancer	cancer	NOUN
ajst-20773	387	12	31	31	NUM
ajst-20773	387	13	growth	growth	NOUN
ajst-20773	387	14	and	and	CCONJ
ajst-20773	387	15	promotes	promote	VERB
ajst-20773	387	16	chemosensitivity	chemosensitivity	NOUN
ajst-20773	387	17	to	to	ADP
ajst-20773	387	18	cisplatin	cisplatin	NOUN
ajst-20773	387	19	.	.	PUNCT
ajst-20773	388	1	aging	aging	NOUN
ajst-20773	388	2	(	(	PUNCT
ajst-20773	388	3	albany	albany	PROPN
ajst-20773	388	4	ny	ny	PROPN
ajst-20773	388	5	)	)	PUNCT
ajst-20773	388	6	,	,	PUNCT
ajst-20773	388	7	12(5	12(5	NUM
ajst-20773	388	8	)	)	PUNCT
ajst-20773	388	9	,	,	PUNCT
ajst-20773	388	10	6720	6720	NUM
ajst-20773	388	11	-	-	SYM
ajst-20773	388	12	6737	6737	NUM
ajst-20773	388	13	.	.	PUNCT
ajst-20773	389	1	[	[	X
ajst-20773	389	2	40	40	NUM
ajst-20773	389	3	]	]	X
ajst-20773	389	4	yi	yi	PROPN
ajst-20773	389	5	,	,	PUNCT
ajst-20773	389	6	m.	m.	NOUN
ajst-20773	389	7	,	,	PUNCT
ajst-20773	389	8	li	li	PROPN
ajst-20773	389	9	,	,	PUNCT
ajst-20773	389	10	a.	a.	PROPN
ajst-20773	389	11	,	,	PUNCT
ajst-20773	389	12	zhou	zhou	PROPN
ajst-20773	389	13	,	,	PUNCT
ajst-20773	389	14	l.	l.	PROPN
ajst-20773	389	15	,	,	PUNCT
ajst-20773	389	16	chu	chu	PROPN
ajst-20773	389	17	,	,	PUNCT
ajst-20773	389	18	q.	q.	PROPN
ajst-20773	389	19	,	,	PUNCT
ajst-20773	389	20	luo	luo	PROPN
ajst-20773	389	21	,	,	PUNCT
ajst-20773	389	22	s.	s.	PROPN
ajst-20773	389	23	,	,	PUNCT
ajst-20773	389	24	wu	wu	PROPN
ajst-20773	389	25	,	,	PUNCT
ajst-20773	389	26	k.	k.	PROPN
ajst-20773	389	27	(	(	PUNCT
ajst-20773	389	28	2021	2021	NUM
ajst-20773	389	29	)	)	PUNCT
ajst-20773	389	30	.	.	PUNCT
ajst-20773	390	1	immune	immune	ADJ
ajst-20773	390	2	signature	signature	NOUN
ajst-20773	390	3	-	-	PUNCT
ajst-20773	390	4	based	base	VERB
ajst-20773	390	5	risk	risk	NOUN
ajst-20773	390	6	stratification	stratification	NOUN
ajst-20773	390	7	and	and	CCONJ
ajst-20773	390	8	prediction	prediction	NOUN
ajst-20773	390	9	of	of	ADP
ajst-20773	390	10	immune	immune	ADJ
ajst-20773	390	11	checkpoint	checkpoint	NOUN
ajst-20773	390	12	inhibitor	inhibitor	NOUN
ajst-20773	390	13	's	's	PART
ajst-20773	390	14	efficacy	efficacy	NOUN
ajst-20773	390	15	for	for	ADP
ajst-20773	390	16	lung	lung	NOUN
ajst-20773	390	17	adenocarcinoma	adenocarcinoma	NOUN
ajst-20773	390	18	.	.	PUNCT
ajst-20773	391	1	cancer	cancer	NOUN
ajst-20773	391	2	immunology	immunology	NOUN
ajst-20773	391	3	research	research	NOUN
ajst-20773	391	4	.	.	PUNCT
ajst-20773	392	1	[	[	X
ajst-20773	392	2	41	41	NUM
ajst-20773	392	3	]	]	X
ajst-20773	392	4	yuan	yuan	NOUN
ajst-20773	392	5	,	,	PUNCT
ajst-20773	392	6	s.	s.	PROPN
ajst-20773	392	7	,	,	PUNCT
ajst-20773	392	8	xiang	xiang	PROPN
ajst-20773	392	9	,	,	PUNCT
ajst-20773	392	10	y.	y.	PROPN
ajst-20773	392	11	,	,	PUNCT
ajst-20773	392	12	guo	guo	PROPN
ajst-20773	392	13	,	,	PUNCT
ajst-20773	392	14	x.	x.	PROPN
ajst-20773	392	15	,	,	PUNCT
ajst-20773	392	16	zhang	zhang	PROPN
ajst-20773	392	17	,	,	PUNCT
ajst-20773	392	18	c.	c.	PROPN
ajst-20773	392	19	,	,	PUNCT
ajst-20773	392	20	li	li	PROPN
ajst-20773	392	21	,	,	PUNCT
ajst-20773	392	22	c.	c.	PROPN
ajst-20773	392	23	,	,	PUNCT
ajst-20773	392	24	&	&	CCONJ
ajst-20773	392	25	xie	xie	PROPN
ajst-20773	392	26	,	,	PUNCT
ajst-20773	392	27	m.	m.	NOUN
ajst-20773	392	28	(	(	PUNCT
ajst-20773	392	29	2020	2020	NUM
ajst-20773	392	30	)	)	PUNCT
ajst-20773	392	31	.	.	PUNCT
ajst-20773	393	1	circulating	circulate	VERB
ajst-20773	393	2	long	long	ADJ
ajst-20773	393	3	noncoding	noncoding	ADJ
ajst-20773	393	4	rnas	rna	NOUN
ajst-20773	393	5	act	act	NOUN
ajst-20773	393	6	as	as	ADP
ajst-20773	393	7	diagnostic	diagnostic	ADJ
ajst-20773	393	8	biomarkers	biomarker	NOUN
ajst-20773	393	9	in	in	ADP
ajst-20773	393	10	non	non	ADJ
ajst-20773	393	11	-	-	ADJ
ajst-20773	393	12	small	small	ADJ
ajst-20773	393	13	cell	cell	NOUN
ajst-20773	393	14	lung	lung	NOUN
ajst-20773	393	15	cancer	cancer	NOUN
ajst-20773	393	16	.	.	PUNCT
ajst-20773	394	1	frontiers	frontier	NOUN
ajst-20773	394	2	in	in	ADP
ajst-20773	394	3	oncology	oncology	NOUN
ajst-20773	394	4	,	,	PUNCT
ajst-20773	394	5	10	10	NUM
ajst-20773	394	6	,	,	PUNCT
ajst-20773	394	7	article	article	NOUN
ajst-20773	394	8	537120	537120	NUM
ajst-20773	394	9	.	.	PUNCT
ajst-20773	395	1	[	[	X
ajst-20773	395	2	42	42	NUM
ajst-20773	395	3	]	]	X
ajst-20773	395	4	zhang	zhang	PROPN
ajst-20773	395	5	,	,	PUNCT
ajst-20773	395	6	x.	x.	PROPN
ajst-20773	395	7	z.	z.	PROPN
ajst-20773	395	8	,	,	PUNCT
ajst-20773	395	9	liu	liu	PROPN
ajst-20773	395	10	,	,	PUNCT
ajst-20773	395	11	h.	h.	PROPN
ajst-20773	395	12	,	,	PUNCT
ajst-20773	395	13	&	&	CCONJ
ajst-20773	395	14	chen	chen	PROPN
ajst-20773	395	15	,	,	PUNCT
ajst-20773	395	16	s.	s.	PROPN
ajst-20773	395	17	r.	r.	PROPN
ajst-20773	395	18	(	(	PUNCT
ajst-20773	395	19	2020	2020	NUM
ajst-20773	395	20	)	)	PUNCT
ajst-20773	395	21	.	.	PUNCT
ajst-20773	395	22	mechanisms	mechanism	NOUN
ajst-20773	395	23	of	of	ADP
ajst-20773	395	24	long	long	ADJ
ajst-20773	395	25	non	non	ADJ
ajst-20773	395	26	-	-	ADJ
ajst-20773	395	27	coding	coding	ADJ
ajst-20773	395	28	rnas	rna	NOUN
ajst-20773	395	29	in	in	ADP
ajst-20773	395	30	cancers	cancer	NOUN
ajst-20773	395	31	and	and	CCONJ
ajst-20773	395	32	their	their	PRON
ajst-20773	395	33	dynamic	dynamic	ADJ
ajst-20773	395	34	regulations	regulation	NOUN
ajst-20773	395	35	.	.	PUNCT
ajst-20773	396	1	cancers	cancer	NOUN
ajst-20773	396	2	,	,	PUNCT
ajst-20773	396	3	12(5	12(5	NUM
ajst-20773	396	4	)	)	PUNCT
ajst-20773	396	5	,	,	PUNCT
ajst-20773	396	6	1245	1245	NUM
ajst-20773	396	7	.	.	PUNCT